



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |   |   |
|---|---|---|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>C12N 15/12, C07K 14/47, C12N 15/62,<br/>C07K 16/18</b>   | <b>A1</b>   | <b>(11) International Publication Number:</b> <b>WO 99/21998</b><br><b>(43) International Publication Date:</b> 6 May 1999 (06.05.99) |
| <b>(21) International Application Number:</b> PCT/US98/22991<br><b>(22) International Filing Date:</b> 29 October 1998 (29.10.98)<br><br><b>(30) Priority Data:</b><br>60/063,704 29 October 1997 (29.10.97) US<br>60/073,612 3 February 1998 (03.02.98) US<br>60/081,695 14 April 1998 (14.04.98) US<br><br><b>(71) Applicant:</b> GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).<br><br><b>(72) Inventors:</b> BOTSTEIN, David, A.; 2539 Somerset Drive, Belmont, CA 94002 (US). COHEN, Robert, L.; 660 Parrott Drive, San Mateo, CA 94402 (US). GURNEY, Austin, L.; 1 Debbie Lane, Belmont, CA 94002 (US). HILLAN, Kenneth; 64 Seward Street, San Francisco, CA 94114 (US). LAWRENCE, David, A.; 1659 12th Avenue, San Francisco, CA 94122 (US). LEVINE, Arnold, J.; 138 FitzRandolph Road, Princeton, NJ 08540 (US). PENNICA, Diane; 2417 Hale Drive, Burlingame, CA 94010 (US). ROY, Margaret, Ann; 2960 Webster Street #4, San Francisco, CA 94123 (US). GODDARD, Audrey; 110 Congo Street, San Francisco, CA 94131 (US). WOOD, William, I.; 35 Southdown Court, Hillsborough, CA 94010 (US). | <b>(74) Agent:</b> BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).<br><br><b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |   |
| <b>(54) Title:</b> WNT-1 INDUCED SECRETED POLYPEPTIDES: WISP-1, -2 AND -3<br><br><b>(57) Abstract</b><br><br>Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.   |   |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |



## WNT-1 INDUCED SECRETED POLYPEPTIDES: WISP-1, -2 AND -3

This invention was made with government support under grant no. 5PO1 CA41086, awarded by the National Institutes of Health, National Cancer Institute. The government has certain rights in the invention.

5 FIELD OF THE INVENTION

The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides having homology to connective tissue growth factor, designated herein as Wnt-1-Induced Secreted Proteins (WISPs).

BACKGROUND OF THE INVENTION

10 Malignant tumors (cancers) are the second leading cause of death in the United States, after heart disease. Boring *et al.*, CA Cancer J. Clin., 43: 7 (1993).

Cancer is characterized by the increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which eventually spread via the blood or lymphatic system to regional lymph nodes and to distant sites (metastasis). In a cancerous state a cell proliferates under conditions in which normal cells would not grow. Cancer manifests itself in a wide variety of forms, characterized by different degrees of invasiveness and aggressiveness.

Alteration of gene expression is intimately related to the uncontrolled cell growth and de-differentiation which are a common feature of all cancers. The genomes of certain well studied tumors have been found to show decreased expression of recessive genes, usually referred to as tumor suppression genes, which would normally function to prevent malignant cell growth, and/or overexpression of certain dominant genes, such as oncogenes, that act to promote malignant growth. Each of these genetic changes appears to be responsible for importing some of the traits that, in aggregate, represent the full neoplastic phenotype. Hunter, Cell, 64: 1129 (1991); Bishop, Cell, 64: 235-248 (1991).

20 A well-known mechanism of gene (*e.g.*, oncogene) overexpression in cancer cells is gene amplification. This is a process where in the chromosome of the ancestral cell multiple copies of a particular gene are produced. The process involves unscheduled replication of the region of chromosome comprising the gene, followed by recombination of the replicated segments back into the chromosome. Alitalo *et al.*, Adv. Cancer Res., 47: 235-281 (1986). It is believed that the overexpression of the gene parallels gene amplification, *i.e.*, is proportionate to the number of copies made.

30 Proto-oncogenes that encode growth factors and growth factor receptors have been identified to play important roles in the pathogenesis of various human malignancies, including breast cancer. For example, it has been found that the human ErbB2 gene (*erbB2*, also known as *her2*, or *c-erbB-2*), which encodes a 185-kd transmembrane glycoprotein receptor (p185<sup>HER2</sup>, HER2) related to the epidermal growth factor receptor (EGFR), is overexpressed in about 25% to 30% of human breast cancer. Slamon *et al.*, Science, 235:177-182 (1987); Slamon *et al.*, Science, 244:707-712 (1989).

35 It has been reported that gene amplification of a protooncogene is an event typically involved in the more malignant forms of cancer, and could act as a predictor of clinical outcome. Schwab *et al.*, Genes

Chromosomes Cancer, 1: 181-193 (1990); Alitalo *et al.*, *supra*. Thus, *erbB2* overexpression is commonly regarded as a predictor of a poor prognosis, especially in patients with primary disease that involves axillary lymph nodes (Slamon *et al.*, (1987) and (1989), *supra*; Ravdin and Chamness, Gene, 150:19-27 (1995); and Hynes and Stern, Biochim Biophys Acta, 1198:165-184 (1994)), and has been linked to sensitivity and/or resistance to hormone therapy and chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and fluoruracil) and anthracyclines. Baselga *et al.*, Oncology, 11(3 Suppl 1):43-48 (1997). However, despite the association of *erbB2* overexpression with poor prognosis, the odds of HER2-positive patients responding clinically to treatment with taxanes were greater than three times those of HER2-negative patients. Baselga *et al.*, *supra*. A recombinant humanized anti-ErbB2 (anti-HER2) monoclonal antibody (a humanized version of the murine anti-ErbB2 antibody 4D5, referred to as rhuMAb HER2 or HERCEPTIN®) has been clinically active in patients with ErbB2-overexpressing metastatic breast cancers that had received extensive prior anticancer therapy. Baselga *et al.*, J. Clin. Oncol., 14:737-744 (1996).

Cytokines have been implicated in the pathogenesis of a number of brain diseases in which neurological dysfunction has been attributed to a change in amino acid neurotransmitter metabolism. In particular, members of the transforming growth factor- $\beta$  (TGF- $\beta$ ) family have been implicated. TGF peptides are small polypeptides that were first identified by their ability to induce proliferation and transformation in noncancerous cells in culture. Although initially defined as a growth factor, TGF- $\beta$  also inhibits proliferation of epithelial, endothelial, lymphoid, and hematopoietic cells. This cytokine is thought to play an important role in regulating the duration of the inflammatory response, allowing the healing process to proceed. It is also a potent immunomodulator, which has many pleiotrophic effects, including regulating many other cytokines.

The TGF- $\beta$  superfamily includes bone morphogenetic proteins (BMP-2, BMP-4, BMP-5, BMP-6, BMP-7), activins A & B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, Inhibin- $\alpha$ , TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 5, and glial-derived neurotrophic factor (GDNF). Atrisano, *et al.*, J. Biochemica et Biophysica Acta, 1222:71-80 (1994). Of particular interest are the growth differentiation factors, for as their name implies, these factors are implicated in the differentiation of cells.

Connective tissue growth factor (CTGF) is a growth factor induced in fibroblasts by many factors, including TGF- $\beta$ , and is essential for the ability of TGF- $\beta$  to induce anchorage-independent growth (AIG), a property of transformed cells. CTGF was discovered in an attempt to identify the type of platelet-derived growth factor (PDGF) dimers present in the growth media of cultured endothelial cells, and is related immunologically and biologically to PDGF. See U.S. Pat. No. 5,408,040. CTGF also is mitogenic and chemotactic for cells, and hence growth factors in this family are believed to play a role in the normal development, growth, and repair of human tissue.

Seven proteins related to CTGF, including the chicken ortholog for Cyr61, CEF10, human, mouse, and *Xenopus laevis* CTGF, and human, chicken, and *Xenopus laevis* Nov have been isolated, cloned, sequenced, and characterized as belonging to the CTGF gene family. Oemar and Luescher, Arterioscler. Thromb. Vasc. Biol., 17: 1483-1489 (1997). The gene encoding Cyr61 has been found to promote angiogenesis, tumor growth, and vascularization. Babic *et al.*, Proc. Natl. Acad. Sci. USA, 95: 6355-6360 (1998). The *nov* gene is expressed in the kidney essentially at the embryonic stage, and alterations of *nov*

expression, relative to the normal kidney, have been detected in both avian nephroblastomas and human Wilms' tumors. Martinier *et al.*, Oncogene, 9: 2729-2732 (1994). Wt1 downregulates human *nov* expression, which downregulation might represent a key element in normal and tumoral nephrogenesis. Martinier *et al.*, Oncogene, 12: 1479-1492 (1996). It has recently been proposed that the CTGF, *nov*, and *cyr61* genes, which encode secreted proteins that contain conserved sequences and IGFBP motifs in their N-termini and bind IGFs with low affinity, represent more members of the IGFBP superfamily, along with the low-affinity mac25/IGFBP-7 (Yamanaka *et al.*, J. Biol. Chem., 272: 30729-30734 (1997)) and the high-affinity IGFBPs 1-6. CTGF under this proposal would be designated IGFBP-8. Kim *et al.*, Proc. Natl. Acad. Sci. USA, 94: 12981-12986 (1997).

Recently, a protein was found in the mouse designated ELM1 that is expressed in low metastatic cells. Hashimoto *et al.*, J. Exp. Med., 187: 289-296 (1998). The *elm1* gene, a mouse homologue of WISP-1 disclosed below, is another member of the CTGF, Cyr61/Cef10, and neuroblastoma overexpressed-gene family and suppresses *in vivo* tumor growth and metastasis of K-1735 murine melanoma cells. Another recent article on rCop-1, the rat orthologue of WISP-2 described below describes the loss of expression of this gene after cell transformation Zhang *et al.*, Mol. Cell. Biol., 18:6131-6141 (1998)

CTGF family members (with the exception of *nov*) are immediate early growth-responsive genes that are thought to regulate cell proliferation, differentiation, embryogenesis, and wound healing. Sequence homology among members of the CTGF gene family is high; however, functions of these proteins *in vitro* range from growth stimulatory (*i.e.*, human CTGF) to growth inhibitory (*i.e.*, chicken Nov and also possibly hCTGF). Further, some molecules homologous to CTGF are indicated to be useful in the prevention of desmoplasia, the formation of highly cellular, excessive connective tissue stroma associated with some cancers, and fibrotic lesions associated with various skin disorders such as scleroderma, keloid, eosinophilic fasciitis, nodular fasciitis, and Dupuytren's contracture. Moreover, CTGF expression has recently been demonstrated in the fibrous stroma of mammary tumors, suggesting cancer stroma formation involves the induction of similar fibroproliferative growth factors as wound repair. Human CTGF is also expressed at very high levels in advanced atherosclerotic lesions, but not in normal arteries, suggesting it may play a role in atherosclerosis. Oemar and Luescher, *supra*. Therefore, molecules homologous to CTGF are of importance.

Extracellular and membrane-bound proteins play important roles in the formation, differentiation, and maintenance of multicellular organisms. The fate of many individual cells, *e.g.*, proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones), which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment, usually at a membrane-bound receptor protein.

Secreted proteins have various industrial applications, including use as pharmaceuticals, diagnostics, biosensors, and bioreactors. In fact, most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secreted proteins. Their receptors, which are membrane-bound proteins, also have potential as therapeutic or

diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interaction. Membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesion molecules like selectins and integrins. Transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.

Efforts are being undertaken by both industry and academia to identify new, native secreted and membrane-bound receptor proteins, particularly those having homology to CTGF. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted and membrane-bound receptor proteins. Examples of screening methods and techniques are described in the literature. See, for example, Klein *et al.*, Proc. Natl. Acad. Sci., 93:7108-7113 (1996); and U.S. Patent No. 5,536,637.

Wnts are encoded by a large gene family whose members have been found in round worms, insects, cartilaginous fish, and vertebrates. Holland *et al.*, Dev. Suppl., 125-133 (1994). Wnts are thought to function in a variety of developmental and physiological processes since many diverse species have multiple conserved *Wnt* genes. McMahon, Trends Genet., 8: 236-242 (1992); Nusse and Varmus, Cell, 69: 1073-1087 (1992). *Wnt* genes encode secreted glycoproteins that are thought to function as paracrine or autocrine signals active in several primitive cell types. McMahon, *supra* (1992); Nusse and Varmus, *supra* (1992). The *Wnt* growth factor family includes more than ten genes identified in the mouse (*Wnt*-1, -2, -3A, -3B, -4, -5A, -5B, -6, -7A, -7B, -8A, -8B, -10B, -11, -12, and -13) (see, e.g., Gavin *et al.*, Genes Dev., 4: 2319-2332 (1990); Lee *et al.*, Proc. Natl. Acad. Sci. USA, 92: 2268-2272 (1995); Christiansen *et al.*, Mech. Dev., 51: 341-350 (1995)) and at least nine genes identified in the human (*Wnt*-1, -2, -3, -5A, -7A, -7B, -8B, -10B, and -11) by cDNA cloning. See, e.g., Vant Veer *et al.*, Mol. Cell. Biol., 4: 2532-2534 (1984).

The *Wnt-1* proto-oncogene (*int-1*) was originally identified from mammary tumors induced by mouse mammary tumor virus (MMTV) due to an insertion of viral DNA sequence. Nusse and Varmus, Cell, 31: 99-109 (1982). In adult mice, the expression level of *Wnt-1* mRNA is detected only in the testis during later stages of sperm development. *Wnt-1* protein is about 42 KDa and contains an amino-terminal hydrophobic region, which may function as a signal sequence for secretion (Nusse and Varmus, *supra*, 1992). The expression of *Wnt-2/irp* is detected in mouse fetal and adult tissues and its distribution does not overlap with the expression pattern for *Wnt-1*. *Wnt-3* is associated with mouse mammary tumorigenesis. The expression of *Wnt-3* in mouse embryos is detected in the neural tubes and in the limb buds. *Wnt-5a* transcripts are detected in the developing fore- and hind limbs at 9.5 through 14.5 days and highest levels are concentrated in apical ectoderm at the distal tip of limbs. Nusse and Varmus, *supra* (1992). Recently, a *Wnt* growth factor, termed *Wnt-x*, was described (WO95/17416) along with the detection of *Wnt-x* expression in bone tissues and in bone-derived cells. Also described was the role of *Wnt-x* in the maintenance of mature



osteoblasts and the use of the Wnt-x growth factor as a therapeutic agent or in the development of other therapeutic agents to treat bone-related diseases.

Wnts may play a role in local cell signaling. Biochemical studies have shown that much of the secreted Wnt protein can be found associated with the cell surface or extracellular matrix rather than freely diffusible in the medium. Papkoff and Schryver, Mol. Cell. Biol., 10: 2723-2730 (1990); Bradley and Brown, EMBO J., 9: 1569-1575 (1990).

Studies of mutations in *Wnt* genes have indicated a role for *Wnts* in growth control and tissue patterning. In *Drosophila*, *wingless* (*wg*) encodes a *Wnt*-related gene (Rijsewijk *et al.*, Cell, 50: 649-657 (1987)) and *wg* mutations alter the pattern of embryonic ectoderm, neurogenesis, and imaginal disc outgrowth. Morata and Lawrence, Dev. Biol., 56: 227-240 (1977); Baker, Dev. Biol., 125: 96-108 (1988); Klingensmith and Nusse, Dev. Biol., 166: 396-414 (1994). In *Caenorhabditis elegans*, *lin-44* encodes a Wnt homolog which is required for asymmetric cell divisions. Herman and Horvitz, Development, 120: 1035-1047 (1994). Knock-out mutations in mice have shown Wnts to be essential for brain development (McMahon and Bradley, Cell, 62: 1073-1085 (1990); Thomas and Cappechi, Nature, 346: 847-850 (1990)), and the outgrowth of embryonic primordia for kidney (Stark *et al.*, Nature, 372: 679-683 (1994)), tail bud (Takada *et al.*, Genes Dev., 8: 174-189 (1994)), and limb bud. Parr and McMahon, Nature, 374: 350-353 (1995). Overexpression of *Wnts* in the mammary gland can result in mammary hyperplasia (McMahon, *supra* (1992); Nusse and Varmus, *supra* (1992)), and precocious alveolar development. Bradbury *et al.*, Dev. Biol., 170: 553-563 (1995).

*Wnt-5a* and *Wnt-5b* are expressed in the posterior and lateral mesoderm and the extraembryonic mesoderm of the day 7-8 murine embryo. Gavin *et al.*, *supra* (1990). These embryonic domains contribute to the AGM region and yolk sac tissues from which multipotent hematopoietic precursors and HSCs are derived. Dzierzak and Medvinsky, Trends Genet., 11: 359-366 (1995); Zon *et al.*, in Gluckman and Coulombel, ed., Colloque, INSERM, 235: 17-22 (1995), presented at the Joint International Workshop on Foetal and Neonatal Hematopoiesis and Mechanism of Bone Marrow Failure, Paris France, April 3-6, 1995; Kanatsu and Nishikawa, Development, 122: 823-830 (1996). *Wnt-5a*, *Wnt-10b*, and other *Wnts* have been detected in limb buds, indicating possible roles in the development and patterning of the early bone microenvironment as shown for *Wnt-7b*. Gavin *et al.*, *supra* (1990); Christiansen *et al.*, Mech. Devel., 51: 341-350 (1995); Parr and McMahon, *supra* (1995).

The Wnt/Wg signal transduction pathway plays an important role in the biological development of the organism and has been implicated in several human cancers. This pathway also includes the tumor suppressor gene, APC. Mutations in the APC gene are associated with the development of sporadic and inherited forms of human colorectal cancer. The Wnt/Wg signal leads to the accumulation of beta-catenin/Armadillo in the cell, resulting in the formation of a bipartite transcription complex consisting of beta-catenin and a member of the lymphoid enhancer binding factor/T cell factor (LEF/TCF) HMG box transcription factor family. This complex translocates to the nucleus where it can activate expression of genes downstream of the Wnt/Wg signal, such as the engrailed and Ultrabithorax genes in *Drosophila*. The downstream target genes of Wnt-1 signaling in vertebrates that presumably function in tumorigenesis, however, are currently unknown.

For a most recent review on Wnt, see Cadigan and Nusse, Genes & Dev., 11: 3286-3305 (1997).

There is a need to elucidate the further members of the above families, including cell-surface molecules that may be tumor-specific antigens or proteins that serve a regulatory function in initiating the Wnt pathway of tumorigenesis. These would also include downstream components of the Wnt signaling pathway that are important to the transformed phenotype and the development of cancer.

#### SUMMARY OF THE INVENTION

Several putative Wnt-1-induced genes have been identified at the mRNA level in a high-throughput cDNA subtraction experiment. Thus, applicants have identified novel cDNA clones (*WISP1*, *WISP2*, and *WISP3*) that encode novel polypeptides of the WISP family, designated as WISP-1, WISP-2, and WISP-3, respectively. This class of polypeptides was formerly referred to as Wnt-1-Induced Gene (WIG) polypeptides, with WISP-1 and WISP-2 formerly designated as WIG-1 and WIG-2, respectively. One of the cDNA clones encodes a novel polypeptide, human WISP-2, having homology to CTGF, wherein the polypeptide is designated in the present application as "human WISP-2" or "PRO261". The WISP-1 and WISP-3 molecules also have homology to CTGF.

In one embodiment, this invention provides isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological activity. In a more preferred embodiment, this nucleic acid has at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO: 3), or (b) the complement of the DNA molecule of (a).

More preferred is the nucleic acid comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or DNA encoding a human WISP-1 polypeptide having amino acid residues 1 to 367 of Figures 3A and 3B (SEQ ID NO:4), or the complement of either of the encoding DNAs. Further preferred is this nucleic acid comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue or a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:5-8, respectively). Further preferred also is this nucleic acid comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue and a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:21-22, respectively).

Also preferred is this nucleic acid comprising DNA encoding a mouse WISP-1 polypeptide having amino acid residues 23 to 367 of Figure 1 (SEQ ID NO:11), or DNA encoding a mouse WISP-1 polypeptide having amino acid residues 1 to 367 of Figure 1 (SEQ ID NO:12), or the complement of either of the encoding DNAs.

Also provided by this invention is isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 85% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological

activity. More preferably, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a).

In another preferred embodiment, the invention provides an isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-1 polypeptide cDNA in ATCC Deposit No. 209533 (pRK5E.h.WISP-1.568.38), or (b) the complement of the DNA molecule of (a). This nucleic acid preferably comprises DNA having at least about 600 nucleotides and at least about a 95% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-1 polypeptide cDNA in ATCC Deposit No. 209533 (pRK5E.h.WISP-1.568.38), or (b) the complement of the DNA molecule of (a).

In another aspect, the invention provides a process for producing a WISP-1 polypeptide comprising culturing a host cell comprising the above nucleic acid under conditions suitable for expression of the WISP-1 polypeptide and recovering the WISP-1 polypeptide from the cell culture. Additionally provided is an isolated WISP-1 polypeptide encoded by the above nucleic acid, including where the polypeptide is human WISP-1 or mouse WISP-1.

In another embodiment, the invention provides isolated nucleic acid comprising SEQ ID NO:23, 24, 25, 26, 27, 28, or 29, and an isolated WISP-1 polypeptide encoded by such a nucleic acid.

Also provided by this invention is an isolated nucleic acid having at least about 600 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.

Further provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological activity. Also, preferably this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a). In another preferred embodiment, this nucleic acid comprises DNA encoding a human WISP-2 polypeptide having amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15), or DNA encoding a human WISP-2 polypeptide having amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16), or a complement of either of the encoding DNAs.



In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 1 to 250 of Figure 4 (SEQ ID NO:16), or (b) the complement of the DNA molecule of (a).

5 In another aspect, the invention provides isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) the complement of the DNA molecule of (a). More preferably, the nucleic acid comprises DNA encoding a mouse WISP-2 polypeptide having amino acid residues 24 to 251 of Figure 2 (SEQ ID NO:19), or DNA encoding a mouse WISP-2 polypeptide having amino acid residues 1 to 251 of Figure 2 (SEQ ID NO:20), or the complement of either of these encoding DNAs.

15 In a further aspect, the invention provides isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 1 to 251 of Figure 2 (SEQ ID NO:20), or (b) the complement of the DNA molecule of (a).

In yet another aspect, the invention provides an isolated nucleic acid comprising DNA having at least about 400 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-2 polypeptide cDNA in ATCC Deposit No. 209391 (DNA33473), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid comprises DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-2 polypeptide cDNA in ATCC Deposit No. 209391 (DNA33473), or (b) the complement of the DNA molecule of (a).

25 In another embodiment, this invention provides an isolated nucleic acid comprising the nucleotide sequence of the full-length coding sequence of clone UNQ228 (DNA33473) deposited under accession number ATCC 209391.

In another aspect, the invention provides a process for producing a WISP-2 polypeptide comprising culturing a host cell comprising the above nucleic acid under conditions suitable for expression of the WISP-2 polypeptide and recovering the WISP-2 polypeptide from the cell culture. Additionally provided is a WISP-2 polypeptide encoded by the isolated nucleic acid, including where the polypeptide is human WISP-2 or mouse WISP-2. In a specific embodiment of this, the invention provides isolated native-sequence human WISP-2 polypeptide comprising amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16) or comprising amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15).

35 In a further embodiment, the invention provides an isolated nucleic acid having at least about 400 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure

4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.

In a still further embodiment, the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

In yet another embodiment, the invention provides isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one WISP biological activity. Preferably, this nucleic acid comprises DNA encoding a human WISP-3 polypeptide having amino acid residues 34 to 372 of Figures 6A and 6B (SEQ ID NO:32) or amino acids 1 to 372 of Figures 6A and 6B (SEQ ID NO:33), or the complement thereof.

In a still further embodiment, the invention provides an isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209706 (DNA56350-1176-2), or (b) the complement of the DNA molecule of (a). A still further aspect of the invention involves a process for producing a WISP-3 polypeptide comprising culturing a host cell comprising WISP-3-encoding nucleic acid under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.

Further provided is an isolated WISP-3 polypeptide encoded by the WISP-3-encoding nucleic acid. Preferably, this polypeptide is human WISP-3.

In another embodiment, the invention provides an isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, isolating the test DNA molecule.

Also provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

In yet another embodiment, the invention provides isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) the complement of the DNA molecule of (a). Preferably, this nucleic acid has at least one

WISP biological activity. Preferably, this nucleic acid comprises DNA encoding a human WISP-3 polypeptide having amino acid residues 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or amino acid residues 1 to 355 of Figures 7A and 7B (SEQ ID NO:37) or the complement thereof.

5 In a still further embodiment, the invention provides an isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209707 (DNA58800-1176-2), or (b) the complement of the DNA molecule of (a).

A still further aspect of the invention involves a process for producing a WISP-3 polypeptide of Fig. 7A and 7B comprising culturing a host cell comprising WISP-3-encoding nucleic acid under conditions 10 suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.

Further provided is an isolated WISP-3 polypeptide of Fig. 7A and 7B encoded by the WISP-3-encoding nucleic acid. Preferably, this polypeptide is human WISP-3.

15 In another embodiment, the invention provides an isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides, isolating the test DNA molecule.

Also provided is a polypeptide produced by (i) hybridizing a test DNA molecule under stringent 20 conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides, (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

25 Preferably the complements of the DNA molecules herein remain stably bound to the primary sequence under at least moderate, and optionally, under high stringency conditions.

Also provided are vectors comprising the above nucleic acids, host cells comprising the vector, preferably wherein the cell is a Chinese hamster ovary (CHO) cell, an *E. coli* cell, a baculovirus-infected cell, or a yeast cell.

30 Additionally provided are a chimeric molecule comprising one of the above polypeptides or an inactivated variant thereof, fused to a heterologous amino acid sequence, wherein the heterologous amino acid sequence may be, for example, an epitope tag sequence, a polyamino acid such as poly-histidine, or an immunoglobulin constant region (Fc). Also provided is an antibody which specifically binds to one of the above polypeptides, wherein the antibody can be a monoclonal antibody.

35 Further provided are a composition comprising one of the above polypeptides and a carrier therefor, and a composition comprising an antagonist to one of the polypeptides and a carrier therefor. In one such embodiment, the invention provides a composition comprising a WISP-1, WISP-2, or WISP-3 polypeptide and a pharmaceutically acceptable carrier. Preferably, the polypeptide is a human polypeptide. Also, preferably, these compositions may also comprise a chemotherapeutic agent or growth-inhibitory agent.

In another aspect, the invention provides a pharmaceutical product comprising:

- (a) the composition comprising WISP-1, WISP-2, or WISP-3 polypeptide and a pharmaceutically acceptable carrier;
- (b) a container containing said composition; and
- 5 (c) a label affixed to said container, or a package insert included in said pharmaceutical product referring to the use of said WISP-1, WISP-2, or WISP-3 polypeptide in the treatment of a WISP-related disorder.

In yet another embodiment, the invention provides a method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of any of the above compositions, including the composition of a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier, and including the composition of an antagonist to a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier. Preferably, the disorder is a malignant disorder or arteriosclerosis. More preferably, the malignant disorder is breast cancer, ovarian cancer, colon cancer, or melanoma. Also, preferably the mammal is human. In another preferred embodiment, the WISP-1, WISP-2, or WISP-3 polypeptide is administered in combination with a chemotherapeutic agent, a growth inhibitory agent, or a cytotoxic agent.

In another embodiment, the invention supplies a process for diagnosing a disease or a susceptibility to a disease related to a mutation in a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

- 20 (a) isolating a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide from a sample derived from a host; and
- (b) determining a mutation in the nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide.

In another embodiment, the invention provides a method of diagnosing a WISP-related disorder in a mammal comprising detecting the level of expression of a gene encoding a WISP-1, WISP-2, or WISP-3 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample indicates the presence of a WISP-related dysfunction in the mammal from which the test tissue cells were obtained. Preferably, such a disorder is a type of cancer and a higher expression level in the test sample indicates the presence of a tumor in the mammal.

In a still further embodiment, the invention provides an isolated antibody binding a WISP-1, WISP-2, or WISP-3 polypeptide. Preferably, the antibody induces death of a cell overexpressing a WISP-1, WISP-2, or WISP-3 polypeptide, more preferably a cancer cell. Also preferred is an antibody that binds to a human WISP-1, WISP-2, or WISP-3 polypeptide, and is a human or humanized antibody. More preferred is a monoclonal antibody, still more preferred, a monoclonal antibody that has complementary-determining regions and constant immunoglobulin regions, and in other embodiments is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody. In addition, the antibody is suitably labeled with a detectable label or immobilized on a solid support.

Also provided is a composition comprising an antibody to a WISP-1, WISP-2, or WISP-3 polypeptide in admixture with a pharmaceutically acceptable carrier. Preferably, the antibody is to a human WISP-1, WISP-2, or WISP-3 polypeptide, and is a human or humanized antibody, most preferably a monoclonal antibody against human WISP-1. Further, the composition may comprise a growth-inhibitory amount of said antibody.

In another embodiment, the invention provides a method for treating cancer in a mammal comprising administering to the mammal an effective amount of the above antibody composition. In a preferred aspect of this method, the cancer is colon cancer, the antibody is against human WISP-1 and is a humanized or human monoclonal antibody, and the mammal is human.

In another aspect, the invention provides a method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of a composition comprising an antagonist to a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier.

In a further aspect, the invention provides a method for inhibiting the growth of tumor cells comprising exposing a cell that overexpresses a Wnt-1-induced gene to an effective amount of an antagonist that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.

A further aspect entails a method for inhibiting the growth of tumor cells comprising exposing said cells to an effective amount of the composition with the growth-inhibiting amount of an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody in admixture with the carrier. In a preferred aspect of this method, the tumor cells are colon cancer cells, the antibody is against human WISP-1 and is a humanized or human monoclonal antibody, and the mammal is human.

Also provided herein is a kit comprising one of the above WISP polypeptides or WISP antagonists, such as anti-WISP antibodies, and instructions for using the polypeptide or antagonist to detect or treat a WISP-related disorder, such as cancer induced by Wnt. One such preferred kit is a cancer diagnostic kit comprising an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and a carrier in suitable packaging. Preferably, this kit further comprises instructions for using said antibody to detect the WISP-1, WISP-2, or WISP-3 polypeptide.

Also provided is a method for inducing cell death comprising exposing a cell which is induced by Wnt to an effective amount of one of the above WISP polypeptides or WISP antagonists, such as anti-WISP antibodies. Preferably, such cell is a cancer cell. More preferably, the cell is in a mammal, more preferably a human. In addition, an effective amount of another chemotherapeutic antibody is used in the exposure of the cell, such as an anti-ErbB2 antibody. Further, optionally the method comprises exposing the cell to a chemotherapeutic agent, a growth-inhibitory agent, or radiation. Optionally, the cell is exposed to the growth-inhibitory agent prior to exposure to the antibody.

In a further aspect, the invention provides an article of manufacture, comprising:  
a container;

a label on the container; and

a composition comprising an active agent contained within the container; wherein the composition is effective for inducing cell death or inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overinduction of Wnt or a WISP-



related disorder or by overexpression of a WISP-1, WISP-2, or WISP-3 polypeptide, and the active agent in the composition is an antagonist to one of the polypeptides, that is, an agent that inhibits the expression and/or activity of the WISP-1, WISP-2, or WISP-3 polypeptide. Preferably, the active agent in such article of manufacture is an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody, and the label on the container indicates that the composition can be used for treating a WISP-related disorder.

In another embodiment, the invention provides a process for identifying agonists to a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

(a) contacting cells and a compound to be screened under conditions suitable for the stimulation of cell proliferation by the polypeptide; and

(b) measuring the proliferation of the cells to determine if the compound is an effective agonist.

Additionally, the invention provides an agonist to a WISP-1, WISP-2, or WISP-3 polypeptide identified by the above process.

Further, the invention provides a method for identifying a compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide, comprising contacting a candidate compound with a WISP-1, WISP-2, or WISP-3 polypeptide under conditions and for a time sufficient to allow the compound and polypeptide to interact. In a preferred embodiment, this method comprises the steps of:

(a) contacting cells and a compound to be screened in the presence of the WISP-1, WISP-2, or WISP-3 polypeptide under conditions suitable for the stimulation of cell proliferation by polypeptide; and

(b) measuring the proliferation of the cells to determine if the compound is an effective antagonist.

Further, a compound identified by this method is provided.

In another aspect, this invention provides a compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.

In another embodiment, the invention provides a method for determining the presence of a WISP-1, WISP-2, or WISP-3 polypeptide comprising exposing a cell suspected of containing the WISP-1, WISP-2, or WISP-3 polypeptide to an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and determining binding of said antibody to said cell.

In another preferred embodiment, the invention provides a method of diagnosing a WISP-related disorder in a mammal comprising (a) contacting an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and the WISP-1, WISP-2, or WISP-3 polypeptide in the test sample. Preferably, said test sample is obtained from an individual suspected to have neoplastic cell growth or proliferation. Also, preferably the antibody is labeled with a detectable label and/or is immobilized on a solid support.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the derived amino acid sequence of a native-sequence mouse WISP-1 protein from amino acids 1 to 367 (SEQ ID NO:12) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:9 and 10, respectively). There is a 1104-bp coding region and 584 bp of 3' untranslated region. In the Figure, amino acids 1 through 22 form a putative signal sequence, amino acids 23 through 367 are the putative mature protein (SEQ ID NO:11), with amino acids 86 to 88, 143 to 145, 284

to 286, and 343 to 345 being potential glycosylation sites. Potential protein kinase C phosphorylation sites are at amino acids 43-45, 159-161, 235-237, 292-294, 295-297, and 345-347. Potential casein kinase II phosphorylation sites are at amino acids 44-47, 131-134, 145-148, and 358-361. Potential N-myristoylation sites are at amino acids 18-23, 72-77, 127-132, 149-154, 231-236, and 289-294. A potential amidation site is at amino acids 269-272. A potential prokaryotic membrane lipoprotein lipid attachment site is at amino acids 113-123. A potential von Willebrand C1 domain is at amino acids 130-146. A potential thrombospondin I domain is at amino acids 223-237. A potential CT module is at amino acids 301-312. A potential IGF binding protein consensus site is at amino acids 72-80.

Figure 2 shows the derived amino acid sequence of a native-sequence mouse WISP-2 protein from amino acids 1 to 251 (SEQ ID NO:20) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:17 and 18, respectively) from a clone 1367.3. There are 756 bp of coding nucleotides and 722 bp of 3' untranslated region. In the Figure, amino acids 1 through 23 form a putative signal sequence; amino acids 24 through 251 are the putative mature protein (SEQ ID NO:19). A potential N-glycosylation site is at amino acids 197-200. A potential glycosaminoglycan attachment site is at amino acids 85-88. Potential protein kinase C phosphorylation sites are at amino acids 85-87 and 112-114. Potential N-myristoylation sites are at amino acids 49-54, 81-86, 126-131, 210-215, and 245-250. A potential amidation site is at amino acids 103-106. A potential phospholipase A2 aspartic acid active site is at amino acids 120-130. A potential IGF binding protein consensus signature is at amino acids 49-64. A potential von Willebrand C1 domain is at amino acids 107-123. A potential thrombospondin I domain is at amino acids 202-216. A potential IGF binding protein consensus site is at amino acids 49-57.

Figures 3A and 3B show the derived amino acid sequence of a native-sequence human WISP-1 protein from amino acids 1 to 367 (SEQ ID NO:4) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:1 and 2, respectively). There are 1104 bp of coding region in this human clone 568.38, and 1638 bp of 3' untranslated region. In the Figure, amino acids 1 through 22 form a putative signal sequence; amino acids 23 through 367 are the putative mature protein (SEQ ID NO:3), with amino acids 85 to 87, 143 to 145, 284 to 286, and 343 to 345 being potential glycosylation sites. A potential cAMP- and cGMP-dependent protein kinase phosphorylation site is from amino acids 171 to 174; potential protein kinase C phosphorylation sites are at amino acids 43-45, 235-237, 292-294, and 345-347. Potential casein kinase II phosphorylation sites are at amino acids 30-33, 145-148, and 358-361. Potential N-myristoylation sites are at amino acids 72-77, 127-132, 149-154, 201-206, 231-236, 289-294, and 327-332. A potential amidation site is at amino acids 269-272. A potential prokaryotic membrane lipoprotein lipid attachment site is at amino acids 113-123. A potential von Willebrand C1 domain is at amino acids 130-146. A potential thrombospondin I domain is at amino acids 223-237. A potential CT (C-Terminal) module is at amino acids 301-312. A potential IGF binding protein consensus site is at amino acids 72-80.

Figure 4 shows the derived amino acid sequence of a native-sequence human WISP-2 protein from amino acids 1 to 250 (SEQ ID NO:16) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:13 and 14, respectively). The coding region is 753 bp and the 3' untranslated region is 519 bp. The putative signal sequence is from amino acid residues 1 through 23 and the putative mature region is from 24 through 250 (SEQ ID NO:15). The clone designated herein as "UNQ228" and/or



"DNA33473-seqmin" (SEQ ID NO:38) begins at nucleotide 13 of SEQ ID NO:13. Potential protein kinase C phosphorylation sites are at amino acids 4-6, 118-120, and 227-229. A potential casein kinase II phosphorylation site is at amino acids 98-101. A potential N-myristoylation site is at amino acids 3-8, 49-54, 81-86, 85-90, 126-131, 164-169, 166-171, 167-172, 183-188, and 209-214. A potential IGF binding protein consensus signature is at amino acids 49-64. A potential von Willebrand C1 domain is at amino acids 107-123. A potential thrombospondin 1 domain is at amino acids 201-215. A potential IGF binding protein consensus site is at amino acids 49-57.

Figure 5 shows a 841-bp consensus nucleotide sequence designated "DNA30843" (SEQ ID NO:39) derived from the nucleotide sequences of twenty different expressed sequence tags from Incyte. When aligned with the other sequences, DNA30843 has 3 gaps. It has 441 bp orf (+1). DNA30843 was used to design probes for isolation of human WISP-2.

Figures 6A and 6B show the derived amino acid sequence of a native-sequence human WISP-3 protein from amino acids 1 to 372 (SEQ ID NO:33) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:30 and 31, respectively). In the Figure, amino acids 1 through 33 form a putative signal sequence, amino acids 34 through 372 are the putative mature protein (SEQ ID NO:32), with amino acids 196 to 198 and 326 to 328 being potential glycosylation sites. Potential protein kinase C phosphorylation sites are at amino acids 209-211, 246-248, 277-279, 308-310, and 342-344. Potential casein kinase II phosphorylation sites are at amino acids 47-50, 254-257, and 293-296. Potential N-myristoylation sites are at amino acids 21-26, 89-94, 139-144, 166-171, 180-185, 185-190, 188-193, 242-247, and 302-307. A potential amidation site is at amino acids 188-191. Potential prokaryotic membrane lipoprotein lipid attachment sites are at amino acids 130-140 and 160-170. A potential IGF binding protein signature site is at amino acids 89-104. A potential IGF binding protein site (less stringent than prosite's) is at amino acids 89-97.

Figures 7A and 7B show the derived amino acid sequence of a native-sequence human WISP-3 protein from amino acids 1 to 355 (SEQ ID NO:37) and the nucleotide sequence (and complementary sequence) encoding the protein (SEQ ID NOS:34 and 35, respectively). This protein is believed to be a splice variant of the nucleotide sequence shown in Figure 6 with a shorter 5' end. In the Figure, amino acids 1 through 15 form a putative signal sequence, amino acids 16 through 355 are the putative mature protein (SEQ ID NO:36), with amino acids 178 to 180 and 308 to 310 being potential glycosylation sites. Potential protein kinase C phosphorylation sites are at amino acids 191-193, 228-230, 259-261, 290-292, and 324-326. Potential casein kinase II phosphorylation sites are at amino acids 29-32, 236-239, and 275-278. Potential N-myristoylation sites are at amino acids 3-8, 71-76, 121-126, 148-153, 162-167, 167-172, 170-175, 224-229, and 284-289. A potential amidation site is at amino acids 170-173. Potential prokaryotic membrane lipoprotein lipid attachment sites are at amino acids 112-122 and 142-152. A potential IGF binding protein signature site is at amino acids 71-87. A potential IGF binding protein site (less stringent than prosite's) is at amino acids 71-79.

Figure 8 shows an alignment of the full-length amino acid sequences of the human and mouse WISP-1 (SEQ ID NOS:4 and 12, respectively).

Figure 9 shows an alignment of the full-length amino acid sequences of the human and mouse WISP-2 (SEQ ID NOS: 16 and 20, respectively).

Figure 10 shows an alignment of the amino acid sequences of the two clones of human WISP-3.

Figures 11A-11C show an alignment of the nucleotide sequences of human WISP-1 and the human WISP-3 shown in Fig. 6.

Figure 12 shows an alignment of the amino acid sequences of human WISP-1 and the human WISP-3 shown in Fig. 6.

Figure 13 shows a map of the vector pBabe puro (5.1 kb) used to transform cells for purposes of differential expression. The vector includes both unique restriction sites and multiple restriction sites. It is shown here in modified form for Wnt-1 cloning wherein the *HindIII* site after the SV40 promoter in the original pBabe puro vector has been removed and a *HindIII* site added to the multiple cloning site of the original pBabe puro vector. Wnt-1 is cloned from *EcoRI-HindIII* in the multiple cloning site. Constructs derived from this vector are selected in ampicillin (100 µg/ml) and the cells infected in culture are selected in 1.0-2.5 µg/ml puromycin.

Figure 14 shows the sequences of the PCR-Select® cDNA synthesis primer (SEQ ID NO:40), adaptors 1 and 2 (SEQ ID NOS:41 and 42, respectively) and complementary sequences for the adaptors (SEQ ID NOS:43 and 44, respectively), PCR primer 1 (SEQ ID NO:45), PCR primer 2 (SEQ ID NO:46), nested PCR primer 1 (SEQ ID NO:47), nested PCR primer 2 (SEQ ID NO:48), control primer G3PDH 5' primer (SEQ ID NO:49), and control primer G3PDH 3' primer (SEQ ID NO:50) used for suppression subtractive hybridization for identifying WISP clones. When the adaptors are ligated to *RsaI*-digested cDNA, the *RsaI* site is restored.

Figure 15 shows the cloning site region of the plasmid pGEM-T used to clone all of the WISP sequences herein (SEQ ID NOS:51 and 52 for 5' and 3' sequences, respectively).

Figures 16A-16D show the sequence (SEQ ID NO:53) of a plasmid that is used to prepare an expression plasmid for expression of mouse WISP-1 in mammalian cells, the latter being designated pRK5.CMV.puro-dhfr.mWISP-1.6His.

Figures 17A-17D show the sequence (SEQ ID NO:54) of plasmid pb.PH.IgG, which is used to prepare an expression plasmid for expression of mouse WISP-1 DNA in baculovirus-infected insect cells.

Figures 18A-18D show the sequence (SEQ ID NO:55) of plasmid pbPH.His.c, which is used to prepare an expression plasmid for expression of mouse WISP-1 DNA in baculovirus-infected insect cells, the latter being designated pbPH.mu.568.8his.baculo.

Figures 19A-19D show graphs of the delta CT in nine colon cancer cell lines and DNA from the blood of ten normal human donors (Nor Hu) as control, for human TNF, human WISP-1, Lyra, and human Apo2 ligand, respectively, using the ABI Prism 7700™ Sequence Detection System procedure for testing genomic amplification.

Figures 20A-20D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for human DCR1, huFAS, human WISP-2, and Apo3, respectively, using the ABI Prism 7700™ Sequence Detection System procedure for testing genomic amplification.

Figures 21A-21D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for three different runs of human WISP-1 (designated in the figure as huWISP-1c, -1b, and -1a) and the average of these three runs of human WISP-1, respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

Figures 22A-22D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for three different runs of human WISP-2 (designated in the figure as huWISP-2c, -2b, and -2a; Figs. 22A, C, and D, respectively) and the average of these three runs of human WISP-2 (Fig. 22B), using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

Figures 23A-23C show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for two different runs of human DR5 (DR5a and DR5b) and the average of these two runs of DR5, respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

Figures 24A-24D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for four different runs of *c-myc* (*c-myc*(a1), *c-myc*(b1), *c-myc*(b), and *c-myc*(a)), respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

Figures 25A-25D show graphs of the delta CT in nine colon cancer cell lines and Nor Hu as control, for two different runs of human WISP-1 (designated in the figure as huWISP-1(a) and huWISP-1(b)) and for two different runs of human WISP-2 (designated in the figure as huWISP-2(a) and huWISP-2(b)), respectively, using the ABI Prism 7700<sup>TM</sup> Sequence Detection System procedure for testing genomic amplification.

Figure 26 shows the sequence (SEQ ID NO:23) of clone 568.13, a potential splice variant of human WISP-1 obtained by screening with a probe derived from clone 568.15A, which is the initial clone isolated from a human lung library in the process to obtain full-length human WISP-1 DNA.

Figure 27 shows the sequence (SEQ ID NO:24) of clone 568.1A, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

Figure 28 shows the sequence (SEQ ID NO:25) of clone 568.39, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

Figure 29 shows the sequence (SEQ ID NO:26) of clone 568.4A, a potential human WISP-1 splice variant obtained by screening with a probe derived from clone 568.15A.

Figure 30 shows the sequence (SEQ ID NO:27) of clone 568.5A, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

Figure 31 shows the sequence (SEQ ID NO:28) of clone 568.6B, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

Figure 32 shows the sequence (SEQ ID NO:29) of clone 568.7, a potential human WISP-1 splice variant, 5' end only, obtained by screening with a probe derived from clone 568.15A.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTSI. Definitions

The term "WISP polypeptide" refers to the family of native- sequence human and mouse WISP proteins and variants described herein whose genes are induced at least by Wnt-1. This term includes WISP-1, WISP-2, and WISP-3.

The terms "WISP-1 polypeptide", "WISP-1 homologue" and grammatical variants thereof, as used herein, encompass native- sequence WISP-1 protein and variants (which are further defined herein). The WISP-1 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

The terms "WISP-2 polypeptide", "WISP-2 homologue", "PRO261", and "PRO261 polypeptide" and grammatical variants thereof, as used herein, encompass native-sequence WISP-2 protein and variants (which are further defined herein). The WISP-2 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

The terms "WISP-3 polypeptide", "WISP-3 homologue", and grammatical variants thereof, as used herein, encompass native-sequence WISP-3 protein and variants (which are further defined herein). The WISP-3 polypeptide may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

A "native-sequence WISP-1 polypeptide" comprises a polypeptide having the same amino acid sequence as a WISP-1 polypeptide derived from nature. Such native-sequence WISP-1 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence WISP-1 polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a WISP-1 polypeptide disclosed herein, naturally occurring variant forms (*e.g.*, alternatively spliced forms or splice variants), and naturally occurring allelic variants of a WISP-1 polypeptide. In one embodiment of the invention, the native-sequence WISP-1 polypeptide is a mature or full-length native-sequence human WISP-1 polypeptide comprising amino acids 23 to 267 of Figures 3A and 3B (SEQ ID NO:3) or amino acids 1 to 267 of Figures 3A and 3B (SEQ ID NO:4), respectively, with or without the N-terminal methionine.

In another embodiment of the invention, the native-sequence WISP-1 polypeptide is the full-length or mature native-sequence human WISP-1 polypeptide comprising amino acids 23 to 267 or 1 to 267 of Figures 3A and 3B wherein the valine residue at position 184 or the alanine residue at position 202 has/have been changed to an isoleucine or serine residue, respectively, (SEQ ID NOS:5-8) with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-1 polypeptide is the full-length or mature native-sequence human WISP-1 polypeptide comprising amino acids 23 to 267 or 1 to 267 of Figures 3A and 3B wherein the valine residue at position 184 and the alanine residue at position 202 has/have been changed to an isoleucine or serine residue, respectively, (SEQ ID NOS:21 and 22, respectively) with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-1 polypeptide is a mature or full-length native-sequence mouse WISP-1 polypeptide

comprising amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or amino acids 1 to 367 of Figure 1 (SEQ ID NO:12), respectively, with or without the N-terminal methionine.

In another embodiment of the invention, the native-sequence WISP-1 polypeptide is one which is encoded by a nucleotide sequence comprising one of the human WISP-1 splice or other native-sequence variants, including SEQ ID NOS:23, 24, 25, 26, 27, 28, or 29, with or without an N-terminal methionine.

A "native-sequence WISP-2 polypeptide" or a "native-sequence PRO261 polypeptide" comprises a polypeptide having the same amino acid sequence as a WISP-2 polypeptide derived from nature. Such native-sequence WISP-2 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence WISP-2 polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a WISP-2 polypeptide disclosed herein, naturally occurring variant forms (*e.g.*, alternatively spliced forms or splice variants), and naturally occurring allelic variants of a WISP-2 polypeptide. In one embodiment of the invention, the native-sequence WISP-2 polypeptide is a mature or full-length native-sequence human WISP-2 polypeptide comprising amino acids 1-24 up to 250 of Figure 4 (SEQ ID NOS:15, 16, and 56-77), including amino acids 24 to 250 and amino acids 1 to 250 of Figure 4 (SEQ ID NOS:15 and 16, respectively), with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-2 polypeptide is a mature or full-length native-sequence mouse WISP-2 polypeptide comprising amino acids 1-24 up to 251 of Figure 2 (SEQ ID NOS:19, 20, and 78-99), including amino acids 24 to 251 and amino acids 1 to 251 of Figure 2 (SEQ ID NOS:19 and 20, respectively), with or without the N-terminal methionine.

A "native-sequence WISP-3 polypeptide" comprises a polypeptide having the same amino acid sequence as a WISP-3 polypeptide derived from nature. Such native-sequence WISP-3 polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native-sequence WISP-3 polypeptide" specifically encompasses naturally occurring truncated or other forms of a WISP-3 polypeptide disclosed herein, naturally occurring variant forms (*e.g.*, alternatively spliced forms or splice variants), and naturally occurring allelic variants of a WISP-3 polypeptide. In one embodiment of the invention, the native-sequence WISP-3 polypeptide is a mature or full-length, native-sequence human WISP-3 polypeptide comprising amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32) or amino acids 1 to 372 of Figures 6A and 6B (SEQ ID NO:33), respectively, with or without the N-terminal methionine. In another embodiment of the invention, the native-sequence WISP-3 polypeptide is a mature or full-length, native-sequence human WISP-3 polypeptide comprising amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36) or amino acids 1 to 355 of Figures 7A and 7B (SEQ ID NO:37), respectively, with or without the N-terminal methionine.

The term "WISP-1 variant" means an active WISP-1 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human mature WISP-1 having the deduced amino acid sequence shown in Figs. 3A and 3B (SEQ ID NO:3), and/or with human full-length WISP-1 having the deduced amino acid sequence shown in Figs. 3A and 3B (SEQ ID NO:4), and/or with mouse mature WISP-1 having the deduced amino acid sequence shown in Fig. 1 (SEQ ID NO:11), and/or with mouse full-length WISP-2 having the deduced amino acid sequence shown in Fig. 1 (SEQ ID NO:12). Such variants include, for



instance, WISP-1 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of Figures 3A-3B and 1 (SEQ ID NOS:4, 3, 12, and 11, respectively), including variants from other species, but excludes a native-sequence WISP-1 polypeptide.

The term "WISP-2 variant" or "PRO261 variant" means an active WISP-2 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human mature WISP-2 having the putative deduced amino acid sequence shown in Fig. 4 (SEQ ID NO:15), and/or with human full-length WISP-2 having the deduced amino acid sequence shown in Fig. 4 (SEQ ID NO:16), and/or with mouse mature WISP-2 having the putative deduced amino acid sequence shown in Fig. 2 (SEQ ID NO:19), and/or with mouse full-length WISP-2 having the deduced amino acid sequence shown in Fig. 2 (SEQ ID NO:20). Such variants include, for instance, WISP-2 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length and putative mature sequences of Figures 4 and 2 (SEQ ID NOS:16, 15, 20, and 19, respectively), including variants from other species, but excludes a native-sequence WISP-2 polypeptide.

The term "WISP-3 variant" means an active WISP-3 polypeptide as defined below having at least about 80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with human mature WISP-3 having the deduced amino acid sequence shown in Figs. 6A and 6B (SEQ ID NO:32), and/or with human full-length WISP-3 having the deduced amino acid sequence shown in Figs. 6A and 6B (SEQ ID NO:33), and/or with human mature WISP-3 having the deduced amino acid sequence shown in Figs. 7A and 7B (SEQ ID NO:36), or with human full-length WISP-3 having the deduced amino acid sequence shown in Figs. 7A and 7B (SEQ ID NO:37). Such variants include, for instance, WISP-3 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of Figures 6A-6B and 7A-7B (SEQ ID NOS:32, 33, 36, and 37, respectively), including variants from other species, but excludes a native-sequence WISP-3 polypeptide.

"Percent (%) amino acid sequence identity" with respect to the WISP sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a WISP polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR<sup>TM</sup>) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

"Percent (%) nucleic acid sequence identity" with respect to the coding region of the WISP sequences identified herein, including UNQ228 (DNA34387-seq min) sequence, and the coding region therein, is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the coding region of the WISP sequence of interest, e.g., in the UNQ228 (DNA34387-seq min) sequence (SEQ ID NO:38) or coding region therein (SEQ ID NO:16), after aligning the sequences and

introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS; or (4) employ a buffer of 10% dextran sulfate, 2 x SSC (sodium chloride/sodium citrate), and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" are described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), and include the use of a washing solution and hybridization conditions (*e.g.*, temperature, ionic strength, and percent SDS) less stringent than described above. An example of moderately stringent conditions is a condition such as overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, *etc.*, as necessary to accommodate factors such as probe length and the like.

"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the WISP natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" nucleic acid encoding a WISP polypeptide or "isolated" DNA33473 or "isolated" PRO261 polypeptide-encoding nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the respective nucleic acid. Isolated DNA33473 or an isolated WISP-encoding nucleic acid



molecule is other than in the form or setting in which it is found in nature. An isolated WISP-encoding or DNA33473 nucleic acid molecule therefore is distinguished from the WISP-encoding or DNA33473 nucleic acid molecule, respectively, as it exists in natural cells. However, an isolated WISP-encoding or DNA33473 nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express WISP-encoding DNA or DNA33473, respectively, where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "antibody" is used in the broadest sense and specifically covers single anti-WISP polypeptide, such as anti-PRO261, monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), and anti-WISP polypeptide, such as anti-PRO261, and antibody compositions with polypeptidic specificity. The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.

"Active" or "activity" or "WISP biological activity", for purposes herein, describes form(s) of a WISP polypeptide, such as PRO261, including its variants, or its antagonists, which retain the biologic and/or immunologic activities of a native or naturally occurring (native-sequence) WISP polypeptide, such as PRO261, or its antagonist. Preferred "activities" for a WISP polypeptide or its antagonist include the ability to inhibit proliferation of tumor cells or to stimulate proliferation of normal cells and to treat arteriosclerosis, including atherosclerosis, as well as to induce wound repair and hematopoiesis, prevent desmoplasia, prevent fibrotic lesions associated with skin disorders such as scleroderma, keloid, eosinophilic fasciitis, nodular fasciitis, and Dupuytren's contracture, to treat bone-related diseases such as osteoporosis, to regulate anabolism including promotion of growth, to treat immune disorders, to treat Wilms' tumor and kidney-related disorders, to treat testis-related disorders, to treat lung-related disorders, and to treat cardiac disorders.

An "antagonist" of a WISP polypeptide is a molecule that inhibits an activity of a WISP polypeptide. Preferred antagonists are those which interfere with or block an undesirable biological activity of a WISP polypeptide, such as where a WISP polypeptide might act to stimulate cancer cells and the antagonist would serve to inhibit the growth of those cells. In some cases, such as with WISP-1, WISP-2, and WISP-3, the

antagonist may be useful to inhibit the binding of a WISP polypeptide to an IGF. Such molecules include antibodies and small molecules that have such inhibitory capability, as well as WISP polypeptide variants or and receptors for WISP polypeptide (if available) or portions thereof that bind to WISP. For example, antagonists can be derived from receptors of WISP-1, WISP-2, and WISP-3 using the predicted family of  
 5 receptors for WISPs-1, -2, and -3 (the CTGF receptors). Thus, the receptor can be expression cloned from the family; then a soluble form of the receptor is made by identifying the extracellular domain and excising the transmembrane domain therefrom. The soluble form of the receptor can then be used as an antagonist, or the receptor can be used to screen for small molecules that would antagonize WISP polypeptide activity.

Alternatively, using the murine sequences shown in Figures 1 and 2 (SEQ ID NOS: 11, 12, 19, and  
 10 20, respectively) or the human sequences shown in Figures 3A-3B, 4, (SEQ ID NOS: 3, 4, 15, and 16, respectively), 6A-6B, and 7A-7B, variants of native WISP-1, WISP-2, or WISP-3, are made that act as antagonists. Using knowledge from the CTGF receptor family, the receptor binding sites of WISP-1, WISP-2, and WISP-3 polypeptides can be determined by binding studies and one of them eliminated by standard techniques (deletion or radical substitution) so that the molecule acts as an antagonist.

Antagonist activity can be determined by several means, including standard assays for induction of  
 15 cell death such as that described herein, *e.g.*,  $^3\text{H}$ -thymidine proliferation assays, or other mitogenic assays, such as an assay measuring the capability of the candidate antagonist of inducing EGF-potentiated anchorage independent growth of target cell lines (Volckaert *et al.*, Gene, 15:215-223 (1981)) and/or growth inhibition of neoplastic cell lines. Roberts *et al.*, Proc. Natl. Acad. Sci. USA, 82:119-123 (1985). Anchorage-  
 20 independent growth refers to the ability of WISP polypeptide-treated, or TGF- $\beta$ -treated and EGF-treated non-neoplastic target cells to form colonies in soft agar, a characteristic ascribed to transformation of the cells. In this assay, the candidate is incubated together with an equimolar amount of a WISP polypeptide otherwise detectable in the EGF-potentiated anchorage-independent target cell growth assay, and the culture observed for failure to induce anchorage-independent growth. In addition, an antagonist may be an IGF such as IGF-I  
 25 or a peptide mimic of IGF-I or a receptor to IGF or a receptor to an IGFBP.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder or condition as well as those in which the disorder or condition is to be prevented.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans,  
 30 domestic, and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, cows, *etc.* Preferably, the mammal is human.

A "disorder" or "WISP-related disorder" is any condition that would benefit from treatment with the WISP polypeptides or WISP antagonists herein. This includes chronic and acute disorders, as well as those pathological conditions which predispose the mammal to the disorder in question. Non-limiting examples  
 35 of disorders to be treated herein include benign and malignant tumors; leukemias and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal, and blastocoelic disorders; hematopoiesis-related disorders; tissue-growth disorders; skin disorders; desmoplasia; fibrotic lesions; kidney disorders; bone-related disorders; trauma such as burns, incisions, and other wounds; catabolic states; testicular-related disorders; and inflammatory, angiogenic, and immunologic disorders.

including arteriosclerosis. A "Wnt-related disorder" is one caused at least by the upregulation of the Wnt gene pathway, including Wnt-1 and Wnt-4, but preferably Wnt-1, and may include cancer.

The terms "cancer", "cancerous", and "malignant" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma including adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer. The preferred cancers for treatment herein are breast, colon, lung, and melanoma.

The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g.,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ ), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof.

A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytosin, Taxol, Etoposide, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan, and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors, such as tamoxifen and onapristone.

A "growth-inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, such as an Wnt-overexpressing cancer cell, either *in vitro* or *in vivo*. Thus, the growth-inhibitory agent is one which significantly reduces the percentage of malignant cells in S phase. Examples of growth-inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13. The 4D5 antibody (and functional equivalents thereof) can also be employed for this purpose if the cancer involves ErbB2-overexpressing cancer cells. See, e.g., WO 92/22653.

"Northern analysis" or "Northern blot" is a method used to identify RNA sequences that hybridize to a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment thereof, or RNA fragment.

The probe is labeled with a radioisotope such as  $^{32}\text{P}$ , or by biotinylation, or with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe, using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook *et al.*, *supra*.

5 The technique of "polymerase chain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Pat. No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The  
10 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, *etc.* See generally Mullis *et al.*, Cold Spring Harbor Symp. Quant. Biol., 51: 263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polymerase  
15 reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

## II. Compositions and Methods of the Invention

### A. Full-length WISP Polypeptide

The present invention provides newly-identified and isolated nucleotide sequences encoding a  
20 polypeptide referred to in the present application as a WISP polypeptide, including a WISP-1, WISP-2, or WISP-3 polypeptide. In particular, cDNAs have been identified and isolated encoding novel murine and human WISP-1 and WISP-2, and human WISP-3 splice variants as disclosed in further detail in the Examples below.

Using BLAST and FastA sequence alignment computer programs, it was found that the coding  
25 sequences of mouse and human WISP-1 and -2, as well as the two coding sequences of human WISP-3 disclosed herein, show significant homology to DNA sequences disclosed in the GenBank database, including those published by Adams *et al.*, Nature, 377: 3-174 (1995).

Further, using BLAST and FastA sequence alignment computer programs, it was found that various  
30 portions of the coding sequences of mouse and human WISP-1 and WISP-2 show significant homology to CTGF, cef-10, Cyr61, and/or Nov protein. In this regard, mouse WISP-1 is 47% homologous to mouse CTGF and 46% homologous to human CTGF, mouse WISP-2 is 46% homologous to chick cef-10 protein precursor and 42% homologous to human Cyr61 protein, human WISP-1 is 47% homologous to mouse CTGF and 48% homologous to human CTGF, and human WISP-2 is 48% homologous to mouse CTGF, 49% homologous to human CTGF precursor, 46% homologous to mouse Nov protein homolog precursor, 49%  
35 homologous to human CTGF, and 48% homologous to mouse CTGF precursor. Further, apparently the amino acid sequences of mouse WISP-1 and mouse ELM1 (Hashimoto *et al.*, *supra*) are identical, and the amino acid sequences of human WISP-1 and mouse ELM1 are 84% identical.

Since these factors have also been correlated with IGFBPs, it is presently believed that the WISP-1 and WISP-2 polypeptides disclosed in the present application are newly identified members of the CTGF or



IGFBP family and possess activity relating to development of normal, injured, and cancerous cells and tissue. More specifically, WISP-1 and WISP-2 may be involved in breast cancer, lung cancer, melanoma, and colon cancer, as well as in wound repair. Further, they may be involved in atherosclerosis.

Further, using BLAST and FastA sequence alignment computer programs, it was found that various portions of the coding sequences of the two splice variants of human WISP-3 show significant homology to mouse ELM1 and CTGF proteins. In this regard, both splice variants of WISP-3 are 45% homologous to mouse ELM1 and 42% homologous to mouse and human CTGF and its precursor, with the longer variant of Fig. 6 being 43% homologous to *Xenopus* CTGF and the shorter variant of Fig. 7 being 42% homologous to *Xenopus* CTGF.

#### 10 B. WISP Polypeptide Variants

In addition to the full-length native-sequence WISP polypeptides described herein, it is contemplated that variants of these sequences can be prepared. WISP variants can be prepared by introducing appropriate nucleotide changes into the WISP-encoding DNA, or by synthesis of the desired variant WISP polypeptides. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the WISP polypeptide, such as changing the number or position of glycosylation sites or altering the membrane-anchoring characteristics, if the native WISP polypeptide is membrane bound.

Variations in the native full-length WISP sequences, or in various domains of the WISP polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion, or insertion of one or more codons encoding the WISP polypeptide that results in a change in the amino acid sequence as compared with the native-sequence WISP polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in any portion of the WISP polypeptide. Guidance in determining which amino acid residue may be inserted, substituted, or deleted without adversely affecting the desired activity may be found by comparing the sequence of the WISP polypeptide with that of homologous known CTGF protein molecules, in the case of WISP-1, WISP-2, and WISP-3, and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, *i.e.*, conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to about 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions, or substitutions of amino acids in the sequence and testing the resulting variants for activity in *in vitro* assays for gene upregulation or downregulation and in transgenic or knockout animals.

The variations can be made on the cloned DNA to produce the WISP DNA or WISP polypeptide variant DNA using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis (Carter *et al.*, Nucl. Acids Res., 13:4331 (1986); Zoller *et al.*, Nucl. Acids Res., 10:6487 (1987)), cassette mutagenesis (Wells *et al.*, Gene, 34:315 (1985)), alanine scanning, PCR mutagenesis, restriction selection mutagenesis (Wells *et al.*, Philos. Trans. R. Soc. London Ser. A, 317:415 (1986)), or other known techniques.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids.

Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions. T.E. Creighton, *Proteins: Structure and Molecular Properties* (W.H. Freeman & Co., San Francisco, 1983); Chothia, *J. Mol. Biol.*, 150:1 (1976). If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

Further deletional variants of the full-length WISP polypeptide include variants from which the N-terminal signal peptide, if any (such as, for example, those putatively identified as amino acids 1 to 22 for WISP-1, 1 to 23 for WISP-2, 1-33 for the WISP-3 of Fig. 6 and 1-15 for the WISP-3 of Fig. 7), and/or the initiating methionine has been deleted.

#### C. Modifications of the WISP Polypeptide

Covalent modifications of the WISP polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a WISP polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues. Derivatization with bifunctional agents is useful, for instance, for crosslinking a WISP polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-WISP antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidylesters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)-dithio)propioimide.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively; hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains (Creighton, *supra*, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. Another type of covalent modification of the WISP polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in the native sequence (either by deleting the underlying glycosylation site or by removing the glycosylation moieties by chemical and/or enzymatic means) and/or adding one or more glycosylation sites that are not present in the native sequence. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportion of the various sugar residues present.

Addition of glycosylation sites to the WISP polypeptide herein may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence (for O-linked glycosylation sites). The amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA

encoding the WISP polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above.

Another means of increasing the number of carbohydrate moieties on the WISP polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the WISP polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, *et al.*, Arch. Biochem. Biophys., 259:52 (1987) and by Edge *et al.*, Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura *et al.*, Meth. Enzymol., 138:350 (1987).

Another type of covalent modification comprises linking the WISP polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth, e.g., in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The WISP polypeptide of the present invention may also be modified in a way to form a chimeric molecule comprising a WISP polypeptide, or a fragment thereof, fused to a heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of the WISP polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of a native or variant WISP molecule. The presence of such epitope-tagged forms can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the WISP polypeptides to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of the WISP polypeptides, or fragments thereof, with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an Ig, such as an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-His) or poly-histidine-glycine (poly-His-Gly) tags; the flu HA tag polypeptide and its antibody 12CA5 (Field *et al.*, Mol. Cell. Biol., 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan *et al.*, Molecular and Cellular Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody. Paborsky *et al.*, Protein Engineering, 3(6):547-553 (1990). Other tag polypeptides include the Flag-peptide (Hopp *et al.*, BioTechnology, 6:1204-1210 (1988)); the KT3 epitope peptide (Martin *et al.*, Science, 255:192-194 (1992)); an  $\alpha$ -tubulin epitope peptide (Skinner *et al.*, J. Biol. Chem., 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag. Lutz-Freyermuth *et al.*, Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990).

#### D. Preparation of WISP Polypeptide

The description below relates primarily to production of WISP polypeptides by culturing cells transformed or transfected with a vector containing at least DNA encoding the mature or full-length sequences



of human or mouse WISP-1 (SEQ ID NOS:3, 4, 11, or 12, respectively), or containing at least DNA encoding the mature or full-length sequences of human or mouse WISP-2 (SEQ ID NOS:15, 16, 19, or 20, respectively), or containing at least DNA encoding the mature or full-length sequences of human WISP-3 of Fig. 6 (SEQ ID NOS:32 or 33, respectively), or containing at least DNA encoding the mature or full-length sequences of human WISP-3 of Fig. 7 (SEQ ID NOS:36 or 37, respectively).

It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare WISP polypeptides. For instance, the WISP polypeptide sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques. See, e.g., Stewart *et al.*, Solid-Phase Peptide Synthesis (W.H. Freeman Co.: San Francisco, CA, 1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963). *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems peptide synthesizer (Foster City, CA) in accordance with manufacturer's instructions. Various portions of WISP polypeptides may be chemically synthesized separately and combined using chemical or enzymatic methods to produce a full-length WISP polypeptide.

#### 1. Isolation of DNA Encoding WISP Polypeptide

DNA encoding a WISP polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the mRNA for WISP polypeptide and to express it at a detectable level. Accordingly, DNA encoding human WISP polypeptide can be conveniently obtained from a cDNA library prepared from human tissue, such as a human fetal liver library or as otherwise described in the Examples. The gene encoding WISP polypeptide may also be obtained from a genomic library or by oligonucleotide synthesis.

A still alternative method of cloning WISP polypeptide is suppressive subtractive hybridization, which is a method for generating differentially regulated or tissue-specific cDNA probes and libraries. This is described, for example, in Diatchenko *et al.*, Proc. Natl. Acad. Sci. USA, 93: 6025-6030 (1996). The procedure is based primarily on a technique called suppression PCR and combines normalization and subtraction in a single procedure. The normalization step equalizes the abundance of cDNAs within the target population and the subtraction step excludes the common sequences between the target and driver populations.

Libraries can be screened with probes (such as antibodies to a WISP polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook *et al.*, *supra*. An alternative means to isolate the gene encoding WISP polypeptide is to use PCR methodology. Sambrook *et al.*, *supra*; Dieffenbach *et al.*, PCR Primer: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1995).

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like <sup>32</sup>P-labeled ATP, biotinylation, or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook *et al.*, *supra*.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as ALIGN, DNASTar, and INHERIT which employ various algorithms to measure homology.

Nucleic acid having polypeptide-coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequences disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook *et al.*, *supra*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for WISP polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook *et al.*, *supra*.

Methods of transfection are known to the ordinarily skilled artisan, for example,  $\text{CaPO}_4$  and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook *et al.*, *supra*, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, Gene, **23**:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb Virology, **52**:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, J. Bact., **130**:946 (1977) and Hsiao *et al.*, Proc. Natl. Acad. Sci. (USA), **76**:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, *e.g.*, polybrene or polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown *et al.*, Methods in Enzymology, **185**:527-537 (1990) and Mansour *et al.*, Nature, **336**:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, *Enterobacteriaceae* such as *Escherichia*, *e.g.*, *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, *e.g.*, *Salmonella typhimurium*, *Serratia*, *e.g.*, *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (*e.g.*, *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325); and K5 772 (ATCC 53,635). These examples

are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA pir3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA pir3 phoA E15 (argF-luc)169 degP ompT karf*; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA pir3 phoA E15 (argF-luc)169 degP ompT rhs7 ilvG karf*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors containing nucleic acid encoding WISP polypeptide. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 (1981); EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer *et al.*, Bio/Technology, 9: 968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt *et al.*, J. Bacteriol., 737 (1983)), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,043), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilae* (ATCC 36,906; Van den Berg *et al.*, Bio/Technology, 8: 135 (1990)), *K. thermotolerans*, and *K. marxianus*; *Yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna *et al.*, J. Basic Microbiol., 28: 265-278 (1988)); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case *et al.*, Proc. Natl. Acad. Sci. USA, 76: 5259-5263 (1979)); *Schwannomyces* such as *Schwannomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance *et al.*, Biochem. Biophys. Res. Commun., 112: 284-289 (1983); Tilburn *et al.*, Gene, 26: 205-221 (1983); Yelton *et al.*, Proc. Natl. Acad. Sci. USA, 81: 1470-1474 (1984)) and *A. niger* Kelly and Hynes, EMBO J., 4: 475-479 (1985). Methylotrophic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 (1982).

Suitable host cells for the expression of glycosylated WISP are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture (Graham *et al.*, J. Gen. Virol., 36: 59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23: 243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor

(MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (*e.g.*, cDNA or genomic DNA) encoding the desired WISP polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The desired WISP polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence, if the WISP polypeptide is conducive to being secreted, or other polypeptide having a specific cleavage site at the N-terminus of the mature or full-length protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the WISP polypeptide that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence such as, for example, the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, *e.g.*, the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders, and including signals from WISP polypeptides.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, *e.g.*, ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, *e.g.*, the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding WISP polypeptide, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub *et al.*, Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7.



Stinchcomb *et al.*, Nature, 282:39 (1979); Kingsman *et al.*, Gene, 7:141 (1979); Tschemper *et al.*, Gene, 10:157 (1980). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85:12 (1977).

Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding WISP polypeptide to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems (Chang *et al.*, Nature, 275:615 (1978); Goeddel *et al.*, Nature, 281:544 (1979)); alkaline phosphatase, a tryptophan (*trp*) promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776), and hybrid promoters such as the *tac* promoter, deBoer *et al.*, Proc. Natl. Acad. Sci. USA, 80:21-25 (1983). Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the WISP polypeptide.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman *et al.*, J. Biol. Chem., 255:2073 (1980)) or other glycolytic enzymes (Hess *et al.*, J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytichrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

WISP transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, and Simian Virus 40 (SV40); from heterologous mammalian promoters, *e.g.*, the actin promoter or an immunoglobulin promoter; and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding a WISP polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the sequence coding for a WISP polypeptide, but is preferably located at a site 5' from the promoter.



Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding WISP polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of WISP polypeptides in recombinant vertebrate cell culture are described in Gething *et al.*, Nature, 293:620-625 (1981); Mantei *et al.*, Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native-sequence WISP polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to DNA encoding WISP polypeptide and encoding a specific antibody epitope.

#### 5. Purification of Polypeptide

Forms of WISP polypeptide may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., Triton-X 100) or by enzymatic cleavage. Cells employed in expression of WISP polypeptides can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify WISP polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, SEPHADEX<sup>TM</sup> G-75; protein A SEPHAROSE<sup>TM</sup> columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the WISP polypeptide. Various methods of protein purification may be employed, and such methods are known in the art and described, for example,

in Deutscher, Methods in Enzymology, 182 (1990); and Scopes, Protein Purification: Principles and Practice (Springer-Verlag: New York, 1982).

In one specific example of purification, either a poly-His tag or the Fc portion of human IgG is added to the C-terminal coding region of the cDNA for WISP-1, WISP-2, or WISP-3 before expression. The conditioned media from the transfected cells are harvested by centrifugation to remove the cells and filtered. For the poly-His-tagged constructs, the protein may be purified using a Ni-NTA column. After loading, the column may be washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein may then be desalted into a storage buffer if desired.

Immunoaffinity (Fc-containing) constructs of the WISP-1, WISP-2, and WISP-3 proteins may be purified from the conditioned media by pumping them onto a 5-ml Protein A column which had been equilibrated in a phosphate buffer. After loading, the column may be washed extensively with equilibration buffer before elution with citric acid. The eluted protein may be immediately neutralized by collecting 1-ml fractions into tubes containing TRIS buffer. The highly purified protein may be subsequently desalted into storage buffer as described above for the poly-His-tagged proteins. The homogeneity of the protein may be assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

The purification step(s) selected will depend, for example, on the nature of the production process used and the particular WISP polypeptide produced.

#### E. Uses for WISP Polypeptide and Its Nucleic Acid

Nucleotide sequences (or their complement) encoding WISP polypeptides have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping, and in the generation of anti-sense RNA and DNA. Nucleic acid encoding WISP polypeptide will also be useful for the preparation of WISP polypeptides by the recombinant techniques described herein.

The full-length nucleotide sequences for mouse or human WISP-1 or WISP-2 (SEQ ID NOS:9, 1, 17, and 13, respectively), or portions thereof, or the full-length nucleotide sequences for human WISP-3 of Fig. 6 (SEQ ID NO:30) or for WISP-3 of Fig. 7 (SEQ ID NO:34) may be used as hybridization probes for a cDNA library to isolate or detect the full-length gene encoding the WISP polypeptide of interest or to isolate or detect still other genes (for instance, those encoding naturally occurring variants of WISP polypeptide, other WISP polypeptide family members, or WISP polypeptides from other species) which have a desired sequence identity to the WISP polypeptide sequences disclosed in Figures 1, 2, 3A and 3B, 4, 6A and 6B, and 7A and 7B (SEQ ID NOS:3, 4, 11, 12, 15, 16, 19, 20, 32, 33, 36, or 37). For example, such procedures as *in situ* hybridization, Northern and Southern blotting, and PCR analysis may be used to determine whether DNA and/or RNA encoding a different WISP is present in the cell type(s) being evaluated. Optionally, the length of the probes will be about 20 to about 50 bases. For example, the hybridization probes may be derived from the UNQ228 (DNA33473-seq min) nucleotide sequence (SEQ ID NO:38) or the full-length human WISP-2 nucleotide sequence (SEQ ID NO:13) as shown in Figure 4 or from genomic sequences including promoters, enhancer elements, and introns of DNA encoding native-sequence WISP polypeptide.

By way of example, a screening method will comprise isolating the coding region of the WISP gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of any of the genes encoding WISP polypeptides of the present invention can be used to screen libraries of human cDNA, genomic DNA, or mRNA to determine to which members of such libraries the probe hybridizes. Hybridization techniques are described in further detail in the Examples below.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related WISP sequences.

Nucleotide sequences encoding a WISP polypeptide can also be used to construct hybridization probes for mapping the gene which encodes that WISP polypeptide and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries. If the amplification of a given gene is functionally relevant, then that gene should be amplified more than neighboring genomic regions which are not important for tumor survival. To test this, the gene can be mapped to a particular chromosome, e.g., by radiation-hybrid analysis. The amplification level is then determined at the location identified, and at neighboring genomic region. Selective or preferential amplification at the genomic region to which the gene has been mapped is consistent with the possibility that the gene amplification observed promotes tumor growth or survival. Chromosome mapping includes both framework and epicenter mapping. For further details see e.g., Stewart *et al.*, Genome Research 7, 422-433 (1997).

Nucleic acid encoding a WISP polypeptide may be used as a diagnostic to determine the extent and rate of the expression of the DNA encoding the WISP polypeptide in the cells of a patient. To accomplish such an assay, a sample of a patient's cells is treated, via *in situ* hybridization, or by other suitable means, and analyzed to determine whether the sample contains mRNA molecules capable of hybridizing with the nucleic acid molecule.

Nucleic acids which encode WISP polypeptides or any of their modified forms can also be used to generate either transgenic animals or "knock-out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding a WISP polypeptide can be used to clone genomic DNA encoding the WISP polypeptide in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding the WISP polypeptide.

Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009 and WO 97/38086. Typically, particular cells would be targeted for WISP transgene incorporation with tissue-specific

enhancers. Transgenic animals that include a copy of a transgene encoding the WISP polypeptide introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding the WISP polypeptide. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of WISP polypeptides can be used to construct a WISP polypeptide "knock-out" animal which has a defective or altered gene encoding a WISP polypeptide as a result of homologous recombination between the endogenous gene encoding the WISP polypeptide and altered genomic DNA encoding the WISP polypeptide introduced into an embryonic cell of the animal. For example, cDNA encoding the WISP polypeptide can be used to clone genomic DNA encoding the WISP polypeptide in accordance with established techniques. A portion of the genomic DNA encoding the WISP polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector. See *e.g.*, Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected. See *e.g.*, Li *et al.*, *Cell*, 69:915 (1992). The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse or rat) to form aggregation chimeras. See *e.g.*, Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock-out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized, for instance, by their ability to defend against certain pathological conditions and by their development of pathological conditions due to absence of the WISP polypeptide.

In particular, assays in which CTGF, IGFBPs, and other members of the CTGF superfamily and other growth factors are usually used are preferably performed with the WISP-1 and WISP-2 polypeptides. For example, an assay to determine whether TGF- $\beta$  induces the WISP polypeptide, indicating a role in cancer, may be performed as known in the art, as well as assays involving induction of cell death and  $^3\text{H}$ -thymidine proliferation assays. Mitogenic and tissue growth assays are also performed with the WISP polypeptide as set forth above. The results are applied accordingly.

The WISP polypeptides of the present invention may also be used to induce the formation of anti-WISP polypeptide antibodies, which are identified by routine screening as detailed below.

In addition to their uses above, the WISP-1, WISP-2, and WISP-3 polypeptides of the present invention are useful as the basis for assays of IGF activity. Importantly, since such an assay measures a physiologically significant binding event, *i.e.*, that of an IGF to its IGFBP, triggering a detectable change (such as phosphorylation, cleavage, chemical modification, *etc.*), it is likely to be both more sensitive and

more accurate than immunoassays, which detect the physiologically non-significant binding of an IGF to anti-WISP polypeptide antibody. Although more sensitive and accurate than antibodies, the WISP-1, WISP-2, and WISP-3 molecules of the invention can be used to assay IGF (such as IGF-I or IGF-II) levels in a sample in the same ways in which antibodies are used.

5 For diagnostic purposes, the WISP-1, WISP-2, or WISP-3 polypeptide can be used in accordance with immunoassay technology. Examples of immunoassays are provided by Wide at pages 199-206 of Radioimmune Assay Method, Kirkham and Huner, ed., E & S. Livingstone, Edinburgh, 1970.

Thus, in one embodiment, WISP-1, WISP-2, and WISP-3 polypeptides can be detectably labeled and incubated with a test sample containing IGF molecules (such as biological fluids, *e.g.*, serum, sputum, urine, *etc.*), and the amount of WISP-1, WISP-2, or WISP-3 molecule bound to the sample ascertained.

10 Immobilization of reagents is required for certain assay methods. Immobilization entails separating the WISP-1, WISP-2, or WISP-3 polypeptide from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the WISP-1, WISP-2, or WISP-3 polypeptide before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich *et al.*, U.S. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the molecule

15 afterward, *e.g.*, by immunoprecipitation.

The foregoing are merely exemplary diagnostic assays for IGF. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof.

WISP-1, WISP-2, and WISP-3 polypeptides are also useful in radioimmunoassays to measure IGFs such as IGF-I or IGF-II. Such a radioimmunoassay would be conducted as described in the literature using the naturally purified or recombinant WISP-1, WISP-2, or WISP-3 as the WISP element.

20 In addition, WISP polypeptides are useful for screening for compounds that bind to them as defined above. Preferably, these compounds are small molecules such as organic or peptide molecules that exhibit one or more of the desired activities. Screening assays of this kind are conventional in the art, and any such screening procedure may be employed, whereby the test sample is contacted with the WISP polypeptide herein and the extent of binding and biological activity of the bound molecule are determined.

More specifically, this invention encompasses methods of screening compounds to identify those that mimic the WISP polypeptide (agonists) or prevent the effect of the WISP polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the WISP polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

30 The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

All assays for antagonists are common in that they call for contacting the drug candidate with a WISP polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.



In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the WISP polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, *e.g.*, on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the WISP polypeptide and drying. Alternatively, an immobilized antibody, *e.g.*, a monoclonal antibody, specific for the WISP polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, *e.g.*, the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, *e.g.*, by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

If the candidate compound interacts with but does not bind to a particular WISP polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, *e.g.*, cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340: 245-246 (1989); Chien *et al.*, Proc. Natl. Acad. Sci. USA, 88: 9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER<sup>TM</sup>) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a WISP polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the

mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

If the WISP polypeptide has the ability to stimulate the proliferation of endothelial cells in the presence of the co-mitogen ConA, then one example of a screening method takes advantage of this ability. Specifically, in the proliferation assay, human umbilical vein endothelial cells are obtained and cultured in 96-well flat-bottomed culture plates (Costar, Cambridge, MA) and supplemented with a reaction mixture appropriate for facilitating proliferation of the cells, the mixture containing Con-A (Calbiochem, La Jolla, CA). Con-A and the compound to be screened are added and after incubation at 37°C, cultures are pulsed with  $^3\text{H}$ -thymidine and harvested onto glass fiber filters (pH: Cambridge Technology, Watertown, MA). Mean  $^3\text{H}$ -thymidine incorporation (cpm) of triplicate cultures is determined using a liquid scintillation counter (Beckman Instruments, Irvine, CA). Significant  $^3\text{H}$ -thymidine incorporation indicates stimulation of endothelial cell proliferation.

To assay for antagonists, the assay described above is performed; however, in this assay the WISP polypeptide is added along with the compound to be screened and the ability of the compound to inhibit  $^3\text{H}$ -thymidine incorporation in the presence of the WISP polypeptide indicates that the compound is an antagonist to the WISP polypeptide. Alternatively, antagonists may be detected by combining the WISP polypeptide and a potential antagonist with membrane-bound WISP polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The WISP polypeptide can be labeled, such as by radioactivity, such that the number of WISP polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan *et al.*, Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the WISP polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the WISP polypeptide. Transfected cells that are grown on glass slides are exposed to labeled WISP polypeptide. The WISP polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled WISP polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled WISP polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

The compositions useful in the treatment of WISP-related disorders include, without limitation, antibodies, small organic and inorganic molecules, peptides, phosphopeptides, antisense and ribozyme molecules, triple-helix molecules, etc., that inhibit the expression and/or activity of the target gene product.

More specific examples of potential antagonists include an oligonucleotide that binds to the WISP polypeptide, (poly)peptide-immunoglobulin fusions, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the WISP polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the WISP polypeptide.

Another potential WISP polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature WISP polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee *et al.*, Nucl. Acids Res., 6: 3073 (1979); Cooney *et al.*, Science, 241: 456 (1988); Dervan *et al.*, Science, 251: 1360 (1991)), thereby preventing transcription and the production of the WISP polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule to the WISP polypeptide (antisense - Okano, Neurochem., 56: 560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the WISP polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the WISP polypeptide, thereby blocking the normal biological activity of the WISP polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Biology, 4: 469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, *e.g.*, PCT publication  
 5 No. WO 97/33551, *supra*.

These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

WISP-1, WISP-2, and WISP-3 polypeptides are additionally useful in affinity purification of an IGF that binds to WISP-1, WISP-2, or WISP-3 (such as, for example, IGF-I) and in purifying antibodies thereto.  
 10 The WISP-1, WISP-2, or WISP-3 is typically coupled to an immobilized resin such as Affi-Gel 10<sup>TM</sup> (Bio-Rad, Richmond, CA) or other such resins (support matrices) by means well known in the art. The resin is equilibrated in a buffer (such as one containing 150 mM NaCl, 20 mM HEPES, pH 7.4 supplemented to contain 20% glycerol and 0.5% NP-40) and the preparation to be purified is placed in contact with the resin, whereby the molecules are selectively adsorbed to the WISP-1, WISP-2, or WISP-3 on the resin.

15 The resin is then sequentially washed with suitable buffers to remove non-adsorbed material, including unwanted contaminants, from the mixture to be purified, using, *e.g.*, 150 mM NaCl, 20 mM HEPES, pH 7.4, containing 0.5% NP-40; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.5 M NaCl and 0.1% NP-40; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.1% deoxycholate; 150 mM NaCl, 20 mM HEPES, pH 7.4 containing 0.1% NP-40; and a solution of 0.1% NP-40, 20% glycerol and 50 mM glycine,  
 20 pH 3. The resin is then treated so as to elute the IGF using a buffer that will break the bond between the IGF and WISP-1, WISP-2, or WISP-3 (using, *e.g.*, 50 mM glycine, pH 3, 0.1% NP-40, 20% glycerol, and 100 mM NaCl).

It is contemplated that the WISP polypeptides of the present invention may be used to treat various conditions, including those characterized by overexpression and/or activation of at least the Wnt pathway.  
 25 Further, since the WISP-1, WISP-2, and WISP-3 molecules respond to hormone-expressed breast cancer in mice and are abnormally expressed in human cancer, and are over-amplified in various colon cancer cell lines, they are useful in diagnosing cancer, for example, as a marker for increased susceptibility to cancer or for having cancer. Exemplary conditions or disorders to be treated with the WISP polypeptides include benign or malignant tumors (*e.g.*, renal, liver, kidney, bladder, testicular, breast, gastric, ovarian, colorectal, prostate,  
 30 pancreatic, lung, esophageal, vulval, thyroid, hepatic carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic disorders; cardiac disorders; renal disorders; catabolic disorders; bone-related disorders such as osteoporosis; and inflammatory, angiogenic, and immunologic disorders, such as arteriosclerosis; as well as connective tissue disorders,  
 35 including wound healing.

The WISP polypeptides of the invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular,



intrasynovial, intrathecal, oral, topical, or inhalation routes. Intravenous or subcutaneous administration of the polypeptide is preferred.

Therapeutic formulations of the WISP polypeptide are prepared for storage by mixing the polypeptide having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (*e.g.*, Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).

Other therapeutic regimens may be combined with the administration of the WISP polypeptides of the instant invention. For example, the patient to be treated with the polypeptides disclosed herein may also receive radiation therapy if the disorder is cancer. Alternatively, or in addition, a chemotherapeutic agent may be administered to the patient with cancer. Preparation and dosing schedules for such chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in Chemotherapy Service, Ed., M.C. Perry (Williams & Wilkins: Baltimore, MD, 1992). The chemotherapeutic agent may precede or follow administration of the polypeptide or may be given simultaneously therewith. The polypeptide may be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as onapristone (see, EP 616812) in dosages known for such molecules.

It may be desirable also to co-administer with the WISP polypeptide (or anti-WISP polypeptide) antibodies against other tumor-associated antigens, such as antibodies which bind to HER-2, EGFR, ErbB2, ErbB3, ErbB4, or vascular endothelial factor (VEGF). Alternatively, or in addition, two or more different anti-cancer antibodies, such as anti-ErbB2 antibodies, may be co-administered to the patient with the WISP polypeptide (or anti-WISP polypeptide antibody). Sometimes, it may be beneficial also to administer one or more cytokines to the patient.

In a preferred embodiment, the WISP polypeptide is co-administered with a growth-inhibitory agent to the cancer patient. For example, the growth-inhibitory agent may be administered first, followed by the WISP polypeptide. However, simultaneous administration or administration of the WISP polypeptide first is also contemplated. Suitable dosages for the growth-inhibitory agent are those presently used and may be lowered due to the combined action (synergy) of the growth-inhibitory agent and polypeptide. The



antibodies, cytotoxic agents, cytokines, or growth-inhibitory agents are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980), *supra*.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated polypeptides remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

For the prevention or treatment of disease or disorder, the appropriate dosage of WISP polypeptide will depend on the type of disorder to be treated, as defined above, the severity and course of the disorder, whether the polypeptide is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the polypeptide, the route of administration, the condition of the patient, and the discretion of the attending physician. The polypeptide is suitably administered to the patient at one time or over a series of treatments.

Depending on the type and severity of the disease, about 1  $\mu$ g/kg to 15 mg/kg (e.g., 0.1-20 mg/kg) of WISP polypeptide is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1  $\mu$ g/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of symptoms of the disorder occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. In another

embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition is the WISP polypeptide. The label on, or associated with, the container indicates that the composition is used for treating the condition or disorder of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

#### F. Anti-WISP Polypeptide Antibodies

The present invention further provides anti-WISP polypeptide antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

##### 1. Polyclonal Antibodies

The anti-WISP polypeptide antibodies of the present invention may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the WISP polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

##### 2. Monoclonal Antibodies

The anti-WISP polypeptide antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the WISP polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as PEG, to form a hybridoma cell. Goding, Monoclonal Antibodies: Principles and Practice (Academic Press: New York, 1986) pp. 59-103.

Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California, and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur *et al.*, Monoclonal Antibody Production Techniques and Applications (Marcel Dekker, Inc.: New York, 1987) pp. 51-63.

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against a WISP polypeptide. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods. Goding, *supra*. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:

6851-6855 (1984)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5 The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy-chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

10 *In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known in the art.

### 3. Humanized Antibodies

15 The anti-WISP antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (*e.g.*, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub>, or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or  
20 substantially all of the CDR regions correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody preferably also will comprise at least a portion of an Fc, typically that of a human immunoglobulin. Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-329 (1988); Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).

30 Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-327 (1988); Verhoeyen *et al.*, Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies

are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks *et al.*, *J. Mol. Biol.*, 222:581 (1991). The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies. Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985); Boerner *et al.*, *J. Immunol.*, 147(1):86-95 (1991).

#### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a WISP polypeptide; the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities. Milstein and Cuello, *Nature*, 305:537-539 (1983). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant-domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

#### 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection. WO 91/00360; WO 92/200373; EP 03089. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving cross-linking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.



### G. Uses for anti-WISP Polypeptide Antibodies

The antibodies of the invention may be used as affinity purification agents. In this process, the antibodies are immobilized on a solid phase such as SEPHADEX<sup>TM</sup> resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing the WISP polypeptide (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the WISP protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the WISP polypeptide from the antibody.

Anti-WISP polypeptide antibodies may also be useful in diagnostic assays for WISP polypeptide, e.g., detecting its expression in specific cells, tissues, or serum. Thus, the antibodies may be used in the diagnosis of human malignancies (see, for example, U.S. Pat. No. 5,183,884).

For diagnostic applications, the antibody typically will be labeled with a detectable moiety. Numerous labels are available which can be preferably grouped into the following categories:

(a) Radioisotopes, such as <sup>35</sup>S, <sup>14</sup>C, <sup>125</sup>I, <sup>3</sup>H, and <sup>131</sup>I. The antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligan *et al.*, Ed., (Wiley-Interscience: New York, 1991), for example, and radioactivity can be measured using scintillation counting.

(b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, and Texas Red are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, *supra*, Coligan, ed., for example. Fluorescence can be quantified using a fluorimeter.

(c) Various enzyme-substrate labels are available, and U.S. Patent No. 4,275,149 provides a review of some of these. The enzyme preferably catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase,  $\beta$ -galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan *et al.*, Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym., Vol. 73, Langone and Van Vunakis, eds. (New York: Academic Press, 1981), pp. 147-166.

Examples of enzyme-substrate combinations include:

(i) Horseradish peroxidase (HRPO) with hydrogen peroxide as a substrate, wherein the hydrogen peroxidase oxidizes a dye precursor (*e.g.*, orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));

(ii) alkaline phosphatase (AP) with para-nitrophenyl phosphate as chromogenic substrate; and

5 (iii)  $\beta$ -D-galactosidase ( $\beta$ -D-Gal) with a chromogenic substrate (*e.g.*, p-nitrophenyl- $\beta$ -D-galactosidase) or fluorogenic substrate (4-methylumbelliferyl- $\beta$ -D-galactosidase).

Numerous other enzyme-substrate combinations are available to those skilled in the art. For a general review of these, see, for example, U.S. Patent Nos. 4,275,149 and 4,318,980.

Sometimes, the label is indirectly conjugated with the antibody. The skilled artisan will be aware  
10 of various techniques for achieving this. For example, the antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or *vice versa*. Biotin binds selectively to avidin, and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (*e.g.*, digoxin) and one of the different types of labels mentioned above is conjugated with an  
15 anti-hapten antibody (*e.g.*, anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved.

In another embodiment of the invention, the anti-WISP polypeptide antibody need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the anti-WISP polypeptide antibody.

20 The antibodies of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques (New York: CRC Press, Inc., 1987), pp.147-158.

Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of antibody. The amount of WISP protein in the test sample is  
25 inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies preferably are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays involve the use of two antibodies, each capable of binding to a different  
30 immunogenic portion, or epitope, of the protein to be detected. In a sandwich assay, the test sample analyte is bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, *e.g.*, U.S. Pat No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For  
35 example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.

For immunohistochemistry, the tumor sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.

The antibodies may also be used for *in vivo* diagnostic assays. Preferably, the antibody is labeled with a radionuclide (such as  $^{111}\text{In}$ ,  $^{99}\text{Tc}$ ,  $^{14}\text{C}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$ ,  $^{32}\text{P}$  or  $^{35}\text{S}$ ) so that the tumor can be localized using immunoscintigraphy.

5 Additionally, anti-WISP polypeptide antibodies may be useful as antagonists to WISP polypeptide functions where WISP polypeptide is upregulated in cancer cells or stimulates their proliferation or is upregulated in atherosclerotic tissue. Hence, for example, the anti-WISP polypeptide antibodies may by themselves or with a chemotherapeutic agent or other cancer treatment or drug such as anti-HER-2 antibodies be effective in treating certain forms of cancer such as breast cancer, colon cancer, lung cancer, and melanoma. Further uses for the antibodies include inhibiting the binding of a WISP polypeptide to its  
10 receptor, if applicable, or to an IGF, if applicable. For therapeutic use, the antibodies can be used in the formulations, schedules, routes, and doses indicated above under uses for the WISP polypeptides. In addition, anti-WISP polypeptide antibody may be administered into the lymph as well as the blood stream.

As a matter of convenience, the anti-WISP antibody of the present invention can be provided as an article of manufacture such as a kit. An article of manufacture containing a WISP polypeptide or antagonists  
15 thereof useful for the diagnosis or treatment of the disorders described above comprises at least a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition that is effective for diagnosing or treating the condition and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection  
20 needle).

The active agent in the composition is the WISP polypeptide or an agonist or antagonist thereto. The label on, or associated with, the container indicates that the composition is used for diagnosing or treating the condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and dextrose  
25 solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. The article of manufacture may also comprise a second or third container with another active agent as described above. A kit format generally is a packaged combination of reagents in predetermined amounts with instructions for performing the diagnostic or treatment assay.

30 If the active agent is an antibody that is labeled with an enzyme, the kit will include substrates and cofactors required by the enzyme (*e.g.*, a substrate precursor which provides the detectable chromophore or fluorophore). In addition, other additives may be included such as stabilizers, buffers (*e.g.*, a block buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents which substantially maximize the sensitivity of the assay.  
35 Particularly, the reagents may be provided as dry powders, usually lyophilized, including excipients which on dissolution will provide a reagent solution having the appropriate concentration.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

### EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, 10801 University Blvd., Manassas, Virginia.

#### EXAMPLE 1: Isolation of cDNA Clones Encoding Mouse WISP-1

Several putative WISP genes have been identified at the mRNA level in a high-throughput PCR-select cDNA subtraction experiment carried out using a mouse mammary cell line (C57MG), which has been transformed by a Wnt-1 retroviral vector and compared with the parental cell line. The WISP family disclosed herein, including the mouse WISP-1 gene, was induced only in the transformed cell line C57MGWnt-1.

#### 1. Suppression Subtractive Hybridization

Mouse WISP-1 was isolated independently by Wnt-1 differential screening using suppression subtractive hybridization (SSH), as described by Diatchenko *et al.*, Proc. Natl. Acad. Sci. USA, **93**: 6025-6030 (1996). SSH was carried out using the PCR-SELECT® cDNA Subtraction Kit (Clontech Laboratories, Inc.) according to the manufacturer's protocol. Driver double-stranded (ds) cDNA was synthesized from 2 micrograms of polyA+ RNA isolated from a mouse mammary cell line (C57MG), obtainable from a mouse breast cancer myoepithelial cell line. This cell line is described in Brown *et al.*, Cell, **46**: 1001-1009 (1986); Olson and Papkoff, Cell Growth and Differentiation, **5**: 197-206 (1994); Wong *et al.*, Mol. Cell. Biol., **14**: 6278-6286 (1994); and Jue *et al.*, Mol. Cell. Biol., **12**: 321-328 (1992), and is responsive to Wnt-1 but not to Wnt-4. Tester ds cDNA was synthesized from 2 micrograms of polyA+ RNA isolated from a transformed version of C57MG, called C57MG/wnt-1.

The C57MG/wnt-1 mouse mammary derivative cell line was prepared by first transforming the parent line with a Wnt-1 retroviral vector, pBabe Puro (5.1 kb). This vector has a 5' LTR, packaging elements, a multiple cloning site, the puromycin-resistance gene driven off the SV40 promoter, a 3' LTR, and the bacterial elements for replication and ampicillin selection. The vector was modified slightly for Wnt-1 cloning by removing the *HindIII* site after the SV40 promoter and adding a *HindIII* site to the multiple cloning site. Wnt-1 is cloned from *EcoRI-HindIII* in the multiple cloning site. Figure 13 shows a map of the vector.

The transformed derivative cells were grown up in a conventional fashion, and the final cell population was selected in DMEM + 10% FCS with 2.5 µg/ml puromycin to stabilize the expression vector.

PCR was performed using the Clontech kit, including the cDNA synthesis primer (SEQ ID NO:40), adaptors 1 and 2 (SEQ ID NOS:41 and 42, respectively) and complementary sequences for the adaptors (SEQ ID NOS:43 and 44, respectively), PCR primer 1 (SEQ ID NO:45), PCR primer 2 (SEQ ID NO:46), nested PCR primer 1 (SEQ ID NO:47), nested PCR primer 2 (SEQ ID NO:48), control primer G3PDH5' primer (SEQ ID NO:49), and control primer G3PDH3' primer (SEQ ID NO:50), shown in Figure 14.

Products generated from the secondary PCR reaction were inserted into the cloning site region of pGEM-T vector (Promega), shown in Figure 15 (SEQ ID NOS:51 and 52 for 5' and 3' sequences, respectively). Plasmid DNAs were prepared using the WIZARD MINIPREP™ Kit (Promega). DNA sequencing of the subcloned PCR fragments was performed manually by the chain termination reaction (SEQUENASE 2.0™ Kit, Pharmacia). Nucleic acid homology searches were performed using the BLAST program noted above.

A total of 1384 clones were sequenced out of greater than 5000 found. A total of 1996 DNA templates were prepared. A program was used to trim the vector off, and a different program used to cluster the clones into two or more identical clones or with an overlap of 50 bases the same. Then a BLAST was performed of a representative clone from the cluster. Primers were designed for RT-PCR to see if the clones were differentially expressed.

## 2. Semi-quantitative RT-PCR

One of the clones was clone 568 having 71 bp, which was identified as encoding mouse WISP-1. There were six clones in this cluster. The nucleotide sequence and putative amino acid sequence of full-length mouse WISP-1 are shown in Figure 1 (SEQ ID NOS:9 and 12, respectively). RT-PCR primers were designed for confirming differential expression, screening for full-length mouse clone, and screening for the human clone. These primers were 568.PCR.top1 (nucleotides 909-932 of the full-length nucleotide sequence encoding mouse WISP-1 (SEQ ID NO:9) of Figure 1) and 568.PCR.bot1 (nucleotides 955-978 of the full-length complementary nucleotide sequence encoding mouse WISP-1 (SEQ ID NO:10) of Figure 1), which are as follows:

568.PCR.top1: 5'-CCAGCCAGAGGAGGCCACGAAC (SEQ ID NO:100)

568.PCR.bot1: 3'-TGTGCGTGGATGGCTGGGTTCATG (SEQ ID NO:101)

For the RT-PCR procedure, cell lines were grown to subconfluence before extracting the RNA. Total RNA was extracted using Stat-60™ (TEL-TEST™ B) per manufacturer's instructions. First-strand cDNA was prepared from 0.1 µg - 3 µg of total RNA with the SUPERScript™ RT kit (Gibco, BRL). PCR amplification of 5 µl of first-strand cDNA was performed in a 50-µl PCR reaction. The above primers were used to amplify first-strand cDNA. As controls, primers corresponding to nucleotide positions 707-729 (sense: 5'-GTGGCCCATGCTCTGGCAGAGGG (SEQ ID NO:102)) or 836-859 (sense: 5'-GACTGGAGCAAGGTCGTCCTCGCC (SEQ ID NO:103)) and 1048-1071 (anti-sense: 5'-GCACCACCCACAAGGAAGCCATCC (SEQ ID NO:104)) of human triosephosphate isomerase (huTPI) (Maquat *et al.*, *J. Biol. Chem.*, **260**: 3748-3753 (1985); Brown *et al.*, *Mol. Cell. Biol.*, **5**: 1694-1706 (1985)) were used to amplify first-strand cDNA. For mouse triosephosphate isomerase, primers corresponding to nucleotide positions 433-456 (sense: 5'-GACGAAAGGGAAGCCGGCATCACQ (SEQ ID NO: 105)) or 457-480 bp (sense: 5'-GAGAAGGTCGTGTTTCGAGCAAACC (SEQ ID NO: 106)) and 577-600 bp (antisense: 5'-CTTCTCGTGTACTTCCTGTGCCTG (SEQ ID NO:107)) or 694-717 bp (antisense: 5'-CACGTCAGCTGGCGTTGCCAGCTC (SEQ ID NO:108)) were used for amplification.

Briefly, 4 µCi of (<sup>32</sup>P)-CTP (3000 Ci/mmol) was added to each reaction with 2.5 U of TAKARA EX TAQ™ (Panvera, Madison, WI) and 0.2 µM of each dNTP. The reactions were amplified in a 480 PCR THERMOCYCLER™ (Perkin Elmer) using the following conditions: 94°C for 1 min., 62°C for 30 sec.,



72°C for 1 min. for 18-25 cycles. 5 µl of PCR products were electrophoresed on a 6% polyacrylamide gel. The gel was exposed to film. Densitometry measurements were obtained using ALPHA EASE VERSION 3.3a<sup>TM</sup> software (Alpha Innotech Corporation) to quantitate the WISP- or TPI-specific gene products.

### 3. Northern Blot Analysis

5 Adult multiple-tissue Northern blots (Clontech) and the Northern blot of the C57MG parent and C57MG/Wnt-1 derivative polyA+RNA (2 µg/lane) were hybridized with a 70-bp mouse WISP-1 probe (amino acids 278 through 300 of Fig. 1; QPEEATNFTLAGCVSTRTYRPKY; SEQ ID NO:109) generated using the primers 568.PCR.top1 and 568.pcr.bot1 noted above. The membranes were washed in 0.1 X SSC at 55-65°C and exposed for autoradiography. Blots were rehybridized with a 75-bp synthetic probe from the  
10 human actin gene. See Godowski *et al.*, Proc. Natl. Acad. Sci. USA, 86: 8083-8087 (1989) for a method for making a probe with overlapping oligos, which is how the actin probe was prepared.

### 4. cDNA Library Screening

Clones encoding the full-length mouse WISP-1 were isolated by screening a λgt10 oligodT primed mouse embryo library (Clontech) with the primers 568.PCR.top1 and 568.PCR.bot1 noted above. The inserts  
15 of 13 of these clones were subcloned into pBLUESCRIPT<sup>TM</sup> IISK+ and their DNA sequences determined by dideoxy DNA sequencing on both strands.

### 5. Results

The recently described technique of SSH combines a high subtraction efficiency with an equalized representation of differentially expressed sequences. This method is based on specific PCR reactions that  
20 permit exponential amplification of cDNAs which differ in abundance, whereas amplification of sequences of identical abundance in two populations is suppressed. The SSH technique was used herein to isolate genes expressed in a mouse mammary myoepithelial cell transformed with *Wnt-1* whose expression is reduced or absent in the parental myoepithelial cell. The polyA<sup>+</sup>RNA extracted from both types of cells was used to synthesize tester and driver cDNAs. The degree of subtraction efficiency was monitored by Southern blot  
25 analysis of unsubtracted and subtracted PCR products using a β-actin probe. No β-actin mRNA was apparent in the subtracted PCR products, confirming the efficiency of the subtraction.

The subtracted cDNA library was subcloned into a pGEM-T vector for further analysis. A random sample of 1996 clones was sequenced from the transformed colonies obtained. To determine if the clones  
30 obtained were differentially expressed, PCR primers were designed for selected clones and semi-quantitative RT-PCR and Northern analyses were performed using mRNA from the mouse mammary cell line and its derivative. It was found that expression of *Wnt-1* in C57MG cells leads to elongated cell morphology and loss of contact inhibition.

One clone (m568.19A) of those that fulfilled the criteria for differential expression was found to  
35 encode full-length mouse WISP-1. By both RT-PCR analysis and Northern analysis, it was found that this clone provided an about three-fold induction in the Wnt-1 cell line over the parent cell line.

The cDNA sequence of this clone and deduced amino acid sequence of full-length mouse WISP-1 are shown in Figure 1 (SEQ ID NOS:9 and 12, respectively). The sequence alignment of human and mouse WISP-1 (SEQ ID NOS:4 and 12, respectively) is shown in Figure 8. *In-situ* analysis of the clone is presented below, along with thymidine incorporation assay and angiostatic assay results.

This clone was placed in pRK5E, an *E. coli*-derived cloning vector having a human cytomegalovirus intermediate early gene promoter, an SV40 origin and polyA site, an *sp6* transcription initiation site, a human immunoglobulin splice acceptor, and *XhoI*/*NotI* cDNA cloning sites. It is a progeny of pRK5D that has an added *SceI* site. Holmes *et al.*, *Science*, 253:1278-1280 (1991). Upon transformation into JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *XbaI* and *BamHI*, a 1140-bp fragment was obtained, and the mouse insert size was 1122 base pairs, from the ATG to the stop codon, including a 3' tag of six histidines.

#### EXAMPLE 2: Isolation of a cDNA Clone Encoding Mouse WISP-2

The cDNA for mouse WISP-2 was isolated independently by Wnt-1 differential screening using the procedure described in Example 1. The initial clone isolated was 318 bp in length and was designated clone 1367. There were four clones in this cluster. The clone was sequenced as described above and RT-PCR primers were designed as follows:

1367.pcr.top1: nucleotides 1604-1627 of Figure 2:

3'-GGTGTGAAGACCGTCCGGTCCCGG (SEQ ID NO:110)

and

1367.pcr.bot1: nucleotides 1438-1461 of Figure 2:

5'-GTGTGCCTTTCCTGATCTGAGAAC (SEQ ID NO:111)

After RT-PCR and Northern blot procedures were carried out as described in Example 1 to confirm differential expression, a five-fold induction in the Wnt-1 cell line was observed.

Clones encoding full-length mouse WISP-2 were isolated from RNA library 211: C57MG/Wnt-1. mRNA for construction of this library was isolated from the C57MG/Wnt-1 cell line described in Example 1. The RNA was used to generate an oligo-dT-primed cDNA library in the cloning vector pRK5E using reagents and protocols from Life Technologies, Gaithersburg, MD (SUPERScript PLASMID SYSTEM<sup>TM</sup>).

In this procedure, the double-stranded cDNA was primed with oligo dT containing a *NotI* site, linked with blunt-to-*SalI* hemikinased adaptors, cleaved with *NotI*, sized to greater than 1000 bp appropriately by gel electrophoresis, and cloned in a defined orientation into the *XhoI*/*NotI*-cleaved pRK5E vector. The library was screened by colony hybridization with a probe 1367.50mer.1 of bases 1463-1512 of Figure 2:

3'-GGGACGGGCCGACCCTTCTTAAAGACCCTTGTACTTCTCTACCTTAGTG (SEQ ID NO:112).

The full-length mouse WISP-2 clone was obtained, designated clone 1367.3.

The cDNA for mouse WISP-2, like the mouse WISP-1 molecule, encodes a novel secreted protein that belongs to the CTGF family and is the mouse homologue of SST DNA33473 of Example 4. (The alignment of human and mouse WISP-2 (SEQ ID NOS:16 and 20, respectively) is shown in Figure 9.) The mouse WISP-2 gene is 38% identical in sequence to mouse WISP-1, disclosed in Example 1, but lacks the C-terminal 95 amino acids thought to be involved in dimerization and receptor binding. Mouse WISP-2 was highly expressed in the lung. *In-situ* analysis of the clone is noted below. The nucleotide sequence and putative amino acid sequence of full-length mouse WISP-2 are shown in Figure 2 (SEQ ID NOS:17 and 20, respectively). The putative signal sequence is from amino acid positions 1 to 23 of SEQ ID:20.

The clone was inserted into pRK5E, described above. Upon transformation of JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *Bam*HI and *Not*I, a 1770-bp fragment was obtained, having a mouse insert of 756 bp from ATG to the stop codon.

EXAMPLE 3: Isolation of a cDNA Clone Encoding Human WISP-1

5 To isolate the full-length human clone corresponding to m568.19A (mouse WISP-1), a human lung cDNA library (Clontech), treated with the SUPERScript™ kit using the pRK5E vector as described above, was screened with a 70-bp probe at low stringency (20% formamide, 1 X SSC, 55°C wash). The probe had the sequence from nucleotides 909-978 of the full-length mouse WISP-1 nucleotide sequence of Figure 1, *i.e.*, the sequence:

10 5'-CCAGCCAGAGGAGGCCACGAACTTCACTCTCGCAGGCTGTGTCAGCACACGCACCTACC  
GACCCAAGTAC (SEQ ID NO:113)

Only one clone was identified, hL.568.15A. The insert to this clone was subcloned into pBLUESCRIPT™ IISK+ and its DNA sequence determined by dideoxy DNA sequencing on both strands. This clone was found to be missing about 280 amino acids. Hence, a new probe (hu.568.50mer.1) was designed from clone 15A having the nucleotides 750-799 of the full-length human WISP-1 nucleotide sequence shown in Figures 3A and 3B, *i.e.*,

5'-GCCCCTGGAGCCCTTGCTCCACCAGCTGCGGCCTGGGGGTCTCCACTCGG (SEQ ID NO:114)

This probe was used to screen a human fetal kidney cDNA library (Clontech), treated with the SUPERScript™ kit using the pRK5E vector as described above, by colony hybridization. A number of  
20 clones were obtained by screening this human fetal kidney cDNA library (clones without the A or B designation) or by screening a human fetal kidney λgt10 library (clones with the A or B designation) using the same probes described above. The inserts of these clones were subcloned into pBLUESCRIPT™ IISK+ and their DNA sequences determined by dideoxy DNA sequencing on both strands.

Two of these clones, designated as 568.1A and 568.4A, have their respective sequences (SEQ ID  
25 NOS:24 and 26) shown in Figures 27 and 29. These clones are missing the von Willebrand C1 domain, the variable domain, and the thrombospondin 1 domain, and have a frameshift. Other clones, designated as 568.13, 568.39, 568.5A, 568.6B, and 568.7 (SEQ ID NOS:23, 25, 27, 28, and 29, respectively; Figs. 26, 28, and 30-32, respectively), were obtained that lack one or more domains and/or short amino-acid stretches (*e.g.*, an 8- amino-acid deletion) or contain additional short amino-acid stretches and may contain introns or  
30 alternative splice variants.

Two clones sharing a significant amount of sequence with the full-length clone 568.38 were identified: 568.23 and 568.35. Human clone 568.38 encoded the full-length human WISP-1. The nucleotide sequence and putative amino acid sequence for clone 568.38 are shown in Figures 3A and 3B (SEQ ID NOS:1 and 4, respectively). The aligning sequences of clones 568.38 and 568.35 differ from the  
35 corresponding aligning sequences of clones 568.15A and 568.23 in that the respective sequences of the latter two clones have an isoleucine residue at amino acid position 184 of Figs. 3A and 3B, whereas the respective corresponding sequences of clones 568.38 and 568.35 have a valine residue at this position. Further, the aligning sequences of clones 568.35 and 568.38 differ from each other in that the sequence of clone 568.35

has a serine residue at amino acid position 202 of Figs. 3A and 3B, whereas the corresponding sequence of clone 568.38 has an alanine residue at this position.

The human WISP-1 polypeptide, by homology searching, is also found to be a member of the CTGF family. The clone was placed in a pRK5E plasmid as described above and deposited with the ATCC. Upon transformation into JM109 cells, the plasmid rendered the cells ampicillin resistant. Digestion with *Cla*I and *Eco*RV yielded a 1435-bp fragment with an insert size of 1104 basepairs from ATG to the stop codon.

*In situ* hybridization of human WISP-1 was performed, with the results given below. Northern analysis of human WISP-1 showed high expression in adult heart tissue and ovary tissue, and in fetal kidney tissue. Also presented below are thymidine incorporation assay, gene amplification assay, and angiostatic assay results.

The chromosomal location of the human WISP genes was determined by radiation hybrid mapping using the Stanford G3<sup>TM</sup> and the MIT Genebridge 4 Radiation Hybrid<sup>TM</sup> panels. WISP-1 resides at approximately 3.48 cR from the meiotic marker AFM259xc5 (LOD score 16.31) on the Genebridge map. This places WISP-1 in band 8q24.1 to 8q24.3, roughly four megabases distal to *c-myc* located at chromosome band 8q24.12-8q24.13. Takahashi *et al.*, Cytogenet. Cell Genet., 57: 109-111 (1991). *c-myc* is a region that is a recurrent site of amplification in non-small cell lung carcinoma.

#### EXAMPLE 4: Isolation of a cDNA Clone Encoding Human PRO261 (designated herein as human WISP-2)

The extracellular domain (ECD) sequences (including the secretion signal, if any) of from about 950 known secreted proteins from the SWISS-PROT<sup>TM</sup> public protein database were used to search expressed sequence tag (EST) databases. The EST databases included public EST databases (*e.g.*, GenBank) and a proprietary EST DNA database (LIFESEQ<sup>TM</sup>, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST2 (Altschul *et al.*, Methods in Enzymology 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6-frame translation of the EST sequence. Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, Washington: <http://bozeman.mbt.washington.edu/phrap.docs/phrap.html>).

A consensus DNA sequence was assembled relative to other EST sequences using phrap. The EST sequences used (from Incyte) were Nos. 2633736, 2118874, 360014, 2316216, 1985573, 2599326, 1544634, 2659601, 1319684, 783649, 627240, 1962606, 2369125, 939761, 1666205, 692911, 984510, 1985843, 2104709, and 2120142. This consensus sequence is herein designated DNA30843 (see Fig. 5). Based on the DNA30843 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PRO261 (human WISP-2). A pair of PCR primers, forward and reverse, were synthesized having the respective sequences:

5'-AAAGGTGCGTACCCAGCTGTGCC (SEQ ID NO:115) and  
3'-TCCAGTCGGCAGAAGCGGTTCTGG (SEQ ID NO:116).

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA30843 sequence, which probe has the sequence:

5'-CCTGGTGCTGGATGGCTGTGGCTGCTGCCGGGTATGTGCACGGCGGCTGGG (SEQ ID NO:117).

For screening several libraries for a source of a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel *et al.*, Current Protocols in Molecular Biology (Green Publishing Associates and Wiley Interscience, N.Y., 1989), with the PCR primer pair identified above. A positive library was then screened by colony hybridization to isolate clones encoding PRO261 (human WISP-2) using the probe oligonucleotide and one of the PCR primers.

RNA for construction of the cDNA libraries was isolated from human fetal lung tissue. The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a *NorI* site, linked with blunt-to-*SaII*-hemikinased adaptors, cleaved with *NorI*, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRK5B or pRK5D; pRK5B is a precursor of pRK5D that does not contain the *SfiI* site; see Holmes *et al.*, Science, 253:1278-1280 (1991)) in the unique *XhoI* and *NorI* sites.

DNA sequencing of the clones isolated as described above gave the DNA sequence for PRO261 (herein designated as UNQ228 (DNA33473-seqmin); SEQ ID NO:38), which begins at nucleotide 13 of SEQ ID NO:13 (Fig. 4) and the derived amino acid sequence for PRO261 (SEQ ID NO:16).

The entire nucleotide sequence encoding human WISP-2 is shown in Figure 4 (SEQ ID NO:13). This sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 22-24 of SEQ ID NO:13 and ending at the stop codon after nucleotide 770 of SEQ ID NO:13 (Figure 4). The predicted polypeptide precursor is 250 amino acids long (Figure 4). The putative signal sequence spans from amino acid positions 1 to 23 of SEQ ID NO:16. Clone UNQ228 (DNA33473-seq min) has been deposited with ATCC and is assigned ATCC deposit no. 209391.

Analysis of the amino acid sequence of the full-length PRO261 polypeptide suggests that portions of it possess significant homology to CTGF, thereby indicating that PRO261 is a novel growth factor.

*In situ* hybridization of human WISP-2 is given below. The chromosomal location of the human WISP-2 gene was determined as described above for human WISP-1. Specifically, WISP-2 is linked to the marker SHGC-33922, with a LOD score of 1000. This places WISP-2 in band 20q12-20q13.1. Human chromosome 20q12 is a frequent site of DNA amplification in human breast cancer. In a *Xenopus* assay, injection of human WISP-2 RNA partially induced axis duplication (see Example 11). Also presented below are thymidine incorporation assay, gene amplification assay, and angiostatic assay results for human WISP-2.

#### EXAMPLE 5: Isolation of cDNA Clones Encoding Human WISP-3

In this example, the gene encoding WISP-3 was cloned twice essentially in parallel. First, it was determined whether the databases described above contained any new members of the WISP family. Two EST homologies to the WISPs were found and both were cloned. Full-length clones were isolated corresponding to each of these EST homologies. The efforts resulted in two full-length clones of the same gene (the original EST homologies had been from distinct regions of the same gene). The first clone obtained was designated as DNA56350 and the second as DNA58800.



DNA56350

Based on the sequence of INCYTE 3208053, a virtual DNA 48917 was obtained and oligonucleotides were synthesized for use as probes to isolate a clone of the full-length coding sequence for PRO956 (human WISP-3). A pair of PCR primers, forward and reverse, were synthesized having the sequences:

5'-GTCTTGTGCAAGCAACAAAATGGACTCC (SEQ ID NO:118)

3'-GACACAATGTAAGTCGGAACGCTGTCTG (SEQ ID NO:119)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the INCYTE sequence, which probe has the sequence:

10 5'-GCTCCAGAACATGTGGGATGGGAATATCTAACAGGGTGACCAATGAAAAQ (SEQ ID NO:120)

A human fetal kidney library primed with oligo dT containing a *XhoI*-*NotI* size cut greater than 3700 kb was screened for a source of a full-length clone by PCR amplification with the PCR primer pair identified above. The positive library was then used to isolate clones encoding PRO956 (human WISP-3) using the probe oligonucleotide and one of the PCR primers.

15 DNA sequencing of the clone isolated as described above gave the DNA sequence for PRO956 (herein designated as UNQ462 (SEQ ID NO:30), and the derived amino acid sequence for PRO956 (SEQ ID NO: 33).

The entire nucleotide sequence encoding human WISP-3 from this clone is shown in Figure 6 (SEQ ID NO:30). This sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 46-48 of SEQ ID NO:30 and ending at the stop codon after nucleotide 1161 of SEQ ID NO:30 (Figure 6). The predicted polypeptide precursor is 372 amino acids long (Figure 6). The putative signal sequence is from amino acid positions 1 to 33 of SEQ ID NO:33. Clone UNQ462 (DNA56350-1176-2) has been deposited with ATCC and is assigned ATCC deposit no. 209706.

25 Analysis of the amino acid sequence of the full-length PRO956 polypeptide suggests that portions of it possess significant homology to CTGF, thereby indicating that PRO956 is a novel growth factor. This clone has an additional methionine just 5' of the first methionine in this clone. The amino acid sequence of this clone is 42% homologous to that of human WISP-1, and 32% homologous to that of human WISP-2.

30 *In situ* hybridization of human WISP-3 is shown below. Using the mapping techniques set forth above, it was found that human WISP-3 was localized to chromosome 6q22-6q23 and was linked to the marker AFM211ze5 with a LOD score of 1000. WISP-3 is approximately 18 megabases proximal to CTGF and 23 megabases proximal to the human cellular oncogene MYB, which are also located at 6q22-6q23. Martinerie *et al.*, Oncogene, 7: 2529-2534 (1992); Meese *et al.*, Genes Chromosomes Cancer, 1: 88-94 (1989).

35 The clone was inserted into pRK5E, described above. Upon transformation of JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *Bam*HI and *Not*I, a fragment was obtained having a human insert from ATG to the stop codon as indicated in Figure 6.

DNA58800

Based on the sequence of HS142L7, a virtual DNA 56506 was obtained and oligonucleotides were synthesized for use as probes to isolate a clone of the full-length coding sequence for PRO790 (human WISP-3). To this end, a pair of PCR primers, forward and reverse, were synthesized having the sequences:

- 5 5'-CCTGGAGTGAGCCTGGTGAGAGA (SEQ ID NO:121)  
3'-ACACTGGGTGTGTTTCCCGACATAACA (SEQ ID NO:122)

Additionally, a synthetic oligonucleotide hybridization probe was constructed from the HS142L7 sequence, which probe has the sequence:

- 5'-TGGTTGCTTGGCACAGATTTTACAGCATCCACAGCCATCTCTCA (SEQ ID NO:123)  
10 A human bone marrow library primed with oligo dT containing a *XhoI*-*NotI* size cut of 1-3 kb was screened for a source of a full-length clone by PCR amplification with the PCR primer pair identified above. The positive library was then used to isolate clones encoding PRO790 (human WISP-3) using the probe oligonucleotide and one of the PCR primers.

- DNA sequencing of the clone isolated as described above gave the DNA sequence for PRO790 (SEQ ID NO:34), and the derived amino acid sequence for PRO790 (SEQ ID NO:37).  
15

- The entire nucleotide sequence encoding human WISP-3 from this clone is shown in Figure 7 (SEQ ID NO:34). This sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 16-18 of SEQ ID NO:34 and ending at the stop codon after nucleotide 1077 of SEQ ID NO:34 (Figure 7). The predicted polypeptide precursor is 355 amino acids long (Figure 7). The putative signal sequence spans from amino acid positions 1 to 15 of SEQ ID NO:37. This clone DNA58800-1176-2  
20 has been deposited with ATCC and is assigned ATCC deposit no. 209707.

- Analysis of the amino acid sequence of the full-length PRO790 polypeptide suggests that portions of it possess significant homology to CTGF, thereby indicating that, like PRO956 which is a splice variant thereof, PRO790 is a novel growth factor.

- 25 *In situ* hybridization of human WISP-3 is shown below.

The clone was inserted into pRK5E, described above. Upon transformation of JM109 cells, the plasmid rendered the cells ampicillin resistant. Upon digestion with *Bam*HI and *Not*I, a fragment was obtained having a human insert from ATG to the stop codon as indicated in Figure 7.

EXAMPLE 6: Use of WISP-Encoding DNA as a Hybridization Probe

- 30 The following method describes use of a nucleotide sequence encoding a WISP polypeptide as a hybridization probe.

- DNA comprising the coding sequence of full-length or mature human WISP-1 (as shown in Figures 3A and 3B, SEQ ID NOS:4 or 3, respectively), or full-length or mature mouse WISP-1 (as shown in Figure 1, SEQ ID NOS:12 or 11, respectively), or of full-length or putative mature human WISP-2 (as shown in Fig. 4, SEQ ID NOS:16 or 15, respectively), or full-length or putative mature mouse WISP-2 (as shown in Figure 2, SEQ ID NOS:20 or 19, respectively) is employed as a probe to screen for homologous DNAs (such as those encoding naturally occurring variants of these particular WISP proteins in human tissue cDNA libraries or human tissue genomic libraries).  
35

Hybridization and washing of filters containing either library DNAs is performed under the following high-stringency conditions. Hybridization of radiolabeled WISP-polypeptide-derived probe (such as UNQ228 (DNA33473-seqmin)-derived probe) to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

DNAs having a desired sequence identity with the DNA encoding a full-length, native-sequence WISP polypeptide can then be identified using standard techniques known in the art.

#### EXAMPLE 7: Expression of WISP Polypeptide in *E. coli*

This example illustrates preparation of an unglycosylated form of WISP polypeptide by recombinant expression in *E. coli*.

The DNA sequence encoding WISP polypeptide is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar *et al.*, Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR-amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode an antibiotic-resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the WISP-coding region, lambda transcriptional terminator, and an *argU* gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook *et al.*, *supra*. Transformants are identified by their ability to grow on LB plates, and antibiotic-resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger-scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After the cells are cultured for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the WISP polypeptide can then be purified using a metal-chelating column under conditions that allow tight binding of the protein.

#### EXAMPLE 8: Expression of WISP Polypeptide in Mammalian Cells

This example illustrates preparation of a potentially glycosylated form of WISP polypeptide by recombinant expression in mammalian cells.

The vector, pRK5E, was employed as the expression vector. The appropriate DNA encoding WISP polypeptide was ligated into pRK5E with selected restriction enzymes to allow insertion of the DNA for WISP polypeptide using ligation methods as described in Sambrook *et al.*, *supra*. The resulting vectors were pRK5E.h.WIG-1.568.38, pRK5E.m.WIG-1.568.6his, pRK5E.m.WIG-2.1367.3, plasmid encoding human

WISP-2, DNA56350-1176-2, and DNA58800-1176-2, all deposited at the ATCC. These vectors are conveniently referred to collectively as pRK5E.WISP in the general description below.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10  $\mu$ g pRK5E.WISP DNA is mixed with about 1  $\mu$ g DNA encoding the VA RNA gene (Thimmappaya *et al.*, Cell, 31:543 (1982)) and dissolved in 500  $\mu$ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M  $\text{CaCl}_2$ . To this mixture is added, dropwise, 500  $\mu$ l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM  $\text{NaPO}_4$ , and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in phosphate-buffered saline (PBS) is added for 30 seconds. The 293 cells are then washed with serum-free medium, fresh medium is added, and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200  $\mu$ Ci/ml  $^{35}\text{S}$ -cysteine and 200  $\mu$ Ci/ml  $^{35}\text{S}$ -methionine. After a 12-hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of the WISP polypeptide. The cultures containing transfected cells may undergo further incubation (in serum-free medium) and the medium is tested in selected bioassays.

In an alternative technique, the WISP polypeptide may be introduced into 293 cells transiently using the dextran sulfate method described by Sompayrac *et al.*, Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700  $\mu$ g pRK5E.WISP DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5  $\mu$ g/ml bovine insulin, and 0.1  $\mu$ g/ml bovine transferrin. After about four days, the conditioned media are centrifuged and filtered to remove cells and debris. The sample containing expressed WISP polypeptide can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, the WISP polypeptide can be expressed in CHO cells. The pRK5E.WISP can be transfected into CHO cells using known reagents such as  $\text{CaPO}_4$  or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as  $^{35}\text{S}$ -methionine. After determining the presence of the WISP polypeptide, the culture medium may be replaced with serum-free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed WISP polypeptide can then be concentrated and purified by any selected method.

Epitope-tagged WISP polypeptide may also be expressed in host CHO cells. The WISP polypeptide may be subcloned out of the pRK5 vector. Suva *et al.*, Science, 237: 893-896 (1987); EP 307,247 published 3/15/89. The subclone insert can undergo PCR to fuse in-frame with a selected epitope tag such as a poly-his tag into a baculovirus expression vector. The poly-his-tagged WISP polypeptide insert can then be subcloned into a SV40-driven vector containing a selection marker such as DHFR for selection of stable clones. Finally,

the CHO cells can be transfected (as described above) with the SV40-driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His-tagged WISP can then be concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

5 In particular, mouse WISP-1 cDNA for insertion into mammalian expression vectors was created via PCR using clone m568.19A (see above) pure phage DNA as template and using as primers m.568.pcr.top4 (5'-TGACTTCCAGGCATGAGGTGGCTCCTG; SEQ ID NO:124) and m.568.pcr.bot3 (5'-ATTGGCAATCTCTTCGAAGTCAGGGTAAGATTCC; SEQ ID NO:125) for the 6-his version, or m.568.pcr.top4 (SEQ ID NO:124) and 568.pcr.bot5, which has a 3'-terminal *Xba*I site (5'-GGTACGTCTAGACTAATTGGCAATCTCTTCGAAGTCAGGG; SEQ ID NO:126) for the non-his version.  
10 The insert integrity was confirmed by sequencing and analyzed. The PCR was run using *Pfu* polymerase and the conditions were:

|                 | <u>temp.</u> | <u>time</u> |
|-----------------|--------------|-------------|
| denaturation    | 94°C         | 1 min       |
| 15 annealing    | 62°C         | 30 sec      |
| extension       | 72°C         | 1.5 min     |
| # of cycles: 25 |              |             |

For transient expression in 293 cells analyzed by Western blot, the above inserts were ligated into the pRK5 vector referred to above at the *Bam*HI/*Xba*I site using the BOEHRINGER MANNHEIM™ rapid  
20 ligation kit. The resulting plasmids were designated pRK5.mu.WISP-1.6his and pRK5.mu.WISP-1.nohis for the His-tagged and non-His-tagged inserts, respectively. Then the 293 cells were plated and allowed to reach approximately 85% confluency overnight (37°C/5%  $\text{CO}_2$ ). The plated cells were transfected with plasmid DNA pRK5.mu.WISP-1.6his or pRK5.mu.WISP-1.nohis by using lipofectamine (Gibco BRL) at a 4.5:1 lipid:DNA ratio.

25 Transfection efficiency (>70% usually) was monitored using a GFP expression plasmid (pGREEN LANTERN™ from Gibco BRL). Approximately 5 hours post-transfection, the medium was changed to fresh SF media (50:50 with 1X L-Glu and 1X P/S) for protein production. The conditioned media was allowed to accumulate for specified amounts of time (depending on the experiment) before harvesting.

The medium was harvested and concentrated in the presence of 1 mM PMSF using the  
30 CENTRICON-10™ concentrator. The concentrated, conditioned media (usually 1.5 ml) was then bound to  $\text{Ni}^{++}$ NTA agarose beads (Qiagen) for 2 hours (for the His-tagged version only). Protein was eluted from the beads by boiling for 10 minutes in 2X SDS loading buffer (Novex) with or without beta-mercaptoethanol for reduced vs. non-reduced protein, respectively.

The protein was visualized by SDS-PAGE using 4-20% gradient TRIS-glycine gels, 10-wells, 1 mm  
35 thickness (Novex). Gels ran at 125 volts (constant) for 95 minutes. Western transfer was achieved using a NOVEX™ transfer apparatus to PVDF membranes (Novex) at 200 mA (constant) for 45 minutes. The blots were blocked for a minimum of 1 hour at room temperature in blocking buffer (PBS + TWEEN-20™ (0.5%), 5% dry milk, and 3% goat serum). Blots were incubated in primary antibody (for His-tagged protein: INVITROGEN™ anti-his(C-terminal)-HRP-conjugated antibody or for the non-His version: polyclonal anti-



murine WISP-1 antibody prepared as described below) at a 1:2000 dilution in fresh blocking buffer for 1 hour at room temperature. The non-His-tagged protein blots were incubated in secondary antibody (PIERCE<sup>TM</sup> goat anti-rabbit IgG(H+L) HRP conjugated) diluted 1:2000 in fresh blocking buffer. The blots were incubated in chemiluminescent substrate (ECL<sup>TM</sup> from Amersham or SUPERSIGNAL<sup>TM</sup> from Pierce) for 1 minute before exposing to film.

For transient expression analyzed by antibody staining, 293 cells were cultured, plated, and transfected as described above. The cells were fixed to culture dishes for 2 minutes in 1:1 methanol:acetone solution. Fixed cells were then incubated in primary antibody (for His-tagged protein: INVITROGEN<sup>TM</sup> anti-his(C-term)-HRP-conjugated antibody or for the non-His version: polyclonal anti-murine WISP-1 antibody prepared as described below) diluted 1:1000 in PBS with 10% fetal bovine serum for 2 hours. The non-His-tagged protein blots were then incubated in secondary antibody (PIERCE<sup>TM</sup> goat anti-rabbit IgG(H+L) HRP conjugated) diluted 1:150 in PBS with 10% fetal bovine serum for 1 hour. The incubation was in color reagent substrate for HRP for up to 1 hour (1.0% O-dianisidine-saturated ETOH, 0.01% hydrogen peroxide in PBS).

For stable expression of mouse WISP-1 in mammalian cells, the starting vector employed was pRK5.CMV.puro-dhfr, the sequence of which is shown in Figures 16A-16D. This vector has two SAR sequences cloned into *KpnI*, *SapI* sites of the SVI5 splice-donor vector, and has the pSVI backbone with the pRK5 cloning linker (pSVI5) and the intron made from pSVI.WTSD.D by adding a linearization linker (LL) into the *HpaI* site. The sequence is edited to include changes in vector puc118 backbone derived from the sequence of pRK5 and includes a four-base insertion after MCS characteristic of the SVI vector.

The above inserts were ligated into pRK5.CMV.puro-dhfr at the *BamHI/XbaI* site using the BOEHRINGER MANNHEIM<sup>TM</sup> rapid ligation kit, producing pRK5.CMV.puro-dhfr.mu.WISP-1.6his or pRK5.CMV.puro-dhfr.mu.WISP-1.nohis. This construct allows for stable selection of expressing cells using either puromycin (2 µg/ml in 293 cells or 10 µg/ml in CHO-DP12 cells) or the DHFR deletion in the CHO-DP12 line, which allows for subsequent amplification in methotrexate. Isolated colonies representative of stably transfected cells were picked, cultured under selective pressure, and analyzed by antibody staining or Western blot as described above.

#### EXAMPLE 9: Expression of WISP Polypeptide in Yeast

The following method describes recombinant expression of a WISP polypeptide in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of a WISP polypeptide from the ADH2/GAPDH promoter. DNA encoding a WISP polypeptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression. For secretion, DNA encoding a WISP polypeptide can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native WISP signal peptide or other mammalian signal peptide or yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be

analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant WISP polypeptide can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing the WISP polypeptide may further be purified using selected column chromatography resins.

EXAMPLE 10: Expression of WISP Polypeptide in Baculovirus-Infected Insect Cells and Purification Thereof

The following method describes recombinant expression of a WISP polypeptide in baculovirus-infected insect cells, and purification thereof.

General

The sequence coding for WISP polypeptide is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-His tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding WISP polypeptide or the desired portion of the coding sequence (such as the sequence encoding the mature protein if the protein is extracellular) is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BACULOGOLD™ virus DNA (Pharmlngen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from Gibco-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley *et al.*, Baculovirus Expression Vectors: A Laboratory Manual (Oxford: Oxford University Press, 1994).

Expressed poly-His-tagged WISP polypeptide can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert *et al.*, Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL HEPES, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8), and filtered through a 0.45 µm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water, and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes non-specifically bound protein. After reaching A<sub>280</sub> baseline again, the column is developed with a 0 to 500 mM imidazole gradient in the secondary wash buffer. One-mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with Ni<sup>2+</sup>-NTA-conjugated to alkaline phosphatase (Qiagen).

Fractions containing the eluted His<sub>10</sub>-tagged WISP polypeptide are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG-tagged (or Fc-tagged) WISP polypeptide can be performed using known chromatography techniques, including, for instance, Protein A or protein G column chromatography.

### Specific

#### 1. Expression

In particular, mouse WISP-1 polypeptide was expressed in a baculovirus expression system similar to that described above using as the baculovirus transfer vector pb.PH.mu.568.9.IgG.baculo or pbPH.mu.568.8his.baculo. Figures 17A-17D show the sequence (SEQ ID NO:54) of plasmid pb.PH.IgG, which was used to prepare pb.PH.mu.568.9.IgG.baculo. Figures 18A-18D show the sequence (SEQ ID NO:55) of plasmid pbPH.His.c, which was used to prepare pbPH.mu.568.8his.baculo.

Both of these baculovirus transfer vectors are based on pVL1393 (Pharmingen), which has neither the His nor Fc tags. The pb.PH.IgG vector (Fig. 17) allows the expression of foreign proteins under control of the AcNPV polyhedrin promoter, which is active in the very late phase of virus infection. The foreign protein can be expressed as a C-terminal human IgG fusion protein. The His(8)-tag will not be translated as a result of the IgG stop codon just 5' of the His(8)-tag. The sequence encoding the foreign protein should be inserted as a 3' blunt-ended fragment into the unique *Sma*I site preceding the His-tag. In that case an additional proline residue will be added. The 5' site can be either *Bam*HI, *Eco*RI, *Not*I, *Nco*I, and *Nhe*I.

The IgG vector was constructed by *Nde*I digestion of the pVL1393.IgG plasmid followed by Klenow treatment to fill in the sticky end site. This is followed by a *Nco*I digest and insertion into the pbPH.His.c x *Nco*I/*Sma*I-digested vector.

The sequence of pbPH.His.c shown in Figs. 18A-18D contains the backbone sequence of the vector pVL1392, which contains approximately the *Eco*RI/*Xma*III fragment of AcMNPV C-6, from position 0.0 to 5.7 mu. Possee *et al.*, *Virology*, **185**: 229-241 (1991). It allows the expression of foreign proteins under control of the *Autographa californica* nuclear polyhedrosis virus (AcNPV) polyhedrin gene promoter, which is active in the very late phase of virus infection.

The foreign protein can be expressed as a C-terminally His- or a IgG (Fc region only)-tagged protein. The sequence encoding the foreign protein should be inserted as a 3'-blunt-ended fragment into the unique *Sma*I site preceding the His-tag or the *Sma*I site for IgG. In that case an additional glycine residue will be added for His tags and a proline will be added for IgG tags. The 5' site can be either *Bam*HI, *Not*I, *Eco*RI, or *Nco*I. *Bam* HI was used for both.

The vectors were constructed by inserting a PCR insert into *Bam*HI/*Sma*I for the His vector and *Bam*HI/*Sma*I for the IgG vector. The PCR insert was made using 5'-phosphorylated primers as follows: m.568.pcr.top6(5'-TTTCCCTTTGGATCCTAAACCAACATGAGGTGGCTCCTGCCC; SEQ ID NO:127) and m.568.pcr.bot3(SEQ ID NO:125), 5' phosphorylated. A twenty-cycle PCR reaction with Pfu polymerase enzyme was performed using the following conditions: 1 min at 95°C, 30 sec at 60°C, 3.5 min at 72°C. The PCR product was purified with QIAQUICK<sup>TM</sup> and digested with *Bam*HI at 37°C for 1 hr. The digested PCR insert was ligated into the digested vector using a 1:3 ratio of insert to vector with 1 µl T4 DNA ligase (Bio

Labs). ULTRA MAX<sup>TM</sup> DH5a FT competent cells. 100  $\mu$ l. (Gibco BRL Cat #10643-013) were added to the ligation product, and the mixture was incubated on ice for 30 min. followed by a heat shock at 42°C for 45 sec. Individual colonies were picked and miniscreen DNA was prepared using QIA PREP<sup>TM</sup> (Qiagen). Construct sequencing was performed using ABI Prism's dRHODAMINE DYE<sup>TM</sup> terminator cycle sequencing.

The plasmid pb.PH.IgG has a polylinker *Bam*HI-*Not*I-*Eco*RI-*Nco*I-*Srf*I-*Stu*I-(IgG Fc region only)-Stop-*Xba*I-*Spe*I-*Pst*I-*Bgl*II. The location of particular regions in this plasmid is as follows: Insertion of polylinker/foreign gene: 4129-4912 (*Bam*HI-*Bgl*II), polh coding: 4913-5479, ORF 1629: 7134-4820; ORF 588 (PK1): 7133-7723; ColEI origin of replication: 7973-8858, and ampicillin coding: 9779-8230. The plasmid pbPH.His.c has a polylinker *Bam*HI-*Not*I-*Eco*RI-*Nco*I-*Srf*I-*Sma*I-(His8)-Stop-*Xba*I-*Spe*I-*Pst*I-*Bgl*II. The *Nco*I site of pbPH.His.c resides within a Kozak sequence. The location of particular regions in this plasmid is as follows: ORF 504 (PTP): 76-582, ORF 984 (ORF2): 1600-614, ORF 453 (ORF3): 2323-1868, conotoxin: 1818-1657, ORF 327 (ORF4): 2352-2681, ORF 630 (lef-2): 2662-3294, ORF 603: 3937-3332, ORF polh: 4093 (mutated codon ATG/ATT), insertion of polylinker/foreign gene: 4129-4218 (*Bam*HI-*Bgl*II), polh coding: 4224-4790, ORF 1629: 6445-4820, ORF 588 (PK1): 6444-7034, ColEI origin of replication: 7284-8169, and ampicillin coding: 9090-8230.

The mouse WISP-1 cDNA disclosed herein was inserted into the vectors pbPH.His.c and pb.PH.IgG to produce the respective expression plasmids by creating a 3' blunt-ended fragment for cloning into the unique *Sma*I site preceding the His-tag or IgG-tag. An additional glycine residue was added to the His protein produced. An additional proline was added to the IgG protein. The 5' site of the cDNA insert was *Bam*HI.

## 2. Purification

For purification purposes, either a poly-His tag or the Fc portion of human IgG was added to the C-terminal coding region of the cDNA before expression. The conditioned media from the transfected cells (0.5 to 2 L) was harvested by centrifugation to remove the cells and filtered through 0.22 micron filters. For the poly-His-tagged constructs, the protein was purified using a Ni<sup>+2</sup>-NTA column (Qiagen). Before purification, imidazole was added to the conditioned media to a concentration of 5 mM. The conditioned media was pumped onto a 6-ml Ni<sup>+2</sup>-NTA column equilibrated in 20 mM HEPES, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min at 4°C. After loading, the column was washed with additional equilibration buffer and the protein was eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein was subsequently desalted into a storage buffer containing 10 mM HEPES, 0.14 M NaCl, and 4% mannitol, pH 6.8, with a 25 ml G25 SUPERFINE<sup>TM</sup> (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs of WISP-1 protein were purified from the conditioned media as follows. The conditioned media was pumped onto a 5-ml Protein A column (Pharmacia) which had been equilibrated in a 20 mM Na phosphate buffer, pH 6.8. After loading, the column was washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein was immediately neutralized by collecting 1-ml fractions into tubes containing 275  $\mu$ L of 1 M Tris, pH 9, buffer. The highly purified protein was subsequently desalted into storage buffer as described above for the poly-His-

tagged proteins. The homogeneity of the protein was assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

#### EXAMPLE 11: Axis Duplication Assay

*Xenopus* embryos were injected with human WISP-2 mRNA into either a presumptive ventral or presumptive dorsal vegetal blastomere at the 8- to 16-cell stage to overexpress locally the encoded protein and assay for its developmental effects. The methods used are described in Sokol *et al.*, Cell, 67: 741-752 (1991).

More specifically, for synthesis of capped RNA, human WISP-2 and mouse Wnt-1 cDNAs were cloned into the pGEMHE vector (gift of Dr. Todd Evans, AECOM) to prepare pGEMHE.hu.WISP-2.8H and pGEMHE.mu.Wnt-1, respectively. The constructs were linearized at the 3' end using the *SphI* restriction enzyme. Capped RNAs were synthesized using AMBION's T7 MESSAGEMACHINE™ RNA synthesis kit.

For obtaining mature oocytes, an adult female *Xenopus laevis* was injected with 200 I.U pregnant mare serum 3 days before use. The night before the experiment, the female frog was injected with 800 I.U of human chorionic gonadotropin. Fresh oocytes were squeezed from female frogs the next morning. *In vitro* fertilization of oocytes was performed by mixing oocytes with minced testes from a sacrificed male frog. Fertilized eggs were dejellied with 2% cysteine (pH 7.8) for 10 minutes. Dejellied eggs were washed once with distilled water and transferred to 0.1 x Modified Barth's Solution (MBS) (Methods in Cell Biology, Volume 36, *Xenopus laevis*: Practical uses in Cell and Molecular Biology, Kay and Peng, Eds (New York: Academic Press, 1991)) with 5% Ficoll. Eggs were lined on injection trays which contained 0.1 x MBS with 5% Ficoll for injection. After injection, embryos were kept in 0.1X MBS in an 18°C incubator. Embryos were staged according to Nieuwkoop and Faber, Normal Table of *Xenopus laevis*: (Daudin) (Amsterdam: North-Holland, 1967).

For animal cap assays, embryos were injected at the 2-cell stage with 1 ng of capped RNA, and animal caps were isolated at stage 8 and cultured in 1 x MMR for another 24 hours for the RT-PCR assay. Total RNA was isolated from harvested animal caps using a RNEASY™ kit (Qiagen). RNA samples (approximately 1 µg) were reverse transcribed using random hexamer and GIBCO BRL SUPERScript II™ reverse transcriptase. The annealing temperature for the PCR reactions was 55°C unless noted otherwise.

For axis duplication assays, embryos at the 8-cell stage were injected with 1 ng capped RNA at either the dorsal or ventral vegetal blastomere and incubated in 0.1X MBS for 72 hours.

The sequences of PCR primers used in this experiment were:

|                  |   |
|------------------|---|
| EF-1a.U:         | 5'-CAGATTGGTGCTGGATATGC (SEQ ID NO:128)   |
| EF-1a.D:         | 5'-ACTGCCTTGATTACTCCTAC (SEQ ID NO:129)   |
| noggin.U:        | 5'-AGTTGCAGATGTGGCTCT (SEQ ID NO:130)     |
| noggin.D:        | 5'-AGTCCAAGAGTCTCAGCA (SEQ ID NO:131)     |
| goosecoid.U:     | 5'-ACAACCTGGAAGCACTGGA (SEQ ID NO:132)    |
| goosecoid.D:     | 5'-TCTTATTCCAGAGGAACC (SEQ ID NO:133)     |
| cardiac-actin.U: | 5'-TCCCTGTACGCTTCTGGTCGTA (SEQ ID NO:134) |
| cardiac-actin.D: | 5'-TCTCAAAGTCCAAAGCCACATA (SEQ ID NO:135) |



NCAM.U: 5'-CACAGTTCCAGCAAATAC (SEQ ID NO:136)

NCAM.D: 5'-GGAATCAGGCGGTACAGT (SEQ ID NO:137)

It was found that human WISP-2 can partially induce axis duplication in this assay.

#### EXAMPLE 12: Thymidine Incorporation Assay

5 In a ( $^3\text{H}$ )-thymidine incorporation assay, 19 different cell lines, including RAG (renal adenocarcinoma, mouse) and NRK-49F (normal kidney fibroblasts, rat) cells, identified in Table I below, were plated in 96-well plates at  $3 \times 10^4$  in HGD MEM with 10% serum. Twenty four hours after plating, the medium was changed to HGD MEM with 0.2% serum before adding the test proteins. WISP proteins were added to a final concentration of approximately 3.6 ng/ $\mu\text{l}$ . Serial dilutions were made in a total volume of 10 70  $\mu\text{l}$ /well of fresh media. After 18 hr incubation at  $37^\circ\text{C}$ , 5  $\mu\text{Ci/ml}$  ( $^3\text{H}$ )thymidine was added for 5 hrs. Medium was aspirated and cells were removed with 1X trypsin onto a GF/C filter using Packard's<sup>TM</sup> 96-well FILTERMATE 196<sup>TM</sup>. The filters were dried and 40  $\mu\text{l}$  of scintillation fluid was added for counting on a top count, microplate scintillation counter (Packard).

The results are shown in Table I:

15

TABLE I

#### $^3\text{H}$ -Thymidine Incorporation Assay Results

| Cell line                 | Type   | ATCC No. | mWISP-1 - IgG  | hWISP-1 - IgG    | hWISP-2 -IgG |
|---------------------------|--|----------|----------------|------------------|--------------|
| 20 HT-29<br>(human colon) | adenocarcinoma moderately well-differentiated        | HTB-38   | No change      | No change        |              |
| Wi-Dr<br>(human colon)    | adenocarcinoma                                       | CCL-218  | No change      | No change        |              |
| 25 Calu-1<br>(human lung) | epidermoid carcinoma grade III, metastasis to pleura | HTB-54   | inhibits ~1.1X | inhibits ~1.2X   |              |
| Calu-6<br>(human lung)    | anaplastic carcinoma, probably lung                  | HTB-56   | No change      | stimulates ~1.4X |              |
| SK-MES-1<br>(human lung)  | squamous carcinoma, pleural effusion                 | HTB-58   | No change      | No change        |              |
| 30 A549<br>(human lung)   | carcinoma  | CCL-185  | inhibits ~1.5X | inhibits ~1.7X   |              |
| H460<br>(human lung)      | large cell carcinoma                                 | HTB-177  | inhibits ~1.4X | inhibits ~1.3X   |              |
| 35 SW900<br>(human lung)  | squamous cell carcinoma                              | HTB-59   | no change      | no change        |              |
| MRC5<br>(human lung)      | normal diploid                                       | CCL-171  | no change      | no change        |              |

|    |   |                   |         |                     |                     |                   |
|----|---|-------------------|---------|---------------------|---------------------|-------------------|
|    | IMR-90<br>(human lung)                        | normal diploid    | CCL-186 | stimulates<br>~1.1X | stimulates<br>~1.5X |                   |
| 5  | Wnt-1<br>C57mg<br>(mouse<br>mammary<br>gland) | myo-epithelial    |         | inhibits ~2X        |                     |                   |
|    | MLg (mouse<br>lung)                           | lung              |         | stimulates ~4X      |                     |                   |
| 10 | LL/2 (mouse<br>lung)                          | lung carcinoma    |         |                     | inhibits ~2X        |                   |
|    | JC (mouse<br>mammary<br>gland)                | carcinoma         |         | inhibits ~2X        | inhibits ~3X        |                   |
| 15 | N MuMG<br>(mouse<br>mammary<br>gland)         | normal            |         | stimulates ~2X      | stimulates<br>~1.4X |                   |
| 20 | NRK-49F<br>(rat kidney)                       | normal fibroblast |         | stimulates ~3X      | stimulates<br>~3.5X |                   |
|    | RAG (mouse<br>kidney)                         | adenocarcinoma    |         | stimulates<br>~4.5X | stimulates ~3X      | stimulates<br>~4X |
| 25 | NIH/3T3<br>(mouse<br>embryo)                  | fibroblast        |         | stimulates ~3X      |                     |                   |
|    | UCLA-P3<br>(human lung)                       | carcinoma         |         | inhibits ~1.5X      | inhibits ~2X        |                   |

It is seen that WISP-1 and WISP-2 exhibit both stimulatory and inhibitory effects on proliferation of normal and tumor cells, depending on the cell line employed.

### 30 EXAMPLE 13: Preparation of Antibodies that Bind WISP Polypeptide

#### 1. Polyclonal Antibodies

35 Polyclonal antisera were generated in female New Zealand White rabbits against murine WISP-1 and human WISP-2. The antigens used were proteins fused with histidine for murine WISP-1 and proteins fused with the Fc portion of IgG for human WISP-2. The same protocol was used for both proteins. Each protein was homogenized with Freund's complete adjuvant for the primary injection and with Freund's incomplete adjuvant for all subsequent boosts. For the primary immunization and the first boost, 3.3 µg per kg body weight was injected directly into the popliteal lymph nodes as described in Bennett *et al.*, J. Biol. Chem., 266: 23060-23067 (1991) and "Production of Antibodies by Inoculation into Lymph Nodes" by Morton Sigel *et al.* in Methods in Enzymology, Vol. 93 (New York: Academic Press, 1983). For all 40 subsequent boosts, 3.3 µg per kg body weight was injected into subcutaneous and intramuscular sites. Injections were done every 3 weeks with bleeds taken on the following two weeks.

#### 2. Monoclonal Antibodies

Techniques for producing monoclonal antibodies that can specifically bind a WISP polypeptide are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified WISP polypeptide, fusion proteins containing WISP polypeptide, and cells expressing recombinant WISP polypeptide on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the WISP immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1 to 100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect antibodies to WISP polypeptide.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of a WISP polypeptide. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% PEG) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597, or x63.Ag8.653 (Kearney *et al.*, J. Immunology, 123: 1548 (1979)). The fusions generate hybridoma cells which can then be plated in 96-well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against a WISP polypeptide. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against a WISP polypeptide is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-WISP polypeptide monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel-exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

Specifically, for each of the human WISP-1 antibodies, five female Balb-c mice were pre-bled and then injected via their hind foot pads with purified human WISP-1, tagged with the Fc portion of IgG and emulsified prior to injection in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) in a 1:1 ratio of WISP antigen to adjuvant. The dosing schedule for the WISP-1 immunogen was as follows:

| <u>Injection</u>  |                  |                    |                      |
|-------------------|------------------|--------------------|----------------------|
| <u>Date</u>       | <u>Dose/Site</u> | <u>Dose/Animal</u> | <u>Concentration</u> |
| Day 16 of month 1 | 50 µl/site       | 100 µl/animal      | 6 µg/animal          |
| Day 12 of month 2 | 50 µl/site       | 100 µl/animal      | 6 µg/animal          |
| Day 21            | 50 µl/site       | 100 µl/animal      | 6 µg/animal          |

|    |                      |            |               |             |
|----|----------------------|------------|---------------|-------------|
|    | of month 2           |            |               |             |
|    | Day 28<br>of month 2 | 50 µl/site | 100 µl/animal | 2 µg/animal |
| 5  | Day 4 of<br>month 3  | 50 µl/site | 100 µl/animal | 2 µg/animal |
|    | Day 11 of<br>month 3 | 50 µl/site | 100 µl/animal | 2 µg/animal |
|    | Day 18 of<br>month 3 | 50 µl/site | 100 µl/animal | 2 µg/animal |
| 10 | Day 25 of<br>month 3 | 50 µl/site | 100 µl/animal | 2 µg/animal |

For WISP-1, the mice were bled on Day 10 of month 4. After the mice were bled, the monoclonal antibodies were made by harvesting their spleens and by fusion as indicated above, using as the murine myeloma cell line X63.Ag8.653.

15 The five monoclonal antibodies generated to human WISP-1 are:

|    |          |                |
|----|----------|----------------|
|    | 10F2.2A7 | gamma 2b/kappa |
|    | 10A9.2B1 | gamma 2a/kappa |
|    | 8F7.1B1  | gamma 1/kappa  |
|    | 1H1.1D5  | gamma 1/kappa  |
| 20 | 2G7.2H4  | gamma 1/kappa  |

For WISP-2 monoclonal antibodies the same regimen is employed except that purified human WISP-2 is used as immunogen in the above protocol rather than purified human WISP-1 and the dosing schedule for the WISP-2 immunogen is as follows:

|    |                      |                  |                    |                      |
|----|----------------------|------------------|--------------------|----------------------|
|    | <u>Injection</u>     |                  |                    |                      |
| 25 | <u>Date</u>          | <u>Dose/Site</u> | <u>Dose/Animal</u> | <u>Concentration</u> |
|    | Day 16 of<br>month 1 | 50 µl/site       | 100 µl/animal      | 6 µg/animal          |
|    | Day 21<br>of month 2 | 50 µl/site       | 100 µl/animal      | 1 µg/animal          |
| 30 | Day 28<br>of month 2 | 50 µl/site       | 100 µl/animal      | 1 µg/animal          |
|    | Day 4 of<br>month 3  | 50 µl/site       | 100 µl/animal      | 1 µg/animal          |
| 35 | Day 11 of<br>month 3 | 50 µl/site       | 100 µl/animal      | 1 µg/animal          |
|    | Day 18 of<br>month 3 | 50 µl/site       | 100 µl/animal      | 1 µg/animal          |
|    | Day 25 of<br>month 3 | 50 µl/site       | 100 µl/animal      | 1 µg/animal          |

EXAMPLE 14: Uses of Antibodies that Bind WISP Polypeptide1. Cell lines

The established human breast tumor cells BT474 and MDA-MB-231 (which are available from ATCC) are grown in minimum essential medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, UT), sodium pyruvate, L-glutamine (2mM), non-essential amino acids, and 2x vitamin solution and maintained at 37°C in 5% CO<sub>2</sub>. Zhang *et al.*, Invas. & Metas., 11:204-215 (1991); Price *et al.*, Cancer Res., 50:717-721 (1990).

2. Antibodies

Anti-WISP-1 or anti-WISP-2 monoclonal antibodies that may be prepared as described above are harvested with PBS containing 25mM EDTA and used to immunize BALB/c mice. The mice are given injections i.p. of 10<sup>7</sup> cells in 0.5 ml PBS on weeks 0, 2, 5 and 7. The mice with antisera that immunoprecipitated <sup>32</sup>P-labeled Wnt-1 are given i.p. injections of a wheatgerm agglutinin-SEPHAROSE™ (WGA)-purified Wnt membrane extract on weeks 9 and 13. This is followed by an i.v. injection of 0.1 ml of the Wnt-1 preparation, and the splenocytes are fused with mouse myeloma line X63-Ag8.653. Hybridoma supernatants are screened for Wnt-1 binding by ELISA and radioimmunoprecipitation. MOPC-21 (IgG1) (Cappell, Durham, NC) is used as an isotype-matched control.

Additionally, the anti-ErbB2 IgG<sub>1</sub>κ murine monoclonal antibodies 4D5 (ATCC CRL 10463 deposited May 24, 1990) and 7C2, specific for the extracellular domain of ErbB2, may be used with the above antibodies. They are produced as described in Fendly *et al.*, Cancer Research, 50:1550-1558 (1990) and WO89/06692.

3. Analysis of cell cycle status and viability

Cells are simultaneously examined for viability and cell cycle status by flow cytometry on a FACSTAR PLUS™ (Becton Dickinson Immunocytometry Systems USA, San Jose, CA). Breast tumor cells are harvested by washing the monolayer with PBS, incubating cells in 0.05% trypsin and 0.53 mM EDTA (Gibco), and resuspending them in culture medium. The cells are washed twice with PBS containing 1% FBS and the pellet is incubated for 30 minutes on ice with 50 µl of 400 µM 7-aminoactinomycin D (7AAD) (Molecular Probes, Eugene, OR), a vital dye which stains all permeable cells. Cells are then fixed with 1.0 ml of 0.5% paraformaldehyde in PBS and simultaneously permeabilized and stained for 16 hours at 4°C with 220 µl of 10 µg/ml HOECHST 33342™ dye (also a DNA binding dye) containing 5% TWEEN 20™.

The data from 1 x 10<sup>4</sup> cells are collected and stored using LYSYS II™ software and analyzed using PAINT-A-GATE™ software (Becton Dickinson). Darzynkiewica *et al.*, Cytometry, 13:795-808 (1992); Picker *et al.*, J. Immunol., 150:1105-1121 (1993). The viability and percentage of cells in each stage of the cell cycle are determined on gated single cells using 7AAD and Hoechst staining, respectively. (Cell doublets are excluded by pulse analysis of width vs. area of the Hoechst signal.) Cell numbers are determined using a hemocytometer.

4. DNA synthesis ((<sup>3</sup>H)-Thymidine Incorporation Assay)

The assay was performed exactly as described in Example 12, except that the WISP polypeptides used as test proteins were replaced by the polyclonal antibodies generated in New Zealand White rabbits



against murine WISP-1 and human WISP-2 described in Example 13, and not all the cell lines in Example 12 were tested. The results are shown in Table II:

TABLE II  
<sup>3</sup>H-Thymidine Incorporation Assay Results

|    |                                 |  |          |                |             |
|----|---------------------------------|--|----------|----------------|-------------|
| 5  | Cell line                       | Type   | ATCC No. | pAB.mWISP-1    | pAB.hWISP-2 |
|    | HT-29<br>(human colon)          | adenocarcinoma<br>moderately well-<br>differentiated | HTB-38   | No change      | No change   |
|    | Wi-Dr (human colon)             | adenocarcinoma                                       | CCL-218  | No change      | No change   |
| 10 | N MuMG (mouse<br>mammary gland) | normal   |          | inhibits ~3X   |             |
|    | NRK-49F (rat kidney)            | normal fibroblast                                    |          | stimulates ~2X |             |
|    | RAG (mouse kidney)              | adenocarcinoma                                       |          | stimulates ~4X |             |
|    | NIH/3T3 (mouse<br>embryo)       | fibroblast   |          | inhibits ~2X   |             |

15 It is seen that the polyclonal antibodies to mouse WISP-1 and to human WISP-2 exhibited both stimulatory and inhibitory effects on proliferation of normal and tumor cells, depending on the cell line employed.

#### 5. Affinity of binding to putative receptor

Radioiodinated anti-WISP-1 and anti-WISP-2 antibodies are prepared by the IODOGEN<sup>TM</sup> method. Fracker *et al.*, Biochem. Biophys. Res. Comm., 80:849-857 (1978). Binding assays are performed using appropriate receptor-expressing cells (such as, for mouse anti-WISP antibodies, MLG, a mouse lung cell line available from the ATCC) cultured in 96-well tissue culture plates (Falcon, Becton Dickinson Labware, Lincoln Park, N.J.). The cells are trypsinized and seeded in wells of 96-well plates at a density of 10<sup>4</sup> cells/well and allowed to adhere overnight. The monolayers are washed with cold culture medium supplemented with 0.1% sodium azide and then incubated in triplicate with 100 µl of serial dilutions of <sup>125</sup>I-anti-WISP-1 or WISP-2 antibodies in cold culture medium containing 0.1% sodium azide for 4 hours on ice. Non-specific binding is estimated by the preincubation of each sample with a 100-fold molar excess of nonradioactive antibodies in a total volume of 100 µl. Unbound radioactivity is removed by two washes with cold medium containing 0.1% sodium azide. The cell-associated radioactivity is detected in a gamma counter after solubilization of the cells with 150 µl of 0.1 M NaOH/well. The WISP-1 and WISP-2 binding constants (K<sub>d</sub>) and anti-WISP antibody binding affinities are determined by Scatchard analysis.

It is expected that the antibodies against WISP-1 and WISP-2 will affect the growth of these cells.

#### EXAMPLE 15: Further Uses of Antibodies that Bind WISP Polypeptide

##### 1. WISP-1 and WISP-2

35 This example shows that the *WISP-1* and *WISP-2* genes are amplified in the genome of certain human lung, colon, and/or breast malignant tumors and/or cell lines. Amplification is associated with overexpression of the gene product, indicating that the WISP-1 and WISP-2 proteins are useful targets for

therapeutic intervention in certain cancers such as colon, lung, breast, and other cancers. A therapeutic agent may take the form of antagonists of WISP molecules, for example, murine-human, chimeric, humanized, or human antibodies against WISP-1 and WISP-2, such as the antibodies prepared as described above.

The starting material for the screen was genomic DNA isolated from a variety of cancers. The DNA is quantitated precisely, *e.g.*, fluorometrically. As a negative control, DNA was isolated from the cells of ten normal healthy individuals, pooled, and used as an assay control for the gene copy in healthy individuals.

The 5' nuclease assay (for example, TAQMAN<sup>TM</sup>) and real-time quantitative PCR (for example, ABI PRIZM 7700<sup>TM</sup> Sequence Detection System<sup>TM</sup> (Perkin Elmer, Applied Biosystems Division, Foster City, CA)), were used to find genes potentially amplified in certain cancers. The results were used to determine whether the DNAs encoding WISP-1 and WISP-2 are over-represented in any of the primary lung or colon cancers or cancer cell lines or breast cancer cell lines that were screened. The primary lung cancers were obtained from individuals with tumors of the type and stage as indicated in Table III. An explanation of the abbreviations used for the designation of the primary tumors listed in Table III and the primary tumors and cell lines referred to throughout this example is given below:

Human lung carcinoma cell lines include A549 (SRCC768), Calu-1 (SRCC769), Calu-6 (SRCC770), H157 (SRCC771), H441 (SRCC772), H460 (SRCC773), SKMES-1 (SRCC774) and SW900 (SRCC775), all available from ATCC. Primary human lung tumor cells usually derive from adenocarcinomas, squamous cell carcinomas, large cell carcinomas, non-small cell carcinomas, small cell carcinomas, and broncho alveolar carcinomas, and include, for example, SRCC724 (squamous cell carcinoma abbreviated as "SqCCa"), SRCC725 (non-small cell carcinoma, abbreviated as "NSCCa"), SRCC726 (adenocarcinoma, abbreviated as "AdenoCa"), SRCC727 (adenocarcinoma), SRCC728 (squamous cell carcinoma), SRCC729 (adenocarcinoma), SRCC730 (adeno/squamous cell carcinoma), SRCC731 (adenocarcinoma), SRCC732 (squamous cell carcinoma), SRCC733 (adenocarcinoma), SRCC734 (adenocarcinoma), SRCC735 (broncho alveolar carcinoma, abbreviated as "BAC"), SRCC736 (squamous cell carcinoma), SRCC738 (squamous cell carcinoma), SRCC739 (squamous cell carcinoma), SRCC740 (squamous cell carcinoma), and SRCC740 (lung cell carcinoma, abbreviated as "LCCa").

Colon cancer cell lines include, for example, ATCC cell lines SW480 (adenocarcinoma, SRCC776), SW620 (lymph node metastasis of colon adenocarcinoma, SRCC777), COLO320 (adenocarcinoma, SRCC778), HT29 (adenocarcinoma, SRCC779), HM7 (carcinoma, SRCC780), CaWiDr (adenocarcinoma, srcc781), HCT116 (carcinoma, SRCC782), SKCO1 (adenocarcinoma, SRCC783), SW403 (adenocarcinoma, SRCC784), LS174T (carcinoma, SRCC785), and HM7 (a high mucin producing variant of ATCC colon adenocarcinoma cell line LS174T, obtained from Dr. Robert Warren, UCSF). Primary colon tumors include colon adenocarcinomas designated CT2 (SRCC742), CT3 (SRCC743), CT8 (SRCC744), CT10 (SRCC745), CT12 (SRCC746), CT14 (SRCC747), CT15 (SRCC748), CT17 (SRCC750), CT1 (SRCC751), CT4 (SRCC752), CT5 (SRCC753), CT6 (SRCC754), CT7 (SRCC755), CT9 (SRCC756), CT11 (SRCC757), CT18 (SRCC758), and DcR3, BACrev, BACfwd, T160, and T159.

Human breast carcinoma cell lines include, for example, HBL100 (SRCC759), MB435s (SRCC760), T47D (SRCC761), MB468 (SRCC762), MB175 (SRCC763), MB361 (SRCC764), BT20 (SRCC765), MCF7 (SRCC766), and SKBR3 (SRCC767).

The results are reported in delta ( $\Delta$ ) CT units. One unit corresponds to one PCR cycle or approximately a 2-fold amplification relative to normal, two units corresponds to 4-fold, 3 units to 8-fold amplification and so on. Quantitation was obtained using primers derived from the 3'-untranslated regions of the *WISP-1* and *WISP-2* cDNAs and a TAQMAN<sup>TM</sup> fluorescent probe corresponding to the respective intervening sequences. Using the 3' region tends to avoid crossing intron-exon boundaries in the genomic DNA, an essential requirement for accurate assessment of gene amplification using this method. The sequences for the primers and probes (forward, reverse, and probe) used for the *WISP-1*-encoding and *WISP-2*-encoding gene amplification were as follows:

WISP-1 probe and primers:

- 10 hu.WISP1.TMP (probe) 5'-AGCCTTTCCAAGTCACTAGAAGTCCTGCTGG (SEQ ID NO:138)  
 hu.WISP1.TMF (forward primer) 5'-CTGGACTACACCCAAGCCTGA (SEQ ID NO:139)  
 hu.WISP1.TMR (reverse primer) 5'-CATTTCTTGGGATTTAGGCAAGA (SEQ ID NO:140)

WISP-2 probe and primers:

- DNA33473.3utr-5 (forward primer) 5'-TCTAGCCCCACTCCCTGCCT (SEQ ID NO:141)  
 15 DNA33473.3utr-3 (reverse primer) 5'-GAAGTCGGAGAGAAAGCTCGC (SEQ ID NO:142)  
 DNA33473.3utr-probe 5'-CACACACAGCCTATATCAAACATGCACACG (SEQ ID NO:143)

The 5' nuclease assay reaction is a fluorescent PCR-based technique which makes use of the 5' exonuclease activity of Taq DNA polymerase enzyme to monitor amplification in real time. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

The 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700<sup>TM</sup> Sequence Detection System<sup>TM</sup>. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

35 5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle. This is defined as the cycle at which the reporter signal accumulates above the background level of fluorescence. The  $\Delta$ Ct values are used as quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer DNA results to normal human DNA results.

The results of the first run performed are shown in Figures 19A-D and 20A-D for *WISP-1* and *WISP-2*, respectively, and controls. Note the pattern shown in Fig. 19B (marked huWISP-1). The standard

deviation for two samples of normal human DNA is shown in the column marked Nor Hu. This was used as a quality control tool. If the standard deviation was unacceptably large, the entire run was repeated. The nine additional columns corresponded to the human colon cancer cell lines noted above. The delta CT's for HT29 and WIDr were  $>3$ , corresponding to an about 8-fold over-representation of the *WISP-1* gene in these samples compared to the normal samples. Similarly, Fig. 19B suggests an about 4-fold amplification of *WISP-1* in the HCT116, SKCo-1, and SW403 cell lines.

As a comparison, see Fig. 20B (marked huFASr). The generally small delta CT values indicate that this gene was not significantly amplified in any of the cell lines (the value of 1 for SW620 corresponding to 2-fold amplification is within the noise level for the assay).

The *WISP-1* result was confirmed in three replicate reactions. See Figures 21A-D, 22A-D, and 23A-C. The pattern and delta CT values obtained were very similar in Figures 21A-C (marked huWISP-1c, huWISP-1b, and huWISP-1a, respectively). The result was essentially identical to that obtained in the first run. HT29 and WIDr showed the highest levels of *WISP-1* amplification, while HCT116, SKCo-1, and SW403 cell lines showed somewhat lower levels of *WISP-1* gene amplification. Two additional reactions from a third run were confirmatory. See Figs. 25A and 25B.

The *WISP-1* gene is located on chromosome 8, in the general vicinity of the *myc* gene, which is known to be amplified in some colon cancer cell lines. The pattern obtained using primers and probe for the *myc* gene, namely,

hu.c-myc.tm.p 5'-CTTGAG<sup>3</sup>CTGAAAGATTTAGCCATAATGTAAACTGCCT (SEQ ID NO:144)

20 hu.c-myc.tm.f 5'-CAAATGCAACCTCACAACCTTG (SEQ ID NO:145), and

hu.c-myc.tm.r 5'-TTCTTTTATGCCCAAAGTCCAATT (SEQ ID NO:146),

is consistent with a published report (Cancer Research, 57: 1769-1775 (1997)), tending to validate the 5' nuclease assay method, but is clearly different from that obtained for *WISP-1*. These data prove that the *myc* gene is not the target of the amplification detected using the primers and probes for *WISP-1*.

25 The data using primers and probes based on the *WISP-2* DNA sequence suggest that this gene may be the target of low-level gene amplification in most of the cell lines examined. See Figs. 20C, 22A-D, and 25C and D. Hence, antibodies to both *WISP-1* and *WISP-2*, particularly humanized antibodies, are expected to be of benefit in combating certain types of cancer such as colon cancer, similar to the humanized anti-HER-2 antibody in clinical use.

## 30 2. WISP-2

### Description of Tumors and Cell Lines

Amplification using several different tumor types was performed for human *WISP-2* (PRO261), as described below. Table III describes the stage, T stage, and N stage of various primary tumors which were used to screen the *WISP-2* compound of the invention.

TABLE III  
Primary Lung and Colon Tumor Profiles

|    | Primary Tumor                               | Stage | Other Stage | Dukes Stage | T Stage | N Stage |
|----|---|-------|-------------|-------------|---------|---------|
|    | Human lung tumor SqCCA (SRCC724) [LT1]      | IB    | --          | --          | T1      | N1      |
| 5  | Human lung tumor NSCCa (SRCC725) [LT1a]     | IA    | --          | --          | T3      | NO      |
|    | Human lung tumor AdenoCa (SRCC726) [LT2]    | IB    | --          | --          | T2      | NO      |
|    | Human lung tumor AdenoCa (SRCC727) [LT3]    | IB    | --          | --          | T1      | N2      |
|    | Human lung tumor SqCCq (SRCC728) [LT4]      | IIB   | --          | --          | T2      | NO      |
|    | Human lung tumor AdenoCa (SRCC729) [LT6]    | IV    | --          | --          | T1      | NO      |
| 10 | Human lung tumor Aden/SqCCa (SRCC730) [LT7] | IB    | --          | --          | T1      | NO      |
|    | Human lung tumor AdenoCa (SRCC731) [LT9]    | IIB   | --          | --          | T2      | NO      |
|    | Human lung tumor SqCCa (SRCC732) [LT10]     | IA    | --          | --          | T2      | N1      |
|    | Human lung tumor AdenoCa (SRCC733) [LT11]   | IB    | --          | --          | T1      | N1      |
|    | Human lung tumor AdenoCa (SRCC734) [LT12]   | IIA   | --          | --          | T2      | NO      |
| 15 | Human lung tumor BAC (SRCC735) [LT13]       | IB    | --          | --          | T2      | NO      |
|    | Human lung tumor SqCCa (SRCC736) [LT15]     | IB    | --          | --          | T2      | NO      |
|    | Human lung tumor SqCCa (SRCC737) [LT16]     | IB    | --          | --          | T2      | NO      |
|    | Human lung tumor SqCCa (SRCC738) [LT17]     | IIB   | --          | --          | T2      | N1      |
|    | Human lung tumor SqCCa (SRCC739) [LT18]     | IB    | --          | --          | T2      | NO      |
| 20 | Human lung tumor SqCCa (SRCC740) [LT19]     | IB    | --          | --          | T2      | NO      |
|    | Human lung tumor LCCa (SRCC741) [LT21]      | IIB   | --          | --          | T3      | N1      |
|    | Human colon AdenoCa (SRCC742) [CT2]         | --    | M1          | D           | pT4     | NO      |
|    | Human colon AdenoCa (SRCC743) [CT3]         |       | --          | B           | pT3     | NO      |
|    | Human colon AdenoCa (SRCC 744) [CT8]        |       |             | B           | T3      | NO      |
| 25 | Human colon AdenoCa (SRCC745) [CT10]        |       |             | A           | pT2     | NO      |
|    | Human colon AdenoCa (SRCC746) [CT12]        |       | MO, R1      | B           | T3      | NO      |



|    |                                      |  |         |    |     |     |
|----|--------------------------------------|--|---------|----|-----|-----|
|    | Human colon AdenoCa (SRCC747) [CT14] |  | pMO, RO | B  | pT3 | pNO |
|    | Human colon AdenoCa (SRCC748) [CT15] |  | M1, R2  | D  | T4  | N2  |
|    | Human colon AdenoCa (SRCC749) [CT16] |  | pMO     | B  | pT3 | pNO |
|    | Human colon AdenoCa (SRCC750) [CT17] |  |         | C1 | pT3 | pN1 |
| 5  | Human colon AdenoCa (SRCC751) [CT1]  |  | MO, R1  | B  | pT3 | NO  |
|    | Human colon AdenoCa (SRCC752) [CT4]  |  |         | B  | pT3 | MO  |
|    | Human colon AdenoCa (SRCC753) [CT5]  |  | G2      | C1 | pT3 | pNO |
|    | Human colon AdenoCa (SRCC754) [CT6]  |  | pMO, RO | B  | pT3 | pNO |
|    | Human colon AdenoCa (SRCC755) [CT7]  |  | G1      | A  | pT2 | pNO |
| 10 | Human colon AdenoCa (SRCC756) [CT9]  |  | G3      | D  | pT4 | pN2 |
|    | Human colon AdenoCa (SRCC757) [CT11] |  |         | B  | T3  | NO  |
|    | Human colon AdenoCa (SRCC758) [CT18] |  | MO, RO  | B  | pT3 | pNO |

#### DNA Preparation:

DNA was prepared from cultured cell lines, primary tumors, and normal human blood (controls and framework and epicenter mapping). The isolation was performed using purification kit #13362 (which includes 10 purification tips with a capacity of 400 µg genomic DNA each), buffer set #1960 and protease #19155 and #19101, all from Qiagen, according to the manufacturer's instructions and the description below.

#### *Cell culture lysis:*

Cells were washed and trypsinized at a concentration of  $7.5 \times 10^8$  per tip and pelleted by centrifuging at 1000 rpm for 5 minutes at 4°C, followed by washing again with 1/2 volume of PBS recentrifugation. The pellets were washed a third time, and the suspended cells collected and washed 2x with PBS. The cells were then suspended into 10 mL PBS. Buffer C1 was equilibrated at 4°C. Protease #19155 (Qiagen) was diluted into 6.25 ml cold ddH<sub>2</sub>O to a final concentration of 20 mg/ml and equilibrated at 4°C. 10 mL of G2 Buffer was prepared by diluting RNase A stock (Qiagen) (100 mg/ml) to a final concentration of 200 µg/ml.

Buffer C1 (10 mL, 4°C) and ddH<sub>2</sub>O (40 mL, 4°C) were then added to the 10 mL of cell suspension, mixed by inverting and incubated on ice for 10 minutes. The cell nuclei were pelleted by centrifuging in a BECKMAN™ swinging bucket rotor at 2500 rpm at 4°C for 15 minutes. The supernatant was discarded and the nuclei were suspended with a vortex into 2 mL Buffer C1 (at 4°C) and 6 mL ddH<sub>2</sub>O, followed by a second 4°C centrifugation at 2500 rpm for 15 minutes. The nuclei were then resuspended into the residual buffer using 200 µl per tip. G2 buffer (10 ml) was added to the suspended nuclei while gentle vortexing was applied. Upon completion of buffer addition, vigorous vortexing was applied for 30 seconds. Qiagen protease (200 µl, prepared as indicated above) was added and incubated at 50°C for 60 minutes. The incubation and centrifugation were repeated until the lysates were clear (e.g., incubating an additional 30-60 minutes, pelleting at 3000 x g for 10 min., 4°C).

*Solid human tumor sample preparation and lysis:*

Tumor samples were weighed and placed into 50-ml conical tubes and held on ice. Processing was limited to no more than 250 mg tissue per preparation (1 tip/preparation). The protease solution was freshly prepared by diluting into 6.25 ml cold ddH<sub>2</sub>O to a final concentration of 20 mg/ml and stored at 4°C. G2 buffer (20 ml) was prepared by diluting DNase A to a final concentration of 200 mg/ml (from 100 mg/ml stock). The tumor tissue was homogenated in 19 ml G2 buffer for 60 seconds using the large tip of the polytron in a laminar-flow TC hood to order to avoid inhalation of aerosols, and held at room temperature. Between samples, the polytron was cleaned by spinning at 2 x 30 seconds each in 2L ddH<sub>2</sub>O, followed by G2 buffer (50 ml). If tissue was still present on the generator tip, the apparatus was disassembled and cleaned.

Protease (Quiagen), prepared as indicated above, 1.0 ml, was added, followed by vortexing and incubation at 50°C for 3 hours. The incubation and centrifugation were repeated until the lysates were clear (e.g., incubating additional 30-60 minutes, pelleting at 3000 x g for 10 min., 4°C).

*Human blood preparation and lysis:*

Blood was drawn from healthy volunteers using standard infectious agent protocols and citrated into 10 ml samples per tip. Protease (Quiagen) was freshly prepared by dilution into 6.25 ml cold ddH<sub>2</sub>O to a final concentration of 20 mg/ml and stored at 4°C. G2 buffer was prepared by diluting RNase A to a final concentration of 200 µg/ml from 100 mg/ml stock. The blood (10 ml) was placed into a 50-ml conical tube, and 10 ml C1 buffer and 30 ml ddH<sub>2</sub>O (both previously equilibrated to 4°C) were added, and the components mixed by inverting and held on ice for 10 minutes. The nuclei were pelleted with a BECKMAN<sup>TM</sup> swinging bucket rotor at 2500 rpm, 4°C for 15 minutes and the supernatant was discarded. With a vortex, the nuclei were suspended into 2 ml C1 buffer (4°C) and 6 ml ddH<sub>2</sub>O (4°C). Vortexing was repeated until the pellet was white. The nuclei were then suspended into the residual buffer using a 200-µl tip. G2 buffer (10 ml) was added to the suspended nuclei while gently vortexing, followed by vigorous vortexing for 30 seconds. Protease (Quiagen) was added (200 µl) and incubated at 50°C for 60 minutes. The incubation and centrifugation were repeated until the lysates were clear (e.g., incubating an additional 30-60 minutes, pelleting at 3000 x g for 10 min., 4°C).

*Purification of cleared lysates: Isolation of genomic DNA:*

Genomic DNA was equilibrated (1 sample per maxi tip preparation) with 10 ml QBT buffer. QF elution buffer was equilibrated at 50°C. The samples were vortexed for 30 seconds, then loaded onto equilibrated tips and drained by gravity. The tips were washed with 2 x 15 ml QC buffer. The DNA was eluted into 30-ml silanized, autoclaved 30-ml COREX<sup>TM</sup> tubes with 15-ml QF buffer (50°C). Isopropanol (10.5 ml) was added to each sample, and the tubes were covered with paraffin and mixed by repeated inversion until the DNA precipitated. Samples were pelleted by centrifugation in the SS-34 rotor at 15,000 rpm for 10 minutes at 4°C. The pellet location was marked, the supernatant discarded, and 10 ml 70% ethanol (4°C) was added. Samples were pelleted again by centrifugation on the SS-34 rotor at 10,000 rpm for 10 minutes at 4°C. The pellet location was marked and the supernatant discarded. The tubes were then placed on their side in a drying rack and dried 10 minutes at 37°C, taking care not to overdry the samples.

After drying, the pellets were dissolved into 1.0 ml TE (pH 8.5) and placed at 50°C for 1-2 hours. Samples were held overnight at 4°C as dissolution continued. The DNA solution was then transferred to 1.5-

ml tubes with a 26-gauge needle on a tuberculin syringe. The transfer was repeated 5x in order to shear the DNA. Samples were then placed at 50°C for 1-2 hours.

*Quantitation of genomic DNA and preparation for gene amplification assay:*

The DNA levels in each tube were quantified by standard A260, A280 spectrophotometry on a 1:20 dilution (5 µl DNA + 95 µl ddH<sub>2</sub>O) using the 0.1-ml quartz cuvettes in the BECKMAN DU640<sup>TM</sup> spectrophotometer. A260/A280 ratios were in the range of 1.8-1.9. Each DNA sample was then diluted further to approximately 200 ng/ml in TE (pH 8.5). If the original material was highly concentrated (about 700 ng/µl), the material was placed at 50°C for several hours until resuspended.

Fluorometric DNA quantitation was then performed on the diluted material (20-600 ng/ml) using the manufacturer's guidelines as modified below. This was accomplished by allowing a HOFFER DYNA QUANT 200<sup>TM</sup> fluorometer to warm up for about 15 minutes. The HOECHST<sup>TM</sup> dye working solution (#H33258, 10 µl, prepared within 12 hours of use) was diluted into 100 ml 1 x TNE buffer. A 2-ml cuvette was filled with the fluorometer solution, placed into the machine, and the machine was zeroed. pGEM 3Zf(+) (2 µl, lot #360851026) was added to 2 ml of fluorometer solution and calibrated at 200 units. A second 2 µl of pGEM 3Zf(+) DNA was then tested and the reading confirmed at 400 +/- 10 units. Each sample was then read at least in triplicate. When 3 samples were found to be within 10% of each other, their average was taken and this value was used as the quantification value.

The fluorometrically-determined concentration was then used to dilute each sample to 10 ng/µl in ddH<sub>2</sub>O. This was done simultaneously on all template samples for a single TAQMAN<sup>TM</sup> plate assay, and with enough material to run 500-1000 assays. The samples were tested in triplicate with both B-actin and GAPDH on a single plate with normal human DNA and no-template controls. The diluted samples were used, provided that the CT value of normal human DNA subtracted from test DNA was +/- 1 CT. The diluted, lot-qualified genomic DNA was stored in 1.0-ml aliquots at -80°C. Aliquots which were subsequently to be used in the gene amplification assay were stored at 4°C. Each 1-ml aliquot is enough for 8-9 plates or 64 tests.

Framework Mapping and Epicenter Marking:

Human WISP-1 was reexamined with both framework and epicenter mapping. Selected tumors from the above initial screen were reexamined with both framework and epicenter mapping. Table IV indicates the chromosomal mapping of the framework markers that were used in the present example. The framework markers are located approximately every 20 megabases along Chromosome 8 and were used to control for aneuploidy.

TABLE IV  
Framework Markers

| Map Position on Chromosome 8 | Stanford Human Genome Center Marker Name |
|------------------------------|--|
| H9                           | EST-00040                                |
| H59                          | WI-961                                   |
| H121                         | SHGC-11323                               |
| H200                         | SHGC-7433                                |
| H256                         | AFMa183zf1                               |

Table V describes the epicenter markers that were employed in association with WISP-1. These markers are located in close proximity to the gene for WISP-1 and are used to assess the amplification status of the region of chromosome 8 in which the gene for WISP-1 is located. The distance between individual markers is measured in centirays (cR), which is a radiation breakage unit approximately equal to a 1% chance of a breakage between two markers. One cR is very roughly equivalent to 20 kilobases. The marker SHGC-32958 is the marker found to be the closest to the location on chromosome 8 to which the gene encoding WISP-1 most closely maps.

TABLE V  
Epicenter Markers

| Map Position on Chromosome 8 | Stanford Human Genome Center Marker Name | Distance to next Marker (cR) |
|------------------------------|--|------------------------------|
| H257                         | AFMa248tel                               | 103(gap)                     |
| H259                         | SHGC-36664                               | 33                           |
| H261                         | AFM259xc5                                | 63                           |
| H266                         | SHGC-32958                               | 41                           |
| H267                         | AFMa175xc1                               | 19                           |
| H268                         | AFM337wg5                                | 87                           |
| H273                         | SHGC-33759                               | 71                           |
| H274                         | SHGC-32752                               | 5                            |
| H275                         | WI-7711                                  | 21                           |
| H277                         | SHGC-34940                               | -                            |

The framework markers for human WISP-2 are located approximately every 20 megabases along Chromosome 20, and are used to control for aneuploidy. The markers are shown in Table VI.

TABLE VI  
Framework Markers

| Map Position on Chromosome 20 | Stanford Human Genome Center Marker Name |
|-------------------------------|--|
| T10                           | SHGC-2797                                |
| T48                           | UT759                                    |
| T73                           | AFMa339xf5                               |
| T115                          | SHGC-33922                               |
| T159                          | SHGC-36268                               |

The marker SHGC-33922 is the marker to which human WISP-2 DNA most closely maps. This marker is between the framework markers. Framework analysis showed that all markers were up in tumors; thus, chromosome 20 was aneuploid in many tumors. Since the markers were up due to aneuploidy, epicenter analysis was not done for human WISP-2 gene.

The  $\Delta C_t$  values of the above described framework markers along Chromosome 8 relative for WISP-1 are indicated for selected tumors in Tables VII and VIII.



TABLE VII

Amplification of framework markers relative to Human WISP-1 DNA Framework Markers ( $\Delta$ ct)

|    |          | Probe/Delta CT |                |                |                 |                |                |                |                |
|----|----------|----------------|----------------|----------------|-----------------|----------------|----------------|----------------|----------------|
|    | Template | c-myc<br>(SD)  | WISP-1<br>(SD) | WISP-2<br>(SD) | H9<br>(SD)      | H59<br>(SD)    | H121<br>(SD)   | H200<br>(SD)   | H256<br>(SD)   |
| 5  | Nor Hu   | 0.00<br>(0.91) | 0.00<br>(0.01) | 0.00<br>(0.20) | 0.00<br>(0.13)  | 0.00<br>(0.20) | 0.00<br>(0.14) | 0.00<br>(0.16) | 0.00<br>(0.04) |
|    | SW480    | 1.86           | 0.84           | 1.92           | -1.18           | 1.01           | 0.17           | 0.65           | 0.81           |
|    | SW620    | 1.45           | 0.98           | 1.60           | 0.45            | 0.75           | 1.00           | 0.81           | 0.52           |
|    | Colo320  | 3.73           | 0.65           | 1.88           | 0.69            | 0.70           | 0.89           | 0.60           | 0.40           |
|    | HT29     | 0.83           | 2.67           | 2.20           | -1.13           | -0.40          | -0.55          | 1.00           | 2.42           |
| 10 | HM7      | -2.03          | 0.07           | -0.28          | -0.28           | 0.24           | -0.48          | 0.12           | -0.26          |
|    | WiDr     | -0.13          | 2.91           | 1.67           | -0.20           | 0.95           | 0.07           | 1.43           | 2.55           |
|    | HCT116   | -0.57          | 1.82           | 1.04           | 1.24            | 1.56           | 0.84           | 1.76           | 1.53           |
|    | SKCO-1   | 0.19           | 1.68           | 0.97           | -0.30           | 0.32           | 0.12           | 1.39           | 1.63           |
|    | SW403    | -0.72          | 1.34           | 1.77           | 0.23            | 0.53           | 0.26           | 1.48           | 1.48           |
| 15 |          |                |                |                |                 |                |                |                |                |
|    | Nor Hu   | ----           | 0.00<br>(0.18) | 0.00<br>(1.02) | 0.00<br>(0.08)  | 0.00<br>(0.13) | 0.00<br>(0.01) | 0.00<br>(0.16) | 0.00<br>(0.37) |
|    | CT-2     | ----           | 0.65           | 0.44           | -0.25           | 0.11           | 0.07           | 0.13           | 0.95           |
|    | CT-3     | ----           | 0.90           | 0.95           | -0.27           | 0.05           | -0.10          | -0.11          | 0.32           |
|    | CT-8     | ----           | 0.47           | -0.34          | 0.07            | -0.20          | 0.00           | -0.04          | 0.07           |
| 20 | CT-10    | ----           | 0.76           | 0.50           | 0.23            | -0.36          | -0.08          | 0.17           | 0.70           |
|    | CT-12    | ----           | 1.30           | 2.14           | -0.70           | -0.45          | 0.24           | 0.47           | 1.75           |
|    | CT-14    | ----           | 1.17           | -0.48          | 0.05            | 0.18           | 0.31           | 0.23           | 1.51           |
|    | CT-15    | ----           | 0.22           | -0.13          | 0.13            | -0.48          | 0.29           | 0.11           | 0.59           |
|    | CT-16    | ----           | 0.26           | 0.10           | 0.00            | -0.15          | -0.23          | -0.09          | 0.95           |
| 25 | CT-17    | ----           | 0.57           | -0.33          | 0.73            | -0.11          | -0.05          | -0.11          | 0.25           |
|    |          |                |                |                |                 |                |                |                |                |
|    | Nor Hu   | ----           | 0.00(0.45)     | 0.00<br>(1.07) | 0.000<br>(0.04) | 0.00<br>(0.21) | 0.00<br>(0.18) | 0.00<br>(0.03) | 0.00<br>(0.18) |
|    | CT-1     | ----           | 0.84           | -0.37          | -0.36           | 0.19           | 0.68           | 0.01           | 0.66           |
|    | CT-4     | ----           | 0.15           | -0.23          | -1.00           | 0.24           | -0.11          | 0.30           | 0.14           |
|    | CT-5     | ----           | 0.86           | -1.23          | -0.60           | -0.25          | 0.22           | 0.51           | 0.62           |

|       |      |       |       |       |      |       |       |       |
|-------|------|-------|-------|-------|------|-------|-------|-------|
| CT-6  | ---- | 0.03  | 0.39  | -0.24 | 0.61 | 0.70  | 0.01  | 0.19  |
| CT-7  | ---- | -0.20 | -1.36 | -0.76 | 0.00 | -0.09 | -0.13 | -0.18 |
| CT-9  | ---- | 0.30  | -0.54 | -0.50 | 0.29 | 0.54  | 0.11  | 0.18  |
| CT-11 | ---- | 0.48  | 0.14  | -0.89 | 0.34 | 0.82  | 0.17  | -0.06 |
| CT-18 | ---- | -0.20 | -1.37 | -0.52 | 0.32 | 0.66  | 0.08  | 0.12  |

TABLE VIII

Amplification of framework markers relative to Human WISP-1 DNA Framework Markers ( $\Delta$ ct)

| Template | Probe/Delta CT |             |             |             |              |                |
|----------|----------------|-------------|-------------|-------------|--------------|----------------|
|          | WISP-2<br>(SD) | T10<br>(SD) | T48<br>(SD) | T73<br>(SD) | T115<br>(SD) | T159<br>(SD)   |
| Nor Hu   | 0.00 (0.05)    | 0.00 (0.16) | 0.00 (0.09) | 0.00 (0.21) | 0.00 (3.22)  | 0.00<br>(0.09) |
| SW480    | 1.31           | 1.32        | 0.63        | 1.94        | -5.66        | 1.61           |
| SW620    | 1.32           | 2.02        | 1.42        | 1.06        | -10.95       | 1.48           |
| Colo320  | 0.43           | 1.35        | 1.37        | 0.61        | 0.30         | 1.37           |
| HT29     | 1.76           | 1.09        | -2.23       | 1.26        | -5.47        | 1.87           |
| HM7      | -0.32          | 0.32        | 0.38        | 0.41        | -6.3         | 0.48           |
| WiDr     | 1.76           | 1.61        | -1.38       | 1.04        | -7.36        | 1.55           |
| HCT116   | 1.18           | 1.24        | 1.15        | 1.46        | -8.38        | 1.49           |
| SKCO-1   | 1.40           | 1.17        | 1.19        | 1.13        | -5.34        | 1.61           |
| SW403    | 1.92           | 2.24        | -17.23      | 1.38        | -3.66        | 2.12           |

Gene Amplification Assay Results:

The human WISP-2 (PRO261) compound of the invention was screened in the following primary tumors and the resulting  $\Delta$ Ct values are reported in Table IX.

TABLE IX

 $\Delta$ Ct values in lung and colon primary tumor models

| Primary Tumor | PRO261 |
|---------------|--------|
| LT1           | 0.41   |
| LT1a          | 1.08   |
| LT2           | 0.27   |
| LT3           | 0.98   |
| LT4           | 0.32   |

|    |        |                         |
|----|--------|-------------------------|
|    | LT6    | 0.45                    |
|    | LT7    | 0.03                    |
|    | LT9    | 0.18                    |
|    | LT10   | 1.16                    |
| 5  | LT11   | 0.67, 1.59, 0.63, 0.19, |
|    | LT12   | 0.80, 1.73, 1.08, 2.23  |
|    | LT13   | 1.02, 1.13, 1.01, 0.29  |
|    | LT15   | 0.97, 2.64, 0.56, 2.38  |
|    | LT16   | 0.80, 0.75, 0.82, 2.05  |
| 10 | LT17   | 1.67, 2.01, 1.43, 0.93  |
|    | LT18   | 1.22, 0.46, 0.15, -0.17 |
|    | LT19   | 0.78, 1.38, 1.39, 2.33  |
|    | LT21   | 0.04, 1.14, 0.48, 3.40  |
|    | CT2    | 1.66                    |
| 15 | CT3    | 2.14                    |
|    | CT8    | 0.55                    |
|    | CT10   | 1.00                    |
|    | CT12   | 0.34                    |
|    | CT14   | 1.03                    |
| 20 | CT15   | 0.67                    |
|    | CT16   | 0.87                    |
|    | CT17   | -0.19                   |
|    | CT1    | -0.06                   |
|    | CT4    | 1.00                    |
| 25 | CT5    | 1.07                    |
|    | CT6    | -0.08                   |
|    | CT7    | 0.15                    |
|    | CT9    | 0.68                    |
|    | CT11   | 0.59                    |
| 30 | CT18   | 0.73                    |
|    | A549   | --                      |
|    | Calu-1 | --                      |
|    | Calu-6 | --                      |

5

10

15

20

|         |  |
|---------|--|
| HI57    | --   |
| H441    | --   |
| H460    | --   |
| SKMES1  | --   |
| SW900   | --   |
| SW480   | 0.62, 1.90, 1.20, 1.57, 1.68, 1.36, 1.59, 1.86, 1.91, 2.36, 1.68, 1.53, 2.50   |
| SW620   | 0.66, 1.65, 1.85, 1.63, 1.61, 1.24, 1.52, 1.98, 1.57, 1.83, 1.41, 1.42, 1.59   |
| Colo320 | -0.33, 0.66, 0.48, 0.91, 0.72, 0.33, 2.49, 0.99, 1.06, 1.24, 1.04, 0.46, 0.27  |
| HT29    | 0.46, 1.95, 1.61, 2.58, 1.49, 1.38, 1.40, 2.00, 2.59, 2.59, 1.39, 1.32         |
| HM7     | -0.70, 0.74, -0.29, 0.66, 0.27, 0.08, 0.54, 0.67, 0.64, 0.34, 0.09, 0.29, 0.21 |
| WiDr    | 0.19, 1.64, 1.00, 1.71, 1.44, 1.57, 0.93, 1.84, 1.58, 0.91, 0.87               |
| HCT116  | 0.25, 1.29, 1.04, 2.01, 1.29, 1.07, 1.08, 2.05, 1.81, 1.56, 1.05, 1.09, 0.96   |
| SKCO1   | 0.73, 1.99, 1.33, 1.00, 1.33, 1.26, 1.19, 2.10, 1.50, 2.13, 1.33, 1.29         |
| SW403   | 0.26, 1.98, 1.42, 2.20, 2.40, 1.50, 1.43, 2.15, 1.52, 1.67, 2.19, 1.40, 1.29   |
| LS174T  | 1.48   |
| HBL100  | 1.40   |
| MB435s  | 1.43   |
| T47D    | 0.38   |
| MB468   | -0.08  |
| MB175   | 0.23   |
| MB361   | 0.37   |
| BT20    | 1.66   |
| MCF7    | 0.53   |
| SKBR3   | 1.73   |

25

The  $\Delta C_t$  values for DNA33473 (PRO261; human WISP-2) in a variety of primary lung and colon tumors as well as lung tumor cell lines are reported in Table IX. A  $\Delta C_t$  value of  $> 1$  was typically used as the threshold value for amplification scoring, as this represents a doubling of the gene copy. Table IX indicates that significant amplification of DNA33474 occurred in: (1) primary lung tumors LT1a, LT10,

LT12, LT15, LT17 and LT19; (2) primary colon tumors CT2, CT3, CT14, and CT5; (3) colon tumor cell lines SW480, SW620, HT29, WiDr, HCT116, SKCO1, SW403, and LS174T and (4) breast tumor cell lines HBL100, MB435s, BT20 and SKBR3.

The  $\Delta C_t$  and average  $\Delta C_t$  values for the primary lung tumors were the following: 1.08, 1.16, 1.17, 1.64, 1.50 and 1.47, respectively; those for the primary colon tumors were 1.16, 2.14, 1.03 and 1.07, respectively; those for the colon tumor cell lines were 1.67, 1.54, 1.73, 1.24, 1.32, 1.35, 1.65, and 1.48, respectively; and those for the breast tumor cell lines were 1.40, 1.43, 1.66, and 1.73, respectively.

For the lung tumors, this represents approximately a 2.1-, 2.2-, 2.2-, 3.1-, 2.8-, and 2.8-, respectively, fold increase in gene copy relative to normal tissue. For the colon tumors, this represents a 2.2-, 4.4-, 2.0-, and 2.1-, respectively, fold increase in gene copy relative to normal tissue. For the colon tumor cell lines, this represents a 3.2-, 2.9-, 3.3-, 2.4-, 2.5-, 2.5-, 3.1-, and 2.8-, respectively, fold increase in gene copy relative to normal tissue. For the breast tumor cell lines, this represents a 2.6-, 2.7-, 3.2-, and 3.3-, respectively, fold increase in gene copy relative to normal tissue. Because amplification of DNA33473 (PRO261) occurs in various tumors, it is likely associated with tumor formation or growth. As a result, antagonists (e.g., antibodies) directed against the protein encoded by DNA33473 (PRO261) would be expected to be useful in cancer therapy.

#### EXAMPLE 16: *In Situ* Hybridization

*In situ* hybridization is a powerful and versatile technique for the detection and localization of nucleic acid sequences within cell or tissue preparations. It may be useful, for example, in identifying sites of gene expression, analyzing the tissue distribution of transcription, identifying and localizing viral infection, following changes in specific mRNA synthesis, and aiding in chromosome mapping.

*In situ* hybridization was performed following an optimized version of the protocol by Lu and Gillett, Cell Vision 1: 169-176 (1994), using PCR-generated  $^{33}\text{P}$ -labeled riboprobes. Briefly, formalin-fixed, paraffin-embedded human tissues were sectioned, deparaffinized, deproteinized in proteinase K (20 g/ml) for 15 minutes at 37°C, and further processed for *in situ* hybridization as described by Lu and Gillett, *supra*. A ( $^{33}\text{P}$ )UTP-labeled antisense riboprobe was generated from a PCR product and hybridized at 55°C overnight. The slides were dipped in KODAK NTB2<sup>TM</sup> nuclear track emulsion and exposed for 4 weeks.

#### $^{33}\text{P}$ -Riboprobe synthesis

6.0  $\mu\text{l}$  (125 mCi) of  $^{33}\text{P}$ -UTP (Amersham BF 1002, SA <2000 Ci/mmol) were speed-vacuum dried. To each tube containing dried  $^{33}\text{P}$ -UTP, the following ingredients were added:

2.0  $\mu\text{l}$  5x transcription buffer  
1.0  $\mu\text{l}$  DTT (100 mM)  
2.0  $\mu\text{l}$  NTP mix (2.5 mM : 10  $\mu\text{l}$  each of 10 mM GTP, CTP & ATP + 10  $\mu\text{l}$  H<sub>2</sub>O)  
1.0  $\mu\text{l}$  UTP (50  $\mu\text{M}$ )  
1.0  $\mu\text{l}$  RNasin  
1.0  $\mu\text{l}$  DNA template (1  $\mu\text{g}$ )



1.0  $\mu$ l H<sub>2</sub>O

1.0  $\mu$ l RNA polymerase (for PCR products T3 = AS, T7 = S, usually)

The tubes were incubated at 37°C for one hour. A total of 1.0  $\mu$ l RQ1 DNase was added, followed by incubation at 37°C for 15 minutes. A total of 90  $\mu$ l TE (10 mM Tris pH 7.6/1 mM EDTA, pH 8.0) was added, and the mixture was pipetted onto DE81 paper. The remaining solution was loaded in a MICROCON-50<sup>TM</sup> ultrafiltration unit, and spun using program 10 (6 minutes). The filtration unit was inverted over a second tube and spun using program 2 (3 minutes). After the final recovery spin, a total of 100  $\mu$ l TE was added. Then 1  $\mu$ l of the final product was pipetted on DE81 paper and counted in 6 ml of BIOFLUOR II<sup>TM</sup>.

10 The probe was run on a TBE/urea gel. A total of 1-3  $\mu$ l of the probe or 5  $\mu$ l of RNA Mrk III was added to 3  $\mu$ l of loading buffer. After heating on a 95°C heat block for three minutes, the gel was immediately placed on ice. The wells of gel were flushed, and the sample was loaded and run at 180-250 volts for 45 minutes. The gel was wrapped in plastic wrap (SARAN<sup>TM</sup> brand) and exposed to XAR film with an intensifying screen in a -70°C freezer one hour to overnight.

15 <sup>33</sup>P-Hybridization

A. Pretreatment of frozen sections

The slides were removed from the freezer, placed on aluminum trays, and thawed at room temperature for 5 minutes. The trays were placed in a 55°C incubator for five minutes to reduce condensation. The slides were fixed for 10 minutes in 4% paraformaldehyde on ice in the fume hood, and washed in 0.5 x SSC for 5 minutes, at room temperature (25 ml 20 x SSC + 975 ml s.c. H<sub>2</sub>O). After deproteinization in 0.5  $\mu$ g/ml proteinase K for 10 minutes at 37°C (12.5  $\mu$ l of 10 mg/ml stock in 250 ml prewarmed RNase-free RNase buffer), the sections were washed in 0.5 x SSC for 10 minutes at room temperature. The sections were dehydrated in 70%, 95%, and 100% ethanol, 2 minutes each.

B. Pretreatment of paraffin-embedded sections

25 The slides were deparaffinized, placed in s.c. H<sub>2</sub>O, and rinsed twice in 2 x SSC at room temperature, for 5 minutes each time. The sections were deproteinized in 20  $\mu$ g/ml proteinase K (500  $\mu$ l of 10 mg/ml in 250 ml RNase-free RNase buffer; 37°C, 15 minutes) for human embryo tissue, or 8 x proteinase K (100  $\mu$ l in 250 ml RNase buffer, 37°C, 30 minutes) for formalin tissues. Subsequent rinsing in 0.5 x SSC and dehydration were performed as described above.

30 C. Prehybridization

The slides were laid out in a plastic box lined with Box buffer (4 x SSC, 50% formamide) The filter paper was saturated. The tissue was covered with 50  $\mu$ l of hybridization buffer (3.75 g dextran sulfate + 6 ml s.c. H<sub>2</sub>O), vortexed, and heated in the microwave for 2 minutes with the cap loosened. After cooling on ice, 18.75 ml formamide, 3.75 ml 20 x SSC, and 9 ml s.c. H<sub>2</sub>O were added, and the tissue was vortexed well and incubated at 42°C for 1-4 hours.

D. Hybridization

1.0 x 10<sup>6</sup> cpm probe and 1.0 µl tRNA (50 mg/ml stock) per slide were heated at 95°C for 3 minutes. The slides were cooled on ice, and 48 µl hybridization buffer was added per slide. After vortexing, 50 µl <sup>33</sup>P mix was added to 50 µl prehybridization on the slide. The slides were incubated overnight at 55°C.

5 E. Washes

Washing was done for 2x10 minutes with 2xSSC, EDTA at room temperature (400 ml 20 x SSC + 16 ml 0.25 M EDTA, V<sub>f</sub>=4L), followed by RNaseA treatment at 37°C for 30 minutes (500 µl of 10 mg/ml in 250 ml RNase buffer = 20 µg/ml). The slides were washed 2x10 minutes with 2 x SSC, EDTA at room temperature. The stringency wash conditions were as follows: 2 hours at 55°C, 0.1 x SSC, EDTA  
10 (20 ml 20 x SSC + 16 ml EDTA, V<sub>f</sub>=4L).

F. Oligonucleotides

*In situ* analysis was performed on DNA sequences disclosed herein. The oligonucleotides employed for these analyses are as follows.

(1) Mouse WISP-1 (Clone 568)

15 Notrim-p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC GTC CCT GGC CAG TGC TGT GAG-3'  
(SEQ ID NO:147)

Notrim-p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA GGG CCA GGC TTT GCT TCC ATT-3'  
(SEQ ID NO:148)

(2) Human WISP-1

20 hmWISP-1 p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC TGG AGG CAT GGC ACA GGA  
AC-3' (SEQ ID NO:149)

hmWISP-1 p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA TCC GGA TCA GGC TTG GGT  
GTA-3' (SEQ ID NO:150)

(3) Mouse WISP-2 (Clone 1367.3)

25 1367.p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC AGC TTG GGA TGG AGG TCT TTC-3'  
(SEQ ID NO:151)

1367.p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA GGG CAC TGG GGT GGT GT-3' (SEQ  
ID NO:152)

(4) Human WISP-2 (DNA33473)

30 DNA33473-p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC GCG AGG ACG GCG GCT TCA-3'  
(SEQ ID NO:153)

DNA33473-p2: 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA AGA GTC GCG GCC GCC CTT  
TTT-3' (SEQ ID NO:154)

(5) Human WISP-3

35 WISP3-p1: 5'-GGA TTC TAA TAC GAC TCA CTA TAG GGC GGG GCT CCT CTT CTC CAC TCT-3'  
(SEQ ID NO:155)

WISP3-p2 5'-CTA TGA AAT TAA CCC TCA CTA AAG GGA GCT GTC GCA AGG CTG AAT GTA-3'  
(SEQ ID NO:156)

### G. Results

*In situ* analysis was performed on the above DNA sequences disclosed herein. The results from these analyses are as follows.

#### (1) Mouse WISP-1

##### Expression in Mouse Tissues

Mouse Fetal Tissues: *In situ* hybridization of mouse WISP-1 showed strong expression in embryonic mesenchymal tissues. At E10.5 expression was observed in tissues that would develop into skeletal elements in the adult; this pattern was maintained at later stages of embryonic development. In later stages (E12.5 and E15.5), expression was highest in osteoblasts at the sites of bone formation. Expression was also observed in the embryonic heart, where the signal was particularly strong in the atria at E12.5 (atria were not included in sections at E15.5).

Mouse Adult Tissues: No expression was observed in any of the adult tissues examined, including heart, lung, kidney, adrenal, liver, pancreas, cerebrum, and cerebellum. These results do not correlate with the Northern data.

Additional sites of expression in the fetus were the walls of developing blood vessels and in fibroblast-like cells within the hepatic portal tract mesenchyme.

##### Expression in Normal and Wnt-1 Transgenic Tumors

Expression with the antisense probe was observed over fibroblast-like cells lying adjacent to the subcutaneous skeletal muscle in P10 (post-natal day 10 pups) and in pregnant females. Expression was not observed over breast epithelial cells at any of the time points examined in the study.

Expression of mouse WISP-1 was high in all three of the Wnt-1 transgenic tumors tested and appeared to be confined to the supporting fibroblast-like cells within the delicate connective tissue stroma. Some expression was seen over the tumor cells themselves; however, this likely represents overspill from tumor fibroblasts, rather than true expression by tumor cells.

In summary, mouse WISP-1 was expressed in embryonic skeletal mesenchyme and at sites of bone formation. It was additionally expressed in fibroblasts in the sub-cutis of growing pups and pregnant females. It is likely to play a role in osteogenesis, and may be involved in repair after injury. Expression was also observed in the embryonic heart.

#### (2) Human WISP-1

##### Expression in Human Tissues

Human Fetal Tissue The fetal tissues examined (E12-E16 weeks) included: placenta, umbilical cord, liver, kidney, adrenals, thyroid, lungs, heart, great vessels, oesophagus, stomach, small intestine, spleen, thymus, pancreas, brain, eye, spinal cord, body wall, pelvis, and lower limb.

Human WISP-1 exhibited expression at sites of connective tissue interfaces in the fetus, for example, developing portal tracts, fascial planes in muscle, and connective tissue surrounding developing

skeletal elements and tendons. Expression also was seen in the epithelium of the developing renal cortex and in spindle-shaped fibroblast-like cells in the fetal adrenal. Human WISP-1 was strongly expressed by osteoblasts at sites of bone formation in the fetal limb.

5        Human Adult Tissue The adult tissues examined were: liver, kidney, adrenal, myocardium, aorta, spleen, lung, skin, chondrosarcoma, eye, stomach, gastric carcinoma, colon, colonic carcinoma, renal cell carcinoma, prostate, bladder mucosa, and gall bladder, as well as tissue with acetaminophen-induced liver injury and hepatic cirrhosis.

No expression was seen in normal or diseased adult tissues in this study.

10        In summary, the overall pattern of expression of human WISP-1 was broadly similar to that observed for the mouse gene as noted above. The human WISP-1 probe did not cross react with the mouse embryo section.

Expression in Human Breast Carcinoma and Normal Breast Tissue

15        Human WISP-1 was negative on benign and malignant epithelial cells, but showed specific hybridization in mesenchymal cells, particularly in areas of tissue repair, including dystrophic ossification. Most positive cells had the morphology of fibroblasts; smooth muscle cells appeared to be negative.

20        In summary, this study shows expression of human WISP-1 RNA in mesenchymal cells involved in tissue repair and/or collagen deposition. The signal was particularly strong in benign fibroblast-like cells adjacent to either infiltrating breast carcinoma cells or tissue destruction due to benign, inflammatory conditions (duct rupture). Of note is the fact that deposition of benign osteoid seemed to correlate with strong expression of the RNA.

(3) Mouse WISP-2

Expression in Normal Mouse Tissues

25        Mouse Fetal Tissues: Expression of mouse WISP-2 was observed in osteoblasts in an E15.5 mouse embryo, within the developing mandible.

30        Mouse Adult Tissues: Expression of mouse WISP-2 was observed in stromal cells around the origin, and within the cusps of the mitral and tricuspid valves of the adult heart. Expression was also observed in the adventitial cells of the renal artery; expression was presumed to be present at this site in all arteries.

All other tissues were negative.

35        Expression in Wnt-1 Tumors

The results demonstrated specific expression of mouse WISP-2 in the stroma of all Wnt-1 tumors examined. There was a signal over mononuclear cells with open vesicular nuclei, possibly macrophages. No expression was observed in either the benign or the malignant epithelium.

(4) Human WISP-2

40        Expression in Human Tissues

Strong expression of the WISP-2-encoding gene was observed in dermal fibroblasts in normal adult skin. Additionally, strong expression was seen in two cirrhotic livers, at sites of active hepatic

fibrosis. Moderate expression was found over fasciculated cells of adrenal cortex. This localization supports a role for human WISP-2 in extracellular matrix formation or turnover.

#### Expression in Human Breast Carcinoma and Normal Breast Tissue, and in Lung Carcinoma

Human WISP-2 showed a similar hybridization pattern to human WISP-1 (described above) in the two breast tumors examined. It was negative on benign and malignant epithelial cells, but showed specific hybridization in mesenchymal cells, particularly in areas of tissue repair, including dystrophic ossification. The signal appeared to localize to the same cell population for both probes WISP-1 and WISP-2; however, in some areas (breast tumor 02), the signal for WISP-2 was significantly stronger than that for human WISP-1. Most positive cells had the morphology of fibroblasts; smooth muscle cells appeared to be negative. The signal for human WISP-2 was less intense in the lung tumor tissue; however, this section also showed less tissue repair compared with the breast tumor slides. Normal lung and kidney tissue were essentially negative for human WISP-2, as for human WISP-1.

In summary, this study shows expression of human WISP-2 RNA in mesenchymal cells involved in tissue repair and/or collagen deposition. The signal was particularly strong in benign fibroblast-like cells adjacent to either infiltrating breast carcinoma cells or tissue destruction due to benign, inflammatory conditions (duct rupture). Of note is the fact that deposition of benign osteoid seemed to correlate with strong expression of the RNA.

#### (5) Human WISP-3

#### Expression in Normal Adult and Fetal Tissues and in Human Breast Carcinoma and Normal Breast Tissue and in Colon Carcinoma

The analysis shows strong expression of human WISP-3 in dermal fibroblasts in normal adult skin and in cirrhotic livers at sites of active hepatic fibrosis. This localization pattern supports a role for this growth factor in extracellular matrix formation and turnover.

The probe for human WISP-3 was negative on most tissues examined. It showed a weak, diffuse positivity on sections of an osteosarcoma; some of the positive cells do represent malignant cells. WISP-3 was negative on all normal and fetal tissues examined.

#### EXAMPLE 17: Ability of WISP Polypeptides to Inhibit VEGF-Stimulated Proliferation of Endothelial Cell Growth

The ability of mouse and human WISP-1 and human WISP-2 polypeptides to inhibit VEGF-stimulated proliferation of endothelial cells was tested. Specifically, bovine adrenal cortical capillary endothelial (ACE) cells (from primary culture, maximum 12-14 passages) were plated on 96-well microtiter plates (Amersham Life Science) at a density of 500 cells/well per 100  $\mu$ L in low-glucose DMEM, 10% calf serum, 2 mM glutamine, 1x pen/strept, and fungizone, supplemented with 3 ng/mL VEGF. Controls were plated the same way but some did not include VEGF. A test sample of either mouse WISP-1, human WISP-1 conjugated to IgG, or human WISP-2 (PRO261) conjugated to poly-His was added in a 100- $\mu$ L volume for a 200- $\mu$ L final volume. Cells were incubated for 5-7 days at 37°C. The media were aspirated and the cells washed 1x with PBS. An acid phosphatase reaction mixture (100  $\mu$ L, 0.1 M sodium acetate, pH 5.5, 0.1% TRITON-100<sup>TM</sup>, 10 mM p-nitrophenyl phosphate) was added. After incubation for 2 hours at 37°C.



the reaction was stopped by addition of 10  $\mu$ L 1 N NaOH. OD was measured on a microtiter plate reader at 405 nm. Controls were: no cells, cells alone, cells + FGF (5 ng/mL), cells + VEGF (3 ng/mL), cells + VEGF (3 ng/mL) + TGF- $\beta$  (1 ng/mL), and cells + VEGF (3 ng/mL) + LIF (5 ng/mL). (TGF- $\beta$  at a 1 ng/mL concentration is known to block 70-90% of VEGF-stimulated cell proliferation.)

5 The results were assessed by calculating the percentage inhibition of VEGF(3ng/mL)-stimulated cell proliferation, determined by measuring acid phosphatase activity at OD405 nm (1) relative to cells without stimulation, and (2) relative to the reference TGF- $\beta$  inhibition of VEGF-stimulated activity. The results, as shown in Table X below, are indicative of the utility of the WISP polypeptides in cancer therapy and specifically in inhibiting tumor angiogenesis. The numerical values (relative inhibition) shown in Table  
10 X are determined by calculating the percent inhibition of VEGF-stimulated proliferation by the mouse WISP-1, human WISP-1-IgG, and human WISP-2-poly-His polypeptides relative to cells without stimulation and then dividing that percentage into the percent inhibition obtained by TGF- $\beta$  at 1 ng/mL, which is known to block 70-90% of VEGF-stimulated cell proliferation. Human WISP-1 and human WISP-2 appear to be particularly useful as angiostatic agents.

15 Table X

|    | <u>Polypeptide</u>    | <u>Concentration (nM)</u> | <u>Relative Inhibition</u> |
|----|-----------------------|---------------------------|----------------------------|
|    | Mouse WISP-1          | 0.1                       | 113                        |
|    | "                     | 1.0                       | 108                        |
|    | "                     | 10.0                      | 109                        |
| 20 | Human WISP-1-IgG      | 1.1                       | 1                          |
|    | "                     | 11.0                      | 0.95                       |
|    | "                     | 110.0                     | 0.9                        |
|    | Human WISP-2-poly-His | 0.01%                     | 0.95                       |
|    | "                     | 0.01%                     | 1.1                        |
| 25 | "                     | 0.1                       | 0.62                       |
|    | "                     | 1.0                       | 1.03                       |
|    | "                     | 1.0                       | 0.5                        |
|    | "                     | 1.0                       | 0.6                        |

Deposit of Material

30 The following materials have been deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA, USA (ATCC):

|    | <u>Material</u>                 | <u>ATCC Dep. No.</u> | <u>Deposit Date</u> |
|----|---------------------------------|----------------------|---------------------|
|    | pRK5E.h.WIG-1.568.38            | 209533               | December 10, 1997   |
|    | pRK5E.m.WIG-1.568.6his          | 209537               | December 10, 1997   |
| 35 | Plasmid (encoding human WISP-2) | 209391               | October 17, 1997    |
|    | pRKE.m.WIG-2.1367.3             | 209538               | December 10, 1997   |

DNA56350-1176-2

209706

March 26, 1998

DNA58800-1176-2

209707

March 26, 1998

5 These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of viable cultures of the deposits for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures of the deposits to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, 10 and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

15 The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited materials is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

20 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposits of materials herein do not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various 25 modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

## WHAT IS CLAIMED IS:

1. Isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a).  
5
2. The nucleic acid of claim 1 having at least one WISP biological activity.
3. The nucleic acid of claim 1 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a).
- 10 4. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or DNA encoding a human WISP-1 polypeptide having amino acid residues 1 to 367 of Figures 3A and 3B (SEQ ID NO:4), or a complement of either of the encoding DNAs.
- 15 5. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue (SEQ ID NOS:5 and 6, respectively).
6. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:7 and 8, respectively).
- 20 7. The nucleic acid of claim 3 comprising DNA encoding a human WISP-1 polypeptide having amino acid residues 23 to 367 or 1 to 367 of Figures 3A and 3B except for an isoleucine residue at position 184 rather than a valine residue and except for a serine residue at position 202 rather than an alanine residue (SEQ ID NOS:21 and 22, respectively).
8. Isolated nucleic acid comprising SEQ ID NO:23, 24, 25, 26, 27, 28, or 29.
- 25 9. The nucleic acid of claim 1 comprising DNA encoding a mouse WISP-1 polypeptide having amino acid residues 23 to 367 of Figure 1 (SEQ ID NO:11), or DNA encoding a mouse WISP-1 polypeptide having

amino acid residues 1 to 367 of Figure 1 (SEQ ID NO:12), or a complement of either of the encoding DNAs.

10. Isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 85% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence  
5 of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) a complement of the DNA molecule of (a).

11. The nucleic acid of claim 10 having at least one WISP biological activity.

12. The nucleic acid of claim 10 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figure 1 (SEQ ID NO:11), or (b) a complement of the DNA molecule of (a).

10 13. Isolated nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-1 polypeptide cDNA in ATCC Deposit No. 209533 (pRK5E.h.WISP-1.568.38), or (b) a complement of the DNA molecule of (a).

14. A vector comprising the nucleic acid of claim 1.

15 15. A host cell comprising the vector of claim 14.

16. A process for producing a WISP-1 polypeptide comprising culturing the host cell of claim 15 under conditions suitable for expression of the WISP-1 polypeptide and recovering the WISP-1 polypeptide from the cell culture.

17. Isolated WISP-1 polypeptide encoded by the nucleic acid of claim 1.

20 18. The polypeptide of claim 17 that is human WISP-1 or mouse WISP-1.

19. Isolated WISP-1 polypeptide encoded by a nucleic acid of claim 8.

20. A chimeric molecule comprising a WISP-1 polypeptide fused to a heterologous amino acid sequence.

21. The chimeric molecule of claim 20 wherein said heterologous amino acid sequence is an epitope tag sequence, a poly-amino acid sequence, or an Fc region.
22. An antibody which specifically binds to a WISP-1 polypeptide.
23. The antibody of claim 22 wherein said antibody is a monoclonal antibody.
- 5 24. Isolated nucleic acid having at least about 600 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.
- 10 25. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-1 polypeptide comprising the sequence of amino acids 23 to 367 of Figures 3A and 3B (SEQ ID NO:3), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the
- 15 polypeptide from the cell culture.
26. Isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a).
27. The nucleic acid of claim 26 having at least one WISP biological activity.
- 20 28. The nucleic acid of claim 26 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a).
29. The nucleic acid of claim 26 comprising DNA encoding a human WISP-2 polypeptide having amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15), or DNA encoding a human WISP-2 polypeptide
- 25 having amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16), or a complement of either of the encoding DNAs.



30. Isolated nucleic acid comprising DNA having at least about an 80% sequence identity to (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 1 to 250 of Figure 4 (SEQ ID NO:16), or (b) a complement of the DNA molecule of (a).

31. Isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) a complement of the DNA molecule of (a).

32. The isolated nucleic acid of claim 31 comprising DNA having at least about a 95% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 24 to 251 of Figure 2 (SEQ ID NO:19), or (b) a complement of the DNA molecule of (a).

33. The nucleic acid of claim 32 comprising DNA encoding a mouse WISP-2 polypeptide having amino acid residues 24 to 251 of Figure 2 (SEQ ID NO:19), or DNA encoding a mouse WISP-2 polypeptide having amino acid residues 1 to 251 of Figure 2 (SEQ ID NO:20), or a complement of either of these encoding DNAs.

34. Isolated nucleic acid comprising DNA having at least about 500 nucleotides and at least about an 80% sequence identity to (a) a DNA molecule encoding a mouse WISP-2 polypeptide comprising the sequence of amino acids 1 to 251 of Figure 2 (SEQ ID NO:20), or (b) a complement of the DNA molecule of (a).

35. Isolated nucleic acid comprising DNA having at least about 400 nucleotides and at least about a 75% sequence identity to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-2 polypeptide cDNA in ATCC Deposit No. 209391 (DNA33473), or (b) a complement of the DNA molecule of (a).

36. The nucleic acid of claim 35 comprising the nucleotide sequence of the full-length coding sequence of clone UNQ228 (DNA33473) deposited under accession number ATCC 209391.

37. A vector comprising the nucleic acid of claim 26.

38. A host cell comprising the vector of claim 37.

39. A process for producing a WISP-2 polypeptide comprising culturing the host cell of claim 38 under conditions suitable for expression of the WISP-2 polypeptide and recovering the WISP-2 polypeptide from the cell culture.

40. Isolated WISP-2 polypeptide encoded by the nucleic acid of claim 26.
41. The polypeptide of claim 40 that is isolated native-sequence human WISP-2 polypeptide comprising amino acid residues 1 to 250 of Figure 4 (SEQ ID NO:16) or comprising amino acid residues 24 to 250 of Figure 4 (SEQ ID NO:15).
- 5 42. A chimeric molecule comprising a WISP-2 polypeptide fused to a heterologous amino acid sequence.
43. An antibody which specifically binds to a WISP-2 polypeptide.
44. The antibody of claim 43 that is a monoclonal antibody.
45. Isolated nucleic acid having at least about 400 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), isolating the test DNA molecule.
- 10
46. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-2 polypeptide comprising the sequence of amino acids 24 to 250 of Figure 4 (SEQ ID NO:15), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has at least about a 75% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
- 15
47. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) a complement of the DNA molecule of (a).
- 20
48. The nucleic acid of claim 47 having at least one WISP biological activity.
49. The nucleic acid of claim 47 comprising DNA encoding a human WISP-3 polypeptide having amino acid residues 34 to 372 of Figures 6A and 6B (SEQ ID NO:32) or amino acid residues 1 to 372 of Figures 6A and 6B (SEQ ID NO:33), or a complement thereof.
- 25

50. A vector comprising the nucleic acid of claim 47.
51. A host cell comprising the vector of claim 50.
52. A process for producing a WISP-3 polypeptide comprising culturing the host cell of claim 51 under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.
53. Isolated WISP-3 polypeptide encoded by the nucleic acid of claim 47.
54. The polypeptide of claim 53 that is human WISP-3.
55. A chimeric molecule comprising the WISP-3 polypeptide of claim 53 fused to a heterologous amino acid sequence.
56. An antibody which specifically binds to the WISP-3 polypeptide of claim 53.
57. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 500 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209706 (DNA56350-1176-2), or (b) a complement of the DNA molecule of (a).
58. Isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) a complement of the DNA molecule of (a), and, if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, isolating the test DNA molecule.
59. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 34 to 372 of Figures 6A and 6B (SEQ ID NO:32), or (b) a complement of the DNA molecule of (a), and if the test DNA molecule has a 100% sequence identity to (a) or (b) in more than about 500 nucleotides, (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

60. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) a complement of the DNA molecule of (a).
- 5 61. The nucleic acid of claim 60 having at least one WISP biological activity.
62. The nucleic acid of claim 60 comprising DNA encoding a human WISP-3 polypeptide having amino acid residues 16 to 355 of Figures 7A and 7B (SEQ ID NO:36) or amino acid residues 1 to 355 of Figures 7A and 7B (SEQ ID NO:37), or a complement thereof.
- 10 63. Isolated nucleic acid comprising DNA having a 100% sequence identity in more than about 400 nucleotides to (a) a DNA molecule encoding the same full-length polypeptide encoded by the human WISP-3 polypeptide cDNA in ATCC Deposit No. 209707 (DNA58800-1176-2), or (b) a complement of the DNA molecule of (a).
64. A vector comprising the nucleic acid of claim 60.
65. A host cell comprising the vector of claim 64.
- 15 66. A process for producing a WISP-3 polypeptide comprising culturing the host cell of claim 65 under conditions suitable for expression of the WISP-3 polypeptide and recovering the WISP-3 polypeptide from the cell culture.
67. Isolated WISP-3 polypeptide encoded by the nucleic acid of claim 60.
68. The polypeptide of claim 67 that is human WISP-3.
- 20 69. A chimeric molecule comprising the WISP-3 polypeptide of claim 67 fused to a heterologous amino acid sequence.
70. An antibody which specifically binds to the WISP-3 polypeptide of claim 67.
- 25 71. Isolated nucleic acid produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) a complement of the DNA molecule of (a), and, if the test

DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides, isolating the test DNA molecule.

72. A polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a human WISP-3 polypeptide comprising the sequence of amino acids 16 to 355 of Figures 7A and 7B (SEQ ID NO:36), or (b) a complement of the DNA molecule of (a), and if the test  
5 DNA molecule has a 100% sequence identity to (a) or (b) in more than about 400 nucleotides, (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

73. A composition comprising the polypeptide of claim 17 and a carrier therefor.

10 74. A composition comprising an antagonist to the polypeptide of claim 17 and a carrier therefor.

75. A composition comprising the polypeptide of claim 19 and a carrier therefor.

76. A composition comprising an antagonist to the polypeptide of claim 19 and a carrier therefor.

77. A composition comprising the polypeptide of claim 40 and a carrier therefor.

78. A composition comprising an antagonist to the polypeptide of claim 40 and a carrier therefor.

15 79. A composition comprising the polypeptide of claim 53 and a carrier therefor.

80. A composition comprising an antagonist to the polypeptide of claim 53 and a carrier therefor.

81. A composition comprising the polypeptide of claim 67 and a carrier therefor.

82. A composition comprising an antagonist to the polypeptide of claim 67 and a carrier therefor.

83. A composition comprising a WISP-1, WISP-2, or WISP-3 polypeptide and a pharmaceutically  
20 acceptable carrier.

84. The composition of claim 83 that further comprises a chemotherapeutic agent or growth-inhibitory agent.



85. The composition of claim 83 wherein the WISP-1, WISP-2, or WISP-3 polypeptide is a human polypeptide.

86. A pharmaceutical product comprising:

- (a) a composition of claim 83;
- 5 (b) a container containing said composition; and
- (c) a label affixed to said container, or a package insert included in said pharmaceutical product referring to the use of said WISP-1, WISP-2, or WISP-3 polypeptide in the treatment of a WISP-related disorder.

10 87. A process for diagnosing a disease or a susceptibility to a disease related to a mutation in a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

- (a) isolating a nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide from a sample derived from a host; and
- (b) determining a mutation in the nucleic acid sequence encoding a WISP-1, WISP-2, or WISP-3 polypeptide.

15 88. A method of diagnosing a WISP-related disorder in a mammal comprising detecting the level of expression of a gene encoding a WISP-1, WISP-2, or WISP-3 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample indicates the presence of a WISP-related dysfunction in the mammal from which the test tissue cells were obtained.

20 89. A method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of the composition of claim 83.

90. The method of claim 89 wherein the disorder is a malignant disorder or arteriosclerosis and the mammal is human.

25 91. The method of claim 90 wherein the malignant disorder is breast cancer, ovarian cancer, colon cancer, or melanoma.

92. An isolated antibody binding a WISP-1, WISP-2, or WISP-3 polypeptide.

93. The antibody of claim 92 that induces death of a cell overexpressing a WISP-1, WISP-2, or WISP-3 polypeptide.

94. The antibody of claim 93 wherein said cell is a cancer cell.
95. The antibody of claim 92 that binds to a human WISP-1, WISP-2, or WISP-3 polypeptide, and is a human or humanized antibody.
96. The antibody of claim 92 that is a monoclonal antibody.
- 5 97. The antibody of claim 96 that is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody.
98. A composition comprising an antibody of claim 92 in admixture with a pharmaceutically acceptable carrier.
99. The composition of claim 98 comprising a growth-inhibitory amount of said antibody.
- 10 100. A method for determining the presence of a WISP-1, WISP-2, or WISP-3 polypeptide comprising exposing a cell suspected of containing the WISP-1, WISP-2, or WISP-3 polypeptide to an anti-WISP-1, WISP-2, or WISP-3 antibody and determining binding of said antibody to said cell.
101. A method for treating a WISP-related disorder in a mammal comprising administering to the mammal an effective amount of a composition comprising an antagonist to a WISP-1, WISP-2, or WISP-3 polypeptide in a pharmaceutically acceptable carrier.
- 15 102. A method for inhibiting the growth of tumor cells comprising exposing a cell that overexpresses a Wnt-1-induced gene to an effective amount of an antagonist that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.
- 20 103. A method for inhibiting the growth of tumor cells comprising exposing said cells to an effective amount of the composition of claim 99.
104. The method of claim 103 wherein the tumor cells are colon cancer cells, the antibody is against human WISP-1 and is a humanized or human monoclonal antibody, and the mammal is human.
- 25 105. A kit comprising a WISP-1, WISP-2, or WISP-3 polypeptide or antagonist and instructions for using the polypeptide or antagonist to detect or treat a WISP-related disorder.

106. The kit of claim 105 comprising an anti-WISP-1, WISP-2, or WISP-3 antibody and a carrier in suitable packaging.

107. A method for inducing cell death comprising exposing a cell that is induced by Wnt to an effective amount of a WISP-1, WISP-2, or WISP-3 polypeptide or antagonist.

5 108. An article of manufacture, comprising:

a container;

a label on the container; and

a composition comprising an active agent contained within the container; wherein the composition is effective for inducing cell death or inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overinduction of Wnt or a WISP-related disorder or by overexpression of a WISP-1, WISP-2, or WISP-3 polypeptide, and the active agent in the composition is an antagonist that inhibits the expression or activity of the WISP-1, WISP-2, or WISP-3 polypeptide.

109 The article of manufacture of claim 108 wherein the active agent is an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody, and wherein the label on the container indicates that the composition can be used for treating a WISP-related disorder.

110. A process for identifying agonists to a WISP-1, WISP-2, or WISP-3 polypeptide comprising:

(a) contacting cells and a compound to be screened under conditions suitable for the stimulation of cell proliferation by the polypeptide; and

20 (b) measuring the proliferation of the cells to determine if the compound is an effective agonist.

111. An agonist to a WISP-1, WISP-2, or WISP-3 polypeptide identified by the process of claim 110.

112. A method for identifying a compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide, comprising contacting a candidate compound with a WISP-1, WISP-2, or WISP-3 polypeptide under conditions and for a time sufficient to allow the compound and polypeptide to interact.

25

113. The method of claim 112 comprising the steps of:

(a) contacting cells and a compound to be screened in the presence of the WISP-1, WISP-2, or WISP-3 polypeptide under conditions suitable for the stimulation of cell proliferation by polypeptide; and

(b) measuring the proliferation of the cells to determine if the compound is an effective antagonist.

114. A compound identified by the method of claim 112.

115. A compound that inhibits the expression or activity of a WISP-1, WISP-2, or WISP-3 polypeptide.

116. A method of diagnosing a WISP-related disorder in a mammal comprising (a) contacting an anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody with a test sample of tissue cells obtained from the  
5 mammal, and (b) detecting the formation of a complex between the anti-WISP-1, anti-WISP-2, or anti-WISP-3 antibody and the WISP-1, WISP-2, or WISP-3 polypeptide in the test sample.

117. The method of claim 116 wherein said test sample is obtained from an individual suspected to have neoplastic cell growth or proliferation.

1 / 49

1 TAACAAGGCN GTCCTGCTTG GAGAGGCATC CGCATCCTCT GGGCTGAGCC GTAGCTCCTG TGACGCTGAC TTCCAGGCAT GAGGTGGCTC CTGCCCTGGA  
ATTGTTCCGN CAGGACGAAC CTCCTCCGTAG CCGACTCGG CATCGAGGAC ACTGCGACTG AAGTCCGTA AGGTCCGTA M R W L L P W T  
1  
101 CGCTGGCAGC CGTGGCAGTC CTGAGGGTGG GCAACATCCTT GGCCACGGCC CTCTCTCCAA CCCCACAAC AATGACCTTC ACCCAGCAC CACTAGAGGA  
GGGACCGTGG GCACCGTCAG GACTCCCACC CGTTGTAGGA CCGGTGCCCG GAGAGAGGTT GGGGTGTTG TTAAGTGAAG TGGGTGCTG GTGATCTCCT  
9 L A A V A V L R V G N I L A T A L S P T P T M T F T P A P L E E  
201 AACGACTACA CGCCCCGAAT TCTGCAAGTG GCCATGTGAG TGCCACAAT CCCCACCTCG CTGCCCCACTG GCGGTCAGCC TAATCACAGA TGGCTGTGAA  
TTGCTGATGT GCGGGGCTTA AGACGTTTAC CCGTACACTC ACGGTGTTA GGGGTGGAGC GACGGGTGAC CCGCAGTCCG ATTAGTGTCT ACCGACACTT  
42 T T T R P E F C K W P C E C P Q S P P R C P L G V S L I T D G C E  
301 TGCTGTAAGA TATGTGCCCC GCAGCTTGGG GACAACTGCA CAGAGGCTGC CATCTGTGAC CCACACCGG GCCTCTACTG CGATTACAGT GGGGATCGCC  
ACGACATTCT ATACACGGGT CGTCGAACCC CTGTTGACGT GTCTCCGACG GTAGACACTG GGTGTGGCCC CGGAGATGAC GCTAATGTCA CCCCTAGCGG  
75 C C K I C A Q Q L G D N C T E A A I C D P H R G L Y C D Y S G D R P  
401 CGAGGTACGC AATAGGAGTG TGTGCACAGG TGGTCGGTGT GGGCTGTGTC CTGGATGSCG TACGCTACAC CAATGGCGAG TCCTTCCAAC CCAACTGCAG  
GCTCCATGCG TTATCCTCAC ACACGTGTCC ACCAGCCACA CCCGACACAG GACCTACCGC ATGCGATGTG GTTACCGCTC AGGAAGGTTG GGTGACGTC  
109 R Y A I G V C A Q V V G V G C V L D G V R Y T N G E S F Q P N C R  
501 GTACAACTGT ACCTGCATTG ATGGCACGGT GGGCTGCACA CCGCTGTGCC TAAGCCCCAG GCCCCCAGC CTCTGTGTGCC GCCAGCCCCG GCACGTGAGA  
CATGTTGACA TGGACGTAAC TACCGTGCCA CCGGACGTTG GCGACACCG ATTCGGGTC CCGGGGTGCG GAGACCACCG CGGTCCGGGC CGTGCACTCT  
142 Y N C T C I D G T V G C T P L C L S P R P P R L W C R Q P R H V R  
601 GTCCCTGGCC AGTCTGTGA GCAGTGGGTG TGTGATGATG ACACAAGGAG ACCACGCCAG ACTGCACTGT TGGACACCAG AGCCTTTGCA GCGTCAGGCG  
CAGGACCGG TCACGACACT CGTCACCCAC AACTACTAC TCGTTCTCTC TGGTCCGTC TGACGTGACA ACCTGTGGTC TCGGAACAGT CGCAGTCCGC  
175 V P G Q C C E Q W V C D D A R R P R Q T A L L D T R A F A A S G A  
701 CCGTGGAGCA ACGGTATGAG AACTGCATAG CCTACACTAG TCCCTGGAGC CCTGTCTTA CCACCTGTGG CCTAGGTATC TCCACTCGGA TCTCTAACGT  
GGCACCTCGT TGCCATACTC TTGACGTATC GGATGTGATC AGGACCTCG GGCACGAGAT GGTGACACC GGATCCATAG AGGTGAGCCT AGAGATTGCA  
209 V E Q R Y E N C I A Y T S P W S P C S T T C G L G I S T R I S N V  
801 CAATGCCCGG TGCTGGCCAG AGCAGGAAAG TCGCCTCTGC AACCTGCGGC CATGTGATGT GGACATCCAA CTACACATCA AGCAGGGA GAAATGCCTG  
GTTACGGGCC ACGACCGGTC TCGTCTCTTC AGCGGAGACG TTGGACCGCG GTACACTACA CCTGTAGGTT GATGTGTAGT TCCGTCCCTT CTTTACGGAC  
242 N A R C W P E Q E S R L C N L R P C D V D I Q L H I K A G K K C L

FIG. 1A



2 / 49

901 GCTGTGTACC AGCCAGAGGA GGCCACGAAC TTCACTCTCG CAGGCTGTGT CAGCACACGC ACCTACCGAC CCAAGTACTG CGAGTCTGT ACTGACAATA  
CGACACATGG TCGGTCTCCT CCGGTGCTTG AAGTGAGAGC GTCCGACACA GTCGTGTGCG TGGATGGCTG GGTTCATGAC GCCTCAGACA TGA CTGTTAT  
275 A V Y Q P E E A T N F T L A G C V S T R T Y R P K Y C G V C T D N R  
1001 GGTGTTGCAT CCCCTACAAG TCCAAGACCA TCAGTGTGGA TTTCAGTGT CCAGAGGGGC CAGGTTTCTC CCGCAGGTC CTATGGATTA ATGCTTGCTT  
CCACAACGTA GGGGATGTTT AGGTTCTGGT AGTCACACCTT AAAGGTCACA GTCTCTCCCG GTCCAAAGAG GGCCGTCCAG GATACCTAAT TACGAAACGAA  
309 C C I P Y K S K T I S V D F Q C P E G P G F S R Q V L W I N A C F  
1101 CTGCAACCTG AGCTGCAGGA ATCCTAACGA TATCTTTGCT GACTTGGAAT CTTACCCCTGA CTTGGAAGAG ATTGCCAATT AGGTGGGTGT GTGGCTCAGG  
GACGTTGGAC TCGACGTCCT TAGGATTGCT ATAGAAACGA CTGAACCTTA GAATGGGACT GAAGCTTCTC TAACGGTTAA TCCACCCACA CACCGAGTCC  
342 C N L S C R N P N D I F A D L E S Y P D F E E I A N O  
1201 GTAAAGTTCC ATGCTGC AAA GCAGCCAGCC CTTTGTGGTC CAGGACTTCA CAATTGAGCC TTATTTTCATC TACTTCCTAC TCGATTCTGA ATTCCCAGTT  
CATTTCAAGG TACGACGTTT CGTCGGTCCG GAAACACCAG GTCCTGAAGT GTTAACCTCG AATAAAGTAG ATGAAGGATG AGCTAAGACT TAAGGGTCAA  
1301 TCTGTTCCCTG TTTTGACAAAT CGTAATGGCC CAGGAGAGTG CTGCTCAGGC TCAGACAATG GGTTCCTCCT TGGGACATT CTACATCAAT CCAAGGAAAA  
AGACAAGGAC AAAACTGTTA GCATTACCGG GTCCCTCTCAC GACGAGTCCG AGTCTGTAC CCAAGGAGGA ACCCTGTAA GATGTAGTAA GGTTCCTTTT  
1401 CACATCTCTG ACTGTTTACA ATGGAAGCAA AGCCTGGCCC AGTAGTCTG GCTCCAGCCT GGGCAAAGTTG TCAGAAGTTG TGATGGGATT GTCCAAGGAA  
GTGTAGAGAC TGACAAGTGT TACCTTCGTT TCGGACCGGG TCGATCAGAC CGAGGTCGGA CCCGTTCAAC AGTCTTCAAC ACTACCCCTAA CAGGTTCCCTT  
1501 AAGCATCAGC TGAAGAACCA GTATCATGAA GTCCCTTCTC AGATGCCAAG CCTAGGATG CTGGGATCCT TTCAGACAGA TGGATGGAT TGGGACACA  
TTCGTAGTCG ACTTCTTGGT CATAGTACTT CAGGAAGGAG TCTACGGTTC GGATCCCTAC GACCCCTAGGA AAGTCTGTCT ACCTACCCTA ACCCCTGTGT  
1601 GGAATAAGCT ATTATTTTAC CCTTGCCAAA TGATACTATC CTGGGTATTT CTGCCATAAA ACATACCAA AGTGTCTTG TTCCACTGAT CTGTATATCA  
CCTTATTCTGA TAATAAAATG GGAACGGTTT ACTATGATAG GACCCATAAA GACGGATTTT TGTATGGTTT TCACAAGAAC AAGGTGACTA GACATATAGT  
1701 CAAGTCACCA AACATTTTCC AGGTAGGAC CCATAGTGT GTCATTTCTGT TTTGCCAATT GAAAAA  
GTTTCAGTGGT TTGTAAAAGG TCCACTCCTG GGTATCAACA CAGTAAGACA AAACGGTTAA CTTTTT

FIG.-1B

3 / 49

1 CCCACGCGTC CGCGCTCCTG ATCTCCAGAG GACCCCGGGC TGGACAGGG GCCTTGCGA GGCTGCAGCT GCTGTGGCAG TAGCTTGGGA TGGAGGTCTT  
GGGTGCGCAG GCGCGAGGAC TAGAGGTCTC TAGAGGTCTC CTGGGGCCCG ACCCTGTCCC CGGAACCGCT CCGACGTCGA CGACACCGTC ATCGAACCTT ACCTCCAGAA

101 TCTTGCTGGG AACTGAGGAG CTGAGAGGCT CCTGTAGGC TCCTGTCTTA AACTCTTGGC ACTTGCGGTG GCTTGGGCTT CACACACTGT CAGACACCTT  
AGAACGACCC TTGACTCCTC GACTCTCCGA GGACAGTCCG AGGACAGGAT TTGAGAACCG TGAACGCCAC CGAACCCGAA GTGTGTGACA GTCTGTGGAA

201 CTTGCTGGCC TCCTCGGCCT CAGGTTTGAA GCTGGCTCCA CAAGGACAC GGTGACATGA GGGCAACCC ACTGATCCAT CTCTGGCCA TTTCTTCCCT  
GAACCAACCG AGGAGCCGGA GTCCAAACTT CGACCGAGGT GTTCCCTGTG CCACTGTACT CCCCCTTGGG TGACTAGTA GAAGACCGGT AAAGGAAGGA

1 M R G N P L I H L L A I S F L

301 CTGCATTCTC TCAATGGTGT ATTCCCAGCT GTGCCCAGCA CCCTGTGCCCT GTCCTTGGAC ACCACCCAG TGCCACCCGG GGTATACCCCT GGTGCTGGAT  
GACGTAAGAG AGTTACCACA TAAGGGTCTA CACGGGTCTG GGGACACGGA CAGGAACCTG TGGTGGGTC ACGGTGGCC CCCATGGGGA CCACGACCTA

16 C I L S M V Y S Q L C P A P C A C P W T P P Q C P P G V P L V L D

401 GGCTGTGGCT GCTGTCGAGT GTGTGCACGG AGGTGGGG AGTCCTGCGA CCACCTGCAT GTCTGCGACC CCAGCCAGGG CCTGGTTGT CAGCCTGGGG  
CCGACACCGA CGACAGCTCA CACACGTGCC TCCGACCCCC TCAGGACGCT CAGACGCTGG GGTGCGTCCC GGACCAACA GTCGGACCCC

49 G C G C C R V C A R C A R R L G E S C D H L H V C D P S Q G L V C Q P G A

501 CAGGCCCCAG TGGCCGTGGT GCTGTGTGCC TCTTCGAAGA GGATGACGG AGCTGTGAGG TGAATGGCCG CAGGTACCTG GATGGGGAGA CCTTAAACC  
GTCCGGGGTC ACCGGCACCA CGACACACGG AGAAGCTTCT CCTACTGCCC TCGACACTCC ACTTACCCGC GTCCATGGAC CTACCCCTCTT GGAAATTTGG

83 G P S G R G A V C L F E E D D G S C E V N G R R Y L D G E T F K P

601 CAATTGCAGG GTTTTGTGCC GCTGTGATGA CCGTGGTTTC ACCTGCCTGC CGCTGTGCAG TGAGGATGTG CGGCTGCCCA GCTGGGACTG CCCACGCCCC  
GTTAACGTCC CAAACACGG CGACACTACT GCCACCAAAG TGGACGGACG GCGACACGTC ACTCCTACAC GCCGACGGGT CGACCTTGAC GGTGCGGGG

116 N C R V L C R C D D G G F T C L P L C S E D V R L P S W D C P R P

701 AGGAGAATAC AGGTGCCAGG AAGGTGCTGC CCCGAGTGG TGTGTGACCA GGCAGTGATG CAGCCGGCAA TCCAGCCCTC CTCAGCCCAA GGACACCAAC  
TCCCTCTATG TCCACGGTCC TTCCACGACG GGGCTCACCC ACACACTGGT CCGTCACTAC GTCGGCCGTT AGGTGCGGAG GAGTCGGGT CCTGTGGTTG

149 R R I Q V P G R C C P E W V C D Q A V M Q P A I Q P S S A Q G H Q L

801 TTTCTGCCCT TGTCACTCCT GCATCTGCCG ATGGCCCTTG TCCAAACTGG AGCACAGCCT GGGGCCCTG CTCAACCACC TGTGGGTGG GCATAGCCAC  
AAAGACGGGA ACAGTGAGGA CGTAGACGGC TACCGGGGAC AGTTTGACC TCGTGTGCGA CCGGGGGAC GAGTTGGTGG ACACCCAAACC CGTATCGGTG

183 S A L V T P A S A D G P C P N W S T A W G P C S T T C G L G I A T

901 CCGAGTATCC AACCAGAACC GATTCTGCCA ACTGGAGATC CAGCGTCGCC TGTGTCTGTC CAGACCCCTGC CTGGCATCCA GGAGCCACGG CTCATGGAAC  
GGCTCATAGG TTGGTCTTGG CTAAGACCGT TGACCTCTAG GTCGCAGCGG ACACAGACAG GTCTGGGACG GACCGTAGGT CCTCGGTGCC GAGTACCTTG

216 R V S N Q N R F C Q L E I Q R R L C L S R P C L A S R S H G S W N

FIG.-2A

4 / 49

1001 AGTGCCTTCT AGAGCCATTG CCGGGATGTG GATACAGGGC CTGCCATTCT CAGCAAAATGT CCCTAGGACC AGGCCCTGGA CTGATGGTAG ATGCCCTCT  
TCACGGAAGA TCTCGGTAAC GCCCCTACAC CTATGTCCCG GACGGTAAGA GTCGTTTACA GGGATCCTGG TCCGGGACCT GACTACCATC TACGGGGAGA  
249 S A F O

1101 CCATGCTCTT GGCTGCAGTT AACTGTCCCTG GGTGGATTCA GTGTCCAGAG CCTCTGAGCG ATCCCTGCTC TGTCTGAGGT GGGGGAAGCA GGTGACCAGC  
GGTACGAGAA CCGACGTCAA TTGACAGGAC CCACCTAAGT CACAGGTCTC GGAGACTCGC TAGGGACGAG ACAGACTCCA CCCCCTTCGT CCACTGGTCG

1201 TCCATTCTTC TGGATTCTGA CCCAGGCTTC TGGGTTCTCC TGGCTAGTTC CTCAAAACTT CCCTGTATGA AAAGGACAAC CAAAAGGACC TTAAAAAGCTA  
AGGTAAAGAG ACCTAAGACT GGGTCCGAAG ACCCAAGAGG ACCGATCAAG GAGTTTGA GGGACATACT TTTCCTGTTG GTTTTCCTGG AAATTTCGAT

1301 AGCTGTA CTG GGCAAGCCTG GCCACCATGC TGGGATAGT GACAGTAATA GGTACCAGGC AGCAGATTGC CTGAAACATC CAGTCCCTT CTTGGACTTC  
TCGACATGAC CCGTTCGGAC CCGTTCGGAC CCGTGGTACG ACCCCTATCA CTGTCAATTAT CCATGGTCCG TCGTCTAACG GACTTTGTAG GTCCAGGGA GAACCTGAAG

1401 TATGTGCTTG TCCCAAAGAT TATGGGTGAC CTTGTAAAGT TGCCTTTCTT GATCTGAGAA CACCCTGCCC GGCTGGGAAG AATTTTCTGG GAACATGAAG  
ATACACGAAC AGGGTTTCTA ATACCCACTG GAACATTCAC ACGGAAAGGA CTAGACTCTT GTGGGACGGG CCGACCCCTC TTAAAAAGACC CTTGTACTTC

1501 AGATGGAATC AACTATTCT TAAGAGCGGT TGCCAAAGTCC AGGAACTTGA CCTTTGTATT TGTAATAATA CACATCTCTT AAATGCTCAC AAAGCAAGAG  
TCTACCTTAG TGTGATAAGA ATTCTCGCAA ACGGTTCAAG TCCTTGAACT GGAAACATAA ACATTTTAT GTGTAGAGAA TTTACGAGTG TTTCTGTTCTC

1601 GCTCCACACT TCTGGCAGGC CAGGGCCCTT CTCTTCAGCA TGAGAGAGAC AAGGAACAGT AGAGTACCCT CCTCTGGAGG ACTGGCCCCG TCTGGAATAA  
CGAGGTGTGA AGACCGTCCG GTCCCCGAAA GAGAAGTCGT ACTCTCTCTG TTCCTTGTC TCTCATGGGA GGAGACCTCC TGACCCGGCC AGACCTTATT

1701 ACACCCAAAT CAAGTGTGGA AAAAAAAA AAAA  
TGTGGGTTA GTTCACACCT TTTT

FIG. 2B

1 CCCACGCGTC CGCTGGGCCC AGCTCCCCCG AGAGTGGTC GGATCCTCTG GGCTGCTCGG TCGATGCCCTG TGCCACTGAC GTCCAGGCAT GAGGTGGTTC  
GGGTGGCAG GCGACCCGGG TCGAGGGGGC TCTCCACCAG CCTAGGAGAC CCGACGAGCC AGCTACGGAC ACGGTGACTG CAGGTCCGTA CTCCACCAAG  
M R W F

101 CTGCCCCGGA CGCTGGCAGC AGTGACAGCA GCAGCCGCCA GCACCGTCCT GGCCACGGCC CTCTCTCCAG CCCCTACGAC CATGGACTTT ACTCCAGCTC  
GACGGGACCT GCGACCGTCTG TCACTGTCTG CCGTGGCGGT CGTGGCAGGA CCGGTGCCGG GAGAGAGTC GGGGATGCTG GTACCTGAAA TGAGGTGCGAG

5 L P W T L A A V T A A A A S T V L A T A L S P A P T T M D F T P A P

201 CACTGGAGGA CACCTCCTCA CGCCCCCAAT TCTGCAAGTG GCCATGTGAG TGCCCGCCAT CCCACCCCG CTGCCCGCTG GGGGTCAGCC TCATCACAGA  
GTGACCTCCT GTGGAGGAGT GCGGGGGTTA AGAGTTTAC CCGTACACTC ACGGGCGGTA GGGGTGGGC GACGGGCGAC CCCAGTGGG AGTAGTGTCT

39 L E D T S S R P Q F C K W P C E C P P S P P R C P L G V S L I T D

301 TGGCTGTGAG TGCTGTAAGA TGTGCGCTCA GCAGTTGGG GACAACTGCA CGGAGGCTGC CATCTGTGAC CCCCACCGGG GCCTCTACTG TGAATACAGC  
ACCGACACTC ACGACATTCT ACACGCGAGT CGTCGAACCC CTGTTGACGT GCCTCCGACG GTAGACACTG GGGGTGGCCC CGGAGATGAC ACTGATGTCTG

72 G C E C C K M C A Q Q L G D N C T E A A I C D P H R G L Y C D Y S

401 GGGGACCGCC CGAGGTACGC AATAGAGTG TGTGCACAGG TGCTCGTGT GGGCTGCTC CTGGATGGG TGCGCTACAA CAACGGCCAG TCCTTCCAGC  
CCCCTGGCG GCTCCATGCG TTATCCTCAC ACACGTGTCC ACCAGCCACA CCCGACGAG GACCTACCC ACCTGATGTT GTTGGCCGTC AGGAAGGTCG

105 G D R P R Y A I G V C A Q V V G V L D G V R Y N N G Q S F Q P

501 CTAAGTCAA GTACAACTGC ACGTGCATCG ACGGCGGGT GGGCTGCACA CCACTGTGCC TCCGAGTGG CCCCCCGCT CTCTGGTGCC CCCACCGCG  
GATTGACGTT CATGTTGACG TGCACGTAGC TGCCCGGCCA CCCGACGTGT GGTGACACGG AGGCTCACGC GGGGGCGCA GAGACCACGG GGGTGGGCGC

139 N C K Y N C T C I D G A V G C T P L C L R V R P P R L W C P H P R

601 GCGCGTGAGC ATACCTGGCC ACTGCTGTGA GCAGTGGTA TGTGAGGAGC ACGCAAGAG GCCACGCAAG ACCGACCCG GTGACACAGG AGCCTTCGAT  
CGCGCACTCG TATGGACCGG TGACGACACT CGTCACCCAT AACTCCTGC TCGGTTCTC CCGTGGCTTC TGGCGTGGG CACTGTGTCC TCGGAAGCTA

172 R V S I P G H C C E Q W V C E D D A K R P R K T A P R D T G A F D

701 GCTGTGGTG AGGTGGAGGC ATGGCACAGG AACTGCATAG CCTACACAAG CCCCTGGAGC CCTTGCTCCA CCAGCTGCGG CCTGGGGGTC TCCACTCGGA  
CGACACCCAC TCCACCTCCG TACCCTGTCC TTGACGTATC GGATGTGTTT GGGGACCTCG GGAACGAGGT GGTCGACGCC GGACCCCCCAG AGGTGAGCCT

205 A V G E V E A W H R N C I A Y T S P W S P C S T S C G L G V S T R I

801 TCTCCAATGT TAACGCCCCAG TGCTGGCCTG AGCAAGAGAG CCGCCTCTGC AACTTGGGC CATGCGATGT GGACATCCAT ACATCATTA AGGCAGGAA  
AGAGGTTACA ATTGCGGGTC ACGACCGGAC TCGTCTCTC GCGGAGAGC TTGAACGCG GTACGTACA CCTGTAGTA TGTAGTAAT TCCGTCCCTT

239 S N V N A Q C W P E Q E S R L C N L R P C D V D I H T L I K A G K

FIG.-3A



6 / 49

901 GAAGTGTCTG GCTGTGTACC AGCCAGAGGC ATCCATGAAC TTACACACTTG CCGGCTGCAT CAGCACACGC TCCTATCAAC CCAAGTACTG TGGAGTTTGC  
CTTCACAGAC CGACACATGG TCGGTCTCCG TAGGTACTTG AAGTGTGAAC GCCCGACGTA GTCGTGTGCG AGGATAGTTG GGTTCATGAC ACCTCAAACG  
272 K C L A V Y Q P E A S M N F T L A G C I S T R S Y Q P K Y C G V C

1001 ATGGACAATA GGTGCTGCAT CCCCTACAAG TCTAAGACTA TCGACGTGTC CTTCCAGTGT CCTGATGGGC TTGGCTTCTC CCGCCAGGTC CTATGGATTA  
TACCTGTTAT CCACGACGTA GGGATGTTT AGATCTGTAT AGCTGCACAG GAAGGTCACA GGAATACCCG AACCGAAGAG GCGGTCCAG GATACCTAAT  
305 M D N R C C I P Y K S K T I D V S F Q C P D G L G F S R Q V L W I N

1101 ATGCCTGCTT CTGTAACCTG AGCTGTAGGA ATCCCAATGA CATCTTTGCT GACTTGGAAT CCTACCCCTGA CTTCTCAGAA ATTGCCAACT AGGCAGGCAC  
TACGGACGAA GACATTGGAC TCGACATCCT TAGGGTTACT GTAGAAACGA CTGAACCTTA GGATGGGACT GAAGAGTCTT TAACGGTTGA TCCGTCCGTG  
339 A C F C N L S C R N P N D I F A D L E S Y P D F S E I A N O

1201 AAATCTTGGG TCTTGGGGAC TAACCCCAATG CCTGTGAAGC AGTCAGCCCT TATGGCCAAT AACTTTTCAC CAATGAGCCT TAGTTACCCCT GATCTGGACC  
TTTAGAACC AGAACCCCTG ATTGGGTTAC GGACACTTCG TCAGTCGGGA ATACCGGTTA TTGAAGAGTG GTTACTCGGA ATCAATGGGA CTAGACCCTGG

1301 CTTGGCCTCC ATTTCTGTCT CTAACCATTC AAATGACGCC TGATGGTGCT GCTCAGGCC ATGCTATGAG TTTTCTCCTT GATATCATTC AGCATCTACT  
GAACCGGAG TAAAGACAGA GATTGGTAAG TTTACTGCG ACTACCACGA CGAGTCCGG TACGATACTC AAAAGAGGAA CTATAGTAAG TCGTAGATGA

1401 CTAAGAAGAA ATGCCTGTCT CTAGCTGTTT TGGACTACAC CCAAGCCTGA TCCAGCCTTT CCAAGTCACT AGAAGTCCTG CTGGATCTTG CCTAAATCCC  
GATTTCTTTT TACGGACAGA GATCGACAAG ACCTGATGTG GGTTCCGGACT AGGTCGGAAA GGTTCAAGTA TCTTCAGGAC GACCTAGAAC GGATTTAGGG

1501 AAGAAATGGA ATCAGGTTGA CTTTAAATAT CACTAATTTT TTCTTTAGAT GCCAAACCAC AAGACTCTTT GGGTCCATTC AGATGAATAG ATGGAATTTG  
TTCTTTACCT TAGTCCATCT GAAATATATA GTGATTAAAG AAGAAATCTA CCGTTTGGTG TTCTGAGAAA CCCAGGTAAG TCTACTTATC TACCTTAAAC

1601 GAACAATAGA ATAATCTATT ATTTGGAGCC TGCCAAAGAGG TACTGTAAATG GGTAATTTCTG ACGTCAGCGC ACCAAAACTA TCCTGATTCC AAATATGTAT  
CTTGTTATCT TATTAGATAA TAAACCTCGG ACGTTCTCC ATGACATTAC CCATTAAAGAC TGCAGTCGGG TGGTTTGTAT AGGACTAAGG TTTATACATA

1701 GCACCTCAAG GTCATCAAAC ATTTGCCAAG TGAGTTGAAT AGTTGCTTAA TTTTGATTTT TAATGGAAAG TTGTATCCAT TAACCTGGGC ATTGTTGAGG  
CGTGGAGTTC CAGTAGTTTG TAAACGGTTC ACTCAACTTA TCAACGAATT AAAACTAAA ATTACCTTTC AACATAGTA ATTGGACCCG TAACAACTCC

1801 TTAAGTTTCT CTTACCCCTT ACACCTGTGA GGTACAGAT TAGGTTGTC CCAGTCAGAA ATAAAATTTG ATAAACATTC CTGTTGATGG GAAAAGCCCC  
AATTCAAAGA GAAGTGGGA TGTGACACTT CCCATGTCTA ATCCAAACAG GGTGAGTCTT TATTTTAAAC TATTTGTAAG GACAACTACC CTTTTCGGGG

1901 CAGTTAATAC TCCAGAGACA GGGAAAGGTC AGCCCATTTT AGAAGGACCA ATTGACTCTC AACTGAATC AGCTGCTGAC TGGCAGGGCT TTGGGCAGTT  
GTCAATTATG AGGTCTCTGT CCGTTTCCAG TCGGGTAAAG TCTTCTGTT TAACTGAGAG TGTGACTTAG TCGACGACTG ACCGTCCCGA AACCCGTCAA

FIG. 3B



7 / 49

2001 GGCCAGGCTC TTCCCTTGAAT CTCTCCCTT GTCCTGCTTG GGTTCATAGG GCCTCTGGAC TGGCCTGTCT GGCCCCTGAG AGTGTGCCCC  
CCGGTCCGAG AAGGAACTTA GAAGAGGGAA CAGGACGAAC CCAAGTATCC TTAACCATTC CGGAGACCTG ACCGGACAGA CCGGGGACTC TCACCACGGG

2101 TGGAACACTC CTCTACTCTT ACAGAGCCCTT GAGAGACCCA GCTGCAGACC ATGCCAGACC CACTGAAATG ACCAAGACAG GTTCAGGTAG GGGTGTGGGT  
ACCTTGTGAG GAGATGAGAA TGTCTCGGAA CTCTCTGGGT CGACGTCTGG TACGGTCTGG GTGACTTTAC TGGTCTGTGTC CAAGTCCATC CCCACACCCA

2201 CAAACCAAGA AGTGGGTGCC CTTGGTAGCA GCCTGGGGTG ACCTCTAGAG CTGGAGGCTG TGGGACTCCA GGGGCCCCCG TGTTCAGGAC ACATCTATTG  
GTTTGGTTCT TCACCCACGG GAACCATCGT CGGACCCAC TGGAGATCTC GACCTCCGAC ACCCTGAGGT CCCCCGGGGC ACAAGTCCCTG TGTAGATAAC

2301 CAGAGACTCA TTTACAGCC TTTCGTCTCTG CTGACCAAAT GGCCAGTTT CTGGTAGGAA GATGGAGGTT TACCAGTTGT TTAGAAACAG AAATAGACTT  
GTCCTCTGAGT AAAGTGTCGG AAAGCAAGAC GACTGGTTTA CCGGTCAAAA GACCATCCTT CTACCTCCAA ATGGTCAACA AATCTTTGTC TTTATCTGAA

2401 AATAAAGGTT TAAAGCTGAA GAGGTTGAAG CTAAAAGGAA AAGGTTGTTG TTAATGAATA TCAGGCTATT ATTTATTGTA TTAGGAAAAA ATAATATTTA  
TTATTTCCTT AATTCGACTT CTCCAACCTC GATTTTCCTT TTCCAACAAC AATTAATAT AGTCCGATAA TAAATAACAT AATCCTTTTA TATTATAAAT

2501 CTGTTAGAAT TCTTTTATTT AGGGCCCTTT CTGTGCCAGA CATTGCTCTC AGTGCTTGC ATGTATTAGC TCACCTGAATC TTCACGACAA TGTGAGAAAG  
GACAAATCTTA AGAAAAATAA TCCCGGAAAC GACACGGTCT GTAACGAGAG TCACGAAACG TACATAATCG AGTGACTTAG AAGTGCTGTT ACAACTCTTC

2601 TTCCCATAT TATTCTGTT CTACAAATG TGAAACGGAA GCTCATAGAG GTGAGAAAAC TCAACCAGAG TCACCCAGTT GGTGACTGGG AAAGTTAGGA  
AAGGGTAATA ATAAAGACAA GAATGTTTAC ACTTTGCCCT CGAGTATCTC CACTCTTTTG AGTTGGTCTC AGTGGGTCAA CCACTGACCC TTTCAAATCCT

2701 TTCAGATCGA AATTGGACTG TCTTTATAAC CCATATTTT CCCCTGTTT TAGAGCTTCC AAATGTGTCA GAATAGGAAA ACATTGCAAT AAATGGCTTG  
AAGTCTAGCT TTAACCTGAC AGAAATATTG GGTATAAAAG GGGACAAAA ATCTCGAAGG TTTACACAGT CTTATCCTTT TGTAACGTTA TTTACCGAAC

2801 ATTTTATAA AAAAAAAA AAAAAAAA  
TAAAAAATTT TTTTTTTTTT TTTTTTTTTT

FIG.-3C

1 CCCACGCGTC CGGCTGGGGA CATGAGAGGC ACACCGAAGA CCCACCTCCT GGCCTCTCTCC CTCCTCTGCC TCCTCTCAAA GGTGCGTACC CAGCTGTGCC  
GGGTGCGCAG GCCGACCCCT GTACTCTCCG TGTGGCTTCT GGTGGAGGA CCGGAAGAGG GAGGAGACGG AGGAGAGTTT CCACGCATGG GTCGACACGG  
1 M R G T P K T H L L A F S L L C L L S K V R T Q L C P

101 CGACACCATG TACCTGCCCC TGGCCACCTC CCCGATGCCC GCTGGAGTA CCCCTGGTGC TGGCTGCTGC CGGGTATGTG CACGGCGGCT  
GCTGTGTAC ATGGACGGG ACCGTGGAG GGGCTACGG GAGCCCTCAT GGGGACCAG ACCTACCGAC ACCGACGACG GCCCATACAC GTGCCGCCGA  
28 T P C T C P W P P P R C P L G V P L V L D G C G C C R V C A R R L

201 GGGGAGCCC TGGACCAAC TCCACGTCTG CGACGCCAGC CAGGGCCTGG TCTGCCAGCC CCGGGCAGGA CCCGGTGGCC GGGGGCCCT GTGCCCTCTG  
CCCCCTCGG ACCTGGTTG AGGTGCAGAC GCTGCGGTG GTCCCGGACC AGACGGTCCG GCCCCGTCCT GGGCCACCGG CCCCCCGGA CACGGAGAAC  
61 G E P C D Q L H V C D A S Q G L V C Q P G A G P G G R G A L C L L

301 GCAGAGGACG ACAGCAGCTG TGAGGTGAAC GGCCGCCCTGT ATCGGGAAGG GGAGACCTTC CAGCCCCACT GCAGCATCCG CTGCCGCTGC GAGGACGGCG  
CGTCTCCTGC TGTCTGTCGAC ACTCCACTTG CCGGCGGACA TAGCCCTTCC CCTCTGGAAG GTCGGGTGA CGTCGTAGGC GACGGCGACG CTCCTGCCGC  
94 A E D D S S C E V N G R L Y R E G E T F Q P H C S I R C R C E D G G

401 GCTTACCTG CGTGCCGCTG TGCAGCGAGG ATGTGCGGCT GCCCAGCTGG GACTGCCCCC ACCCCAGGAG GGTGAGGTC CTGGGCAAGT GTGCCCTGA  
CGAAGTGGAC GCACGGCGAC ACCTCGCTCC TACACGCCGA CCGGTGCGG TTCTTGGGT CCAAGAGAGG GAGGCTCCAG GACCCGTTCA CGACGGGACT  
128 F T C V P L C S E D V R L P S W D C P H P R R V E V L G K C C P E

501 GTGGGTGTC GGCCAAGGAG GGGGACTGGG GACCCAGCCC CTTCAGCCC AAGGACCCCA GTTTCTTGGC CTTGTCTCTT CCTGCCCCC TGGTGTCCCC  
CACCCACAG CCGGTTCTC CCGGTGCCC CCGGTGCCC CCGGTGCCC GAGGTGCGG GAAGTCCGG TTCTTGGGT CAAAGAGCCG GAACAGAGAA GGGACGGGG ACCACAGGG  
161 W V C G Q G G L G T Q P L P A Q F S G L V S S L P P G V P

601 TGCCAGAAAT GGAGCAGGC CTGGGACCC TGCTCGACCA CCTGTGGGT GGCATGGCC ACCCGGGTGT CCAACCAGAA CCGCTTCTGC CGACTGGAGA  
ACGGGTCTTA CCTCGTCCG GACCCCTGG GACCCCTGG ACAGCTGGT GGACACCCGA CCGGTACCG TGGGCCACA GGTGGTCTT GGCGAAGACG GCTGACCTCT  
194 C P E W S T A W G P C S T T C G L G M A T R V S N Q N R F C R L E T

701 CCCAGCGCG CCTGTGCTG TCCAGGCCCT GCCCACCCTC CAGGGTGC AGTCCACAA ACAGTGCCTT CTAGAGCCCG GCTGGGAATG GGGACACGGT  
GGGTGCGGC GGACACGGAC AGTCCGGGA CCGGTGGAG GTCCCGAGG TCAGGTGTTT TGTCACGGA GATCTCGGC CGACCCCTAC CCTGTGCCA  
228 Q R R L C L S R P C P P S R G R S P Q N S A F O

801 GTCCACCATC CCCAGCTGT GGGCCCTGCTG CTGGCCCTG GGTGATGA AGATGGTCCG TGCCAGGCC CTTGGCTGA GGCAACACTT TAGCTTGGT  
CAGGTGGTAG GGTGACCA CCGGACACG GACCCGGAC CCGACTACCT TCTACCAGC ACGGGTCCG GAACCGACGT CCGTGTGAA ATCGAACCCA

9 / 49

901 CCACCATGCA GAACACCAAT ATTAACACGC TGCCCTGGTCT GTCTGGATCC CGAGGTATGG CAGAGGTGCA AGACCTAGTC CCCTTTCCCTC TAACTCACTG  
GGTGGTACGT CTTGTGGTTA TAATTGTGCG ACGGACCAGA CAGACCTAGG GCTCCATACC GTCTCCACGT TCTGGATCAG GGGAAAGGAG ATTGAGTGAC

1001 CCTAGGAGGC TGGCCAAGGT GTCCAGGGTC CTCTAGCCCA CTCCCTGCCT ACACACACAG CCTATATCAA ACATGCACAC GGCGAGCTT TCTCTCCGAC  
GGATCCTCCG ACCGGTTCCA CAGGTCCCAG GAGATCGGGT GAGGACCGA TGTGTGTGTC GGATATAGTT TGTACGTGTG CCGCTCGAA AGAGAGGCTG

1101 TTCCCCCTGG CAAGAGATGG GACAAGCAGT CCCTTAATAT TGAGGCTGCA GCAGGTGCTG GGCTGGA CTG GGCATTTTC TGGGGGTAGG ATGAAGAGAA  
AAGGGACCC GTTCTCTACC CTGTTCTGTC GGAATTATA ACTCCGACGT CGTCCACGAC CCGACCTGAC CGGTAAAG AACCCCATCC TACTTCTCTT

1201 GGCACACAGA GATTCTGGAT CTCCTGCTGC CTTTCTGGA GTTTGTAAA TTGTTCCCTGA ATACAAGCCT ATGCGTGAAA AAAAAAAAA AAA  
CCGTGTGTCT CTAAGACCTA GAGGACGACG GAAAAGACCT CAAACATTTT ACAAAGGACT TATGTTCCGA TACGCACCTT TTTTTTTTTT TTT

**FIG. 4B**

10 / 49

1 5' -CTGCAGGGGACATGAGAGGCACACCGAAGACCCACCTCCTGGCCTTCTC  
51 CCTCCTCTGCCTCCTCTCAAAGGTGCGTACCCAGCTGTGCCCCGACACCAT  
101 GTACCTGCCCCCTGGCCACCTCCCCGATGCCCCGCTGGGAGTACCCCTGGTG  
151 GTGGATGGCTGTGGCTGCTGCCGGGTATGTGCACGGCGGCTGGGGGAGCC  
201 CTGCGACCAACTCCACGTCTGCGACGCCAGCCAGGGCCTGGTCTGCCAGC  
251 CCGGGGCAGGACCCGGTGGCCGGGGGGCCCTGTGCCTCTTGGCAGAGGAC  
301 GACAGCAGCTGTGAGGTGAACGGCCGCCTGTATCGGGAAGGGGAGACCTT  
351 CCAGCCCCACTGCAGCATCCGCTGCCGCTGCGAGGACGGCGGCTTCACCT  
401 GCGTGCCGCTGTGCAGCGAGGATGTGCGGCTGCCAGCTGGGACTGCCCC  
451 CACCCAGGAGGGTCGAGGTCCTGGGCAAGTGCTGCCCTGAGTGGGTGTG  
501 CGGCCAAGGAGGGGGACTGGGGACCAGCCCTTCCAGCCCAAGGACCCC  
551 AGTTTTCTGGCCTTGTCTCTTCCCTGCCCCCTGGTGTCCCCTGCCCAGAA  
601 TGGAGCACGGCCTGGGGACCCTGCTCGACCACCTGTGGGCTGGGCATGGC  
651 CACCCGGGTGTCCAACCAGAACCGCTTCTGCCGACTGGAGACCCAGCGCC  
701 GCCTGTGCCTGTCCAGGCCCTGCCACCCTCCAGGGGTGCGAGTCCACAA  
751 AACAGTGCCTTCTAGAGCCGGGCTGGGAATGGGGACACGGTGTCCACCAT  
801 CCCCAGCTGGTGGCCCTGTGCCTGGGCCCTGGGCTGATGGAAGA

**FIG. 5**

1 GTGGGTTTGCAGAGAGAGAGGGGAGCTTTGTGTACCCGGAGCAATGAACAAGCGGCGACTTCTCTACC  
CACCCCAAACGTCTCCTCTGTCTCCCTCGAAACACACATGGGCCCTCGTTACTTGTTCGCCCGCTGAAGAGATGG  
M N K R R L L Y P  
1  
71 CCTCAGGGTGGCTCCACGGTCCAGCGACA  
GGAGTCCCACCGAGGTGCCAGGGTCCGCTGT  
10 S G W L H G P S D M  
101 TGCAGGGGCTCCTTCTCCACTCTTCTGCTTGTGGCCTGGCACAGTTCTGCTGCAGGGTACAGGCAC  
ACGTCCCCGAGGAGAAGAGGTGAGAAAGACGACCGGACCGGTGTCAAGACGACGTCCCATGTCCCGTG  
20 Q G L L F S T L L L A G L A Q F C C R V Q G T  
171 TGGACCATTAGATACAAACACCTGAAGGAAG  
ACCTGGTAATCTATGTTGTGGACTTCCTTC  
43 G P L D T T P E G R  
201 GCCTGGAGAAGTGTGATGCACCTCAGCGTAACAGTTTGTCACTGGCCCTGCAATGCCCTCAGCAG  
CGGACCTCTTCACAGTCTACGTGAGTCGCATTTGTCAAAACAGTGACCGGGACGTTTACGGGAGTCGTC  
53 P G E V S D A P Q R K Q F C H W P C K C P Q Q  
271 AAGCCCCGTTGCCCTCCTGGAGTGAGCCTG  
TTCGGGGCAACGGGAGGACCTCACTCGGAC  
76 K P R C P P G V S L  
301 GTGAGAGATGGCTGTGGATGCTGTAAATCTGTGCCAAGCAACCAGGGAAATCTGCAATGAAGTGACC  
CACTCTCTACCGACACCTACGACATTTTAGACACGGTTCGTTGGTCCCTTTAGACGTTACTTCGACTGG  
86 V R D G C G C C K I C A K Q P G E I C N E A D L  
371 TCTGTGACCCACACAAAGGCGTGATTGTG  
AGACACTGGGTGTGTTTCCCGACATAACAC  
110 C D P H K G L Y C D  
401 ACTACTCAGTAGACAGGCCCTAGGTACGAGACTGGAGTGTGTGCATACCTTGTAGCTGTGGTGCGAGTT  
TGATGAGTCATCTGTCCGGATCCATGCTCTGACCTCACACACGATGGAACATCGACAACCCACGCTCAA  
120 Y S V D R P R Y E T G V C A Y L V A V G C E F  
471 CAACCAGGTACATTATCATATAATGGCCCAAGT  
GTTGGTCCATGTAATAGTATTACCGGTTCA  
143 N Q V H Y H N G Q V

FIG. 6A



501 GTTTCAGCCCAACCCCTTGTTCAGCTGCCCTCTGTGTGAGTGGGGCCATTTGGATGCACACCTCTGTTCATA  
CAAAGTCGGGTTGGGGAACAAGTCGACGGAGACACACTCACCCCGGTAACTACGTGTGGAGACAAGTAT  
153 F Q P N P L F S C L C V S G A I G C T P L F I

571 CCAAAGCTGGCTGGCAGTCACCTGCTCTGGA  
GGTTTCGACCGACCGTCAGTCAGTCAGACCT  
176 P K L A G S H C S G

601 GCTAAAGGTGGAAGAAGTCTGATCAGTCAAACTGTAGCCTGGAACCACTTACTACAGCAGCTTCAACAA  
CGATTTCCACCTTTCTTCAGACTAGTCAGTTTGACATCGGACCTTGGTAATGATGTCGTCGAAAGTTGTT  
186 A K G G K K S D Q S N C S L E P L L Q Q L S T S

671 GCTACAAACAATGCCAGCTTATAGAGATC  
CGATGTTTGTGTTACGGTCCGAATATCTCTAG  
210 Y K T M P A Y R D L

701 TCCCACCTTATTGGAAAAAATGTCTTGTGCAAGCAACAATAATGGACTCCCTGCTCCAGAACATGTGG  
AGGGTGAATAAACCTTTTTTTACAGAACACGTTCTGTTGTTTACCTGAGGACGAGGTCTTGTACACC  
220 P L I W K K K C L V Q A T K W T P C S R T C G

771 GATGGGAATATCTAACAGGGTGACCAATGA  
CTACCCCTTATAGATTGTCCCACTGGTTACT  
243 M G I S N R V T N E

801 AACAGCAACTGTGAAATGAGAAAAGAGAAAGACTGTGTACATTCAGCCTTGCGACAGCAATATATTA  
TTTGTCTGTTGACACTTTACTCTTTTCTCTTTCTGACACAATGTAAGTCGGAACGCTGTCGTTATATAAT  
253 N S N C E M R K E K R L C Y I Q P C D S N I L

871 AAGACAATAAAGATTCCCAAGGAAAAACA  
TTCTGTTATTCTAAGGGTTTCCTTTTGT  
276 K T I K I P K G K T

901 TGCCAAACCTACTTTCCAACTCTCCAAAGCTGAAAAATTGTCTTTTCTGGATGCTCAAGTACTCAGAGTT  
ACGGTTGATGAAAGGTTGAGAGGTTTCGACTTTTAAACAGAAAAAGACCTACGAGTTCATGAGTCTCAA  
286 C Q P T F Q L S K A E K F V F S G C S S T Q S Y

971 ACAAAACCCACTTTTGTGGAATATGCTTGG  
TGTTTGGGTGAAAAACACCTTATACGAACC  
310 K P T F C G I C L D

FIG.-6B

13 / 49

1001 ATAAGAGATGCTGTATCCCTAATAAGTCTAAAATGATTACTATTCAATTGTGATTGCCCAAATGAGGGGTC  
TATTCTCTACGACATAGGGATTATTCAGATTTTTACTAATGATAAGTTAACTAAACGGGTTTACTCCTCCAG  
320 K R C C I P N K S K M I T I Q F D C P N E G S  
1071 ATTTAAATGGAAGATGCTGTGGATTACATC  
TAAATTTACCTTCTACGACACCTAATGTAG  
343 F K W K M L W I T S  
1101 TTGTGTGTGCAGAGAACTGCAGAGAACCTGGAGATATATTTTCTGAGCTCAAGATTCTGTAAACCAA  
AACACACACAGTCTCTTTGACGTCTCTTGGACCTCTATATAAAAGACTCGAGTTCTAAGACATTTTGGTT  
353 C V C Q R N C R E P G D I F S E L K I L O  
1171 GCAAAATGGGGGAAAGTTAGTCAATCCTGT  
CGTTTACCCCTTTTCAATCAGTTAGGACA  
1201 CATANAATAAAAAATTAGTGAGTATAAAATGGTGGCAATCTACTTTGTTTAAACACAGTATGAATGCCT  
GTATNTTATTTTAAATCACTCATATTTTACCACCGTTTAGATGAACAAATTTTGTCTACTTACGGA  
1271 ATTCTCAGATCACTACATTTAAGGCATTAG  
TAAGAGTCTAGTGATGTAAATTCCTGTAATC  
1301 AAACCTTTTAAAAAGTTANCTTAAAAATATACATAA  
TTTGAAAAATTTTCAATNGAATTTTATATATGTATT

FIG. 6C

1 CACGGTCCAGCGACATGCAGGGGCTCCTTCTTCCACTCTTCTGCTGGCCTGGCACAGTTCTGCT  
 GTGCCAGGGTCGCTGTACGTCCCGAGGAGAGGTGAGAAAGACGACCGGACCGTGTCAAGACGA  
 1 M Q G L L F S T L L A G L A Q F C C  
 71 GCAGGGTACAGGGCACTGGACCATTAGATA  
 CGTCCCATGTCCCGTGACCTGGTAATCTAT  
 20 R V Q G T G P L D T  
 101 CAACACCTGAAGGAAGGCCCTGGAGAAGTGTGAGATGCACCTCAGCGTAAACAGTTTGTCACTGGCCCTG  
 GTTGTGGACTTCTTCCGGACCTCTTCACAGTCTACGTGGAGTCGCATTTGTCAAAACAGTGACCGGGAC  
 30 T P E G R P G E V S D A P Q R K Q F C H W P C  
 171 CAAATGCCCTCAGCAGAGCCCGTTGCC  
 GTTTACGGGAGTCGTCTTCGGGCAACGGG  
 53 K C P Q Q K P R C P  
 201 TCCTGGAGTGAGCCCTGGTGAGAGATGGCTGTGGATGCTGTAAATCTGTGCCAAGCAACAGGGAAATC  
 AGGACCTCACTCGGACCACTCTCTACCGACACCTTACGACATTTTAGACACGGTTCGTTGGTCCCTTTAG  
 63 P G V S L V R D G C C K I C A K Q P G E I  
 271 TGCAATGAAGCTGACCTCTGTGACCCACAC  
 ACGTTACTTCGACTGGAGACACTGGGTGTG  
 86 C N E A D L C D P H  
 301 AAAGGGCTGTATTGTGACTACTCAGTAGACAGGCCCTAGTACGAGACTGGAGTGTGTCATACCTTGTAG  
 TTTCCCGACATAACACTGATGATCATCTGTCCGGATCCATGCTCTGACCTCACACAGTATGGAACATC  
 96 K G L Y C D Y S V D R P R Y E T G V C A Y L V A  
 371 CTGTTGGTGCGAGTTCAACCAGGTACATT  
 GACAACCCACGCTCAAGTTGGTCCATGTAA  
 120 V G C E F N Q V H Y  
 401 ATCATAATGGCCAAGTGTTCAGCCCCAACCCCTTGTTCAGCTGCCCTCTGTGTGAGTGGGCCATTGGATG  
 TAGTATTACCGGTTTCAAAAGTCGGGTGGGGAACAAGTCGACGGAGACACACTCACCCCGGTAACTAC  
 130 H N G Q Q V F Q P N P L F S C L C V S G A I G C  
 471 CACACCTCTGTTTCATACCAAGCTGGCTGG  
 GTGTGGAGACAAGTATGGTTTCGACCGACC  
 153 T P L F I P K L A G

FIG.-7A

15 / 49

501 CAGTCACTGCTCTGGAGCTAAAGGTGGAAGAAGTCTGATCAGTCAAACTGTAGCCTGGAACCATTA  
GTCAGTGACGAGACCTCGATTTCACCTTTCTTCAGACTAGTCAGTTTGACATCGGACCTTGGTAATGAT  
163 S H C S G A K G G K K S D Q S N C S L E P L L  
  
571 CAGCAGCTTTCACAAGCTACAAAACAATG  
GTCGTCGAAAGTTGTTCGATGTTTGTGTTAC  
186 Q Q L S T S Y K T M  
  
601 CCAGCTTATAGAAATCTCCCACTTATTGGAATAAAATGTCTGTGCAAGCAACAAATGGACTCCCT  
GGTCGAATATCTTTAGAGGGTGAATAAACCTTTTTTTACAGAACACGTTTCGTTGTTTACCTGAGGGA  
196 P A Y R N L P L I W K K C L V Q A T K W T P C  
  
671 GCTCCAGAACATGTGGGATGGGAATATCTA  
CGAGTCTTGTACACCCCTACCCCTTATAGAT  
220 S R T C G M G I S N  
  
701 ACAGGGTGACCAATGAAACAGCAACTGTGAATGAGAAAGAGAAAGACTGTGTACATTCAGCCTTG  
TGTCCTCACTGGTACTTTTGTGCTGACACTTTACTCTTTTCTCTGACACAAATGTAAGTCGGAAC  
230 R V T N E N S N C E M R K E K R L C Y I Q P C  
  
771 CGACAGCAATATATAAGACAATAAAGAT  
GCTGTCGTTATATAATTCTCTGTTATTCTA  
253 D S N I L K T I K I  
  
801 TCCCAAAGGAAACATGCCAACCTACTTTCCAACTCTCCAAAGCTGAAATAATTGTCTTTCTGGATGC  
AGGGTTTCCTTTTGTACGGTTGGATGAAAGGTTGAGAGGTTTCGACTTTTAAACAGAAAAGACCTACG  
263 P K G K T C Q P T F Q L S K A E K F V F S G C  
  
871 TCAAGTACTCAGAGTTACAACCCACTTTT  
AGTTCATGAGTCTCAATGTTTGGGTGAAAA  
286 S S T Q S Y K P T F

**FIG. 7B**

16 / 49

901 TGTGGAATATGCTTGGATAAGAGATGCTGTATCCCTAATAAGTCTAAAGTACTATTAATTTGATT  
ACACCTTATACGAACCTATTCTCTACGACATAGGGATTATTCAGATTCTTACTAATGATAAGTTAAACTAA  
296 C G I C L D K R C C I P N K S K M I T I Q F D C  
971 GCCCAAATGAGGGTCATTAAATGGAAGA  
CGGGTTTACTCCCCAGTAAATTTACCTTCT  
320 P N E G S F K W K M  
1001 TGCTGTGGATTACATCTTGTGTGTCAGAGAACTGCAGAGAACCTGGAGATATATTTCTGAGCTCAA  
ACGACACCTAATGTAGAACACACACAGTCTCTTTGACGCTCTTGGACCTCTATATATAAAGACTCGAGTT  
330 L W I T S C V C Q R N C R E P G D I F S E L K  
1071 GATTCTGTAAACCAAGCAAAATGGGGGAAA  
CTAAGACATTTTGGTTCGTTTACCCCTTT  
353 I L O  
1101 AGTTAGTCAATCCTGTCATATAATAAAAAAATTAGTGAGTAAAAAATAAAAAAATAAAAAA  
TCAATCAGTTAGGACAGTATATTATTTTAAATCACTCATTTTCTTTTCTTTTCTTTTCTTTT  
1171 AAAAAAAAAAAAAAAAAAAGAAAAAAAA  
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT  
1201 AAAAAAAAAAAA  
TTTTTTTTTTTT

**FIG.-7C**



|              |     |                                     |   |   |                       |                     |               |      |       |    |      |
|--------------|-----|-------------------------------------|---|---|-----------------------|---------------------|---------------|------|-------|----|------|
| mouse.wisp-1 | 1   | MRWL                                | LPWTLAAV                                      | AVLRVGNIL                                   | LATALSP               | PTTMT               | FTPAPLE       | ET   | TT    | RP | EFCK |
| human.wisp-1 | 1   | MRWF                                | LPWTLAAV                                      | TAAASTV                                     | LATALSP               | PTTMD               | FTPAPLE       | DT   | SS    | RP | QFCK |
| mouse.wisp-1 | 51  | WPCECP                              | QSP   | PRCPLGVSLIT                                 | DGGCECCK              | I                   | CAQQLGDNCTEAA | ICDP | HRGLY |    |      |
| human.wisp-1 | 51  | WPCECP                              | PSP   | PRCPLGVSLIT                                 | DGGCECCK              | M                   | CAQQLGDNCTEAA | ICDP | HRGLY |    |      |
| mouse.wisp-1 | 101 | CDYSGDR                             | P R Y A I G V C A Q V V G V G C V L D G V R Y | T N G E                                     | S F Q P N C R         | Y N C T C I D G T   |               |      |       |    |      |
| human.wisp-1 | 101 | CDYSGDR                             | P R Y A I G V C A Q V V G V G C V L D G V R Y | N N G Q                                     | S F Q P N C K         | Y N C T C I D G A   |               |      |       |    |      |
| mouse.wisp-1 | 151 | V G C T P L C L S P                 | R P P R L W C R Q                             | P R H V R V P G Q                           | C C E Q W V C D D A R | R P R Q T A L L D T |               |      |       |    |      |
| human.wisp-1 | 151 | V G C T P L C L R V                 | R P P R L W C P H P R R V S I P G H           | C C E Q W V C E D D A K                     | R P R K T A P R D T   |                     |               |      |       |    |      |
| mouse.wisp-1 | 201 | R A F A S G A V E                   | Q R Y E N C I A Y T S P W S P C S T           | T C G L G I                                 | S T R I S N V N A R   | C W P E Q E         |               |      |       |    |      |
| human.wisp-1 | 201 | G A F D A V G E V E                 | A W H R N C I A Y T S P W S P C S T           | S C G L G V                                 | S T R I S N V N A Q   | C W P E Q E         |               |      |       |    |      |
| mouse.wisp-1 | 251 | S R L C N L R P C D V D I           | Q L H I K A G K K C L A V Y Q P E             | E A T N F T L A G C V                       | S T R T Y R P K Y     |                     |               |      |       |    |      |
| human.wisp-1 | 251 | S R L C N L R P C D V D I           | H T L I K A G K K C L A V Y Q P E             | A S M N F T L A G C I                       | S T R S Y Q P K Y     |                     |               |      |       |    |      |
| mouse.wisp-1 | 301 | C G V C T D N R C C I P Y K S K T I | S V D F Q C P E G P                           | G F S R Q V L W I N A C F C N L S C R N P N |                       |                     |               |      |       |    |      |
| human.wisp-1 | 301 | C G V C M D N R C C I P Y K S K T I | D V S F Q C P D G L                           | G F S R Q V L W I N A C F C N L S C R N P N |                       |                     |               |      |       |    |      |
| mouse.wisp-1 | 351 | D I F A D L E S Y P D F             | E E I A N                                     |   |                       |                     |               |      |       |    |      |
| human.wisp-1 | 351 | D I F A D L E S Y P D F             | S E I A N                                     |   |                       |                     |               |      |       |    |      |

FIG 8

FIG.\_8

|              |     |      |    |     |      |    |    |    |    |    |    |    |    |   |    |   |    |    |    |    |    |    |    |     |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|--------------|-----|------|----|-----|------|----|----|----|----|----|----|----|----|---|----|---|----|----|----|----|----|----|----|-----|-----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mouse.wisp-2 | 1   | MRGN | PL | I   | HLLA | IS | FL | CI | LS | MS | YS | QL | CP | A | PC | A | CP | WT | PP | QC | PP | GV | PL | VLD | GGC |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| human.wisp-2 | 1   | MRGT | PK | T   | HLLA | FS | LL | CL | LS | KV | RT | QL | CP | T | PC | T | CP | WP | PP | RC | PL | GV | PL | VLD | GGC |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| mouse.wisp-2 | 51  | GCCR | VC | ARR | L    | G  | E  | S  | C  | D  | H  | L  | H  | V | C  | D | P  | S  | Q  | G  | L  | V  | C  | Q   | P   | G | A | G | P | S | G | R | G | A | V | C | L | F | E | E | D | D | G | S | C |   |   |   |   |   |   |
| human.wisp-2 | 51  | GCCR | VC | ARR | L    | G  | E  | P  | C  | D  | Q  | L  | H  | V | C  | D | A  | S  | Q  | G  | L  | V  | C  | Q   | P   | G | A | G | P | G | G | R | G | A | L | C | L | A | E | D | D | S | S | C |   |   |   |   |   |   |   |
| mouse.wisp-2 | 101 | EVNG | RR | Y   | L    | D  | G  | E  | T  | F  | K  | P  | N  | C | R  | V | L  | C  | R  | C  | D  | D  | G  | G   | F   | T | C | L | P | L | C | S | E | D | V | R | L | P | S | W | D | C | P | R | P | R | R |   |   |   |   |
| human.wisp-2 | 101 | EVNG | RL | Y   | R    | E  | G  | E  | T  | F  | Q  | P  | H  | C | S  | I | R  | C  | R  | C  | E  | D  | G  | G   | F   | T | C | V | P | L | C | S | E | D | V | R | L | P | S | W | D | C | P | H | P | R | R |   |   |   |   |
| mouse.wisp-2 | 151 | I    | Q  | V   | P    | G  | R  | C  | C  | P  | E  | W  | V  | C | D  | Q | A  | V  | M  | Q  | P  | A  | I  | Q   | P   | S | S | A | Q | G | H | Q | L | S | A | L | V | T | P | A | S | A | D | G | P | C | P | N | W | S | T |
| human.wisp-2 | 151 | V    | E  | V   | L    | G  | K  | C  | C  | P  | E  | W  | V  | C | G  | Q | G  | G  | -  | G  | L  | G  | T  | Q   | P   | L | P | A | Q | G | P | Q | F | S | G | L | V | S | S | L | P | P | G | V | P | C | P | E | W | S | T |
| mouse.wisp-2 | 201 | A    | W  | G   | P    | C  | S  | T  | T  | C  | G  | L  | G  | I | A  | T | R  | V  | S  | N  | Q  | N  | R  | F   | C   | Q | L | E | I | Q | R | R | L | C | L | S | R | P | C | L | A | S | R | S | H | G | S | W | N | S | A |
| human.wisp-2 | 200 | A    | W  | G   | P    | C  | S  | T  | T  | C  | G  | L  | G  | M | A  | T | R  | V  | S  | N  | Q  | N  | R  | F   | C   | R | L | E | T | Q | R | R | L | C | L | S | R | P | C | P | P | S | R | G | R | S | P | Q | N | S | A |
| mouse.wisp-2 | 251 | F    |    |     |      |    |    |    |    |    |    |    |    |   |    |   |    |    |    |    |    |    |    |     |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| human.wisp-2 | 250 | F    |    |     |      |    |    |    |    |    |    |    |    |   |    |   |    |    |    |    |    |    |    |     |     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

FIG.-9

19 / 49

|                  |                 |               |              |             |       |
|------------------|-----------------|---------------|--------------|-------------|-------|
|                  | 10              | 20            | 30           | 40          | 50    |
| hWISP-3.DNA56350 | MNKRRLLYPSGWLHG | PSDMQGLLFSTLL | LAGLAQFCCR   | VQGTGPLD    | TTPE  |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 |                 | MQGLLFSTLL    | LAGLAQFCCR   | VQGTGPLD    | TTPE  |
|                  |                 | 10            | 20           | 30          |       |
|                  | 60              | 70            | 80           | 90          | 100   |
| hWISP-3.DNA56350 | GRPGEVSDAPQRKQ  | FCHWPCKCPQQK  | PRCPPGVSLVRD | GCGCKICAKQP |       |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | GRPGEVSDAPQRKQ  | FCHWPCKCPQQK  | PRCPPGVSLVRD | GCGCKICAKQP |       |
|                  | 40              | 50            | 60           | 70          | 80    |
|                  | 110             | 120           | 130          | 140         | 150   |
| hWISP-3.DNA56350 | GEICNEADLCDPHK  | GLYCDYSVDRPR  | YETGVCAYLVA  | VGCEFNQVHY  | HNG   |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | GEICNEADLCDPHK  | GLYCDYSVDRPR  | YETGVCAYLVA  | VGCEFNQVHY  | HNG   |
|                  | 90              | 100           | 110          | 120         | 130   |
|                  | 160             | 170           | 180          | 190         | 200   |
| hWISP-3.DNA56350 | QVFQPNPLFSCLC   | VSGAIGCTPLFI  | PKLAGSHCSGA  | KGGKSDQSNC  | SLE   |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | QVFQPNPLFSCLC   | VSGAIGCTPLFI  | PKLAGSHCSGA  | KGGKSDQSNC  | SLE   |
|                  | 140             | 150           | 160          | 170         | 180   |
|                  | 210             | 220           | 230          | 240         | 250   |
| hWISP-3.DNA56350 | PLLQQLSTSYKTM   | PAYRDLPLIWKK  | CLVQATKWTPC  | SRTCGMGISNR | V     |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | PLLQQLSTSYKTM   | PAYRDLPLIWKK  | CLVQATKWTPC  | SRTCGMGISNR | V     |
|                  | 190             | 200           | 210          | 220         | 230   |
|                  | 260             | 270           | 280          | 290         | 300   |
| hWISP-3.DNA56350 | NENSNCEMRKEKR   | LCYIQPCDSN    | ILKTIKIPKGK  | TCQPTFQLSKA | EKFVF |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | NENSNCEMRKEKR   | LCYIQPCDSN    | ILKTIKIPKGK  | TCQPTFQLSKA | EKFVF |
|                  | 240             | 250           | 260          | 270         | 280   |
|                  | 310             | 320           | 330          | 340         | 350   |
| hWISP-3.DNA56350 | SGCSSTQSYKPTF   | CGICLDKRCCIP  | NKSKMITIQFDC | PNEGSFKWKML | WI    |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | SGCSSTQSYKPTF   | CGICLDKRCCIP  | NKSKMITIQFDC | PNEGSFKWKML | WI    |
|                  | 290             | 300           | 310          | 320         | 330   |
|                  | 360             | 370           |              |             |       |
| hWISP-3.DNA56350 | TSCVCQRNCREPG   | DIFSELKIL     |              |             |       |
|                  | *****           |               |              |             |       |
| hWISP-3.DNA58800 | TSCVCQRNCREPG   | DIFSELKIL     |              |             |       |
|                  | 340             | 350           |              |             |       |

**FIG. 10**

20 / 49

hWISP-3.DNA56350 GTGGGGTTTGCAGAGGAGACAGGGGAGCTTTGTGTACCCGGAGCAATGAA  
10 20 30 40 50

huWISP-1 A  
\*

hWISP-3.DNA56350 CAAGCGGCGACTTCTCTACCCCTCAGGGTGGCTCCACGGTCCCAGCGACA  
60 70 80 90 100

10 20 30 40  
huWISP-1 TGAGGTGGTTCCTGCCCTGGAC---GCTGGCAGCAGTGACAGCAGCAGCC  
\*\* \* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

hWISP-3.DNA56350 TGCAGGGGCTCCTCTTCTCCACTCTTCTGCTTGCTGGCCTGGCACAGTTC  
110 120 130 140 150

50 60 70 80 90  
huWISP-1 GCCAGCACCGTCCTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGA  
\* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

hWISP-3.DNA56350 TGCTGCAGGGTACAGGGCACTG-----GACCATTAGATAACAACACTGA  
160 170 180 190

100 110 120 130 140  
huWISP-1 CTTTACTCCAGCTCCACTGGAGGACACCTCCTCACGCCCCCAATTCTGCA  
\* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

hWISP-3.DNA56350 AGGAAGGCCTGGAGAAGTGTGATGCACCTCAGCGTAAACAGTTTGTGTC  
200 210 220 230 240

150 160 170 180 190  
huWISP-1 AGTGGCCATGTGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTC  
\* \*\* \* \*\* \* \*\* \* \*\* \* \*\* \*

hWISP-3.DNA56350 ACTGGCCCTGCAAATGCCCTCAGCAGAAGCCCGTTGCCCTCCTGGAGTG  
250 260 270 280 290

200 210 220 230 240  
huWISP-1 AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAGCAGCT  
\*\*\*\*\* \* \* \*\*\*\*\* \*\*\*\*\* \*\* \* \*\* \*

hWISP-3.DNA56350 AGCCTGGTGAGAGATGGCTGTGGATGCTGTAAAATCTGTGCCAAGCAACC  
300 310 320 330 340

250 260 270 280 290  
huWISP-1 TGGGGACAACCTGCACGGAGGCTGCCATCTGTGACCCCCACCGGGGCCTCT  
\*\*\*\*\* \* \*\*\*\*\* \* \*\*\*\*\* \*\*\*\*\* \*\* \* \*\* \*

hWISP-3.DNA56350 AGGGGAAATCTGCAATGAAGCTGACCTCTGTGACCCACACAAAGGGCTGT  
350 360 370 380 390

300 310 320 330 340  
huWISP-1 ACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATAGGAGTGTGTGCA  
\* \*\*\*\*\* \* \*\* \* \*\* \*\*\*\*\* \* \*\*\*\*\*

hWISP-3.DNA56350 ATTGTGACTACTCAGTAGACAGGCCTAGGTACGAGACTGGAGTGTGTGCA  
400 410 420 430 440

350 360 370 380 390  
huWISP-1 CAGGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGG  
\* \* \*\* \* \*\* \* \*\* \* \* \* \*\* \* \*\* \*

hWISP-3.DNA56350 TACCTTGTAGCTGTTGGGTGCGAGTTCAACCAGGTACATTATCATAATGG  
450 460 470 480 490

**FIG. 11A**

SUBSTITUTE SHEET ( rule 26 )

21 / 49

|                  |   |                       |       |          |              |
|------------------|---|-----------------------|-------|----------|--------------|
| huWISP-1         | 400   | 410                   | 420   | 430      | 440          |
|                  | CCAGTCCTTCCAGCCTAACTGCAAGTACA                       | ACTGCACGTGCATCGACGGCG |       |          |              |
|                  | ***   | ** *****              | **    | ** ***** | ** * ** *    |
| hWISP-3.DNA56350 | CCAAGTGTTTCAGCCCAACCCCTTGTTCAGCTGCCTCTGTGTGAGTGGGG  |                       |       |          |              |
|                  | 500   | 510                   | 520   | 530      | 540          |
| huWISP-1         | 450   | 460                   | 470   | 480      | 490          |
|                  | CGGTGGGCTGCACACCACTGTGCCTCCGAGTGC                   | CGCCCCCGCGTCTCTGG     |       |          |              |
|                  | *   | * ** *****            | ***** | * * * *  | ** * ****    |
| hWISP-3.DNA56350 | CCATTGGATGCACACCTCTGTTTCATACCAAAGC                  | -----TGGCTGG          |       |          |              |
|                  | 550   | 560                   | 570   |          | 580          |
| huWISP-1         | 500   | 510                   | 520   | 530      | 540          |
|                  | TGCCCCCACCCGCGGCGCGTGAGC-ATACCTGGCCACTGCTGTGAGCAGT  |                       |       |          |              |
|                  | **  | * * * *               | ***** | * * *    | * * * * *    |
| hWISP-3.DNA56350 | -----CAGTCACTGCTCTGGAGCTAAAGGTGGAAAGAAGTCTGATCAGT   |                       |       |          |              |
|                  | 590   | 600                   | 610   | 620      |              |
| huWISP-1         | 550   | 560                   | 570   | 580      | 590          |
|                  | GGGTATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCCGTGAC  |                       |       |          |              |
|                  | ***   | **                    | *     | ***      | * * * *      |
| hWISP-3.DNA56350 | CAAAGTGT-AGCCTGGAACCATTA--CTACAGCAGCTTTCAACAAGCTAC  |                       |       |          |              |
|                  | 630   | 640                   | 650   | 660      | 670          |
| huWISP-1         | 600   | 610                   | 620   | 630      | 640          |
|                  | ACAGGAGCCTTCGATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACTG  |                       |       |          |              |
|                  | * * *   | * * *                 | * *   | ***      | * * ** *     |
| hWISP-3.DNA56350 | AAAACAATGCCAGCTTATAGAGATCTCCCACTTATTTGGAAAAAAAAAATG |                       |       |          |              |
|                  | 680   | 690                   | 700   | 710      | 720          |
| huWISP-1         | 650   | 660                   | 670   | 680      | 690          |
|                  | CATAGCCTACACAAGCCCCTGGAGCCCTTGCTCCACCAGCTGCGGCCTGG  |                       |       |          |              |
|                  | * *   | * ***                 | ***** | ** ***** | * ** ** *    |
| hWISP-3.DNA56350 | TCTTGTCAGCAAGCAACAAATGGACTCCCTGCTCCAGAACATGTGGGATGG |                       |       |          |              |
|                  | 730   | 740                   | 750   | 760      | 770          |
| huWISP-1         | 700   | 710                   | 720   | 730      | 740          |
|                  | GGGTCTCCACTCGGATCTCCAATGTTAACGCCAGTGCTGGCCTGAGCAA   |                       |       |          |              |
|                  | *   | * ** *                | ** *  | *****    | *** * * ** * |
| hWISP-3.DNA56350 | GAATATCTAACAGGGTGACCAATGAAACAGCAACTGTGAAATGAGAAAA   |                       |       |          |              |
|                  | 780   | 790                   | 800   | 810      | 820          |
| huWISP-1         | 750   | 760                   | 770   | 780      | 790          |
|                  | GAGAGCCGCTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACT     |                       |       |          |              |
|                  | ****  | * ** *                | ** *  | *****    | * ** *       |
| hWISP-3.DNA56350 | GAGAAAAGACTGTGTTACATTCAGCCTTGCGACAGCAATATATTAAAGAC  |                       |       |          |              |
|                  | 830   | 840                   | 850   | 860      | 870          |
| huWISP-1         | 800   | 810                   | 820   | 830      | 840          |
|                  | CATTAAG-----GCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGG   |                       |       |          |              |
|                  | ** ***  | *** ** *              | ** *  | **       | * *** *      |
| hWISP-3.DNA56350 | AATAAGATTCCCAAAGGAAAAACATGCCAACCTACTTTCCAACCTCTCCA  |                       |       |          |              |
|                  | 880   | 890                   | 900   | 910      | 920          |
| huWISP-1         | 850   | 860                   | 870   | 880      | 890          |
|                  | CATCCATGAACCTTCACACTTGCGGGCTGCATCAGCACACGCTCCTATCAA |                       |       |          |              |
|                  | * *   | ** **                 | ** *  | ** ** *  | ** **        |
| hWISP-3.DNA56350 | AAGCTGAAAAATTTGTCTTTTCTGGATGCTCAAGTACTCAGAGTTACAAA  |                       |       |          |              |
|                  | 930   | 940                   | 950   | 960      | 970          |

**FIG. 11B**

SUBSTITUTE SHEET (RULE 26)



22 / 49

|                  |  |      |      |      |      |
|------------------|--|------|------|------|------|
|                  | 900  | 910  | 920  | 930  | 940  |
| huWISP-1         | CCCAAGTACTGTGGAGTTTGCATGGACAATAGGTGCTGCATCCCCTACAA |      |      |      |      |
|                  | **** * ***** * *** ***** ** ** ***** ***** * **    |      |      |      |      |
| hWISP-3.DNA56350 | CCCACCTTTTGTGGAATATGCTTGGATAAGAGATGCTGTATCCCTAATAA |      |      |      |      |
|                  | 980  | 990  | 1000 | 1010 | 1020 |
| huWISP-1         | 950  | 960  | 970  | 980  | 990  |
|                  | GTCTAAGACTATCGACGTGTCCTTCCAGTGTCTGATGGGCTTGGCTTCT  |      |      |      |      |
|                  | ***** * ** * ** * ** * ** * ** *                   |      |      |      |      |
| hWISP-3.DNA56350 | GTCTAAAATGATTACTATTCAATTTGATTGCCCAAATGAGGGGTCATTTA |      |      |      |      |
|                  | 1030   | 1040 | 1050 | 1060 | 1070 |
| huWISP-1         | 1000   | 1010 | 1020 | 1030 | 1040 |
|                  | CCCGCCAGGTCCTATGGATTAATGCCTGCTTCTGTAACTGAGCTGTAGG  |      |      |      |      |
|                  | * ** * ** ***** * ** * ** * * ** *                 |      |      |      |      |
| hWISP-3.DNA56350 | AATGGAAGATGCTGTGGATTACATCTTGTGTGTGTCAGAGAACTGCAGA  |      |      |      |      |
|                  | 1080   | 1090 | 1100 | 1110 | 1120 |
| huWISP-1         | 1050   | 1060 | 1070 | 1080 | 1090 |
|                  | AATCCCAATGACATCTTTGCTGACTTGGAATCCTACCCTGACTTCTCAGA |      |      |      |      |
|                  | * ** ** ** ** ** * ** * ** *                       |      |      |      |      |
| hWISP-3.DNA56350 | GAACCTGGAGATATATTTTCTGAGCTCAAGATTCTGTAAAACCAAGCAAA |      |      |      |      |
|                  | 1130   | 1140 | 1150 | 1160 | 1170 |
| huWISP-1         | 1100   |      |      |      |      |
|                  | AATTGCCAAC   |      |      |      |      |
|                  | * **   |      |      |      |      |
| hWISP-3.DNA56350 | TGGGGGAAAAGTTAGTCAATCCTGTCATANAATAAAAAAATTAGTGAGTA |      |      |      |      |
|                  | 1180   | 1190 | 1200 | 1210 | 1220 |
| hWISP-3.DNA56350 | TAAAATGGTGGCAAATCTACTTTGTTTAAAACAGTATGAATGCCTATTCT |      |      |      |      |
|                  | 1230   | 1240 | 1250 | 1260 | 1270 |
| hWISP-3.DNA56350 | CAGATCACTACATTTAAGGCATTAGAACTTTTAAAAAGTTANCTTAAAA  |      |      |      |      |
|                  | 1280   | 1290 | 1300 | 1310 | 1320 |
| hWISP-3.DNA56350 | ATATACATAA   |      |      |      |      |
|                  | 1330   |      |      |      |      |

**FIG. 11C**

23 / 49

|                  |   |                          |                     |                     |
|------------------|---|--------------------------|---------------------|---------------------|
|                  | 10  | 20                       | 30                  | 40                  |
| hWISP-3.DNA56350 | MNKRRLLYPSGWLHG                                 | PSDMQGLLFSTL-LLAGLAQFCCR | VQGTGPLD            | TTP                 |
|                  |   | * . * ** . . . *         |                     | * **                |
| huWISP-1         |   | MRWFLPWT                 | LA                  | AVTAAASTVLATALSPAPT |
|                  |   | 10                       | 20                  | 30                  |
|                  | 50  | 60                       | 70                  | 80                  |
| hWISP-3.DNA56350 | EGRPGEVSDAPQRKQFCHWPCKCPQQKPRCPPGVSLVRD         | GCGCKICAKQ               |                     |                     |
|                  | . * . * . * * * * * * * * * *                   |                          |                     |                     |
| huWISP-1         | DFTPAPLEDTSSRPQFCKWPCECPPSPPRCPLGVSLITD         | GCECKMCAQQ               |                     |                     |
|                  | 40  | 50                       | 60                  | 70                  |
|                  | 80  |                          |                     |                     |
|                  | 100   | 110                      | 120                 | 130                 |
| hWISP-3.DNA56350 | PGEICNEADLCDPHKGLYCDYSVDRPRYETGVCA              | YLVAVGCEFNQVHYHN         |                     |                     |
|                  | * . * ** . * * * * * * * * *                    |                          |                     |                     |
| huWISP-1         | LGDNCTEAAICDPHRGLYCDYSGDRPRYAIGVCAQVVG          | VGCVLDGVR                | YNN                 |                     |
|                  | 90  | 100                      | 110                 | 120                 |
|                  | 130   |                          |                     |                     |
|                  | 150   | 160                      | 170                 | 180                 |
| hWISP-3.DNA56350 | GQVFQPNPLFSCLCVSGAIGCTPL-FIPKLAGSHCSGAK---      | GGKSDQ                   |                     |                     |
|                  | ** * * * * . . * * . * * * * * . . . . *        |                          |                     |                     |
| huWISP-1         | GQSFQPNCKYNCTCIDGAVGCTPLCLRVRPRLWCPHPRRV        | SIPGHCCEQ                |                     |                     |
|                  | 140   | 150                      | 160                 | 170                 |
|                  | 180   |                          |                     |                     |
|                  | 200   | 210                      | 220                 | 230                 |
| hWISP-3.DNA56350 | SNCSLEPLLQQLSTSYKTMPAYRDLPLI--WKKKCLVQATKWTPCS  | RTCG                     |                     |                     |
|                  | * . . . . . * . . . * . . . * * * * *           |                          |                     |                     |
| huWISP-1         | WVCEDDAKRPRKTAP-RDTGAFDAVGEVEAWHRNCIAYTSPWSPCST | SCG                      |                     |                     |
|                  | 190   | 200                      | 210                 | 220                 |
|                  | 230   |                          |                     |                     |
|                  | 250   | 260                      | 270                 | 280                 |
| hWISP-3.DNA56350 | MGISNRVTNENSNC                                  | EMRKEKRLCYIQPCDSN        | ILKTIKIPKGKTCQPTFQL |                     |
|                  | . * . * * . * . * . * * * * . * * * * . *       |                          |                     |                     |
| huWISP-1         | LGVSTRISNVNAQCWPEQESRLCNLRPCD                   | VDIHTLIK--AGKKCLAVYQP    |                     |                     |
|                  | 240   | 250                      | 260                 | 270                 |
|                  |   |                          |                     |                     |
|                  | 300   | 310                      | 320                 | 330                 |
| hWISP-3.DNA56350 | SKAEKFVFSGCSSTQSYKPTFCGICLDKRCCIPNKS            | KMITIQFDCPNEGS           |                     |                     |
|                  | . . * . * * * * * * * * * * * * * * *           |                          |                     |                     |
| huWISP-1         | EASMNFTLAGCISTR                                 | SYQPKYCGVCM              | DNRC                | CI                  |
|                  | 280   | 290                      | 300                 | 310                 |
|                  | 320   |                          |                     |                     |
|                  | 350   | 360                      | 370                 |                     |
| hWISP-3.DNA56350 | FKWKMLWITSCVCQRNCREPGDIFSELKIL                  |                          |                     |                     |
|                  | * . . * * * . * * . * * * * * * *               |                          |                     |                     |
| huWISP-1         | FSRQVLWINACFCNLSCRNPNDIFADLESYPDFSEIAN          |                          |                     |                     |
|                  | 330   | 340                      | 350                 | 360                 |

FIG. 12




FIG. 13





FIG. 14



**FIG. 15**



27 / 49

TTCGAGCTCGCCCCGACATTGATTATTGACTAGAGTCGATCACCGGTTATTAATAGTAATC  
AATTACGGGGTCATAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTA  
AATGGCCCCGCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTAT  
GTTCCCATAGTAACGCCAATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGG  
TAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGAC  
GTCAATGACGGTAAATGGCCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT  
CCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGG  
CAGTACATCAATGGGCGTGGATAGCGGTTTTGACTCACGGGGATTTCGAAGTCTCCACCCC  
ATTGACGTCAATGGGAGTTTGTTTTTGGCACCAAATCAACGGGACTTTCCAAAATGTCGT  
ACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATA  
AGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGAC  
CTGGGCCCCGGCCGAGGCCGCTCGGCCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTT  
TTTGGAGGCCTAGGCTTTTGCAAAAAGCTAGCTTATCCGGCCGGGAACGGTGCATTGGAA  
CGCGGATTCCCCGTGCCAAGAGT  
><splice donor>  
GACGTAAGTACCGCCTATAGAGCGACTAGTCCACC  
><PUR>  
ATGACCGAGTACAAGCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCGCGGGCCGTA  
CGCACCCCTCGCCGCGCGGTTTCGCCGACTACCCCGCCACGCGCCACACCGTAGACCCGGAC  
CGCCACATCGAGCGGGTCAACGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGAC  
ATCGGCAAGGTGTGGGTGCGGACGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAG  
AGCGTCGAAGCGGGGGCGGTGTTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGT  
TCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGCAACCGGCCCAAGGAG  
CCCGCGTGGTTCCTGGCCACCGTCGGCGTCTCGCCCCGACCACCAGGGCAAGGGTCTGGGC  
AGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCTTG  
GAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGCC  
GACGTCGAGTGCCCCGAAGGACCGCGCGACCTGGTGCATGACCCGCAAGCCCGGTGCCAAC  
><DHFR ATG>  
ATGGTTCGACCATTGAACTGCATCGTCGCCGTGTCCCAAATATGGGGATTGGCAAGAAC  
GGAGACCTACCCCTGCCCTCCGCTCAGGAACGCGTTCAAGTACTTCCAAAGAATGACCACA  
ACCTCTTCAGTGGAAGGTAAACAGAATCTGGTGATTATGGGTAGGAAAACCTGGTTCCTCC  
ATTCTTGAGAAGAATCGACCTTTAAAGGACAGAATTAATATAGTTCTCAGTAGAGAACTC  
AAAGAACCACACGAGGAGCTCATTTTCTTGCCAAAAGTTTGGATGATGCCTTAAGACTT  
ATTGAACAACCGGAATTGGCAAGTAAAGTAGACATGGTTTGGATAGTCGGAGGCAGTTCT  
GTTTACCAGGAAGCCATGAATCAACCAGGCCACCTTAGACTCTTTGTGACAAGGATCATG  
CAGGAATTTGAAAGTGACACGTTTTTCCCAGAAATTGATTTGGGGAAATATAAACCTCTC  
CCAGAATACCCAGGCGTCCTCTCTGAGGTCCAGGAGGAAAAGGCATCAAGTATAAGTTT  
GAAGTCTACGAGAAGAAAGACTAA  
><End DHFR>  
CGTTAACTGCTCCCCTCCTAAAGCTATGCATTTTTTATAAGACCATGGGACTTTTGCTGGC  
TTTAGATCCCCCTTGGCTTCGTTAGAACGCAGCTACAATTAATACATAACCTTATGTATCA  
TACACATACGATTTAGGTGACACTATAGATAACATCCACTTTGCCTTTCTCTCCACAGGT  
GTCCACTCCCAGGTCCAACCTGCACCTCGGTTCTATCGATTGAATTCCCCGGGGATCCTCT  
AGAGTCGACCTGCAGAAGCTTCGATGGCCGCCATGGCCCAACTTGTTTATTGCAGCTTAT  
AATGGTTACAAATAAAGCAATAGCATCACAAATTCACAAATAAAGCATTTTTTTTCACTG  
CATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCGATCGG  
<sv40 origin>  
GAATTAATTCCGGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTA  
<Kpn-SAR-Kpn insert here>  
GGTACCGACTAGTCGCGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCAA

**FIG. 16A**

28 / 49

CGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGAC  
TTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCA  
AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCGCCTG  
GCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT  
AGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCG  
GTTTGACTCACGGGGATTTCOAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGTTTTG  
ACTAGTAGCAAGGTCGCCACGCACAAGATCAATATTAACAATCAGTCATCTCTCTTTAGC  
AATAAAAAGGTGAAAAATTACATTTTAAAAATGACACCATAGACGATGTATGAAAAATAAT  
CTACTTGGAAATAAATCTAGGCAAAGAAGTGCAAGACTGTTACCCAGAAAACTTACAAAT  
TGTAATGAGAGGTTAGTGAAGATTTAAATGAATGAAGATCTAAATAAACTTATAAATTG  
TGAGAGAAATTAATGAATGTCTAAGTTAATGCAGAAACGGAGAGACATACTATATTCATG  
AACTAAAAGACTTAATATTGTGAAGGTATACTTTCTTTTTCACATAAATTTGTAGTCAATA  
TGTTCACCCCAAAAAGCTGTTTGTTAACTTGTCAACCTCATTTCAAAATGTATATAGAA  
AGCCCAAAGACAATAACAAAAATATTCTTGTAGAACAATAATGGGAAAGAATGTTCCACTA  
AATATCAAGATTTAGAGCAAAGCATGAGATGTGTGGGGATAGACAGTGAGGCTGATAAAA  
TAGAGTAGAGCTCAGAAACAGACCCATTGATATATGTAAGTGACCTATGAAAAAAATATG  
GCATTTTACAATGGGAAAATGATGATCTTTTTTCTTTTTTTAGAAAAACAGGGAAATATATT  
TATATGTAAAAAATAAAAGGGAACCCATATGTCATACCATAACACAAAAAAATTCAGT  
GAATTATAAGTCTAAATGGAGAAGGCCAAAACCTTTAAATCTTTTAGAAAAATAATATAGAAG  
CATGCCCATCATGACTTCAGTGTAGAGAAAAATTTCTTATGACTCAAAGTCCTAACCAAA  
AGAAAAGATTGTTAATTAGATTGCATGAATATTAAGACTTATTTTTTAAATTAAAAAACC  
ATTAAGAAAAGTCAGGCCATAGAATGACAGAAAATATTTGCAACACCCCAAGTAAAGAGAA  
TTGTAATATGCAGATTATAAAAAGAAGTCTTACAAATCAGTAAAAAATAAACTAGACAA  
AAATTTGAACAGATGAAAGAGAACTCTAAATAATCATTACACATGAGAACTCAATCTC  
AGAAATCAGAGAACTATCATTTGCATATACACTAAATTAGAGAAATATTAAAGGCTAAGT  
AACATCTGTGGCAATATTGATGGTATATAACCTTGATATGATGTGATGAGAACAGTACTT  
TACCCCATGGGCTTCCTCCCCAAACCCTTACCCCAAGTATAAATCATGACAAATATACTTT  
AAAAACCATTACCCTATATCTAACCAGTACTCCTCAAACCTGTCAAGGTCATCAAAAATA  
AGAAAAGTCTGAGGAACTGTCAAACTAAGAGGAACCCAAGGAGACATGAGAATTATATG  
TAATGTGGCATTCTGAATGAGATCCCAGAACAGAAAAAGAACAGTAGCTAAAAAACTAAT  
GAAATATAAATAAAGTTTGAACCTTTAGTTTTTTTTTAAAAAAGAGTAGCATTAACACGGCA  
AAGTCATTTTTCATATTTTTTCTTGAACATTAAGTACAAGTCTATAATTAAAAATTTTTTAA  
ATGTAGTCTGGAACATTGCCAGAAACAGAAGTACAGCAGCTATCTGTGCTGTCGCCTAAC  
TATCCATAGCTGATTGGTCTAAAATGAGATACATCAACGCTCCTCCATGTTTTTTTGTTTT  
CTTTTTAAATGAAAACTTTATTTTTTTAAGAGGAGTTTCAGGTTTCATAGCAAAATTGAGA  
GGAAGGTACATTCAAGCTGAGGAAGTTTTCTCTATTCCTAGTTTACTGAGAGATTGCAT  
CATGAATGGGTGTTAAATTTTGTCAAATGCTTTTTTCTGTGTCTATCAATATGACCATGTG  
ATTTTCTTCTTTAACCTGTTGATGGGACAAATTACGTTAATTGATTTTCAAACGTTGAAC  
CACCTTACATATCTGGAATAAATCTACTTGGTTGTGGTGTATATTTTTTTGATACATTC  
TTGGATTCTTTTTTGCTAATATTTTGTTGAAAATGTTTGTATCTTTGTTTCATGAGAGATAT  
TGGTCTGTTGTTTTTCTTTTCTTGTAAATGTCATTTTCTAGTTCCGGTATTAAGGTAATGCT  
GGCCTAGTTGAATGATTTAGGAAGTATTCCTCTGCTTCTGTCTTCTGAGGTACCGCGGC  
CGCCCGTCGTTTTAC

**FIG. 16B**

29 / 49

<start pUC118>  
<linearization linker inserted into HpaI site>  
AACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCC  
CTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGC  
GCAGCCTGAATGGCGAATGGC  
<start M13>  
GCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCCGCATACGTCAAA  
GCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGGGTGTGGTGGTTACGCG  
CAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCTTCCCTTC  
CTTTCCTCGCCACGTTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGG  
GTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTGCGGTGATGGTTC  
ACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTT  
CTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTC  
TTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTTA  
ACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTTATGGTGCACCTCT  
CAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGC  
TGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGT  
CTCCGGGAGCTGCATGTGTCAGAGGTTTTTCACCGTCATCACCGAAACGCGCGAG  
< Hinc II (2271) to GTCATC>  
< Pst I (1973) to CTGCTG>  
< Acc I (183) delete 6 bp>  
<Arbitrarily change EcoRI (1) to GAATAC>  
<pUCx 83.11.25 sequence not fully known>  
ACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTC  
TTAGACGTCAGGTGGCACCTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTT  
CTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCCTGATAAATGCTTCAATA  
ATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCGCCCTTATTCCTTTTT  
TGCGGCATTTTGCCCTTCCTGTTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAGATGC  
TGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAAGAT  
CCTTGAGAGTTTTTCGCCCCGAAGAACGTTTTTCCAATGATGAGCACTTTTAAAGTTCTGCT  
ATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCCGCATACA  
CTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGG  
CATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAA  
CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGG  
GGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGA  
CGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGG  
CGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGT  
TGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTC  
CCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA  
GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACCTGTCAGACCAAGTTTACTC  
ATATATACTTTAGATTGATTTAAAACTTCATTTTTTAATTTAAAGGATCTAGGTGAAGAT  
CCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTTCGTTCCACTGAGCGTC  
AGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTG  
CTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAGAGCT  
ACCAACTCTTTTTCCGAAGGTAACCTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCT  
TCTAGTGTAAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCT  
CGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGG  
GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTC

**FIG. 16C**

SUBSTITUTE SHEET ( rule 26 )



30 / 49

GTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA  
GCTATGAGAAAGCGCCACGCTTCCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG  
CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTA  
TAGTCCTGTCTGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTTGTGATGCTCGTCAGG  
GGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCCTTTTTACGGTTCCTGGCCTTTTG  
CTGGCCTTTTGCTCACATGTTCTTTCTGCGTTATCCCCTGATTCTGTGGATAACCGTAT  
TACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTC  
AGTGAGCGAGGAAGCG

<Sap-SAR-Sap insert here>

GAAGAGCCCCGCGGGCAAGGTGCGCCACGCACAAGATCAATATTAACAATCAGTCATCTCTC  
TTTAGCAATAAAAAGGTGAAAAATTACATTTTAAAAATGACACCATAGACGATGTATGAA  
AATAATCTACTTGGAATAAATCTAGGCAAAGAAGTGCAAGACTGTTACCCAGAAAACCTT  
ACAAATTGTAAATGAGAGGTTAGTGAAGATTTAAATGAATGAAGATCTAAATAAACTTAT  
AAATTGTGAGAGAAATTAATGAATGTCTAAGTTAATGCAGAAACGGAGAGACATACTATA  
TTCATGAACTAAAAGACTTAATATTGTGAAGGTATACTTTCTTTTCACATAAATTTGTAG  
TCAATATGTTTACCCCCAAAAAAGCTGTTTGTTAACCTTGTC AACCTCATTTC AAAATGTAT  
ATAGAAAGCCCAAAGACAATAACAAAAATATTCTTGTAGAACAAAATGGGAAAGAATGTT  
CCACTAAATATCAAGATTTAGAGCAAAGCATGAGATGTGTGGGGATAGACAGTGAGGCTG  
ATAAAATAGAGTAGAGCTCAGAAACAGACCCATTGATATATGTAAGTGACCTATGAAAAA  
AATATGGCATTTTTACAATGGGAAAATGATGATCTTTTTCTTTTTTAGAAAAACAGGGAAA  
TATATTTATATGTAAAAAATAAAAGGGAACCCATATGTCATACCATAACACAAAAAAAT  
TCCAGTGAATTATAAGTCTAAATGGAGAAGGCAAACTTTAAATCTTTTAGAAAAATAATA  
TAGAAGCATGCCATCATGACTTCAGTGTAGAGAAAAATTTCTTATGACTCAAAGTCCTAA  
CCACAAAGAAAAGATTGTTAATTAGATTGCATGAATATTAAGACTTATTTTTTAAATTA  
AAAACCATTAAGAAAAGTCAGGCCATAGAATGACAGAAAATATTTGCAACACCCCAGTAA  
AGAGAATTGTAATATGCAGATTATAAAAAGAAGTCTTACAAATCAGTAAAAAATAAACT  
AGACAAAAATTTGAACAGATGAAAGAGAACTCTAAATAATCATTACACATGAGAACTC  
AATCTCAGAAATCAGAGAACTATCATTGCATATACACTAAATTAGAGAAATATTAAAGG  
CTAAGTAACATCTGTGGCAATATTGATGGTATATAACCTTGATATGATGTGATGAGACA  
GTACTTTACCCCATGGGCTTCCTCCCCAAACCCTTACCCAGTATAAATCATGACAAATA  
TACTTTAAAAACCATTACCCTATATCTAACCAGTACTCCTCAAACTGTCAAGGTCATCA  
AAAATAAGAAAAGTCTGAGGAACTGTCAAACTAAGAGGAACCCAAGGAGACATGAGAAT  
TATATGTAATGTGGCATTCTGAATGAGATCCCAGAACAGAAAAAGAACAGTAGCTAAAAA  
ACTAATGAAATATAAATAAAGTTTGAACCTTTAGTTTTTTTTTAAAAAAGAGTAGCATTAA  
ACGGCAAAGTCATTTTCATATTTTTCTTGAACATTAAGTACAAGTCTATAATTAAAAATT  
TTTTAAATGTAGTCTGGAACATTGCCAGAAACAGAAGTACAGCAGCTATCTGTGCTGTCTG  
CCTAACTATCCATAGCTGATTGGTCTAAAATGAGATACATCAACGCTCCTCCATGTTTTT  
TGTTTTCTTTTTTAAATGAAAACTTTATTTTTTAAAGAGGAGTTTCAGGTTTCATAGCAAAA  
TTGAGAGGAAGGTACATTCAAGCTGAGGAAGTTTTCCTCTATTCTTAGTTTACTGAGAGA  
TTGCATCATGAATGGGTGTTAAATTTTGTCAAATGCTTTTTCTGTGTCTATCAATATGAC  
CATGTGATTTTCTTCTTTAACCTGTTGATGGGACAAATTACGTTAATTGATTTTCAAACG  
TTGAACCACCCTTACATATCTGGAATAAATTCTACTTGGTTGTGGTGTATATTTTTTTGAT  
ACATTCTTGGATTCTTTTTTGCTAATATTTTGTGAAAATGTTTGTATCTTTGTTTCATGAG  
AGATATTGGTCTGTTGTTTTCTTTTCTTGTAAATGTCATTTTCTAGTTCCGGTATTAAGGT  
AATGCTGGCCTAGTTGAATGATTTAGGAAGTATTCCCTCTGCTTCTGTCTTCTGAAGCGG  
AAGAGC

<end M13>

GCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACG  
ACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA  
CTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTG  
TGAGCGGATAACAATTTACACAGGAAACAGCTATGACATGATTACGAATTAA

**FIG. 16D**

SUBSTITUTE SHEET ( rule 26 )

31 / 49

AAGCTTTACTCGTAAAGCGAGTTGAAGGATCATATTTAGTTGCGTTTATGAGATAAGATT  
GAAAGCACGTGTAAA

><start ORF504 (PTP)>

ATGTTTCCCGCGCGTTGGCACAACCTATTTACAATGCGGCCAAGTTATAAAAGATTCTAAT  
CTGATATGTTTTTAAACACCTTTGCGGCCCGAGTTGTTTGCGTACGTGACTAGCGAAGAA  
GATGTGTGGACCGCAGAACAGATAGTAAACAAAACCCTAGTATTGGAGCAATAATCGAT  
TTAACCAACACGTCTAAATATTATGATGGTGTGCATTTTTTTGCGGGCGGGCCTGTTATAC  
AAAAAAATTCAAGTACCTGGCCAGACTTTGCCGCCTGAAAGCATAGTTCAAGAATTTATT  
GACACGGTAAAAGAATTTACAGAAAAGTGTCCCGGCATGTTGGTGGGCGTGCACCTGCACA  
CACGGTATTAATCGCACCCGGTTACATGGTGTGCAGATATTTAATGCACACCCTGGGTATT  
GCGCCGCAGGAAGCCATAGATAGATTCGAAAAAGCCAGAGGTCACAAAATTGAAAGACAA  
AATTACGTTCAAGATTTATTAATTTAATTAATATTATTTGCATTCCTTTAACAAATACTTT  
ATCCTATTTTCAAATTGTTGCGCTTCTTCCAGCGAACCAAAACTATGCTTCGCTTGCTCC  
GTTTAGCTTGTAGCCGATCAGTGGCGTTGTTCCAATCGACGGTAGGATTAGGCCGGATAT  
TCTCCACCACAATGTTGGCAACGTTGATGTTACGTTTATGCTTTTGGTTTTCCACGTACG  
TCTTTTGGCCGGTAATAGCCGTAAACGTAGTGCCGTCGCGCGTCACGCACAACACCGGAT  
GTTTGCGCTTGTCCGCGGGGTATTGAACCGCGCGATCCGACAAATCCACCACCTTTGGCAA  
CTAAATCGGTGACCTGCGCGTCTTTTTTCTGCATTATTTTCGTCTTTCTTTTGCATGGTTT  
CCTGGAAGCCGGTGTACATGCGGTTTAGATCAGTCATGACGCGCGTGACCTGCAAATCTT  
TGGCCTCGATCTGCTTGTCTTGATGGCAACGATGCGTTCAATAAACTCTTGTTTTTTAA  
CAAGTTCCTCGGTTTTTTTGCGCCACCACCGCTTGCAGCGCGTTTGTGTGCTCGGTGAATG  
TCGCAATCAGCTTAGTCACCAACTGTTTGCTCTCCTCCTCCCGTTGTTTGATCGCGGGAT  
CGTACTTGCCGGTGCAGAGCACTTGAGGAATTACTTCTTCTAAAAGCCATTCTTGTAATT  
CTATGGCGTAAGGCAATTTGGACTTCATAATCAGCTGAATCACGCCGGATTAGTAATGA  
GCACTGTATGCGGCTGCAAATACAGCGGGTCGCCCCCTTTTCACGACGCTGTTAGAGGTAG  
GGCCCCCATTTTGGATGGTCTGCTCAAATAACGATTTGTATTTATTGTCTACATGAACAC  
GTATAGCTTTATCACAACTGTATATTTTAAACTGTTAGCGACGTCCTTGGCCACGAACC  
GGACCTGTTGGTCGCGCTCTAGCACGTACCGCAGGTTGAACGTATCTTCTCCAAATTTAA  
ATTCTCCAATTTTAACGCGAGCCA

><start ORF984 (ORF2)>

TTTTGATACACGTGTGTCGATTTTGCAACAACCTATTGTTTTTTAACGCAAACCTAACTTA  
TTGTGGTAAGCAATAATTAAATATGGGGGAACATGCGCCGCTACAACACTCGTCGTTATG  
AACGCAGACGGCGCCGGTCTCGGCGCAAGCGGCTAAAACGTGTTGCGCGTTCAACGCGGC  
AAACATCGCAAAAGCCAATAGTACAGTTTTGATTTGCA

><start conotoxin>

TATTAACGGCGATTTTTTAAATTATCTTATTTAATAAATAGTTATGACGCCTACAACCTCC  
CCGCCCCGCGTTGACTCGCTGCACCTCGAGCAGTTCGTTGACGCCTTCCTCCGTGTGGCCG  
AACACGTGAGCGGGTGGTCGATGACCAGCGGCGTGCCGCACGCGACGCACAAGTATCTG  
TACACCGAATGATCGTCGGGCGAAGGCACGTGCGCCTCCAAGTGGCAATATTGGCAAATT  
CGAAAATATATACAGTTGGGTGTTTGCGCATATCTATCGTGGCGTTGGGCATGTACGTC  
CGAACGTTGATTTGCATGCAAGCCGAAATTAATCATTTGCGATTAGTGCGATTAAAACGT  
TGTACATCCTCGCTTTTAATCATGCCGTCGATTAAATCGCGCAATCGAGTCAAGTGATCA  
AAGTGTGGAATAATGTTTTCTTTGTATTCCCGAGTCAAGCGCAGCGCGTATTTTAACAAA  
CTAGCCATCTTGTAAGTTAGTTTCA

><start ORF453>

TTTAATGCAACTTTATCCAATAATATATT

><start ORF327>

ATGTATCGCACGTCAAGAATTAACAATGCGCCCGTTGTCGCATCTCAACACGACTATGAT  
AGAGATCAAATAAAGCGCGAATTAAATAGCTTGCGACGCAACGTGCACGATCTGTGCACG  
CGTTCCGGCACGAGCTTTGATTGTAATAAGTTTTTACGAAGCGATGACATGACCCCCGTA  
GTGACAACGATCACGCCCAAAGAACTGCCGACTACAAAATTACCGAGTATGTCGGTGAC  
GTTAAAACCTATTAAGCCATCCAATCGACCGTTAGTCGAATCAGGACCGCTGGTGCGAGAA  
GCCGCGAAGT

><start ORF630>



32 / 49

ATGGCGAATGCATCGTATAACGTGTGGAGTCCGCTCATTAGAGCGTCATGTTTAGACAAG  
 AAAGCTACATATTTAATTGATCCCGATGATTTTATTGATAAATTGACCCTAACTCCATAC  
 ACGGTATTCTACAATGGCGGGGTTTGGTCAAAATTTCCGGACTGCGATTGTACATGCTG  
 TTAACGGCTCCGCCCCACTATTAATGAAATTAAAAATTTCCAATTTTAAAAAACGCAGCAAG  
 AGAAACATTTGTATGAAAGAATGCGTAGAAGGAAAGAAAAATGTCGTCGACATGCTGAAC  
 AACAAGATTAATATGCCTCCGTGTATAAAAAAATATTGAACGATTTGAAAGAAAACAAT  
 GTACCGCGCGGGCGGTATGTACAGGAAGAGGTTTATACTAAACTGTTACATTGCAAACGTG  
 GTTTCGTGTGCCAAGTGTGAAAACCGATGTTTAATCAAGGCTCTGACGCATTTCTACAAC  
 CACGACTCCAAGTGTGTGGGTGAAGTCATGCATCTTTTAATCAAATCCCAAGATGTGTAT  
 AAACCACCAAACCTGCCAAAAAATGAAAACCTGTCGACAAGCTCTGTCCGTTTGCTGGCAAC  
 TGCAAGGGTCTCAATCCTATTTGTAATTATTGAATAATAAAACAATTATAAATGCTAAAT  
 TTGTTTTTTTATTAACGATACAAACCAAACGCAACAAGAACATTTGTAGTATTATCTATAA  
 TTGAAAACGCGTAGTTATAATCGCTGAGGTAATATTTAAAATCATTTTCAAATGATTCAC  
 AGTTAATTTGCGACAATATAATTTTATTTTCACATAAACTAGACGCCTTGTCGTCCTTCTT  
 CTTTCGTATTCCTTCTCTTTTTCATTTTCTCCTCATAAAAATTAACATAGTTATTATCGT  
 ATCCATATATGTATCTATCGTATAGAGTAAATTTTTTGTGTCATAAATATATATGTCTT  
 TTTTAATGGGGTGTATAGTACCGCTGCGCATAGTTTTTCTGTAATTTACAACAGTGCTAT  
 TTTCTGGTAGTTCTTCGGAGTGTGTTGCTTTAATTATTAAATTTATATAATCAATGAATT  
 TGGGATCGTCGGTTTTGTACAATATGTTGCCGGCATAGTACGCAGCTTCTTCTAGTTCAA  
 TTACACCATTTTTTAGCAGCACCGGATTAACATAACTTTCCAAAATGTTGTACGAACCGT  
 TAAACAAAACAGTTCACCTCCCTTTTCTATACTATTGTCTGCGAGCAGTTGTTTGTGT  
 TAAAAATAACAGCCA

><start ORF603>

TTGTAATGAGACGCACAACTAATATCACAACTGGAAATGTCTATCAATATATAGTTGC  
 TGATATCATGGAGATAATTAAAATGATAACCATCTCGCAAATAAA

><start of polh transcription>

TAAGTATTTTACTGTTTTTCGTAACAGTTTTTGTAAATAAAAAAACCTATAAAT

><mutated polh start codon>

ATTCCGGATTATTCATACCGTCCCACCATCGGGCGC

><start polylinker >

GGATCCGCGGCGCGGAATTCTAAACCACCATGGCTAGCAGGCCT

><start of IgG>

GACAAAACCTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTC  
 TTCCTCTTCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA  
 TCGGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC  
 GCGGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTAC  
 CGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAG  
 TGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAA  
 GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAAGAGATGACCAAG  
 AACCAGGTGACCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATCGCCGTGGAG  
 TGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGGACTCC  
 GACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGG  
 AACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC  
 CTCTCCCTGTCTCCGGGTAAA

><end of IgG>

TGACATAGGG

><untranslated His tag>

CATCATCATCATCATCATCATTAATTCTAGACTAGTCTGCAGATC

><end polylinker>

T

**FIG. 17B**

33 / 49

&gt;&lt;polh coding sequences&gt;

GATCCTTTCCTGGGACCCGGCAAGAACCAAAAACCTCACTCTCTTCAAGGAAATCCGTAAT  
GTTAAACCCGACACGATGAAGCTTGTCTGTTGGATGGAAAGGAAAAGAGTTCTACAGGGAA  
ACTTGGACCCGCTTCATGGAAGACAGCTTCCCCATTGTTAACGACCAAGAAGTGATGGAT  
GTTTTCTTGTGTCAACATGCGTCCCCTAGACCCAACCGTTGTTACAAATTCCTGGCC  
CAACACGCTCTGCGTTGCGACCCCGACTATGTACCTCATGACGTGATTAGGATCGTCGAG  
CCTTCATGGGTGGGCAGCAACAACGAGTACCGCATCAGCCTGGCTAAGAAGGGCGGCGGC  
TGCCCAATAATGAACCTTCACTCTGAGTACACCAACTCGTTCGAACAGTTCATCGATCGT  
GTCATCTGGGAGAACTTCTACAAGCCCATCGTTTACATCGGTACCGACTCTGCTGAAGAG  
GAGGAAATTCTCCTTGAAGTTTCCCTGGTGTTCAAAGTAAAGGAGTTTGCACCAGACGCA  
CCTCTGTTCACTGGTCCGGCGTATTAAACACGATACATTGTTATTAGTACATTTATTAA  
GCGCTAGATTCTGTGCGTTGTTGATTTACAGACAATTGTTGTACGTATTTTAATAATTCA  
TTAAATTTATAATCTTTAGGGTGGTATGTTAGAGCGAAAATCAAATGATTTTTCAGCGTCT  
TTATATCTGAATTTAAATATTAAATCCTCAATAGATTTGTAAAATAGGTTTCGATTAGTT  
TCAAACAAGGGTTGTTTTTCCGAACCGATGGCTGGACTATCTAATGGATTTTCGCTCAAC  
GCCACAAAACCTTGCCAAATCTTGTAGCAGCAATCTAGCTTTGTGCGATATTCGTTTGTGTT  
TTGTTTTGTAAATAAAGGTTTCGACGTCGTTCAAATATTATGCGCTTTTGTATTTCTTTCA  
TCACTGTCGTTAGTGTACAATTGACTCGACGTAAACACGTTAAATAAAGCTTGGACATAT  
TTAACATCGGGCGTGTTAGCTTTATTAGGCCGATTATCGTCGTCGTCCTCAACCTCGTCG  
TTAGAAGTTGCTTCCGAAGACGATTTTGCCATAGCCACACGACGCCTATTAATTGTGTCG  
GCTAACACGTCCGCGATCAAATTTGTAGTTGAGCTTTTTTGGAAATTATTTCTGATTGCGGG  
CGTTTTTGGGCGGGTTTCAATCTAACTGTGCCCGATTTTAATTCAGACAACACGTTAGAA  
AGCGATGGTGCAGGCGGTGGTAACATTTTCAGACGGCAAATCTACTAATGGCGGCGGTGGT  
GGAGCTGATGATAAATCTACCATCGGTGGAGGCGCAGGCGGGGCTGGCGGCGGAGGCGGA  
GGCGGAGGTGGTGGCGGTGATGCAGACGGCGGTTTAGGCTCAAATGTCTCTTTAGGCAAC  
ACAGTCGGCACCTCAACTATTGTACTGGTTTCGGGCGCCGTTTTTGGTTTGACCGGTCTG  
AGACGAGTGCGATTTTTTTTCGTTTCTAATAGCTTCCAACAATTGTTGTCTGTCTCTAAA  
GGTGCAGCGGGTTGAGGTTCGTCGCGCATTTGGTGGAGCGGGCGGCAATTCAGACATCGAT  
GGTGGTGGTGGTGGTGGAGGCGCTGGAATGTTAGGCACGGGAGAAGGTGGTGGCGGCGGT  
GCCGCCGGTATAATTTGTTCTGGTTTAGTTTGTTCGCGCACGATTGTGGGCACCGGCGCA  
GGCGCCGCTGGCTGCACAACGGAAGGTCTGCTCTGCTTCGAGGCAGCGCTTGGGGTGGTGGC  
AATTCAATATTATAATTGGAATACAAATCGTAAAAATCTGCTATAAGCATTGTAATTTTCG  
CTATCGTTTACCGTGCCGATATTTAACAACCGCTCAATGTAAGCAATTGTATTGTAAAGA  
GATTGTCTCAAGCTCCGCACGCCGATAACAAGCCTTTTCATTTTTACTACAGCATTGTAG  
TGGCGAGACACTTCGCTGTCGTCGACGTACATGTATGCTTTGTTGTCAAAAACGTCGTTG  
GCAAGCTTTAAAATATTTAAAAGAACATCTCTGTTTCAGCACCACCTGTGTTGTCTGTAATG  
TTGTTTTTGATAATTTGCGCTTCCGCAGTATCGACACGTTCAAAAAATTGATGCGCATCA  
ATTTTGTGTTCTTATTATTGAATAAATAAGATTGTACAGATTCATATCTACGATTCGTC

&gt;&lt;start ORF588&gt;

A

&gt;&lt;start ORF1629&gt;

TGGCCACCACAAATGCTACGCTGCAAACGCTGGTACAATTTTACGAAAACCTGCAAAAACG  
TCAAAACTCGGTATAAAATAATCAACGGGCGCTTTGGCAAATATCTATTTTATCGCACA  
AGCCCACTAGCAAATTGTATTTGCAGAAAACAATTTTCGGCGCACAAATTTTAACGCTGACG  
AAATAAAAGTTCACCAGTTAATGAGCGACCACCCAAATTTTATAAAAATCTATTTTAAATC  
ACGGTTCCATCAACAACCAAGTGATCGTGATGGACTACATTGACTGTCCCGATTTATTTG  
AAACACTACAAATTAAAGGCGAGCTTTCGTACCAACTTGTTAGCAATATTATTAGACAGC  
TGTGTGAAGCGCTCAACGATTTGCACAAGCACAATTTTCATACACAACGACATAAAACTCG  
AAAATGTCTTATATTTCGAAGCACTTGATCGCGTGTATGTTTGCGATTACGGATTGTGCA  
AACACGAAAACCTCACTTAGCGTGCACGACGGCACGTTGGAGTATTTTAGTCCGGAAAAAA  
TTCGACACACAACCTATGCACGTTTCGTTTGACTGGTACGCGGCGTGTTAACATACAAGTT  
GCTAACCGGCGG

**FIG. 17C**

SUBSTITUTE SHEET ( rule 26 )

34 / 49

&gt;&lt;end of polh locus fragment&gt;

TTCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACA  
CAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCATAATGAGTGAGCTAACT  
CACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCT  
GCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTG

&gt;&lt;border ColE1 origin&gt;

GGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCCGGCTGCGGCGAG  
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAG  
GAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC  
TGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTC  
AGAGGTGGCGAAACCCGACAGGACTATAAAGATAACCAGGCGTTTCCCCCTGGAAGCTCCC  
TCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT  
CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTG  
TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTAT  
CCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG  
CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT  
GGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGC  
CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTA  
GCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAG  
ATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAACTCACGTTAAGGGA  
TTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT

&gt;&lt;border ColE1 origin&gt;

AAATTAAAAATGAAGTTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAG  
TTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCAT  
AGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCC  
CAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAA  
CCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCCTCCATCCA  
GTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTTCGCCAGTTAATAGTTTGCGCAA  
CGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATT  
CAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAGC  
GGTTAGCTCCTTCGGTCCTCCGATCGTTGTGAGAAGTAAGTTGGCCGCAGTGTTATCACT  
CATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTC  
TGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTG  
CTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCT  
CATCATTGGAAAACGTTCTTCGGGGCGAAACTCTCAAGGATCTTACCGCTGTTGAGATC  
CAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTTACCAG  
CGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGAC  
ACGGAAATGTTGAATACTCA

&gt;&lt;Start Amp&gt;

TACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGAT  
ACATATTTGAATGTATTTAGAAAAATAACAAATAGGGGTTCCGCGCACATTTCCCCGAA  
AAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGC  
GTATCACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACA  
TGCAGCTCCCGGAGACGGTCACAGCTTGCTGTGTAAGCGGATGCCGGGAGCAGACAAGCCC  
GTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACCTATGCGGCATCAG  
AGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG  
GAGAAAATACCGCATCAGGCGCCATTTCGCCATTTCAGGCTGCGCAACTGTTGGGAAGGGCG  
ATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCG  
ATTAAGTTGGGTAAACGCCAGGGTTTTCACAGTCACGACGTTGTAAACGACGGCCAGTGC  
C

**FIG. 17D**

SUBSTITUTE SHEET ( rule 26 )



35 / 49

AAGCTTTACTCGTAAAGCGAGTTGAAGGATCATATTTAGTTGCGTTTATGAGATAAGATT  
GAAAGCACGTGTAAA

><start ORF504 (PTP)>

ATGTTTCCCGCGCGTTGGCACAACTATTTACAATGCGGCCAAGTTATAAAAGATTCTAAT  
CTGATATGTTTTAAACACCTTTGCGGCCCGAGTTGTTTGCGTACGTGACTAGCGAAGAA  
GATGTGTGGACCGCAGAACAGATAGTAAACAAAACCCTAGTATTGGAGCAATAATCGAT  
TTAACCAACACGTCTAAATATTATGATGGTGTGCATTTTTTTGCGGGCGGGCCTGTTATAC  
AAAAAAATTCAAGTACCTGGCCAGACTTTGCCGCCTGAAAGCATAGTTCAAGAATTTATT  
GACACGGTAAAAGAATTTACAGAAAAGTGTCCCGGCATGTTGGTGGGCGTGCACCTGCACA  
CACGGTATTAATCGCACCGGTTACATGGTGTGCAGATATTTAATGCACACCCTGGGTATT  
GCGCCGCAGGAAGCCATAGATAGATTGAAAAAGCCAGAGGTCACAAAATTGAAAGACAA  
AATTACGTTCAAGATTTATTAATTTAATTAATATTATTTGCATTCTTTAACAAATACTTT  
ATCCTATTTTCAAATTGTTGCGCTTCTTCCAGCGAACCAAACTATGCTTCGCTTGCTCC  
GTTTAGCTTGTAGCCGATCAGTGGCGTTGTTCCAATCGACGGTAGGATTAGGCCGGATAT  
TCTCCACCACAATGTTGGCAACGTTGATGTTACGTTTATGCTTTTGGTTTTCCACGTACG  
TCTTTTGGCCGGTAATAGCCGTAAACGTAGTGCCGTCGCGCGTCACGCACAACACCGGAT  
GTTTGCGCTTGTCCGCGGGGTATTGAACCGCGCGATCCGACAAATCCACCACCTTTGGCAA  
CTAAATCGGTGACCTGCGCGTCTTTTTTCTGCATTATTTTCGTCTTTCTTTTGCATGGTTT  
CCTGGAAGCCGGTGTACATGCGGTTTAGATCAGTCATGACGCGCGTGACCTGCAAATCTT  
TGGCCTCGATCTGCTTGTCTTGATGGCAACGATGCGTTCAATAAACTCTTGTTTTTTAA  
CAAGTTCCTCGGTTTTTTTGGCGCCACCACCGCTTGCAGCGCGTTTGTGTGCTCGGTGAATG  
TCGCAATCAGCTTAGTCACCAACTGTTTGCTCTCCTCCTCCCGTTGTTTGATCGCGGGAT  
CGTACTTGCCGGTGCAGAGCACTTGAGGAATTACTTCTTCTAAAAGCCATTCTTGTAATT

CTATGGCGTAAGGCAATTTGGACTTCATAATCAGCTGAATCACGCCGGATTTAGTAATGA  
GCACTGTATGCGGCTGCAAATACAGCGGGTCGCCCCCTTTTCACGACGCTGTTAGAGGTAG  
GGCCCCCATTTTGGATGGTCTGCTCAAATAACGATTTGTATTTATTGTCTACATGAACAC  
GTATAGCTTTATCACAACTGTATATTTTAAACTGTTAGCGACGTCCTTGGCCACGAACC  
GGACCTGTTGGTCGCGCTCTAGCACGTACCGCAGGTTGAACGTATCTTCTCAAATTTAA  
ATTCTCCAATTTTAACGCGAGCCA

><start ORF984 (ORF2)>

TTTTGATACACGTGTGTGCGATTTTGCAACAACCTATTGTTTTTTAACGCAAACCTAACTTA  
TTGTGGTAAGCAATAATTAAATATGGGGGAACATGCGCCGCTACAACACTCGTCGTTATG  
AACGCAGACGGCGCCGGTCTCGGCGCAAGCGGCTAAAACGTGTTGCGCGTTCAACGCGGC  
AAACATCGCAAAGCCAATAGTACAGTTTTGATTTGCA

><start conotoxin>

TATTAACGGCGATTTTTTAAATTATCTTATTTAATAAATAGTTATGACGCCTACAACCTCC  
CCGCCCCGCGTTGACTCGCTGCACCTCGAGCAGTTTCGTTGACGCCTTCCTCCGTGTGGCCG  
AACACGTCGAGCGGGTGGTCGATGACCAGCGGCGTGCCGCACGCGACGCACAAGTATCTG  
TACACCGAATGATCGTCGGGCGAAGGCACGTCGGCCTCCAAGTGGCAATATTGGCAAATT  
CGAAAATATATACAGTTGGGTGTTTGGCGCATATCTATCGTGGCGTTGGGCATGTACGTC  
CGAACGTTGATTTGCATGCAAGCCGAAATTAATCATTGCGATTAGTGCGATTAAAACGT  
TGTACATCCTCGCTTTTAATCATGCCGTCGATTAAATCGCGCAATCGAGTCAAGTGATCA  
AAGTGTGGAATAATGTTTTCTTTGTATTCCCGAGTCAAGCGCAGCGCGTATTTTAACAA  
CTAGCCATCTTGTAAGTTAGTTTCA

**FIG. 18A**

36 / 49

><start ORF453>  
TTTAATGCAACTTTTATCCAATAATATATT  
><start ORF327>  
ATGTATCGCACGTCAAGAATTAACAATGCGCCCGTTGTTCGCATCTCAACACGACTATGAT  
AGAGATCAAATAAAGCGCGAATTAAATAGCTTGCGACGCAACGTGCACGATCTGTGCACG  
CGTTCCGGCACGAGCTTTGATTGTAATAAGTTTACGAAGCGATGACATGACCCCCGTA  
GTGACAACGATCACGCCCAAAGAACTGCCGACTACAAAATTACCGAGTATGTCGGTGAC  
GTTAAACTATTAAGCCATCCAATCGACCGTTAGTCGAATCAGGACCGCTGGTGCGAGAA  
GCCGCGAAGT  
><start ORF630>  
ATGGCGAATGCATCGTATAACGTGTGGAGTCCGCTCATTAGAGCGTCATGTTTAGACAAG  
AAAGCTACATATTTAATTGATCCCGATGATTTTATTGATAAATTGACCCTAACTCCATAC  
ACGGTATTCTACAATGGCGGGGTTTGGTCAAAATTTCCGGACTGCGATTGTACATGCTG  
TTAACGGCTCCGCCCACTATTAATGAAATTAAAAATTCCAATTTTAAAAAACGCAGCAAG  
AGAAACATTTGTATGAAAGAATGCGTAGAAGGAAAGAAAAATGTCGTCGACATGCTGAAC  
AACAAGATTAATATGCCTCCGTGTATAAAAAAATATTGAACGATTTGAAAGAAAACAAT  
GTACCGCGCGGGCGGTATGTACAGGAAGAGGTTTATACTAACTGTTACATTGCAAACGTG  
GTTTCGTGTGCCAAGTGTGAAAACCGATGTTTAATCAAGGCTCTGACGCATTTCTACAAC  
CACGACTCCAAGTGTGTGGGTGAAGTCATGCATCTTTTAATCAAATCCCAAGATGTGTAT  
AAACCACCAAACCTGCCAAAAAATGAAAACCTGTCGACAAGCTCTGTCCGTTTGCTGGCAAC  
TGCAAGGGTCTCAATCCTATTTGTAATTATTGAATAATAAAACAATTATAAATGCTAAAT  
TTGTTTTTTATTAACGATACAAACCAACGCAACAAGAACATTTGTAGTATTATCTATAA  
TTGAAAACGCGTAGTTATAATCGCTGAGGTAATATTAAAATCATTTTCAAATGATTCAC  
AGTTAATTTGCGACAATATAATTTTATTTTCACATAAACTAGACGCCTTGTCGTCTTCTT  
CTTCGTATTCCTTCTCTTTTTTCATTTTTCTCCTCATAAAAATTAACATAGTTATTATCGT  
ATCCATATATGTATCTATCGTATAGAGTAAATTTTTTGTGTGCATAAATATATATGTCTT  
TTTTAATGGGGTGTATAGTACCGCTGCGCATAGTTTTTCTGTAATTTACAACAGTGCTAT  
TTTCTGGTAGTTCTTCGGAGTGTGTTGCTTTAATTATTAAATTTATATAATCAATGAATT  
TGGGATCGTCGGTTTTGTACAATATGTTGCCGGCATAGTACGCAGCTTCTTCTAGTTCAA  
TTACACCATTTTTTTAGCAGCACCGGATTAACATAACTTTCCAAAATGTTGTACGAACCGT  
TAAACAAAAACAGTTCACCTCCCTTTTCTATACTATTGTCTGCGAGCAGTTGTTTGTGT  
TAAAAATAACAGCCA  
><start ORF603>  
TTGTAATGAGACGCACAACTAATATCACAACTGGAAATGTCTATCAATATATAGTTGC  
TGATATCATGGAGATAATTAAAATGATAACCATCTCGCAAATAAA  
><start of polh transcription>  
TAAGTATTTTACTGTTTTTCGTAACAGTTTTGTAAATAAAAAAACCTATAAAT  
><mutated polh start codon>  
ATTCCGGATTATTCATACCGTCCCACCATCGGGCGC  
><start polylinker >  
GGATCCGCGGCCGCGAATTCTAAACCACCATGGGCAGCTGCCCCGGG  
><His tag>  
CATCATCATCATCATCATCATTAATTCTAGACTAGTCTGCAGATC  
><end polylinker>  
T

**FIG. 18B**



37 / 49

&gt;&lt;polh coding sequences&gt;

GATCCTTTCCTGGGACCCGGCAAGAACCACAAAACTCACTCTCTTCAAGGAAATCCGTAAT  
GTAAACCCGACACGATGAAGCTTGTCGTTGGATGGAAAGGAAAAGAGTTCTACAGGGAA  
ACTTGGACCCGCTTCATGGAAGACAGCTTCCCCATTGTTAACGACCAAGAAGTGATGGAT  
GTTTTCTTGTGTCAACATGCGTCCCCTAGACCCAACCGTTGTTACAAATTCCTGGCC  
CAACACGCTCTGCGTTGCGACCCCGACTATGTACCTCATGACGTGATTAGGATCGTTCGAG  
CCTTCATGGGTGGGCAGCAACAACGAGTACCGCATCAGCCTGGCTAAGAAGGGCGGCGGC  
TGCCCAATAATGAACCTTCACTCTGAGTACACCAACTCGTTCGAACAGTTCATCGATCGT  
GTCATCTGGGAGAACTTCTACAAGCCCATCGTTTACATCGGTACCGACTCTGCTGAAGAG  
GAGGAAATTCTCCTTGAAGTTTCCCTGGTGTTCAAAGTAAAGGAGTTTGCACCAGACGCA  
CCTCTGTTCACTGGTCCGGCGTATTAAACACGATACATTGTTATTAGTACATTTATTAA  
GCGCTAGATTCTGTGCGTTGTTGATTTACAGACAATTGTTGTACGTATTTTAATAATTCA  
TTAAATTTATAATCTTTAGGGTGGTATGTTAGAGCGAAAATCAAATGATTTTTCAGCGTCT  
TTATATCTGAATTTAAATATTAAATCCTCAATAGATTTGTAAAATAGGTTTCGATTAGTT  
TCAAACAAGGGTTGTTTTTCCGAACCGATGGCTGGACTATCTAATGGATTTTCGCTCAAC  
GCCACAAAACCTTGCCAAATCTTGTAGCAGCAATCTAGCTTTGTCGATATTCGTTTGTGTT  
TTGTTTTGTAAATAAAGGTTTCGACGTCGTTCAAATATTTATGCGCTTTTGTATTTCTTTCA  
TCACTGTCGTTAGTGTAATTTGACTCGACGTAAACACGTTAAATAAAGCTTGGACATAT  
TTAACATCGGGCGTGTTAGCTTTATTAGGCCGATTATCGTCGTCGTCCCAACCCTCGTCG  
TTAGAAGTTGCTTCCGAAGACGATTTTGCCATAGCCACACGACGCCTATTAATTGTGTCG  
GCTAACACGTCGCGCATCAAATTTGTAGTTGAGCTTTTTTGGAAATTATTTCTGATTGCGGG  
CGTTTTTTGGGCGGGTTTCAATCTAACTGTGCCCCGATTTTAATTCAGACAACACGTTAGAA  
AGCGATGGTGCAGGCGGTGGTAACATTTTCAGACGGCAAATCTACTAATGGCGGCGGTGGT  
GGAGCTGATGATAAATCTACCATCGGTGGAGGCGCAGGCGGGGCTGGCGGCGGAGGCGGA  
GGCGGAGGTGGTGGCGGTGATGCAGACGGCGGTTTAGGCTCAAATGTCTCTTTAGGCAAC  
ACAGTCGGCACCTCAACTATTGTACTGGTTTCGGGCGCCGTTTTTGGTTTGACCGGTCTG  
AGACGAGTGCGATTTTTTTTCGTTTCTAATAGCTTCCAACAATTGTTGTCTGTCTCTAAA  
GGTGCAGCGGGTTGAGGTTCCGTCGGCATTGGTGGAGCGGGCGGCAATTCAGACATCGAT  
GGTGGTGGTGGTGGTGGAGGCGCTGGAATGTTAGGCACGGGAGAAGGTGGTGGCGGCGGT  
GCCGCCGGTATAATTTGTTCTGGTTTAGTTTGTTCGCGCACGATTGTGGGCACCGGCGCA  
GGCGCCGCTGGCTGCACAACGGAAGGTCGTCTGCTTCGAGGCAGCGCTTGGGGTGGTGGC  
AATTCAATATTATAATTGGAATACAAATCGTAAAAATCTGCTATAAGCATTGTAATTTTCG  
CTATCGTTTACCGTGCCGATATTTAACAACCGCTCAATGTAAGCAATTGTATTGTAAAGA  
GATTGTCTCAAGCTCCGCACGCCGATAACAAGCCTTTTCATTTTTACTACAGCATTGTAG  
TGGCGAGACACTTCGCTGTCTGTCGACGTACATGTATGCTTTGTTGTCAAAAACGTCGTTG  
GCAAGCTTTAAATATTAAAGAACATCTCTGTTTACGACCACTGTGTTGTCTGTAATG  
TTGTTTTTGATAATTTGCGCTTCCGCAGTATCGACACGTTCAAAAAATTGATGCGCATCA  
ATTTTGTGTTCTTATTATTGAATAAATAAGATTGTACAGATTCATATCTACGATTCGTC

&gt;&lt;start ORF588&gt;

A

&gt;&lt;start ORF1629&gt;





TGGCCACCACAAATGCTACGCTGCAAACGCTGGTACAATTTTACGAAAACCTGCAAAAACG  
TCAAAACTCGGTATAAAATAATCAACGGGCGCTTTGGCAAAATATCTATTTTATCGCACA  
AGCCCCTAGCAAATTGTATTTGCAGAAAACAATTTGGCGGCACAATTTTAACGCTGACG  
AAATAAAAGTTCACCAGTTAATGAGCGACCACCCAAATTTTATAAAAATCTATTTTAATC  
ACGGTTCCATCAACAACCAAGTGATCGTGATGGACTACATTGACTGTCCTCGATTATTTG  
AAACACTACAAATTAAAGGCGAGCTTTCGTACCAACTTGTTAGCAATATTATTAGACAGC  
TGTGTGAAGCGCTCAACGATTTGCACAAGCACAATTCATACACAACGACATAAAACTCG  
AAAATGTCTTATATTTTGAAGCACTTGATCGCGTGTATGTTTGCAGATTACGGATTGTGCA

**FIG. 18C**

38 / 49

AACACGAAAACCTCACTTAGCGTGCACGACGGCACGTTGGAGTATTTTAGTCCGGAAAAAA  
TTCGACACACAACCTATGCACGTTTCGTTTGACTGGTACGCGGCGGTGTTAACATACAAGTT  
GCTAACCGGCGG  
><end of polh locus fragment>  
TTCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACA  
CAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACT  
CACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCT  
GCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTG  
><border Cole1 origin>  
GGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTGTTCCGGCTGCGGCGAG  
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAG  
GAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGC  
TGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCAGAAAAATCGACGCTCAAGTC  
AGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCC  
TCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTT  
CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCTG  
TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTTCAGCCCGACCGCTGCGCCTTAT  
CCGGTAACCTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG  
CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT  
GGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGC  
CAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTA  
GCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAG  
ATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAACTCACGTTAAGGGA  
TTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT  
><border Cole1 origin>  
AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAG  
TTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCAT  
AGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCC  
CAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAA  
CCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTTGCAACTTTATCCGCCTCCATCCA  
GTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAA  
CGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTTCGTTTGGTATGGCTTCATT  
CAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGC  
GGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGCAGTGTTATCACT  
CATGGTTATGGCAGCACTGCATAATTCTCTTACTGTGATGCCATCCGTAAGATGCTTTTC  
TGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTG  
CTCTTGCCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCT  
CATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATC  
CAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAG  
CGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGAC  
ACGGAAATGTTGAATACTCA  
><Start Amp>  
TACTCTTCCTTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGAT  
ACATATTTGAATGTATTTAGAAAAATAACAAATAGGGGTTCCGCGCACATTTCCCCGAA  
AAGTGCCACCTGACGTCTAAGAAACCATTTATTATCATGACATTAACCTATAAAAATAGGC  
GTATCACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACA  
TGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCC  
GTCAGGGCGCGTCAGCGGGTGTGCGGGGTGTCGGGGCTGGCTTAACCTATGCGGCATCAG  
AGCAGATTGTACTGAGAGTGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAG  
GAGAAAATACCGCATCAGGCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCG  
ATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCG  
ATTAAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTGTAAAACGACGGCCAGTGC  
C

**FIG. 18D**






FIG. 20B




FIG. 20D




FIG. 20A















FIG. 20C























46 / 49

5' -GCCAGTCTGGGCCCAGCTCCCCCGAGAGGTGGTCGGATCCTCTGGGCTGCTCGGTTCGATG  
CCTGTGCCACTGACGTCCAGGCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGAC  
AGCAGCAGCCGCCAGCACCGTCCTGGCCACGGCCCTCTCTCCAGCCCCCTACGACCATGGA  
CTTTACCCCAGCTCCACTGGAGGACACCTCCTCACGCCCCCAATTCTGCAAGTGGCCATG  
TGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTTCAGCCTCATCACAGATGGCTG  
TGAGTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACCTGCACGGAGGCTGCCATCTG  
TGACCCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCCGAGAGGTGGTCGGTG  
TGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAGTCCTTCCAGCCTAACTGCA  
AGTACAACCTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTCCGAGTGC  
GCCCCCGCGTCTCTGGTGCCCCCACC CGCGCGGTGAGCATACTGGCCACTGCTGTG  
AGCAGTGGGTATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCCGTGACACAG  
GAGCCTTCGATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACCTGCATAGCCTACACAA  
GCCCTGGAGCCCTTGCTCCACCAGCTGCGGCCTGGGGGTCTCCACTCGGATCTCCAATG  
TTAACGCCCAGTGCTGGCCTGAGCAAGAGAGCCGCCTCTGCAACTTGCGGCCATGCGATG  
TGGACATCCATACACTCATTAAGGCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGG  
CATCCATGAACCTTCACACTTGCGGGCTGCATCAGCACACGCTCCTATCAACCCAAGTACT  
GTGGAGTTTGATGGACAATAGGTGCTGCATCCCCCTACAAGTCTAAGACTATCGACGTGT  
CCTTCCAGTGTCCTGATGGGCTTGGCTTCTCCCGCCAGGTCTTATGGATTAATGCCTGCT  
TCTGTAACCTGAGCTGTAGGAATCCCAATGACATCTTTGCTGACTTGGAACTCCTACCCTG  
ACTTCTCAGAAATTGCCAACTAGGCAGGCACAAATCTTGGGTCTTGGGGACTAACCCAAT  
GCCTGTGAAGCAGTCAGCCCTTATGGCCAATAACTTTTCACCAATGAGCCTTAGTTACCC  
TGATCTGGACCCTTGGCCTCCATTTCTGTCTCTAACCATTCAAATGACGCCTGATGGTGC  
TGCTCAGGCCCATGCTATGAGTTTTCTCCTTGATATCATTCAGCATCTACTCTAAAGAAA  
AATGCCTGTCTCTAGCTGTTCTG

**FIG. 26**

5' -TTTAATTAAACCCCCAAGGGCTGCGGAAGGAGCATATCTGGTGCTCCTGATGGGCCGGCC  
AGTCTGGGCCCAGCTCCCCCGAGAGGTGGTCGGATCCTCTGGGCTGCTCGGTTCGATGCCT  
GTGCCACTGACGTCCAGGCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGC  
AGCAGCCGCCAGCACCGTCCTGGCCACGGCCCTCTCTCCAGCCCCCTACGACCATGGACTT  
TACCCCAGCTCCACTGGAGGACACCTCCTCACGCCCCCAATTCTGCAAGTGGCCATGTGA  
GTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTTCAGCCTCATCACAGATGGCTGTGA  
GTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACCTGCACGGAGGCTGCCATCTGTGA  
CCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCCGAGGTACGCAATAGGAGT  
GTGTGCACGCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACCTTCA  
CACTTGCGGGCTGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTGATGG  
ACAACAGGTGCTGCATCCCCCTACAAGTCTAAGACTATCGACGTGTCCTTCCAGTGTCCTG  
ATGGGCTTGGCTTCTCCCGCCAGGTCTTATGGA

**FIG. 27**



47 / 49

5' -CAGAATTTGAACTGGGATCCACCTGTCTCTAAAGATGGGTTTCCTCCCATGCTTCCACAC  
TGCCTCTCTTGATCAGAAACATACAAGGAGCTGAGAACATGTCCTCCACTCCCTGGGTAC  
CTTTGCTGGTTAGAAGCCAACCTTGCTGTCCTGTGGGGAGGTACAGCCAATTTCTGTGTTC  
CTCTGAGTTCTGGGGACCGCAGACCTTAGTGTGGTGAAAGTGAGCGTTGGGGGCTGGTGG  
GAGCTGTAGATTCATGCAGATTCTGTTCCCCACACACAGATGCTGTGGGTGAGGTGGAGG  
CATGGCACAGGAACTGCATAGCCTACACAAGCCCCTGGAGCCCTTGCTCCACCAGCTGCG  
GCCTGGGGGTCTCCACTCGGATCTCCAATGTTAACGCCAGTGCTGGCCTGAGCAAGAGA  
GCCGCCTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACACTCATTAAGGCAGGGA  
AGAAGTGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACTTCACACTTGCGGGCTGCA  
TCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTGCATGGACAATAGGTGCTGCA  
TCCCCCTACAAGTCTAAGACTATCGACGTGTCCTTCCAGTGTCTGATGGGCTTGGCTTCT  
CCCGCCAGGTCTGATGGATTAAT

**FIG. 28**

5' -GTCTGGGCCCAGCTCCCCGAGAGGTGGTCGGATCCTCTGGGCTGCTCGGTCGATGCCTG  
TGCCACTGACGTCCAGGCATGAGGTGGTTCTTGCCCTGGACGCTGGCAGCAGTGACAGCA  
GCAGCCGCCAGCACCGTCTTGCCACGGCCCTCTCTCCAGCCCCCTACGACCATGGACTTT  
ACCCAGCTCCACTGGAGGACACCTCCTCACGCCCCCAATTCTGCAAGTGGCCATGTGAG  
TGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTCAGCCTCATCACAGATGGCTGTGAG  
TGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACCTGCACGGAGGCTGCCATCTGTGAC  
CCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATAGGAGTG  
TGTGCACGCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACTTCAC  
ACTTGCGGGCTGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTGCATGGA  
CAACAGGTGCTGCATCCCCCTACAAGTCTAAGACTATCGACGTGTCCTTCCAGTGTCTGA  
TGGGCTTGGCTTCTCCCGCCAGGTCTATGGATTAATGCCTGCTTCTGTAACCTGAGCTG  
TAGGAATCCCAATGACATCTTTGCTGACTTGGAATCCTACCCTGACTTCTCAGAAATTGC  
CAACTAGGCAGGCACAAATCTTGGGTCTTGGGGACTAACCCAATGCCTGTGAAGCAGTCA  
GCCCTTATGGCCAATAACTTTTCACCAATGAGCCTTAGTTACCCTGATCTGGACCCTTGG  
CCTCCATTTCTGTCTCTAACCATTCAAATGACGCCTGATGGTGCTGCTCAGGCCCATGCT  
ATGAGTTTTCTCCTTGATATCATTCAGCATCTACTCTAAAGAAAAATGCCTGTCTCTAGC  
TGTTCTGGACTACACCCAAGCCTGATCCAGCCTTTCCAAGTCACTAGAAGTCCTGCTGGA  
TCTTGCCATAATCCCAAGAAATGGAATCAGGTAGACTTTTAATATCACTAATTTCTTCTT  
TAGATGCCAAACCACAAGACTCTTTGGGTCCATTTCAGATGAATAGATGGAATTTGGAACA  
ATAGAATAATCTATTATTTGGAGCCTGCCAAGAGGTACTGTAATGGGTAATTCTGACGTC  
AG

**FIG. 29**

48 / 49

5' - CAGAACAGCTAGAGACAGGCATTTTTCTTTAGAGTAGATGCTGAATGATATCAAGGAGAA  
AACTCATAGCATGGGCCTGAGCAGCACCATCAGGCGTCATTTGAATGGTTAGAGACAGAA  
ATGGAGGCCAAGGGTCCAGATCAGGGTAACTAAGGCTCATTGGTGAAAAGTTATTGGCCA  
TAAGGGCTGACTGCTTCACAGGCATTGGGTAGTCCCCAAGACCCAAGATTTGTGCCTGC  
CTAGTTGGCAATTTCTGAGAAGTCAGGGTAGGATTCCAAGTCAGCAAAGATGTCATTGGG  
ATTCTTACAGCTCAGGTTACAGAAGCAGGCATTAATCCATAGGACCTGGCGGGAGAAGCC  
AAGCCCATCAGGACACTGGAAGGACACGTCGATAGTCTTAGACTTGTAGGGGATGCAGCA  
CCTATTGTCCATGCAAACCTCCACAGTACTTGGGTGATAGGAGCGTGTGCTGATGCAGCC  
CGCAAGTGTGAAGTTCATGGATGCCTCTGGCTGGTACACAGCCAGACACTTCTTCCCTGC  
CTTAATGAGTGTATGGATGTCCACATCGCATGGCCGCAAGTTGCAGAGGCGGCTCTCTTG  
CTCAGGCCAGCACTGGGCGTTAACATTGGAGATCCGAGTGGAGACCCCCAGGCCGCAGCT  
GGTGGAGCAAGGGCTCCAGGGGCTTGTGTAGGCTATGCAGTTCCTGTGCCATGCCTCCAC  
CTCACCCACAGCATCTGTGTGTGGGGAACAGAATCTGCATGAATCTACAGCTCCCACCAG  
CCCCAACGCTCACTTTCACCACACTAAGGTCTGCGGTCCCCAGAACTCAGAGGAACACA  
GAAATTGGCTGTACCTCCCCACAGGACAGCAAGTTGGCTTCTAACCAGCAAAGGTACCCA  
GGGAGTGGAGGACATGTTCTCAGCTCCTTGTATGTTTCTGATCAAGAGAGGCAGTGTGGA  
AGCATGGGAGGAAACCCATCTTTAGAGACAGGTGGATCCCAGTTCAAATTCTGCTCTACC  
ACCTACAAGCTGTGTGATCTTAGATAACCCACCCTGGGCCTGTCTCCCCATTAGAACAAT  
AACACCTGCCTGTGCGGCTGGCAACACAATAATAAGGGCCTAGATTTTACTGAGTATGC  
ATCAATCATCCTTGCTAAGTGCTGGGAATGGGACTTTTTTTTTT

**FIG. 30**

5' - CCTGATCTGGACCCTTGGCCTCCAATTCTGTCTGTAACCATTCAAATGACGCCTGGTGGT  
GCTGCTCAGGCCCATAGCAAGGTTCAAGCCTGGTTAAGTCCAAGCTGAATTAGCGGCCGCG  
TCGACAGTAGGAGTGTGTGCACATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACTGC  
ATAGCCTACACAAGCCCCTGGAGCCCTTGCTCCACCAGCTGCGGCCTGGGGGTCTCCACT  
CGGATCTCCAATGTTAACGCCCAGTGCTGGCCTGAGCAAGAGAGCCGCCTCTGCAACTTG  
CGGCCATGCGATGTGGACATCCATACACTCATTAAAGGCAGGGAAGAAGTGTCTGGCTGTG  
TACCAGCCAGAGGCATCCATGAACTTCACACTTGCGGGCTGCATCAGCACACGCTCCTAT  
CAACCCAAGTACTGTGGAGTTTGCATGGACAATAGGTGCTGCATCCCCTACAAGTCTAAG  
ACTATCGACGTGTCCTTCCAGTGTCTGATGGGCTTGGCTTCTCCCGCCAGGTCCTATGG  
ATTAAT

**FIG. 31**

49 / 49

5' - GGCCCAGCTCCCCCGAGAGGTGGTCGGATCCTCTGGGCTGCTCGGTCGATGCCTGTGCCA  
CTGACGTCCAGGCATGAGGTGGTTCCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGC  
CGCCAGCACCGTCCTGGCCACGGCCCTCTCTCCAGCCCCCTACGACCATGGACTTTACCCC  
AGCTCCACTGGAGGACACCTCCTCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCC  
GCCATCCCCACCCCGCTGCCCGCTGGGGGTGAGCCTCATCACAGATGGCTGTGAGTGCTG  
TAAGATGTGCGCTCAGCAGCTTGGGGACAACCTGCACGGAGGCTGCCATCTGTGACCCCCA  
CCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGAGGTGGTCGGTGTGGGCTGCG  
TCCTGGATGGGGTGCGCTACAACAACGGCCAGTCCTTCCAGCCTAACTGCAAGTACAACCT  
GCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTCCGAGTGCGCCCCCGC  
GTCTCTGGTGCCCCCACC CGCGCGGTGAGCATACCTGGCCACTGCTGTGAGCAGTGGA  
TATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCCGTGACACAGGAGCCTTCG  
ATGCCAGAAGCGCCCGCTCCCTCAGAGATGTGACAACCAAAATCATCTCCAGACCTTTCC  
AAATACACCCTAGGAGACAAAATTGCTCGGTGGAGAAGCAGTCCTGTGAGGACAGGAGGA  
GGCGTGGAGGAAAGCTTTGTCCCCAGCAGCCCCAGGGAAGCAAGGCAGCTCTCCCACCAC  
CACCTCCCCAGGAGGGCCACACGAGGGTACGCGGGGGGAGCAGGGAGGCGGAAGCTGTCTG  
CCATTGTGTCTGGCCCAGTGACCCTGTTCTGACCGAGCACAAGCGGAGCCCCTGCCTAGC  
CGAGATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACTGCATAGCCTACACAAGCCCC  
TGGAGCCCTTGCTCCACCAGCTGCGGCCTGGGGGTCTCCACTCGGATCTCCAATGTTAAC  
GCCCAGTGCTGGCCTGAGCAA

**FIG. 32**

## Sequence Listing

<110> Genentech, Inc.

<120> WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

<130> P1176R2PCT

5 <141> 1998-10-29

<160> 156

<210> 1

<211> 2830

<212> DNA

10 <213> Human

<400> 1

```

cccacgcgtc cgctgggccc agctcccccg agaggtggtc ggatcctctg 50
ggctgctcgg tcgatgcctg tgccactgac gtccaggcat gaggtgggtc 100
ctgccctgga cgctggcagc agtgacagca gcagccgcca gcaccgtcct 150
ggccacggcc ctctctccag cccctacgac catggacttt actccagctc 200
cactggagga cacctcctca cgcccccaat tctgcaagtg gccatgtgag 250
tgcccgccat cccacccccg ctgcccgctg ggggtcagcc tcatcacaga 300
tggctgtgag tgctgtaaga tgtgcgctca gcagcttggg gacaactgca 350
cggaggctgc catctgtgac cccacccggg gcctctactg tgactacagc 400
ggggaccgcc cgaggtacgc aataggagtg tgtgcacagg tggtcggtgt 450
gggctgcgtc ctggatgggg tgcgctacaa caacggccag tccttccagc 500
ctaactgcaa gtacaactgc acgtgcatcg acggcgcggt gggctgcaca 550
ccactgtgcc tccgagtgcg cccccgcgt ctctggtgcc cccacccgcg 600
gcgcgtgagc atacctggcc actgctgtga gcagtgggta tgtgaggacg 650
acgccaagag gccacgcaag accgcacccc gtgacacagg agccttcgat 700
gctgtgggtg aggtggaggc atggcacagg aactgcatag cctacacaag 750
cccctggagc ccttgctcca ccagctgcgg cctgggggtc tccactcgga 800
tctccaatgt taacgcccag tgctggcctg agcaagagag ccgcctctgc 850
aacttgcggc catgcgatgt ggacatccat acactcatta aggcagggaa 900
gaagtgtctg gctgtgtacc agccagaggc atccatgaac ttcacacttg 950
cgggctgcat cagcacacgc tcctatcaac ccaagtactg tggagtttgc 1000
atggacaata ggtgctgcat cccctacaag tctaagacta tcgacgtgtc 1050

```

cttccagtgt ccgatgggc ttggcttctc ccgccaggtc ctatggalta 1100  
atgcctgctt ctgtaacctg agctgtagga atcccaatga catctttgct 1150  
gacttggaat cctaccctga cttctcagaa attgccaaact aggcaggcac 1200  
aaatcttggg tcttggggac taaccaaatg cctgtgaagc agtcagccct 1250  
5 tatggccaat aacttttcac caatgagcct tagttaccct gatctggacc 1300  
cttggcctcc atttctgtct ctaaccattc aaatgacgcc tgatggtgct 1350  
gctcaggccc atgctatgag ttttctcctt gatatcattc agcatctact 1400  
ctaaagaaaa atgcctgtct ctagctgttc tggactacac ccaagcctga 1450  
tccagccttt ccaagtcact agaagtcctg ctggatcttg cctaaatccc 1500  
10 aagaaatgga atcaggtaga cttttaatat cactaatttc ttcttttagat 1550  
gccaaaccac aagactcttt gggtcattc agatgaatag atggaatttg 1600  
gaacaataga ataatctatt atttgagacc tgccaagagg tactgtaatg 1650  
ggtaattctg acgtcagcgc accaaaacta tcctgattcc aaatatgtat 1700  
gcacctcaag gtcacaaac atttgccaag tgagttgaat agttgcttaa 1750  
15 ttttgatttt taatggaaag ttgtatccat taacctgggc attgttgagg 1800  
ttaagtttct cttcaccctt acactgtgaa gggtagagat taggtttgtc 1850  
ccagtcagaa ataaaatttg ataaacattc ctgttgatgg gaaaagcccc 1900  
cagttaatac tccagagaca gggaaaggte agccatttc agaaggacca 1950  
attgactctc aactgaate agctgctgac tggcagggct ttgggcagtt 2000  
20 ggccaggctc ttccttgaat cttctccctt gtctgcttg ggttcatagg 2050  
aattggtaag gcctctggac tggcctgtct ggccctgag agtggtgccc 2100  
tggaacactc ctctactctt acagagcctt gagagacca gctgcagacc 2150  
atgccagacc cactgaaatg accaagacag gttcaggtag ggggtgtgggt 2200  
caaaccaaga agtgggtgcc cttggtagca gcctggggtg acctctagag 2250  
25 ctggaggctg tgggactcca ggggcccccg tgttcaggac acatctattg 2300  
cagagactca tttcacagcc tttcgttctg ctgaccaaact ggccagtttt 2350  
ctggtaggaa gatggagggt taccagttgt ttagaaacag aaatagactt 2400  
aataaagggt taaagctgaa gaggttgaag ctaaaaggaa aaggttgttg 2450  
ttaatgaata tcaggctatt atttattgta ttaggaaaat ataatttta 2500  
30 ctgttagaat tcttttattt agggcctttt ctgtgccaga cattgctctc 2550



agtgctttgc atgtattagc tcactgaatc ttcacgacaa tgttgagaag 2600  
 ttcccattat tatttctgtt cttacaaatg tgaaacggaa gctcatagag 2650  
 gtgagaaaac tcaaccagag tcacccagtt ggtgactggg aaagttagga 2700  
 ttcagatcga aattggactg tctttataac ccatattttc cccctgtttt 2750  
 5 tagagcttcc aaatgtgtca gaataggaaa acattgcaat aaatggcttg 2800  
 attttttaaa aaaaaaaaaa aaaaaaaaaa 2830  
  
 <210> 2  
 <211> 1101  
 <212> DNA  
 10 <213> Human  
  
 <400> 2  
 gttggcaatt tctgagaagt cagggtagga ttccaagtca gcaaagatgt 50  
 cattgggatt cctacagctc aggttacaga agcaggcatt aatccatagg 100  
 acctggcggg agaagccaag cccatcagga cactggaagg acacgtcgat 150  
 15 agtcttagac ttgtagggga tgcagcacct attgtccatg caaactccac 200  
 agtacttggg ttgataggag cgtgtgctga tgcagcccg c aagtgtgaag 250  
 ttcattggatg cctctggctg gtacacagcc agacacttct tccctgcctt 300  
 aatgagtgtg tggatgtcca catcgcatgg ccgcaagttg cagaggcggc 350  
 tctcttgctc aggccagcac tgggcgttaa cattggagat ccgagtggag 400  
 20 acccccaggc cgcagctggg ggagcaaggg ctccaggggc ttgtgtaggc 450  
 tatgcagttc ctgtgccatg cctccacctc acccacagca tcgaaggctc 500  
 ctgtgtcacg ggggtgcggtc ttgctgggcc tcttggcgtc gtcttcacat 550  
 acccactgct cacagcagtg gccaggtatg ctacgcgcc gcgggtgggg 600  
 gcaccagaga cgcggggggc gcactcggag gcacagtggg gtgcagccca 650  
 25 ccgcgccgtc gatgcacgtg cagttgtact tgcagttagg ctggaaggac 700  
 tggccgttgt tgtagcgcac cccatccagg acgcagccca caccgaccac 750  
 ctgtgcacac actcctattg cgtacctcgg gcggtccccg ctgtagtcac 800  
 agtagaggcc ccggtggggg tcacagatgg cagcctccgt gcagttgtcc 850  
 ccaagctgct gagcgacat cttacagcac tcacagccat ctgtgatgag 900  
 30 gctgaccccc agcgggcagc ggggtgggga tggcgggcac tcacatggcc 950  
 acttgcagaa ttgggggcgt gaggaggtgt cctccagtgg agctggagta 1000  
 aagtccatgg tcgtaggggc tggagagagg gccgtggcca ggacggtgct 1050

ggcggctgct gctgtcactg ctgccagcgt ccagggcagg aaccacctca 1100

t 1101

<210> 3

<211> 345

5 <212> PRT

<213> Human

<400> 3

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Thr | Ala | Leu | Ser | Pro | Ala | Pro | Thr | Thr | Met | Asp | Phe | Thr | Pro | Ala |
|    | 23  |     | 25  |     |     |     |     | 30  |     |     |     |     | 35  |     |     |
| 10 | Pro | Leu | Glu | Asp | Thr | Ser | Ser | Arg | Pro | Gln | Phe | Cys | Lys | Trp | Pro |
|    |     |     | 40  |     |     |     |     | 45  |     |     |     |     | 50  |     |     |
|    | Cys | Glu | Cys | Pro | Pro | Ser | Pro | Pro | Arg | Cys | Pro | Leu | Gly | Val | Ser |
|    |     |     | 55  |     |     |     |     | 60  |     |     |     |     | 65  |     |     |
| 15 | Leu | Ile | Thr | Asp | Gly | Cys | Glu | Cys | Cys | Lys | Met | Cys | Ala | Gln | Gln |
|    |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |     |     |
|    | Leu | Gly | Asp | Asn | Cys | Thr | Glu | Ala | Ala | Ile | Cys | Asp | Pro | His | Arg |
|    |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |     |
|    | Gly | Leu | Tyr | Cys | Asp | Tyr | Ser | Gly | Asp | Arg | Pro | Arg | Tyr | Ala | Ile |
|    |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |
| 20 | Gly | Val | Cys | Ala | Gln | Val | Val | Gly | Val | Gly | Cys | Val | Leu | Asp | Gly |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |
|    | Val | Arg | Tyr | Asn | Asn | Gly | Gln | Ser | Phe | Gln | Pro | Asn | Cys | Lys | Tyr |
|    |     |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |
| 25 | Asn | Cys | Thr | Cys | Ile | Asp | Gly | Ala | Val | Gly | Cys | Thr | Pro | Leu | Cys |
|    |     |     | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |
|    | Leu | Arg | Val | Arg | Pro | Pro | Arg | Leu | Trp | Cys | Pro | His | Pro | Arg | Arg |
|    |     |     | 160 |     |     |     |     | 165 |     |     |     |     | 170 |     |     |
|    | Val | Ser | Ile | Pro | Gly | His | Cys | Cys | Glu | Gln | Trp | Val | Cys | Glu | Asp |
|    |     |     | 175 |     |     |     |     | 180 |     |     |     |     | 185 |     |     |
| 30 | Asp | Ala | Lys | Arg | Pro | Arg | Lys | Thr | Ala | Pro | Arg | Asp | Thr | Gly | Ala |
|    |     |     | 190 |     |     |     |     | 195 |     |     |     |     | 200 |     |     |
|    | Phe | Asp | Ala | Val | Gly | Glu | Val | Glu | Ala | Trp | His | Arg | Asn | Cys | Ile |
|    |     |     | 205 |     |     |     |     | 210 |     |     |     |     | 215 |     |     |
| 35 | Ala | Tyr | Thr | Ser | Pro | Trp | Ser | Pro | Cys | Ser | Thr | Ser | Cys | Gly | Leu |
|    |     |     | 220 |     |     |     |     | 225 |     |     |     |     | 230 |     |     |
|    | Gly | Val | Ser | Thr | Arg | Ile | Ser | Asn | Val | Asn | Ala | Gln | Cys | Trp | Pro |
|    |     |     | 235 |     |     |     |     | 240 |     |     |     |     | 245 |     |     |
|    | Glu | Gln | Glu | Ser | Arg | Leu | Cys | Asn | Leu | Arg | Pro | Cys | Asp | Val | Asp |
|    |     |     | 250 |     |     |     |     | 255 |     |     |     |     | 260 |     |     |
| 40 | Ile | His | Thr | Leu | Ile | Lys | Ala | Gly | Lys | Lys | Cys | Leu | Ala | Val | Tyr |

|    |   |  |     |  |         |
|----|---|--|-----|--|---------|
|    | 265   |  | 270 |  | 275     |
|    | Gln Pro Glu Ala Ser Met Asn Phe Thr Leu Ala Gly Cys Ile Ser |  |     |  |         |
|    | 280   |  | 285 |  | 290     |
| 5  | Thr Arg Ser Tyr Gln Pro Lys Tyr Cys Gly Val Cys Met Asp Asn |  |     |  |         |
|    | 295   |  | 300 |  | 305     |
|    | Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Asp Val Ser Phe |  |     |  |         |
|    | 310   |  | 315 |  | 320     |
|    | Gln Cys Pro Asp Gly Leu Gly Phe Ser Arg Gln Val Leu Trp Ile |  |     |  |         |
|    | 325   |  | 330 |  | 335     |
| 10 | Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile |  |     |  |         |
|    | 340   |  | 345 |  | 350     |
|    | Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Ser Glu Ile Ala Asn |  |     |  |         |
|    | 355   |  | 360 |  | 365 367 |
| 15 | <210> 4   |  |     |  |         |
|    | <211> 367   |  |     |  |         |
|    | <212> PRT   |  |     |  |         |
|    | <213> Human   |  |     |  |         |
|    | <400> 4   |  |     |  |         |
| 20 | Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala |  |     |  |         |
|    | 1 5 10 15   |  |     |  |         |
|    | Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr |  |     |  |         |
|    | 20 25 30  |  |     |  |         |
|    | Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg |  |     |  |         |
|    | 35 40 45  |  |     |  |         |
| 25 | Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro |  |     |  |         |
|    | 50 55 60  |  |     |  |         |
|    | Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys |  |     |  |         |
|    | 65 70 75  |  |     |  |         |
| 30 | Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala |  |     |  |         |
|    | 80 85 90  |  |     |  |         |
|    | Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly |  |     |  |         |
|    | 95 100 105  |  |     |  |         |
|    | Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly |  |     |  |         |
|    | 110 115 120   |  |     |  |         |
| 35 | Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser |  |     |  |         |
|    | 125 130 135   |  |     |  |         |
|    | Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala |  |     |  |         |
|    | 140 145 150   |  |     |  |         |
| 40 | Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu |  |     |  |         |
|    | 155 160 165   |  |     |  |         |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Trp   | Cys   | Pro | His | Pro | Arg | Arg | Val | Ser | Ile | Pro | Gly | His | Cys | Cys |  |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Glu   | Gln   | Trp | Val | Cys | Glu | Asp | Asp | Ala | Lys | Arg | Pro | Arg | Lys | Thr |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| 5  | Ala   | Pro   | Arg | Asp | Thr | Gly | Ala | Phe | Asp | Ala | Val | Gly | Glu | Val | Glu |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Ala   | Trp   | His | Arg | Asn | Cys | Ile | Ala | Tyr | Thr | Ser | Pro | Trp | Ser | Pro |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 10 | Cys   | Ser   | Thr | Ser | Cys | Gly | Leu | Gly | Val | Ser | Thr | Arg | Ile | Ser | Asn |  |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Val   | Asn   | Ala | Gln | Cys | Trp | Pro | Glu | Gln | Glu | Ser | Arg | Leu | Cys | Asn |  |
|    |       |       |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |  |
|    | Leu   | Arg   | Pro | Cys | Asp | Val | Asp | Ile | His | Thr | Leu | Ile | Lys | Ala | Gly |  |
|    |       |       |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |  |
| 15 | Lys   | Lys   | Cys | Leu | Ala | Val | Tyr | Gln | Pro | Glu | Ala | Ser | Met | Asn | Phe |  |
|    |       |       |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |  |
|    | Thr   | Leu   | Ala | Gly | Cys | Ile | Ser | Thr | Arg | Ser | Tyr | Gln | Pro | Lys | Tyr |  |
|    |       |       |     |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |  |
| 20 | Cys   | Gly   | Val | Cys | Met | Asp | Asn | Arg | Cys | Cys | Ile | Pro | Tyr | Lys | Ser |  |
|    |       |       |     |     | 305 |     |     |     |     | 310 |     |     |     |     | 315 |  |
|    | Lys   | Thr   | Ile | Asp | Val | Ser | Phe | Gln | Cys | Pro | Asp | Gly | Leu | Gly | Phe |  |
|    |       |       |     |     | 320 |     |     |     |     | 325 |     |     |     |     | 330 |  |
|    | Ser   | Arg   | Gln | Val | Leu | Trp | Ile | Asn | Ala | Cys | Phe | Cys | Asn | Leu | Ser |  |
|    |       |       |     |     | 335 |     |     |     |     | 340 |     |     |     |     | 345 |  |
| 25 | Cys   | Arg   | Asn | Pro | Asn | Asp | Ile | Phe | Ala | Asp | Leu | Glu | Ser | Tyr | Pro |  |
|    |       |       |     |     | 350 |     |     |     |     | 355 |     |     |     |     | 360 |  |
|    | Asp   | Phe   | Ser | Glu | Ile | Ala | Asn |     |     |     |     |     |     |     |     |  |
|    |       |       |     |     | 365 |     | 367 |     |     |     |     |     |     |     |     |  |
| 30 | <210> | 5     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> | 345   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 35 | <400> | 5     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Thr   | Ala   | Leu | Ser | Pro | Ala | Pro | Thr | Thr | Met | Asp | Phe | Thr | Pro | Ala |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Pro   | Leu   | Glu | Asp | Thr | Ser | Ser | Arg | Pro | Gln | Phe | Cys | Lys | Trp | Pro |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Cys   | Glu   | Cys | Pro | Pro | Ser | Pro | Pro | Arg | Cys | Pro | Leu | Gly | Val | Ser |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 40 | Leu   | Ile   | Thr | Asp | Gly | Cys | Glu | Cys | Cys | Lys | Met | Cys | Ala | Gln | Gln |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg | 65  | 70  | 75  |
|    | Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile | 80  | 85  | 90  |
| 5  | Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly | 95  | 100 | 105 |
|    | Val Arg Tyr Asn Asn Gly Gln Ser Phe Gln Pro Asn Cys Lys Tyr | 110 | 115 | 120 |
| 10 | Asn Cys Thr Cys Ile Asp Gly Ala Val Gly Cys Thr Pro Leu Cys | 125 | 130 | 135 |
|    | Leu Arg Val Arg Pro Pro Arg Leu Trp Cys Pro His Pro Arg Arg | 140 | 145 | 150 |
|    | Val Ser Ile Pro Gly His Cys Cys Glu Gln Trp Ile Cys Glu Asp | 155 | 160 | 165 |
| 15 | Asp Ala Lys Arg Pro Arg Lys Thr Ala Pro Arg Asp Thr Gly Ala | 170 | 175 | 180 |
|    | Phe Asp Ala Val Gly Glu Val Glu Ala Trp His Arg Asn Cys Ile | 185 | 190 | 195 |
| 20 | Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Ser Cys Gly Leu | 200 | 205 | 210 |
|    | Gly Val Ser Thr Arg Ile Ser Asn Val Asn Ala Gln Cys Trp Pro | 215 | 220 | 225 |
|    | Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp | 230 | 235 | 240 |
| 25 | Ile His Thr Leu Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr | 245 | 250 | 255 |
|    | Gln Pro Glu Ala Ser Met Asn Phe Thr Leu Ala Gly Cys Ile Ser | 260 | 265 | 270 |
| 30 | Thr Arg Ser Tyr Gln Pro Lys Tyr Cys Gly Val Cys Met Asp Asn | 275 | 280 | 285 |
|    | Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Asp Val Ser Phe | 290 | 295 | 300 |
|    | Gln Cys Pro Asp Gly Leu Gly Phe Ser Arg Gln Val Leu Trp Ile | 305 | 310 | 315 |
| 35 | Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile | 320 | 325 | 330 |
|    | Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Ser Glu Ile Ala Asn | 335 | 340 | 345 |
| 40 | <210> 6   |     |     |     |
|    | <211> 345   |     |     |     |



&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 6

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| 5  | Thr | Ala | Leu | Ser | Pro | Ala | Pro | Thr | Thr | Met | Asp | Phe | Thr | Pro | Ala | 1   | 5   | 10  | 15 |
|    | Pro | Leu | Glu | Asp | Thr | Ser | Ser | Arg | Pro | Gln | Phe | Cys | Lys | Trp | Pro | 20  | 25  | 30  |    |
|    | Cys | Glu | Cys | Pro | Pro | Ser | Pro | Pro | Arg | Cys | Pro | Leu | Gly | Val | Ser | 35  | 40  | 45  |    |
| 10 | Leu | Ile | Thr | Asp | Gly | Cys | Glu | Cys | Cys | Lys | Met | Cys | Ala | Gln | Gln | 50  | 55  | 60  |    |
|    | Leu | Gly | Asp | Asn | Cys | Thr | Glu | Ala | Ala | Ile | Cys | Asp | Pro | His | Arg | 65  | 70  | 75  |    |
| 15 | Gly | Leu | Tyr | Cys | Asp | Tyr | Ser | Gly | Asp | Arg | Pro | Arg | Tyr | Ala | Ile | 80  | 85  | 90  |    |
|    | Gly | Val | Cys | Ala | Gln | Val | Val | Gly | Val | Gly | Cys | Val | Leu | Asp | Gly | 95  | 100 | 105 |    |
|    | Val | Arg | Tyr | Asn | Asn | Gly | Gln | Ser | Phe | Gln | Pro | Asn | Cys | Lys | Tyr | 110 | 115 | 120 |    |
| 20 | Asn | Cys | Thr | Cys | Ile | Asp | Gly | Ala | Val | Gly | Cys | Thr | Pro | Leu | Cys | 125 | 130 | 135 |    |
|    | Leu | Arg | Val | Arg | Pro | Pro | Arg | Leu | Trp | Cys | Pro | His | Pro | Arg | Arg | 140 | 145 | 150 |    |
| 25 | Val | Ser | Ile | Pro | Gly | His | Cys | Cys | Glu | Gln | Trp | Val | Cys | Glu | Asp | 155 | 160 | 165 |    |
|    | Asp | Ala | Lys | Arg | Pro | Arg | Lys | Thr | Ala | Pro | Arg | Asp | Thr | Gly | Ser | 170 | 175 | 180 |    |
|    | Phe | Asp | Ala | Val | Gly | Glu | Val | Glu | Ala | Trp | His | Arg | Asn | Cys | Ile | 185 | 190 | 195 |    |
| 30 | Ala | Tyr | Thr | Ser | Pro | Trp | Ser | Pro | Cys | Ser | Thr | Ser | Cys | Gly | Leu | 200 | 205 | 210 |    |
|    | Gly | Val | Ser | Thr | Arg | Ile | Ser | Asn | Val | Asn | Ala | Gln | Cys | Trp | Pro | 215 | 220 | 225 |    |
| 35 | Glu | Gln | Glu | Ser | Arg | Leu | Cys | Asn | Leu | Arg | Pro | Cys | Asp | Val | Asp | 230 | 235 | 240 |    |
|    | Ile | His | Thr | Leu | Ile | Lys | Ala | Gly | Lys | Lys | Cys | Leu | Ala | Val | Tyr | 245 | 250 | 255 |    |
|    | Gln | Pro | Glu | Ala | Ser | Met | Asn | Phe | Thr | Leu | Ala | Gly | Cys | Ile | Ser | 260 | 265 | 270 |    |
| 40 | Thr | Arg | Ser | Tyr | Gln | Pro | Lys | Tyr | Cys | Gly | Val | Cys | Met | Asp | Asn |     |     |     |    |

|    | 275   | 280 | 285 |
|----|---|-----|-----|
|    | Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Asp Val Ser Phe |     |     |
|    | 290   | 295 | 300 |
| 5  | Gln Cys Pro Asp Gly Leu Gly Phe Ser Arg Gln Val Leu Trp Ile |     |     |
|    | 305   | 310 | 315 |
|    | Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile |     |     |
|    | 320   | 325 | 330 |
|    | Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Ser Glu Ile Ala Asn |     |     |
|    | 335   | 340 | 345 |
| 10 | <210> 7   |     |     |
|    | <211> 367   |     |     |
|    | <212> PRT   |     |     |
|    | <213> Human   |     |     |
|    | <400> 7   |     |     |
| 15 | Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala |     |     |
|    | 1   | 5   | 10  |
|    | Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr |     |     |
|    | 20  | 25  | 30  |
| 20 | Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg |     |     |
|    | 35  | 40  | 45  |
|    | Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro |     |     |
|    | 50  | 55  | 60  |
|    | Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys |     |     |
|    | 65  | 70  | 75  |
| 25 | Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala |     |     |
|    | 80  | 85  | 90  |
|    | Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly |     |     |
|    | 95  | 100 | 105 |
| 30 | Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly |     |     |
|    | 110   | 115 | 120 |
|    | Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser |     |     |
|    | 125   | 130 | 135 |
|    | Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala |     |     |
|    | 140   | 145 | 150 |
| 35 | Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu |     |     |
|    | 155   | 160 | 165 |
|    | Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys |     |     |
|    | 170   | 175 | 180 |
| 40 | Glu Gln Trp Ile Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr |     |     |
|    | 185   | 190 | 195 |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Ala   | Pro   | Arg | Asp | Thr | Gly | Ala | Phe | Asp | Ala | Val | Gly | Glu | Val | Glu |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Ala   | Trp   | His | Arg | Asn | Cys | Ile | Ala | Tyr | Thr | Ser | Pro | Trp | Ser | Pro |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 5  | Cys   | Ser   | Thr | Ser | Cys | Gly | Leu | Gly | Val | Ser | Thr | Arg | Ile | Ser | Asn |  |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Val   | Asn   | Ala | Gln | Cys | Trp | Pro | Glu | Gln | Glu | Ser | Arg | Leu | Cys | Asn |  |
|    |       |       |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |  |
| 10 | Leu   | Arg   | Pro | Cys | Asp | Val | Asp | Ile | His | Thr | Leu | Ile | Lys | Ala | Gly |  |
|    |       |       |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |  |
|    | Lys   | Lys   | Cys | Leu | Ala | Val | Tyr | Gln | Pro | Glu | Ala | Ser | Met | Asn | Phe |  |
|    |       |       |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |  |
|    | Thr   | Leu   | Ala | Gly | Cys | Ile | Ser | Thr | Arg | Ser | Tyr | Gln | Pro | Lys | Tyr |  |
|    |       |       |     |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |  |
| 15 | Cys   | Gly   | Val | Cys | Met | Asp | Asn | Arg | Cys | Cys | Ile | Pro | Tyr | Lys | Ser |  |
|    |       |       |     |     | 305 |     |     |     |     | 310 |     |     |     |     | 315 |  |
|    | Lys   | Thr   | Ile | Asp | Val | Ser | Phe | Gln | Cys | Pro | Asp | Gly | Leu | Gly | Phe |  |
|    |       |       |     |     | 320 |     |     |     |     | 325 |     |     |     |     | 330 |  |
| 20 | Ser   | Arg   | Gln | Val | Leu | Trp | Ile | Asn | Ala | Cys | Phe | Cys | Asn | Leu | Ser |  |
|    |       |       |     |     | 335 |     |     |     |     | 340 |     |     |     |     | 345 |  |
|    | Cys   | Arg   | Asn | Pro | Asn | Asp | Ile | Phe | Ala | Asp | Leu | Glu | Ser | Tyr | Pro |  |
|    |       |       |     |     | 350 |     |     |     |     | 355 |     |     |     |     | 360 |  |
|    | Asp   | Phe   | Ser | Glu | Ile | Ala | Asn |     |     |     |     |     |     |     |     |  |
|    |       |       |     |     | 365 |     | 367 |     |     |     |     |     |     |     |     |  |
| 25 | <210> | 8     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> | 367   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 30 | <400> | 8     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Met   | Arg   | Trp | Phe | Leu | Pro | Trp | Thr | Leu | Ala | Ala | Val | Thr | Ala | Ala |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Ala   | Ala   | Ser | Thr | Val | Leu | Ala | Thr | Ala | Leu | Ser | Pro | Ala | Pro | Thr |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
| 35 | Thr   | Met   | Asp | Phe | Thr | Pro | Ala | Pro | Leu | Glu | Asp | Thr | Ser | Ser | Arg |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
|    | Pro   | Gln   | Phe | Cys | Lys | Trp | Pro | Cys | Glu | Cys | Pro | Pro | Ser | Pro | Pro |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Arg   | Cys   | Pro | Leu | Gly | Val | Ser | Leu | Ile | Thr | Asp | Gly | Cys | Glu | Cys |  |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
| 40 | Cys   | Lys   | Met | Cys | Ala | Gln | Gln | Leu | Gly | Asp | Asn | Cys | Thr | Glu | Ala |  |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly | 95  | 100 | 105 |
|    | Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly | 110 | 115 | 120 |
| 5  | Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser | 125 | 130 | 135 |
|    | Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala | 140 | 145 | 150 |
| 10 | Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu | 155 | 160 | 165 |
|    | Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys | 170 | 175 | 180 |
|    | Glu Gln Trp Val Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr | 185 | 190 | 195 |
| 15 | Ala Pro Arg Asp Thr Gly Ser Phe Asp Ala Val Gly Glu Val Glu | 200 | 205 | 210 |
|    | Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro | 215 | 220 | 225 |
| 20 | Cys Ser Thr Ser Cys Gly Leu Gly Val Ser Thr Arg Ile Ser Asn | 230 | 235 | 240 |
|    | Val Asn Ala Gln Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn | 245 | 250 | 255 |
|    | Leu Arg Pro Cys Asp Val Asp Ile His Thr Leu Ile Lys Ala Gly | 260 | 265 | 270 |
| 25 | Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Ala Ser Met Asn Phe | 275 | 280 | 285 |
|    | Thr Leu Ala Gly Cys Ile Ser Thr Arg Ser Tyr Gln Pro Lys Tyr | 290 | 295 | 300 |
| 30 | Cys Gly Val Cys Met Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser | 305 | 310 | 315 |
|    | Lys Thr Ile Asp Val Ser Phe Gln Cys Pro Asp Gly Leu Gly Phe | 320 | 325 | 330 |
|    | Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser | 335 | 340 | 345 |
| 35 | Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro | 350 | 355 | 360 |
|    | Asp Phe Ser Glu Ile Ala Asn                                 | 365 | 367 |     |

&lt;210&gt; 9

40 &lt;211&gt; 1766

&lt;212&gt; DNA

&lt;213&gt; Mouse

&lt;220&gt;

&lt;221&gt; Unknown

5 &lt;222&gt; 10

&lt;223&gt; Any nucleotide

&lt;400&gt; 9

taacaaggcn gtcttgcttg gagaggcatc cgcacccctct gggctgagcc 50  
 gtagctcctg tgacgctgac ttccaggcat gaggtggctc ctgccctgga 100  
 10 cgctggcagc cgtggcagtc ctgaggggtgg gcaacatcct ggccacggcc 150  
 ctctctccaa cccccacaac aatgaccttc accccagcac cactagagga 200  
 aacgactaca cgccccgaat tctgcaagtg gccatgtgag tgcccacaat 250  
 cccacacctg ctgcccactg ggcgtcagcc taatcacaga tggctgtgaa 300  
 tgctgtaaga tatgtgcca gcagcttggg gacaactgca cagaggctgc 350  
 15 catctgtgac ccacaccggg gcctctactg cgattacagt ggggatcgcc 400  
 cgaggtagc aataggagtg tgtgcacagg tggtcgggtgt gggctgtgtc 450  
 ctggatggcg tacgctacac caatggcgag tccttccaac ccaactgcag 500  
 gtacaactgt acctgcattg atggcacggg gggctgcaca ccgctgtgcc 550  
 taagccccag gccccacgc ctctgggtgcc gccagccccg gcacgtgaga 600  
 20 gtccctggcc agtgctgtga gcagtgggtg tgtgatgatg acgcaaggag 650  
 accacgccag actgcactgt tggacaccag agcctttgca gcgtcaggcg 700  
 ccgtggagca acggtatgag aactgcatag cctacactag tccctggagc 750  
 ccctgctcta ccacctgtgg cctaggtatc tccactcgga tctctaactg 800  
 caatgcccgg tgctggccag agcaggaaag tcgcctctgc aacctgcggc 850  
 25 catgtgatgt ggacatccaa ctacacatca aggcaggga gaaatgcctg 900  
 gctgtgtacc agccagagga ggccacgaac ttcactctcg caggctgtgt 950  
 cagcacacgc acctaccgac ccaagtactg cggagtctgt actgacaata 1000  
 ggtgttgcat cccctacaag tccaagacca tcagtgtgga tttccagtgt 1050  
 ccagaggggc caggtttctc ccggcaggtc ctatggatta atgcttgctt 1100  
 30 ctgcaacctg agctgcagga atcctaacga tatctttgct gacttggaat 1150  
 cttacctga cttcgaagag attgccaat aggtgggtgt gtggctcagg 1200  
 gtaaagttcc atgctgcaaa gcagccagcc ctttgtggtc caggacttca 1250



caattgagcc ttatttcac tacttcctac tcgattctga attcccagtt 1300  
 tctgttcctg ttttgacaat cgtaatggcc caggagagtg ctgctcaggc 1350  
 tcagacaatg ggttcctcct tggggacatt ctacatcatt ccaaggaaaa 1400  
 cacatctctg actgttcaca atggaagcaa agcctggccc agctagtctg 1450  
 5 gctccagcct gggcaagttg tcagaagttg tgatgggatt gtccaaggaa 1500  
 aagcatcagc tgaagaacca gtatcatgaa gtccttcctc agatgccaag 1550  
 cctagggatg ctgggaccc ttccagacaga tggatgggat tggggacaca 1600  
 ggaataagct attattttac ccttgccaaa tgatactatc ctgggtattt 1650  
 ctgcctaaaa acataccaaa agtgttcttg ttccactgat ctgtatatca 1700  
 10 caagtcacca aacattttcc aggtgaggac ccatagttgt gtcattctgt 1750  
 tttgccaatt gaaaaa 1766

&lt;210&gt; 10

&lt;211&gt; 1140

&lt;212&gt; DNA

15 &lt;213&gt; Mouse

&lt;400&gt; 10

attggcaatc tcttcgaagt cagggtaaga ttccaagcca gcaaagatat 50  
 cgtaggatt cctgcagctc aggttgcaga agcaagcatt aatccatagg 100  
 acctgccggg agaaacctgg cccctctgga cactggaaat ccacactgat 150  
 20 ggtcttggac ttgtagggga tgcaacacct attgtcagta cagactccgc 200  
 agtacttggg tcggtaggtg cgtgtgctga cacagcctgc gagagtgaag 250  
 ttctgtggct cctctggctg gtacacagcc aggcatttct tccctgcctt 300  
 gatgtgtagt tggatgtcca catcacatgg ccgcagggtg cagaggcgac 350  
 tttcctgctc tggccagcac cgggcattga cgtagagat ccgagtggag 400  
 25 atacctaggc cacaggtggt agagcagggg ctccaggac tagtgtaggc 450  
 tatgcagttc tcataccgtt gctccacggc gcctgacgct gcaaaggctc 500  
 tgggtgtccaa cagtgcagtc tggcgtggtc tccttgctc atcatcacac 550  
 acccactgct cacagcactg gccagggact ctacgtgcc ggggctggcg 600  
 gcaccagagg cgtggggggc tggggcttag gcacagcggg gtgcagccca 650  
 30 ccgtgccatc aatgcaggta cagttgtacc tgcagttggg ttggaaggac 700  
 tcgccattgg tgtagcgtac gccatccagg acacagccca caccgaccac 750  
 ctgtgcacac actcctattg cgtacctcgg gcgatcccca ctgtaatcgc 800

agtagaggcc ccggtgtggg tcacagatgg cagcctctgt gcagttgtcc 850  
 ccaagctgct gggcacatat cttacagcat tcacagccat ctgtgattag 900  
 gctgacgccc agtgggcagc gaggtgggga ttgtgggcac tcacatggcc 950  
 acttgcagaa ttcggggcgt gtagtcgttt cctctagtgg tgctgggggtg 1000  
 5 aaggtcattg ttccggaatc ctctagtggg gctgggggtga aggtcattgt 1050  
 tgtggggggtt ggagagaggg ccgtggccag gatgttgccc accctcagga 1100  
 ctgccacggc tgccagcgtc cagggcagga gccacctcat 1140

<210> 11  
 <211> 345  
 10 <212> PRT  
 <213> Mouse

<400> 11  
 Thr Ala Leu Ser Pro Thr Pro Thr Thr Met Thr Phe Thr Pro Ala  
 1 5 10 15  
 15 Pro Leu Glu Glu Thr Thr Thr Arg Pro Glu Phe Cys Lys Trp Pro  
 20 25 30  
 Cys Glu Cys Pro Gln Ser Pro Pro Arg Cys Pro Leu Gly Val Ser  
 35 40 45  
 20 Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Ile Cys Ala Gln Gln  
 50 55 60  
 Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg  
 65 70 75  
 Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile  
 80 85 90  
 25 Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly  
 95 100 105  
 Val Arg Tyr Thr Asn Gly Glu Ser Phe Gln Pro Asn Cys Arg Tyr  
 110 115 120  
 30 Asn Cys Thr Cys Ile Asp Gly Thr Val Gly Cys Thr Pro Leu Cys  
 125 130 135  
 Leu Ser Pro Arg Pro Pro Arg Leu Trp Cys Arg Gln Pro Arg His  
 140 145 150  
 Val Arg Val Pro Gly Gln Cys Cys Glu Gln Trp Val Cys Asp Asp  
 155 160 165  
 35 Asp Ala Arg Arg Pro Arg Gln Thr Ala Leu Leu Asp Thr Arg Ala  
 170 175 180  
 Phe Ala Ala Ser Gly Ala Val Glu Gln Arg Tyr Glu Asn Cys Ile  
 185 190 195

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Thr Cys Gly Leu | 200 | 205 | 210 |
|    | Gly Ile Ser Thr Arg Ile Ser Asn Val Asn Ala Arg Cys Trp Pro | 215 | 220 | 225 |
| 5  | Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp | 230 | 235 | 240 |
|    | Ile Gln Leu His Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr | 245 | 250 | 255 |
| 10 | Gln Pro Glu Glu Ala Thr Asn Phe Thr Leu Ala Gly Cys Val Ser | 260 | 265 | 270 |
|    | Thr Arg Thr Tyr Arg Pro Lys Tyr Cys Gly Val Cys Thr Asp Asn | 275 | 280 | 285 |
|    | Arg Cys Cys Ile Pro Tyr Lys Ser Lys Thr Ile Ser Val Asp Phe | 290 | 295 | 300 |
| 15 | Gln Cys Pro Glu Gly Pro Gly Phe Ser Arg Gln Val Leu Trp Ile | 305 | 310 | 315 |
|    | Asn Ala Cys Phe Cys Asn Leu Ser Cys Arg Asn Pro Asn Asp Ile | 320 | 325 | 330 |
| 20 | Phe Ala Asp Leu Glu Ser Tyr Pro Asp Phe Glu Glu Ile Ala Asn | 335 | 340 | 345 |
|    | <210> 12  |     |     |     |
|    | <211> 367   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Mouse   |     |     |     |
| 25 | <400> 12  |     |     |     |
|    | Met Arg Trp Leu Leu Pro Trp Thr Leu Ala Ala Val Ala Val Leu | 1   | 5   | 10  |
|    | Arg Val Gly Asn Ile Leu Ala Thr Ala Leu Ser Pro Thr Pro Thr | 20  | 25  | 30  |
| 30 | Thr Met Thr Phe Thr Pro Ala Pro Leu Glu Glu Thr Thr Thr Arg | 35  | 40  | 45  |
|    | Pro Glu Phe Cys Lys Trp Pro Cys Glu Cys Pro Gln Ser Pro Pro | 50  | 55  | 60  |
| 35 | Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys | 65  | 70  | 75  |
|    | Cys Lys Ile Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala | 80  | 85  | 90  |
|    | Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly | 95  | 100 | 105 |
| 40 | Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly | 110 | 115 | 120 |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Val Gly Cys Val Leu Asp Gly Val Arg Tyr Thr Asn Gly Glu Ser | 125 | 130 | 135 |
|    | Phe Gln Pro Asn Cys Arg Tyr Asn Cys Thr Cys Ile Asp Gly Thr | 140 | 145 | 150 |
| 5  | Val Gly Cys Thr Pro Leu Cys Leu Ser Pro Arg Pro Pro Arg Leu | 155 | 160 | 165 |
|    | Trp Cys Arg Gln Pro Arg His Val Arg Val Pro Gly Gln Cys Cys | 170 | 175 | 180 |
| 10 | Glu Gln Trp Val Cys Asp Asp Asp Ala Arg Arg Pro Arg Gln Thr | 185 | 190 | 195 |
|    | Ala Leu Leu Asp Thr Arg Ala Phe Ala Ala Ser Gly Ala Val Glu | 200 | 205 | 210 |
|    | Gln Arg Tyr Glu Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro | 215 | 220 | 225 |
| 15 | Cys Ser Thr Thr Cys Gly Leu Gly Ile Ser Thr Arg Ile Ser Asn | 230 | 235 | 240 |
|    | Val Asn Ala Arg Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn | 245 | 250 | 255 |
| 20 | Leu Arg Pro Cys Asp Val Asp Ile Gln Leu His Ile Lys Ala Gly | 260 | 265 | 270 |
|    | Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Glu Ala Thr Asn Phe | 275 | 280 | 285 |
|    | Thr Leu Ala Gly Cys Val Ser Thr Arg Thr Tyr Arg Pro Lys Tyr | 290 | 295 | 300 |
| 25 | Cys Gly Val Cys Thr Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser | 305 | 310 | 315 |
|    | Lys Thr Ile Ser Val Asp Phe Gln Cys Pro Glu Gly Pro Gly Phe | 320 | 325 | 330 |
| 30 | Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser | 335 | 340 | 345 |
|    | Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro | 350 | 355 | 360 |
|    | Asp Phe Glu Glu Ile Ala Asn                                 | 365 | 367 |     |
| 35 | <210> 13  |     |     |     |
|    | <211> 1293  |     |     |     |
|    | <212> DNA   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 13  |     |     |     |
| 40 | cccacgcgtc cggctgggga catgagagggc acaccgaaga cccacctcct 50  |     |     |     |

ggccttctcc ctccctctgcc tectctcaaa ggtgcgtacc cagctgtgcc 100  
cgacaccatg tacctgcccc tggccacctc cccgatgccc gctgggagta 150  
cccttggtgc tggatggctg tggctgctgc cgggtatgtg cacggcggct 200  
gggggagccc tgcgaccaac tccacgtctg cgacgccagc cagggcctgg 250  
5 tctgccagcc cggggcagga cccggtggcc ggggggccct gtgcctcttg 300  
gcagaggacg acagcagctg tgaggtgaac ggccgcctgt atcgggaagg 350  
ggagaccttc cagccccact gcagcatccg ctgccgctgc gaggacggcg 400  
gcttcacctg cgtgccgctg tgcagcgagg atgtgcggct gccagctgg 450  
gactgcccc accccaggag ggtcgaggtc ctgggcaagt gctgccctga 500  
10 gtgggtgtgc ggccaaggag ggggactggg gaccagccc cttccagccc 550  
aaggaccca gttttctggc cttgtctctt cctgcccc tggtgtcccc 600  
tgcccagaat ggagcacggc ctggggaccc tgctcgacca cctgtgggct 650  
gggcatggcc acccgggtgt ccaaccagaa ccgcttctgc cgactggaga 700  
cccagcgccg cctgtgcctg tccaggccct gccaccctc caggggtcgc 750  
15 agtccacaaa acagtgcctt ctagagccgg gctgggaatg gggacacggt 800  
gtccaccatc cccagctggt ggccctgtgc ctgggccctg ggctgatgga 850  
agatgggtccg tgcccaggcc cttggctgca ggcaacactt tagcttgggt 900  
ccaccatgca gaacaccaat attaacacgc tgccctggtct gtctggatcc 950  
cgaggtatgg cagaggtgca agacctagtc ccctttcctc taactcactg 1000  
20 cctaggaggc tggccaaggc gtccagggtc ctctagccca ctccctgcct 1050  
acacacacag cctatatcaa acatgcacac gggcgagctt tctctccgac 1100  
ttcccctggg caagagatgg gacaagcagt cccttaatat tgaggctgca 1150  
gcaggtgctg ggctggactg gccatttttc tgggggtagg atgaagagaa 1200  
ggcacacaga gattctggat ctctgctgc cttttctgga gtttgtaaaa 1250  
25 ttgttctga atacaagcct atgcgtgaaa aaaaaaaaaa aaa 1293

&lt;210&gt; 14

&lt;211&gt; 750

&lt;212&gt; DNA

&lt;213&gt; Human

30 &lt;400&gt; 14

gaaggcactg ttttgtggac tgcgaccctt ggagggtggg cagggcctgg 50

acaggcacag gcggcgctgg gtctccagtc ggcagaagcg gttctggttg 100



gacacccggg tggccatgcc cagcccacag gtggctcagc agggccccca 150  
 ggccgtgctc cattctgggc aggggacacc agggggcagg gaagagacaa 200  
 ggccagaaaa ctgggggtcct tgggctggaa ggggctgggt ccccagtccc 250  
 cctccttggc cgcacaccca ctcagggcag cacttgccca ggacctcgac 300  
 5 cctcctgggg tgggggcagt cccagctggg cagccgcaca tcctcgctgc 350  
 acagcggcac gcaggtgaag ccgccgtcct cgcagcggca gcggatgctg 400  
 cagtggggct ggaaggtctc cccttcccga tacaggcggc cgttcacctc 450  
 acagctgctg tcgtcctctg ccaagaggca cagggcccc cggccaccgg 500  
 gtctgcccc gggctggcag accaggccct ggctggcgtc gcagacgtgg 550  
 10 agttggctgc agggctcccc cagccgccgt gcacataccc ggcagcagcc 600  
 acagccatcc agcaccaggg gtactcccag cgggcatcgg ggaggtggcc 650  
 aggggcaggt acatggtgtc gggcacagct gggtagcac ctttgagagg 700  
 aggcagagga gggagaaggc caggaggtgg gtcttcgggtg tgcctctcat 750

15 <210> 15  
 <211> 227  
 <212> PRT  
 <213> Human

<400> 15  
 20 Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg  
 1 5 10 15  
 Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys  
 20 25 30  
 Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His  
 35 40 45  
 25 Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly  
 50 55 60  
 Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser  
 65 70 75  
 30 Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe  
 80 85 90  
 Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe  
 95 100 105  
 Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp  
 110 115 120  
 35 Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys  
 125 130 135

Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu Gly Thr Gln Pro  
140 145 150

Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu  
155 160 165

5 Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro  
170 175 180

Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn  
185 190 195

10 Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu  
200 205 210

Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser  
215 220 225

Ala Phe  
227

15 <210> 16  
<211> 250  
<212> PRT  
<213> Human

<400> 16

20 Met Arg Gly Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu  
1 5 10 15

Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys  
20 25 30

25 Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu  
35 40 45

Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu  
50 55 60

Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly  
65 70 75

30 Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu  
80 85 90

Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg  
95 100 105

35 Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg  
110 115 120

Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser  
125 130 135

Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg  
140 145 150

40 Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln  
155 160 165

Gly Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln  
 170 175 180  
 Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro  
 185 190 195  
 5 Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu  
 200 205 210  
 Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu  
 215 220 225  
 10 Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser  
 230 235 240  
 Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
 245 250

<210> 17  
 <211> 1734  
 15 <212> DNA  
 <213> Mouse

<400> 17  
 cccacgcgtc cgcgctcctg atctccagag gaccccgggc tgggacaggg 50  
 gccttggcga ggctgcagct gctgtggcag tagcttggga tggaggtctt 100  
 20 tcttgctggg aactgaggag ctgagaggct cctgtcaggc tcctgtccta 150  
 aactcttggc acttgcggtg gcttgggctt cacacactgt cagacacctt 200  
 cttggtggcc tcctcggcct caggtttgaa gctggctcca caagggacac 250  
 ggtgacatga ggggcaaccc actgatccat cttctggcca ttctcttctt 300  
 ctgcattctc tcaatggtgt attcccagct gtgcccagca ccctgtgcct 350  
 25 gtccttggac accaccccag tgcccaccgg gggtaccctt ggtgctggat 400  
 ggctgtggct gctgtcgagt gtgtgcacgg aggctggggg agtcctgcga 450  
 ccacctgcat gtctgcgacc ccagccaggg cctggtttgt cagcctgggg 500  
 caggccccag tggecggtgt gctgtgtgcc tcttcgaaga ggatgacggg 550  
 agctgtgagg tgaatggccg caggtaacctg gatggggaga cctttaaac 600  
 30 caattgcagg gttttgtgcc gctgtgatga cggtgggttc acctgcctgc 650  
 cgctgtgcag tgaggatgtg cggctgcccga gctgggactg cccacgcccc 700  
 aggagaatac aggtgccagg aaggtgctgc cccgagtggg tgtgtgacca 750  
 ggcagtgatg cagccggcaa tccagccctc ctacgcccga ggacaccaac 800  
 tttctgcctt tgtcactcct gcatctgccc atggcccctg tccaaactgg 850  
 35 agcacagcct ggggcccctg ctcaaccacc tgtgggttgg gcatagccac 900

ccgagtatcc aaccagaacc gattctgcc aactggagatc cagcgtcgcc 950  
 tgtgtctgtc cagaccctgc ctggcatcca ggagccacgg ctcatggaac 1000  
 agtgccttct agagccattg cggggatgtg gatacagggc ctgccattct 1050  
 cagcaaattg ccctaggacc aggccttggc ctgatggtag atgccccctt 1100  
 5 ccatgctctt ggctgcagtt aactgtcctg ggtggattca gtgtccagag 1150  
 cctctgagcg atccctgctc tgtctgaggt gggggaagca ggtgaccagc 1200  
 tccatttctc tggattctga cccaggcttc tgggttctcc tggctagttc 1250  
 ctcaaaactt ccctgtatga aaaggacaac caaaaggacc tttaaagcta 1300  
 agctgtactg ggcaagcctg gccaccatgc tggggatagt gacagtaata 1350  
 10 ggtaccaggc agcagattgc ctgaaacatc caggctccctt cttggacttc 1400  
 tatgtgcttg tcccaaagat tatgggtgac cttgtaagtg tgcctttcct 1450  
 gatctgagaa caccctgccc ggctgggaag aattttcttg gaacatgaag 1500  
 agatggaatc acactattct taagagcgtt tgccaagtcc aggaacttga 1550  
 cctttgtatt tgtaaaaata cacatctctt aaatgctcac aaagcaagag 1600  
 15 gctccacact tctggcaggc cagggccttt ctcttcagca tgagagagac 1650  
 aaggaacagt agagtaccct cctctggagg actggcccgg tctggaataa 1700  
 acacccaaat caagtgtgga aaaaaaaaaa aaaa 1734

<210> 18  
 <211> 753  
 20 <212> DNA  
 <213> Mouse

<400> 18  
 gaaggcactg ttccatgagc cgtggctcct ggatgccagg cagggtctgg 50  
 acagacacag ggcagcgtgg atctccagtt ggcagaatcg gttctgggtg 100  
 25 gatactcggg tggctatgcc caaccacag gtggttgagc aggggccccca 150  
 ggctgtgctc cagtttggac aggggccatc ggcagatgca ggagtgacaa 200  
 gggcagaaag ttggtgtcct tgggctgagg agggctggat tgccggctgc 250  
 atcactgcct ggtcacacac ccactcgggg cagcaccttc ctggcacctg 300  
 tattctcctg gggcgtgggc agtcccagct gggcagccgc acatcctcac 350  
 30 tgcacagcgg caggcaggtg aaaccaccgt catcacagcg gcacaaaacc 400  
 ctgcaattgg gtttaaaggt ctccccatcc aggtacctgc ggccattcac 450  
 ctcacagctc ccgtcatcct cttcgaagag gcacacagca ccacggccac 500

tggggcctgc cccaggctga caaaccaggc cctggctggg gtcgcagaca 550  
 tgcaggtggt cgcaggactc ccccagcctc cgtgcacaca ctcgacagca 600  
 gccacagcca tccagcacca ggggtacccc cgggtgggcac tgggggtggtg 650  
 tccaaggaca ggcacagggt gctgggcaca gctgggaata caccattgag 700  
 5 agaatgcaga ggaaggaaat ggccagaaga tggatcagtg ggttgcccct 750  
 cat 753

<210> 19  
 <211> 228  
 <212> PRT  
 10 <213> Mouse

<400> 19  
 Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln  
 1 5 10 15  
 Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys  
 15 20 25 30  
 Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His  
 35 40 45  
 Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly  
 50 55 60  
 20 Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly  
 65 70 75  
 Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe  
 80 85 90  
 Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe  
 25 95 100 105  
 Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp  
 110 115 120  
 Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys  
 125 130 135  
 30 Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln  
 140 145 150  
 Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro  
 155 160 165  
 Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly  
 35 170 175 180  
 Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser  
 185 190 195  
 Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys  
 200 205 210



Ser Ala Phe  
228

-23-

Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe  
245 250 251

<210> 21  
<211> 345  
5 <212> PRT  
<213> Human

<400> 21  
Thr Ala Leu Ser Pro Ala Pro Thr Thr Met Asp Phe Thr Pro Ala  
1 5 10 15

10 Pro Leu Glu Asp Thr Ser Ser Arg Pro Gln Phe Cys Lys Trp Pro  
20 25 30

Cys Glu Cys Pro Pro Ser Pro Pro Arg Cys Pro Leu Gly Val Ser  
35 40 45

15 Leu Ile Thr Asp Gly Cys Glu Cys Cys Lys Met Cys Ala Gln Gln  
50 55 60

Leu Gly Asp Asn Cys Thr Glu Ala Ala Ile Cys Asp Pro His Arg  
65 70 75

Gly Leu Tyr Cys Asp Tyr Ser Gly Asp Arg Pro Arg Tyr Ala Ile  
80 85 90

20 Gly Val Cys Ala Gln Val Val Gly Val Gly Cys Val Leu Asp Gly  
95 100 105

Val Arg Tyr Asn Asn Gly Gln Ser Phe Gln Pro Asn Cys Lys Tyr  
110 115 120

25 Asn Cys Thr Cys Ile Asp Gly Ala Val Gly Cys Thr Pro Leu Cys  
125 130 135

Leu Arg Val Arg Pro Pro Arg Leu Trp Cys Pro His Pro Arg Arg  
140 145 150

Val Ser Ile Pro Gly His Cys Cys Glu Gln Trp Ile Cys Glu Asp  
155 160 165

30 Asp Ala Lys Arg Pro Arg Lys Thr Ala Pro Arg Asp Thr Gly Ser  
170 175 180

Phe Asp Ala Val Gly Glu Val Glu Ala Trp His Arg Asn Cys Ile  
185 190 195

35 Ala Tyr Thr Ser Pro Trp Ser Pro Cys Ser Thr Ser Cys Gly Leu  
200 205 210

Gly Val Ser Thr Arg Ile Ser Asn Val Asn Ala Gln Cys Trp Pro  
215 220 225

Glu Gln Glu Ser Arg Leu Cys Asn Leu Arg Pro Cys Asp Val Asp  
230 235 240

40 Ile His Thr Leu Ile Lys Ala Gly Lys Lys Cys Leu Ala Val Tyr  
245 250 255

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Gln         | Pro | Glu | Ala | Ser | Met | Asn | Phe | Thr | Leu | Ala | Gly | Cys | Ile | Ser |  |
|    |             |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |  |
|    | Thr         | Arg | Ser | Tyr | Gln | Pro | Lys | Tyr | Cys | Gly | Val | Cys | Met | Asp | Asn |  |
|    |             |     |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |  |
| 5  | Arg         | Cys | Cys | Ile | Pro | Tyr | Lys | Ser | Lys | Thr | Ile | Asp | Val | Ser | Phe |  |
|    |             |     |     |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |  |
|    | Gln         | Cys | Pro | Asp | Gly | Leu | Gly | Phe | Ser | Arg | Gln | Val | Leu | Trp | Ile |  |
|    |             |     |     |     | 305 |     |     |     |     | 310 |     |     |     |     | 315 |  |
| 10 | Asn         | Ala | Cys | Phe | Cys | Asn | Leu | Ser | Cys | Arg | Asn | Pro | Asn | Asp | Ile |  |
|    |             |     |     |     | 320 |     |     |     |     | 325 |     |     |     |     | 330 |  |
|    | Phe         | Ala | Asp | Leu | Glu | Ser | Tyr | Pro | Asp | Phe | Ser | Glu | Ile | Ala | Asn |  |
|    |             |     |     |     | 335 |     |     |     |     | 340 |     |     |     |     | 345 |  |
|    | <210> 22    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> 367   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 15 | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <400> 22    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Met         | Arg | Trp | Phe | Leu | Pro | Trp | Thr | Leu | Ala | Ala | Val | Thr | Ala | Ala |  |
|    | 1           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
| 20 | Ala         | Ala | Ser | Thr | Val | Leu | Ala | Thr | Ala | Leu | Ser | Pro | Ala | Pro | Thr |  |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Thr         | Met | Asp | Phe | Thr | Pro | Ala | Pro | Leu | Glu | Asp | Thr | Ser | Ser | Arg |  |
|    |             |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 25 | Pro         | Gln | Phe | Cys | Lys | Trp | Pro | Cys | Glu | Cys | Pro | Pro | Ser | Pro | Pro |  |
|    |             |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Arg         | Cys | Pro | Leu | Gly | Val | Ser | Leu | Ile | Thr | Asp | Gly | Cys | Glu | Cys |  |
|    |             |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Cys         | Lys | Met | Cys | Ala | Gln | Gln | Leu | Gly | Asp | Asn | Cys | Thr | Glu | Ala |  |
|    |             |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
| 30 | Ala         | Ile | Cys | Asp | Pro | His | Arg | Gly | Leu | Tyr | Cys | Asp | Tyr | Ser | Gly |  |
|    |             |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Asp         | Arg | Pro | Arg | Tyr | Ala | Ile | Gly | Val | Cys | Ala | Gln | Val | Val | Gly |  |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 35 | Val         | Gly | Cys | Val | Leu | Asp | Gly | Val | Arg | Tyr | Asn | Asn | Gly | Gln | Ser |  |
|    |             |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Phe         | Gln | Pro | Asn | Cys | Lys | Tyr | Asn | Cys | Thr | Cys | Ile | Asp | Gly | Ala |  |
|    |             |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Val         | Gly | Cys | Thr | Pro | Leu | Cys | Leu | Arg | Val | Arg | Pro | Pro | Arg | Leu |  |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| 40 | Trp         | Cys | Pro | His | Pro | Arg | Arg | Val | Ser | Ile | Pro | Gly | His | Cys | Cys |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |

Glu Gln Trp Ile Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr  
 185 190 195  
 Ala Pro Arg Asp Thr Gly Ser Phe Asp Ala Val Gly Glu Val Glu  
 200 205 210  
 5 Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro  
 215 220 225  
 Cys Ser Thr Ser Cys Gly Leu Gly Val Ser Thr Arg Ile Ser Asn  
 230 235 240  
 10 Val Asn Ala Gln Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn  
 245 250 255  
 Leu Arg Pro Cys Asp Val Asp Ile His Thr Leu Ile Lys Ala Gly  
 260 265 270  
 Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Ala Ser Met Asn Phe  
 275 280 285  
 15 Thr Leu Ala Gly Cys Ile Ser Thr Arg Ser Tyr Gln Pro Lys Tyr  
 290 295 300  
 Cys Gly Val Cys Met Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser  
 305 310 315  
 20 Lys Thr Ile Asp Val Ser Phe Gln Cys Pro Asp Gly Leu Gly Phe  
 320 325 330  
 Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser  
 335 340 345  
 Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro  
 350 355 360  
 25 Asp Phe Ser Glu Ile Ala Asn  
 365 367

<210> 23  
 <211> 1403  
 <212> DNA  
 30 <213> Human

<400> 23  
 gccagtctgg gccagctcc cccgagaggt ggtcggatcc tctgggctgc 50  
 tcggtegatg cctgtgccac tgacgtccag gcatgagggtg gttcctgccc 100  
 tggacgctgg cagcagtgac agcagcagcc gccagcaccg tcctggccac 150  
 35 ggccctctct ccagccccta cgaccatgga ctttacccca gctccactgg 200  
 aggacacctc ctcacgcccc caattctgca agtggccatg tgagtgcccg 250  
 ccatccccac cccgctgccc gctggggggtc agcctcatca cagatggctg 300  
 tgagtgctgt aagatgtgcg ctcagcagct tggggacaac tgcacggagg 350

ctgccatctg tgacccccac cggggcctct actgtgacta cagcggggac 400  
 cgcccgagag gtggtcggtg tgggctgcgt cctggatggg gtgcgctaca 450  
 acaacggcca gtccttccag cctaactgca agtacaactg cacgtgcac 500  
 gacggcgcgg tgggctgcac accactgtgc ctccgagtgc gcccccgcg 550  
 5 tctctggtgc cccacccgc ggcgcgtgag catacctggc cactgctgtg 600  
 agcagtgggt atgtgaggac gacgccaaga ggccacgcaa gaccgcaccc 650  
 cgtgacacag gagccttcga tgctgtgggt gaggtggagg catggcacag 700  
 gaactgcata gcctacacaa gccctggag cccttgcctc accagctgcg 750  
 gcctgggggt ctccactcgg atctccaatg ttaacgcca gtgctggcct 800  
 10 gagcaagaga gccgcctctg caacttgcg ccatgcgatg tggacatcca 850  
 tacactcatt aaggcagga agaagtgtct ggctgtgtac cagccagagg 900  
 catccatgaa cttcacactt gcgggctgca tcagcacacg ctccatcaa 950  
 cccaagtact gtggagtttg catggacaat aggtgctgca tcccctacaa 1000  
 gtctaagact atcgacgtgt ccttccagtg tctgatggg cttggcttct 1050  
 15 cccgccaggt cctatggatt aatgctgct tctgtaacct gagctgtagg 1100  
 aatcccaatg acatctttgc tgacttgga tctaccctg acttctcaga 1150  
 aattgccaac taggcaggca caaatcttg gtcttgggga ctaaccaat 1200  
 gcctgtgaag cagtcagccc ttatggccaa taacttttca ccaatgagcc 1250  
 ttagttaccc tgatctggac ccttggcctc catttctgtc tctaaccatt 1300  
 20 caaatgacgc ctgatggtgc tgctcaggcc catgctatga gttttctcct 1350  
 tgatatcatt cagcatctac tctaaagaaa aatgcctgtc tctagctgtt 1400  
 ctg 1403

25 <210> 24  
 <211> 693  
 <212> DNA  
 <213> Human

<400> 24  
 tttaattaaa cccccaaggg ctgcggaagg agcatatctg gtgctcctga 50  
 tgggccggcc agtctgggccc cagctcccc gagaggtgggt cggatcctct 100  
 30 gggctgctcg gtcgatgcct gtgccactga cgtccaggca tgaggtgggt 150  
 cctgccctgg acgctggcag cagtgcagc agcagccgcc agcaccgtcc 200  
 tggccacggc cctctctcca gccctacga ccatggactt taccacagct 250



ccactggagg acacctcttc acgcccccaa ttctgcaagt ggccatgtga 300  
 gtgcccgcga tccccacccc gctgcccgcct gggggtcagc ctcatcacag 350  
 atggctgtga gtgctgtaag atgtgcgctc agcagcttgg ggacaactgc 400  
 acggaggctg ccatctgtga cccccaccgg ggcctctact gtgactacag 450  
 5 cggggaccgc ccgaggtacg caataggagt gtgtgcacgc agggagaagaag 500  
 tgtctggctg tgtaccagcc agaggcatcc atgaacttca cacttgccggg 550  
 ctgcatcagc acacgctcct atcaacccaa gtactgtgga gtttgcattg 600  
 acaacaggtg ctgcatcccc tacaagtcta agactatcga cgtgtccttc 650  
 cagtgtcctg atgggcttgg cttctcccg caggctctat gga 693

10 <210> 25  
 <211> 683  
 <212> DNA  
 <213> Human

<400> 25  
 15 cagaatttga actgggatcc acctgtctct aaagatgggt ttctcccat 50  
 gcttccacac tgctctctct gatcagaaac atacaaggag ctgagaacat 100  
 gtctccact ccctgggtac ttttgctggg tagaagccaa cttgctgtcc 150  
 tgtggggagg tacagccaat ttctgtgttc ctctgagttc tggggaccgc 200  
 agaccttagt gtggtgaaag tgagcgcttg gggctgggtg gagctgtaga 250  
 20 ttcatgcaga ttctgttccc cacacacaga tgctgtgggt gaggtggagg 300  
 catggcacag gaactgcata gcctacacaa gccctggag cccttgctcc 350  
 accagctgcg gcctgggggt ctccactcgg atctccaatg ttaacgcca 400  
 gtgctggcct gagcaagaga gccgcctctg caacttgccg ccatgcgatg 450  
 tggacatcca tacactcatt aaggcaggga agaagtgtct ggctgtgtac 500  
 25 cagccagagg catccatgaa cttcacactt gcgggctgca tcagcacacg 550  
 ctctatcaa cccaagtact gtggagtttg catggacaat aggtgctgca 600  
 tcccctacaa gtctaagact atcgacgtgt ccttccagtg tctgatggg 650  
 cttggcttct cccgccagg cgtatggatt aat 683

30 <210> 26  
 <211> 1202  
 <212> DNA  
 <213> Human

<400> 26  
 gtctgggccc agctcccccg agaggtgggc ggatcctctg ggctgctcgg 50

tcgatgcctg tgccactgac gtccaggcat gaggtgggtc ctgccctgga 100  
 cgctggcagc agtgacagca gcagccgcca gcaccgtcct ggccacggcc 150  
 ctctctccag cccctacgac catggacttt accccagctc cactggagga 200  
 cacctectca cgcccccaat tctgcaagtg gccatgtgag tgcccgccat 250  
 5 cccacccccg ctgcccgtg ggggtcagcc tcatcacaga tggctgtgag 300  
 tgctgtaaga tgtgcgtca gcagcttggg gacaactgca cggaggctgc 350  
 catctgtgac cccacccggg gcctctactg tgactacagc ggggaccgcc 400  
 cgaggtacgc aataggagtg tgtgcacgca gggaagaagt gtctggctgt 450  
 gtaccagcca gaggcattca tgaacttcac acttgccggc tgcatcagca 500  
 10 cacgtccta tcaacccaag tactgtggag tttgcatgga caacaggctgc 550  
 tgcattccct acaagtctaa gactatcgac gtgtccttcc agtgtcctga 600  
 tgggcttggc ttctcccgcc aggtcctatg gattaatgcc tgcttctgta 650  
 acctgagctg taggaatccc aatgacatct ttgctgactt ggaatcctac 700  
 cctgacttct cagaaattgc caactaggca ggcacaaatc ttgggtcttg 750  
 15 gggactaacc caatgccgt gaagcagtca gcccttatgg ccaataactt 800  
 ttcaccaatg agccttagtt accctgatct ggacccttgg cctccatttc 850  
 tgtctctaac cattcaaag acgcctgatg gtgctgctca ggcccatgct 900  
 atgagttttc tccttgatat cattcagcat ctactctaaa gaaaaatgcc 950  
 tgtctctagc tgttctggac tacacccaag cctgatccag cctttccaag 1000  
 20 tcactagaag tcctgctgga tcttgccctaa atcccaagaa atggaatcag 1050  
 gtagactttt aatatcacta atttcttctt tagatgccaa accacaagac 1100  
 tctttgggtc cattcagatg aatagatgga atttggaaca atagaataat 1150  
 ctattatttg gagcctgcca agaggctactg taatgggtaa ttctgacgtc 1200  
 ag 1202  
 25 <210> 27  
 <211> 1183  
 <212> DNA  
 <213> Human  
 <400> 27  
 30 cagaacagct agagacaggc atttttcttt agagtagatg ctgaatgata 50  
 tcaaggagaa aactcatagc atgggcctga gcagcaccat caggcgtcat 100  
 ttgaatggtt agagacagaa atggaggcca agggccaga tcagggtaac 150

taaggctcat tgytgaaaag ttattggcca taagggtga ctgcttcaca 200  
 ggcattgggt tagtcccca gacccaagat ttgtgcctgc ctagttggca 250  
 atttctgaga agtcagggtta ggattccaag tcagcaaaga tgtcattggg 300  
 attcctacag ctcagggttac agaagcaggc attaatccat aggacctggc 350  
 5 gggagaagcc aagcccatca ggacactgga aggacacgtc gatagtctta 400  
 gacttgtagg ggatgcagca cctattgtcc atgcaaactc cacagtactt 450  
 gggttgatag gagcgtgtgc tgatgcagcc cgcaagtgtg aagttcatgg 500  
 atgcctctgg ctggtacaca gccagacact tcttccctgc cttaatgagt 550  
 gtatggatgt ccacatcgca tggccgcaag ttgcagaggc ggctctcttg 600  
 10 ctcaggccag cactgggcgt taacattgga gatccgagtg gagaccccca 650  
 ggccgcagct ggtggagcaa gggctccagg ggcttggtga ggctatgcag 700  
 ttctgtgcc atgcctccac ctcaccaca gcatctgtgt gtggggaaca 750  
 gaatctgcat gaatctacag ctcccaccag cccccaacgc tcactttcac 800  
 cacactaagg tctgcggtcc ccagaactca gaggaacaca gaaattggct 850  
 15 gtacctccc acaggacagc aagttggctt ctaaccagca aaggtaacca 900  
 gggagtggag gacatgttct cagctccttg tatgtttctg atcaagagag 950  
 gcagtgtgga agcatgggag gaaaccatc tttagagaca ggtggatccc 1000  
 agttcaaatt ctgctctacc acctacaagc tgtgtgatct tagataacc 1050  
 accctgggcc tgtctccca ttagaacaat aacacctgcc tgtgcggctg 1100  
 20 gcaacacaat aataagggcc tagattttta ctgagtatgc atcaatcatc 1150  
 cttgctaagt gctgggaatg ggactttttt ttt 1183  
  
 <210> 28  
 <211> 546  
 <212> DNA  
 25 <213> Human  
  
 <400> 28  
 cctgatctgg acccttggcc tccaattctg tctgtaacca ttcaaatgac 50  
 gcctggtggt gctgctcagg cccatagcaa ggttcagcct ggttaagtcc 100  
 aagctgaatt agcggccgcg tcgacagtag gagtgtgtgc acatgctgtg 150  
 30 ggtgaggtgg aggcattgga caggaaactgc atagcctaca caagcccctg 200  
 gagcccttgc tccaccagct gcggcctggg ggtctccact cggatctcca 250  
 atgttaacgc ccagtgtgtg cctgagcaag agagccgcct ctgcaacttg 300

cggccatgcg atgtggacat ccatacactc attaaggcag ggaagaagtg 350  
 tctggctgtg taccagccag aggcattccat gaacttcaca cttgcgggct 400  
 gcatcagcac acgctcctat caacccaagt actgtggagt ttgcatggac 450  
 aataggtgct gcatccccta caagtctaag actatcgacg tgccttcca 500  
 5 gtgtcctgat gggcttggct tctcccgcca ggtcctatgg attaata 546  
  
 <210> 29  
 <211> 1101  
 <212> DNA  
 <213> Human  
  
 10 <400> 29  
 ggcccagctc ccccgagagg tggtcggatc ctctgggctg ctcggtcgat 50  
 gcctgtgcca ctgacgtcca ggcattgaggt ggttcctgcc ctggacgctg 100  
 gcagcagtga cagcagcagc cgccagcacc gtcctggcca cggccctctc 150  
 tccagcccct acgaccatgg actttacccc agctccactg gaggacacct 200  
 15 cctcacgccc ccaattctgc aagtggccat gtgagtgcc gccatcccca 250  
 ccccgctgcc cgctgggggt cagcctcatc acagatggct gtgagtgctg 300  
 taagatgagc gctcagcagc ttggggacaa ctgcacggag gctgccatct 350  
 gtgaccccca ccggggcctc tactgtgact acagcgggga ccgcccgaga 400  
 ggtggtcggt gtgggctgcg tcctggatgg ggtgcgctac aacaacggcc 450  
 20 agtccttcca gcctaactgc aagtacaact gcacgtgcat cgacggcgcg 500  
 gtgggctgca caccactgtg cctccgagtg cccccccgc gtctctgggtg 550  
 cccccaccg cggcgctga gcatacctgg cactgctgt gagcagtgga 600  
 tatgtgagga cgacgccaag aggccacgca agaccgcacc ccgtgacaca 650  
 ggagccttcg atgccagaag cggccgctcc ctgagagatg tgacaaccaa 700  
 25 aatcatctcc agacctttcc aaatacacc taggagacaa aattgctcgg 750  
 tggagaagca gtcctgtgag gacaggagga ggcgtggagg aaagctttgt 800  
 ccccagcagc ccaggggaag caaggcagct ctcccaccac cacctcccca 850  
 ggagggccac acgaggggtca cggggggagc agggaggcgg aagctgtctg 900  
 ccattgtgtc tggcccagtg accctgttct gaccgagcac aagcggagcc 950  
 30 cctgcctagc cgagatgctg tgggtgaggt ggaggcatgg cacaggaact 1000  
 gcatagccta cacaagcccc tggagccctt gctccaccag ctgcggcctg 1050  
 ggggtctcca ctcgatctc caatgttaac gccagtgct ggcctgagca 1100

a 1101

<210> 30  
 <211> 1335  
 <212> DNA  
 5 <213> Human

<220>  
 <221> Unknown  
 <222> 1205  
 <223> Any nucleotide

10 <220>  
 <221> Unknown  
 <222> 1318  
 <223> Any nucleotide

<400> 30

15 gtgggggtttg cagaggagac aggggagctt tgtgtacccg gagcaatgaa 50  
 caagcggcga cttctctacc cctcaggggtg gctccacggg cccagcgaca 100  
 tgcaggggct cctcttctcc actcttctgc ttgctggcct ggcacagttc 150  
 tgctgcaggg tacagggcac tggaccatta gatacaacac ctgaaggaag 200  
 gcctggagaa gtgtcagatg cacctcagcg taaacagttt tgtcactggc 250  
 20 ctgcaaagt cctcagcag aagccccgtt gccctcctgg agtgagcctg 300  
 gtgagagatg gctgtggatg ctgtaaaatc tgtgccaagc aaccagggga 350  
 aatctgcaat gaagctgacc tctgtgaccc acacaaaggg ctgtattgtg 400  
 actactcagt agacaggcct aggtacgaga ctggagtgtg tgcatacctt 450  
 gtagctgttg ggtgcgagtt caaccaggta cattatcata atggccaagt 500  
 25 gtttcagccc aacccttgt tcagctgcct ctgtgtgagt ggggccattg 550  
 gatgcacacc tctgttcata ccaaagctgg ctggcagtca ctgctctgga 600  
 gctaaagggtg gaaagaagtc tgatcagtca aactgtagcc tggaaccatt 650  
 actacagcag ctttcaacaa gctacaaaac aatgccagct tatagagatc 700  
 tcccacttat ttggaaaaaa aaatgtcttg tgcaagcaac aaaatggact 750  
 30 ccctgctcca gaacatgtgg gatgggaata tctaacaggg tgaccaatga 800  
 aaacagcaac tgtgaaatga gaaaagagaa aagactgtgt tacattcagc 850  
 cttgcgacag caatatatta aagacaataa agattcccaa aggaaaaaca 900  
 tgccaaccta ctttccaact ctccaaagct gaaaaatttg tcttttctgg 950  
 atgctcaagt actcagagtt acaaaccac tttttgtgga atatgcttgg 1000  
 35 ataagagatg ctgtatccct aataagtcta aaatgattac tattcaattt 1050



gattgccc aa atgagggggtc atttaa atgg aagatgctgt ggattacatc 1100  
 ttgtgtgtgt cagagaaact gcagagaacc tggagatata ttttctgagc 1150  
 tcaagattct gtaaaaccaa gcaaatgggg gaaaagttag tcaatcctgt 1200  
 catanaataa aaaaattagt gagtataaaa tgggtggcaaa tctactttgt 1250  
 5 ttaaaacagt atgaatgcct attctcagat cactacattt aaggcattag 1300  
 aaacttttaa aaagttanct taaaaatata cataa 1335  
  
 <210> 31  
 <211> 1335  
 <212> DNA  
 10 <213> Human  
  
 <220>  
 <221> Unknown  
 <222> 131  
 <223> Any nucleotide  
  
 15 <220>  
 <221> Unknown  
 <222> 18  
 <223> Any nucleotide  
  
 <400> 31  
 20 ttatgtatat ttttaagnta acttttttaa agtttcta at gccttaa atg 50  
 tagtgatctg agaataggca ttcatactgt tttaa acaaa gtagatttgc 100  
 caccatttta tactcactaa tttttttatt ntatgacagg attgactaac 150  
 ttttccccca ttgcttggt ttacagaat cttgagctca gaaaatatat 200  
 ctccaggttc tctgcagttt ctctgacaca cacaagatgt aatccacagc 250  
 25 atcttccatt taaatgaccc ctcat tggg caatcaaatt gaatagtaat 300  
 catttttagac ttattaggga tacagcatct cttatccaag catattccac 350  
 aaaaagtggg ttgtaactc tgagtacttg agcatccaga aaagacaaat 400  
 ttttcagctt tggagagttg gaaagtaggt tggcatgttt ttcctttggg 450  
 aatctttatt gtctttaata tattgctgtc gcaaggctga atgtaacaca 500  
 30 gtcttttctc ttttctcatt tcacagttgc tgttttcatt ggtcaccttg 550  
 ttagatatte ccatcccaca tgttctggag caggaggtcc attttgttgc 600  
 ttgcacaaga catttttttt tccaaataag tgggagatct ctataagctg 650  
 gcattgtttt gtagcttggt gaaagctgct gtagtaatgg ttccaggcta 700  
 cagtttgact gatcagactt ctttccacct ttagctccag agcagtgact 750  
 35 gccagccagc ttggtatga acagaggtgt gcatccaatg gcccactca 800

cacagaggca gctgaacaag ggggtgggct gaaacacttg gccattatga 850  
 taatgtacct ggttgaactc gcacccaaca gctacaaggt atgcacacac 900  
 tccagtctcg tacctaggcc tgtctactga gtagtcacaa tacagccctt 950  
 tgtgtgggtc acagagggtca gcttcattgc agatttcccc tgggttgcttg 1000  
 5 gcacagattt tacagcatcc acagccatct ctcaccaggc tcaactccagg 1050  
 agggcaacgg ggcttctgct gagggcattt gcagggccag tgacaaaact 1100  
 gtttacgctg aggtgcatct gacacttctc caggccttcc ttcagggtgtt 1150  
 gtatctaata gtcacagtgc ctgtaccctg cagcagaact gtgccaggcc 1200  
 agcaagcaga agagtggaga agaggagccc ctgcatgtcg ctgggaccgt 1250  
 10 ggagccaccc tgaggggtag agaagtcgcc gcttggtcat tgctccgggt 1300  
 acacaaagct cccctgtctc ctctgcaaac cccac 1335

&lt;210&gt; 32

&lt;211&gt; 339

&lt;212&gt; PRT

15 &lt;213&gt; Human

&lt;400&gt; 32

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Gln | Phe | Cys | Cys | Arg | Val | Gln | Gly | Thr | Gly | Pro | Leu | Asp | Thr | Thr |
|    | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |
| 20 | Pro | Glu | Gly | Arg | Pro | Gly | Glu | Val | Ser | Asp | Ala | Pro | Gln | Arg | Lys |
|    |     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |
|    | Gln | Phe | Cys | His | Trp | Pro | Cys | Lys | Cys | Pro | Gln | Gln | Lys | Pro | Arg |
|    |     |     |     | 35  |     |     |     |     |     | 40  |     |     |     |     | 45  |
|    | Cys | Pro | Pro | Gly | Val | Ser | Leu | Val | Arg | Asp | Gly | Cys | Gly | Cys | Cys |
|    |     |     |     | 50  |     |     |     |     |     | 55  |     |     |     |     | 60  |
| 25 | Lys | Ile | Cys | Ala | Lys | Gln | Pro | Gly | Glu | Ile | Cys | Asn | Glu | Ala | Asp |
|    |     |     |     | 65  |     |     |     |     |     | 70  |     |     |     |     | 75  |
|    | Leu | Cys | Asp | Pro | His | Lys | Gly | Leu | Tyr | Cys | Asp | Tyr | Ser | Val | Asp |
|    |     |     |     | 80  |     |     |     |     |     | 85  |     |     |     |     | 90  |
| 30 | Arg | Pro | Arg | Tyr | Glu | Thr | Gly | Val | Cys | Ala | Tyr | Leu | Val | Ala | Val |
|    |     |     |     | 95  |     |     |     |     |     | 100 |     |     |     |     | 105 |
|    | Gly | Cys | Glu | Phe | Asn | Gln | Val | His | Tyr | His | Asn | Gly | Gln | Val | Phe |
|    |     |     |     | 110 |     |     |     |     |     | 115 |     |     |     |     | 120 |
|    | Gln | Pro | Asn | Pro | Leu | Phe | Ser | Cys | Leu | Cys | Val | Ser | Gly | Ala | Ile |
|    |     |     |     | 125 |     |     |     |     |     | 130 |     |     |     |     | 135 |
| 35 | Gly | Cys | Thr | Pro | Leu | Phe | Ile | Pro | Lys | Leu | Ala | Gly | Ser | His | Cys |
|    |     |     |     | 140 |     |     |     |     |     | 145 |     |     |     |     | 150 |
|    | Ser | Gly | Ala | Lys | Gly | Gly | Lys | Lys | Ser | Asp | Gln | Ser | Asn | Cys | Ser |

|    |                 |                     |                         |     |  |     |
|----|-----------------|---------------------|-------------------------|-----|--|-----|
|    |                 | 155                 |                         | 160 |  | 165 |
|    | Leu Glu Pro Leu | Leu Gln Gln Leu Ser | Thr Ser Tyr Lys Thr Met |     |  |     |
|    |                 | 170                 |                         | 175 |  | 180 |
| 5  | Pro Ala Tyr Arg | Asp Leu Pro Leu Ile | Trp Lys Lys Lys Cys Leu |     |  |     |
|    |                 | 185                 |                         | 190 |  | 195 |
|    | Val Gln Ala Thr | Lys Trp Thr Pro Cys | Ser Arg Thr Cys Gly Met |     |  |     |
|    |                 | 200                 |                         | 205 |  | 210 |
|    | Gly Ile Ser Asn | Arg Val Thr Asn Glu | Asn Ser Asn Cys Glu Met |     |  |     |
|    |                 | 215                 |                         | 220 |  | 225 |
| 10 | Arg Lys Glu Lys | Arg Leu Cys Tyr Ile | Gln Pro Cys Asp Ser Asn |     |  |     |
|    |                 | 230                 |                         | 235 |  | 240 |
|    | Ile Leu Lys Thr | Ile Lys Ile Pro Lys | Gly Lys Thr Cys Gln Pro |     |  |     |
|    |                 | 245                 |                         | 250 |  | 255 |
| 15 | Thr Phe Gln Leu | Ser Lys Ala Glu Lys | Phe Val Phe Ser Gly Cys |     |  |     |
|    |                 | 260                 |                         | 265 |  | 270 |
|    | Ser Ser Thr Gln | Ser Tyr Lys Pro Thr | Phe Cys Gly Ile Cys Leu |     |  |     |
|    |                 | 275                 |                         | 280 |  | 285 |
|    | Asp Lys Arg Cys | Cys Ile Pro Asn Lys | Ser Lys Met Ile Thr Ile |     |  |     |
|    |                 | 290                 |                         | 295 |  | 300 |
| 20 | Gln Phe Asp Cys | Pro Asn Glu Gly Ser | Phe Lys Trp Lys Met Leu |     |  |     |
|    |                 | 305                 |                         | 310 |  | 315 |
|    | Trp Ile Thr Ser | Cys Val Cys Gln Arg | Asn Cys Arg Glu Pro Gly |     |  |     |
|    |                 | 320                 |                         | 325 |  | 330 |
| 25 | Asp Ile Phe Ser | Glu Leu Lys Ile Leu |                         |     |  |     |
|    |                 | 335                 |                         | 339 |  |     |
|    | <210>           | 33                  |                         |     |  |     |
|    | <211>           | 372                 |                         |     |  |     |
|    | <212>           | PRT                 |                         |     |  |     |
|    | <213>           | Human               |                         |     |  |     |
| 30 | <400>           | 33                  |                         |     |  |     |
|    | Met Asn Lys Arg | Arg Leu Leu Tyr Pro | Ser Gly Trp Leu His Gly |     |  |     |
|    | 1               | 5                   | 10                      |     |  | 15  |
|    | Pro Ser Asp Met | Gln Gly Leu Leu Phe | Ser Thr Leu Leu Leu Ala |     |  |     |
|    |                 | 20                  | 25                      |     |  | 30  |
| 35 | Gly Leu Ala Gln | Phe Cys Cys Arg Val | Gln Gly Thr Gly Pro Leu |     |  |     |
|    |                 | 35                  | 40                      |     |  | 45  |
|    | Asp Thr Thr Pro | Glu Gly Arg Pro Gly | Glu Val Ser Asp Ala Pro |     |  |     |
|    |                 | 50                  | 55                      |     |  | 60  |
| 40 | Gln Arg Lys Gln | Phe Cys His Trp Pro | Cys Lys Cys Pro Gln Gln |     |  |     |
|    |                 | 65                  | 70                      |     |  | 75  |

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Lys | Pro | Arg | Cys | Pro | Pro | Gly | Val | Ser | Leu | Val | Arg | Asp | Gly | Cys |  |
|    |     |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Gly | Cys | Cys | Lys | Ile | Cys | Ala | Lys | Gln | Pro | Gly | Glu | Ile | Cys | Asn |  |
|    |     |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
| 5  | Glu | Ala | Asp | Leu | Cys | Asp | Pro | His | Lys | Gly | Leu | Tyr | Cys | Asp | Tyr |  |
|    |     |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
|    | Ser | Val | Asp | Arg | Pro | Arg | Tyr | Glu | Thr | Gly | Val | Cys | Ala | Tyr | Leu |  |
|    |     |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Val | Ala | Val | Gly | Cys | Glu | Phe | Asn | Gln | Val | His | Tyr | His | Asn | Gly |  |
| 10 |     |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Gln | Val | Phe | Gln | Pro | Asn | Pro | Leu | Phe | Ser | Cys | Leu | Cys | Val | Ser |  |
|    |     |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Gly | Ala | Ile | Gly | Cys | Thr | Pro | Leu | Phe | Ile | Pro | Lys | Leu | Ala | Gly |  |
|    |     |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
| 15 | Ser | His | Cys | Ser | Gly | Ala | Lys | Gly | Gly | Lys | Lys | Ser | Asp | Gln | Ser |  |
|    |     |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Asn | Cys | Ser | Leu | Glu | Pro | Leu | Leu | Gln | Gln | Leu | Ser | Thr | Ser | Tyr |  |
|    |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Lys | Thr | Met | Pro | Ala | Tyr | Arg | Asp | Leu | Pro | Leu | Ile | Trp | Lys | Lys |  |
| 20 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
|    | Lys | Cys | Leu | Val | Gln | Ala | Thr | Lys | Trp | Thr | Pro | Cys | Ser | Arg | Thr |  |
|    |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Cys | Gly | Met | Gly | Ile | Ser | Asn | Arg | Val | Thr | Asn | Glu | Asn | Ser | Asn |  |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |  |
| 25 | Cys | Glu | Met | Arg | Lys | Glu | Lys | Arg | Leu | Cys | Tyr | Ile | Gln | Pro | Cys |  |
|    |     |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |  |
|    | Asp | Ser | Asn | Ile | Leu | Lys | Thr | Ile | Lys | Ile | Pro | Lys | Gly | Lys | Thr |  |
|    |     |     |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |  |
|    | Cys | Gln | Pro | Thr | Phe | Gln | Leu | Ser | Lys | Ala | Glu | Lys | Phe | Val | Phe |  |
| 30 |     |     |     |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |  |
|    | Ser | Gly | Cys | Ser | Ser | Thr | Gln | Ser | Tyr | Lys | Pro | Thr | Phe | Cys | Gly |  |
|    |     |     |     |     | 305 |     |     |     |     | 310 |     |     |     |     | 315 |  |
|    | Ile | Cys | Leu | Asp | Lys | Arg | Cys | Cys | Ile | Pro | Asn | Lys | Ser | Lys | Met |  |
|    |     |     |     |     | 320 |     |     |     |     | 325 |     |     |     |     | 330 |  |
| 35 | Ile | Thr | Ile | Gln | Phe | Asp | Cys | Pro | Asn | Glu | Gly | Ser | Phe | Lys | Trp |  |
|    |     |     |     |     | 335 |     |     |     |     | 340 |     |     |     |     | 345 |  |
|    | Lys | Met | Leu | Trp | Ile | Thr | Ser | Cys | Val | Cys | Gln | Arg | Asn | Cys | Arg |  |
|    |     |     |     |     | 350 |     |     |     |     | 355 |     |     |     |     | 360 |  |
|    | Glu | Pro | Gly | Asp | Ile | Phe | Ser | Glu | Leu | Lys | Ile | Leu |     |     |     |  |
| 40 |     |     |     |     | 365 |     |     |     |     | 370 |     | 372 |     |     |     |  |

<210> 34  
 <211> 1212  
 <212> DNA  
 <213> Human

5 <400> 34  
 cacggtccca gcgacatgca ggggctcctc ttctccactc ttctgcttgc 50  
 tggcctggca cagttctgct gcagggtaca gggcactgga ccattagata 100  
 caacacctga aggaaggcct ggagaagtgt cagatgcacc tcagcgtaaa 150  
 cagttttgtc actggccctg caaatgccct cagcagaagc cccgttgccc 200  
 10 tcctggagtg agcctgggtga gagatggctg tggatgctgt aaaatctgtg 250  
 ccaagcaacc aggggaaatc tgcaatgaag ctgacctctg tgacccacac 300  
 aaagggtgtg attgtgacta ctcagtagac aggcctaggt acgagactgg 350  
 agtgtgtgca taccttgtag ctgttgggtg cgagttcaac caggtacatt 400  
 atcataatgg ccaagtgttt cagcccaacc ccttgttcag ctgcctctgt 450  
 15 gtgagtgggg ccattggatg cacacctctg ttcataccaa agctggctgg 500  
 cagtcaactgc tctggagcta aagggtgaaa gaagtctgat cagtcaaact 550  
 gtagcctgga accattacta cagcagcttc caacaagcta caaaacaatg 600  
 ccagcttata gaaatctccc acttatttgg aaaaaaaaaat gtcttgtgca 650  
 agcaacaaaa tggactccct gctccagaac atgtgggatg ggaatatcta 700  
 20 acagggtgac caatgaaaac agcaactgtg aaatgagaaa agagaaaaga 750  
 ctgtgttaca ttcagccttg cgacagcaat atattaaaga caataaagat 800  
 tcccaaagga aaaacatgcc aacctacttt ccaactctcc aaagctgaaa 850  
 aatttgtctt ttctggatgc tcaagtactc agagttacaa acccactttt 900  
 tgtggaatat gcttggataa gagatgctgt atccctaata agtctaaaat 950  
 25 gattactatt caatttgatt gcccaaatga ggggtcattt aaatggaaga 1000  
 tgctgtggat tacatcttgt gtgtgtcaga gaaactgcag agaacctgga 1050  
 gatataat ttt ctgagctcaa gattctgtaa aaccaagcaa atgggggaaa 1100  
 agttagtcaa tcctgtcata taataaaaaa attagttagt aaaaaaaaaa 1150  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agaaaaaaaa 1200  
 30 aaaaaaaaaa aa 1212

<210> 35  
 <211> 1212  
 <212> DNA



<213> Human

<400> 35

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1212

<210> 36

<211> 339

30 <212> PRT

<213> Human

<400> 36

|    |   |  |
|----|---|--|
|    | Gln Phe Cys Cys Arg Val Gln Gly Thr Gly Pro Leu Asp Thr Thr |  |
|    | 1 5 10 15   |  |
|    | Pro Glu Gly Arg Pro Gly Glu Val Ser Asp Ala Pro Gln Arg Lys |  |
|    | 20 25 30  |  |
| 5  | Gln Phe Cys His Trp Pro Cys Lys Cys Pro Gln Gln Lys Pro Arg |  |
|    | 35 40 45  |  |
|    | Cys Pro Pro Gly Val Ser Leu Val Arg Asp Gly Cys Gly Cys Cys |  |
|    | 50 55 60  |  |
| 10 | Lys Ile Cys Ala Lys Gln Pro Gly Glu Ile Cys Asn Glu Ala Asp |  |
|    | 65 70 75  |  |
|    | Leu Cys Asp Pro His Lys Gly Leu Tyr Cys Asp Tyr Ser Val Asp |  |
|    | 80 85 90  |  |
|    | Arg Pro Arg Tyr Glu Thr Gly Val Cys Ala Tyr Leu Val Ala Val |  |
|    | 95 100 105  |  |
| 15 | Gly Cys Glu Phe Asn Gln Val His Tyr His Asn Gly Gln Val Phe |  |
|    | 110 115 120   |  |
|    | Gln Pro Asn Pro Leu Phe Ser Cys Leu Cys Val Ser Gly Ala Ile |  |
|    | 125 130 135   |  |
| 20 | Gly Cys Thr Pro Leu Phe Ile Pro Lys Leu Ala Gly Ser His Cys |  |
|    | 140 145 150   |  |
|    | Ser Gly Ala Lys Gly Gly Lys Lys Ser Asp Gln Ser Asn Cys Ser |  |
|    | 155 160 165   |  |
|    | Leu Glu Pro Leu Leu Gln Gln Leu Ser Thr Ser Tyr Lys Thr Met |  |
|    | 170 175 180   |  |
| 25 | Pro Ala Tyr Arg Asn Leu Pro Leu Ile Trp Lys Lys Lys Cys Leu |  |
|    | 185 190 195   |  |
|    | Val Gln Ala Thr Lys Trp Thr Pro Cys Ser Arg Thr Cys Gly Met |  |
|    | 200 205 210   |  |
| 30 | Gly Ile Ser Asn Arg Val Thr Asn Glu Asn Ser Asn Cys Glu Met |  |
|    | 215 220 225   |  |
|    | Arg Lys Glu Lys Arg Leu Cys Tyr Ile Gln Pro Cys Asp Ser Asn |  |
|    | 230 235 240   |  |
|    | Ile Leu Lys Thr Ile Lys Ile Pro Lys Gly Lys Thr Cys Gln Pro |  |
|    | 245 250 255   |  |
| 35 | Thr Phe Gln Leu Ser Lys Ala Glu Lys Phe Val Phe Ser Gly Cys |  |
|    | 260 265 270   |  |
|    | Ser Ser Thr Gln Ser Tyr Lys Pro Thr Phe Cys Gly Ile Cys Leu |  |
|    | 275 280 285   |  |
| 40 | Asp Lys Arg Cys Cys Ile Pro Asn Lys Ser Lys Met Ile Thr Ile |  |
|    | 290 295 300   |  |

Gln Phe Asp Cys Pro Asn Glu Gly Ser Phe Lys Trp Lys Met Leu  
 305 310 315  
 Trp Ile Thr Ser Cys Val Cys Gln Arg Asn Cys Arg Glu Pro Gly  
 320 325 330  
 5 Asp Ile Phe Ser Glu Leu Lys Ile Leu  
 335 339  
 <210> 37  
 <211> 354  
 <212> PRT  
 10 <213> Human  
 <400> 37  
 Met Gln Gly Leu Leu Phe Ser Thr Leu Leu Leu Ala Gly Leu Ala  
 1 5 10 15  
 15 Gln Phe Cys Cys Arg Val Gln Gly Thr Gly Pro Leu Asp Thr Thr  
 20 25 30  
 Pro Glu Gly Arg Pro Gly Glu Val Ser Asp Ala Pro Gln Arg Lys  
 35 40 45  
 Gln Phe Cys His Trp Pro Cys Lys Cys Pro Gln Gln Lys Pro Arg  
 50 55 60  
 20 Cys Pro Pro Gly Val Ser Leu Val Arg Asp Gly Cys Gly Cys Cys  
 65 70 75  
 Lys Ile Cys Ala Lys Gln Pro Gly Glu Ile Cys Asn Glu Ala Asp  
 80 85 90  
 25 Leu Cys Asp Pro His Lys Gly Leu Tyr Cys Asp Tyr Ser Val Asp  
 95 100 105  
 Arg Pro Arg Tyr Glu Thr Gly Val Cys Ala Tyr Leu Val Ala Val  
 110 115 120  
 Gly Cys Glu Phe Asn Gln Val His Tyr His Asn Gly Gln Val Phe  
 125 130 135  
 30 Gln Pro Asn Pro Leu Phe Ser Cys Leu Cys Val Ser Gly Ala Ile  
 140 145 150  
 Gly Cys Thr Pro Leu Phe Ile Pro Lys Leu Ala Gly Ser His Cys  
 155 160 165  
 35 Ser Gly Ala Lys Gly Gly Lys Lys Ser Asp Gln Ser Asn Cys Ser  
 170 175 180  
 Leu Glu Pro Leu Leu Gln Gln Leu Ser Thr Ser Tyr Lys Thr Met  
 185 190 195  
 Pro Ala Tyr Arg Asn Leu Pro Leu Ile Trp Lys Lys Lys Cys Leu  
 200 205 210  
 40 Val Gln Ala Thr Lys Trp Thr Pro Cys Ser Arg Thr Cys Gly Met  
 215 220 225

Gly Ile Ser Asn Arg Val Thr Asn Glu Asn Ser Asn Cys Glu Met  
 230 235 240  
 Arg Lys Glu Lys Arg Leu Cys Tyr Ile Gln Pro Cys Asp Ser Asn  
 245 250 255  
 5 Ile Leu Lys Thr Ile Lys Ile Pro Lys Gly Lys Thr Cys Gln Pro  
 260 265 270  
 Thr Phe Gln Leu Ser Lys Ala Glu Lys Phe Val Phe Ser Gly Cys  
 275 280 285  
 10 Ser Ser Thr Gln Ser Tyr Lys Pro Thr Phe Cys Gly Ile Cys Leu  
 290 295 300  
 Asp Lys Arg Cys Cys Ile Pro Asn Lys Ser Lys Met Ile Thr Ile  
 305 310 315  
 Gln Phe Asp Cys Pro Asn Glu Gly Ser Phe Lys Trp Lys Met Leu  
 320 325 330  
 15 Trp Ile Thr Ser Cys Val Cys Gln Arg Asn Cys Arg Glu Pro Gly  
 335 340 345  
 Asp Ile Phe Ser Glu Leu Lys Ile Leu  
 350 354

20 <210> 38  
 <211> 738  
 <212> DNA  
 <213> Human

<400> 38  
 ccgaagaccc acctcctggc cttctccctc ctctgcctcc tctcaaaggt 50  
 25 gcgtacccag ctgtgcccga caccatgtac ctgcccctgg ccacctcccc 100  
 gatgcccgtt gggagtaccc ctggtgctgg atggctgtgg ctgctgccgg 150  
 gtatgtgcac ggcggctggg ggagccctgc gaccaactcc acgtctgcga 200  
 cgccagccag ggcctggtct gccagcccgg ggcaggaccc ggtggccggg 250  
 gggccctgtg cctcttggca gaggacgaca gcagctgtga ggtgaacggc 300  
 30 cgctgtatc gggaagggga gaccttccag cccactgca gcatccgctg 350  
 ccgctgcgag gacggcggct tcacctgcgt gccgctgtgc agcgaggatg 400  
 tgcggctgcc cagctgggac tgccccacc ccaggagggt cgaggtcctg 450  
 ggcaagtgtt gccctgagtg ggtgtgcggc caaggagggg gactggggac 500  
 ccagcccctt ccagcccaag gacccagtt ttctggcctt gtctcttccc 550  
 35 tgccccctgg tgccccctgc ccagaatgga gcacggcctg gggaccctgc 600  
 tcgaccacct gtgggctggg catggccacc cgggtgtcca accagaaccg 650

cttctgccga ctggagaccc agcgccgcct gtgcctgtcc aggccctycc 700

caccctccag gggtcgcagt ccacaaaaca gtgccttc 738

<210> 39

<211> 841

5 <212> DNA

<213> Artificial

<220>

<221> Artificial

<222> 1-841

10 <223> Sequence is synthesized

<400> 39

ctgcagggga catgagaggg acaccgaaga cccacctcct ggccttctcc 50

ctcctctgcc tctctcaaa ggtgcgtacc cagctgtgcc cgacaccatg 100

tacctgcccc tggccacctc cccgatgccc gctgggagta cccctgggtg 150

15 tggatggctg tggctgctgc cgggtatgtg cacggcggct gggggagccc 200

tgcgaccaac tccacgtctg cgacgccagc cagggcctgg tctgccagcc 250

cggggcagga cccggtggcc ggggggcccct gtgcctcttg gcagaggacg 300

acagcagctg tgaggtgaac ggccgcctgt atcggaagg ggagaccttc 350

cagccccact gcagcatccg ctgccgctgc gaggacggcg gcttcacctg 400

20 cgtgccgctg tgcagcgagg atgtgcggct gccagctgg gactgcccc 450

accccaggag ggtcgaggtc ctgggcaagt gctgccctga gtgggtgtgc 500

ggccaaggag ggggactggg gaccagccct tccagcccaa ggaccccagt 550

tttctggcct tgtctcttcc ctgccccctg gtgtcccctg cccagaatgg 600

agcacggcct ggggacctg ctcgaccacc tgtgggctgg gcatggccac 650

25 ccgggtgtcc aaccagaacc gcttctgccg actggagacc cagcgccgcc 700

tgtgcctgtc caggccctgc ccacctcca ggggtcgcag tccacaaaac 750

agtgccttct agagccgggc tgggaatggg gacacggtgt ccaccatccc 800

cagctgggtg ccctgtgcct gggccctggg ctgatggaag a 841

<210> 40

30 <211> 14

<212> DNA

<213> Artificial sequence

<220>

<221> Artificial

35 <222> 1-14

<223> Sequence is synthesized



<400> 40  
ttttgtacaa gctt 14

<210> 41  
<211> 44  
5 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-44  
10 <223> Sequence is synthesized

<400> 41  
ctaatacgac tcactatagg gctcgagcgg ccgcccgggc aggt 44

<210> 42  
<211> 43  
15 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-43  
20 <223> Sequence is synthesized

<400> 42  
tgtagcgtga agacgacaga aagggcgtgg tgcggagggc ggt 43

<210> 43  
<211> 10  
25 <212> DNA  
<213> Artificial Sequence

<220>  
<221> Artificial  
<222> 1-10  
30 <223> Sequence is synthesized

<400> 43  
acctgcccgg 10

<210> 44  
<211> 11  
35 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-11  
40 <223> Sequence is synthesized

<400> 44  
accgccctcc g 11

<210> 45  
<211> 22  
45 <212> DNA  
<213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

5 <400> 45  
ctaatacgac tcactatagg gc 22

<210> 46  
<211> 21  
<212> DNA  
10 <213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-21  
<223> Sequence is synthesized

15 <400> 46  
tgtagcgtga agacgacaga a 21

<210> 47  
<211> 22  
<212> DNA  
20 <213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

25 <400> 47  
tcgagcggcc gcccgggcag gt 22

<210> 48  
<211> 22  
<212> DNA  
30 <213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

35 <400> 48  
agggcgtggt gcggagggcg gt 22

<210> 49  
<211> 20  
<212> DNA  
40 <213> Artificial sequence

<220>  
<221> Artificial  
<222> 1-20  
<223> Sequence is synthesized

45 <400> 49  
accacagtcc atgccatcac 20

<210> 50  
 <211> 20  
 <212> DNA  
 <213> Artificial sequence

5 <220>  
 <221> Artificial  
 <222> 1-20  
 <223> Sequence is synthesized

10 <400> 50  
 tccaccaccc tggtgctgta 20

<210> 51  
 <211> 163  
 <212> DNA  
 <213> Artificial sequence

15 <220>  
 <221> Artificial  
 <222> 1-163  
 <223> Sequence is synthesized

20 <400> 51  
 tgtaatacga ctactatag ggcgaattgg gcccgacgtc gcatgctccc 50  
 ggccgccatg gccgcgggat tactactagt gcggccgcct gcaggtegcac 100  
 catatgggag agctcccaac gcgttggatg catagctga gtattctata 150  
 gtgtcaccta aat 163

25 <210> 52  
 <211> 163  
 <212> DNA  
 <213> Artificial sequence

30 <220>  
 <221> Artificial  
 <222> 1-163  
 <223> Sequence is synthesized

35 <400> 52  
 atttaggtga cactatagaa tactcaagct atgcatccaa cgcgttggga 50  
 gctctcccat atggtcgacc tgcaggcggc cgcactagtg attatcccgc 100  
 ggccatggcg gccgggagca tgcgacgtcg ggcccaattc gccctatagt 150  
 gagtcgtatt aca 163

40 <210> 53  
 <211> 10325  
 <212> DNA  
 <213> Artificial

<220>  
 <221> Artificial  
 <222> 1-10325

<223> Sequence is synthesized

<400> 53

ttcgagctcg cccgacattg attattgact agagtcgac accggttatt 50  
aatagtaatc aattacgggg tcatagttca tagcccatat atggagttcc 100  
5 gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac 150  
ccccgcccac tgacgtcaat aatgacgtat gttcccatag taacgccaat 200  
agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc 250  
acttggcagt acatcaagtg tatcatatgc caagtacgcc cctattgac 300  
gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt 350  
10 atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta 400  
ccatgggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt 450  
gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt 500  
gttttggcac caaatcaac gggactttcc aaaatgtcgt aacaactccg 550  
ccccattgac gcaaatgggc ggtaggcgtg tacgggtggga ggtctatata 600  
15 agcagagctc gtttagtgaa ccgtcagatr gcctggagac gccatccacg 650  
ctgttttgac ctgggcccgc ccgaggccgc ctcgccctct gagctattcc 700  
agaagtagtg aggaggcttt ttggaggcc taggcttttg caaaaagcta 750  
gcttatccgg ccggaacgg tgcattggaa cgcggattcc ccgtgccaaag 800  
agtgacgtaa gtaccgccta tagagcgact agtccaccat gaccgagtac 850  
20 aagcccacgg tgcgcctcgc caccgcgcac gacgtcccgc gggcgtacg 900  
caccctcgcc gccgcgttcg ccgactacc cgcacgcgc cacaccgtag 950  
accgagaccg ccacatcgag cgggtcaccg agctgcaaga actcttcctc 1000  
acgcgcgtcg ggctcgacat cggcaagggt tgggtcgcgg acgacggcgc 1050  
cgcggtggcg gtctggacca cgccggagag cgtcgaagcg ggggcggtgt 1100  
25 tcgccgagat cgccccgcgc atggccgagt tgagcggttc ccggctggcc 1150  
gcgcagcaac agatggaagg cctcctggcg ccgcaccggc ccaaggagcc 1200  
cgcgtggttc ctggccaccg tcggcgtctc gcccgaccac cagggcaagg 1250  
gtctgggcag cgcgcgtcgt ctcgccggag tggaggcggc cgagcgcgcc 1300  
ggggtgcccg ccttcctgga gacctcgcg ccccgcaacc tccccttcta 1350  
30 cgagcggctc ggcttcaccg tcaccgccga cgtcagagtgc ccgaaggacc 1400

gcgcgacctg gtgcatgacc cgcaagccccg gtgccaacat ggttcgacca 1450  
ttgaactgca tcgtcgccgt gtcccaaaat atggggattg gcaagaacgg 1500  
agacctaccc tgccctccgc tcaggaacgc gttcaagtac ttccaaagaa 1550  
tgaccacaac ctcttcagtg gaaggtaaac agaactctgg gattatgggt 1600  
5 aggaaaacct ggttctccat tcctgagaag aatcgacctt taaaggacag 1650  
aattaatata gttctcagta gagaactcaa agaaccacca cgaggagctc 1700  
atcttcttgc caaaagtttg gatgatgcct taagacttat tgaacaaccg 1750  
gaattggcaa gtaaagtaga catggtttgg atagtcggag gcagttctgt 1800  
ttaccaggaa gccatgaatc aaccaggcca ccttagactc tttgtgacaa 1850  
10 ggatcatgca ggaatttgaa agtgacacgt ttttcccaga aattgatttg 1900  
gggaaatata aacctctccc agaataccca ggcgtcctct ctgaggcca 1950  
ggaggaaaaa ggcatacagt ataagtttga agtctacgag aagaaagact 2000  
aacgttaact gctcccctcc taaagctatg catttttata agaccatggg 2050  
acttttgctg gctttagatc cccttggtt cgtagaacg cagctacaat 2100  
15 taatacataa ccttatgtat catacacata cgatttaggt gacactatag 2150  
ataacatcca ctttgccctt ctctccacag gtgtccactc ccaggcca 2200  
ctgcacctcg gttctatcga ttgaattccc cggggatcct ctagagtcga 2250  
cctgcagaag cttcgatggc cgccatggcc caacttggtt attgcagctt 2300  
ataatgggta caaataaagc aatagcatca caaatttcac aaataaagca 2350  
20 tttttttcac tgcattctag ttgtggtttg tccaaactca tcaatgtatc 2400  
ttatcatgtc tggatcgatc gggaattaat tcggcgcagc accatggcct 2450  
gaaataacct ctgaaagagg aacttggtta ggtaccgact agtcgcgtta 2500  
cataacttac ggtaaattggc ccgcctggct gaccgcccac cgacccccgc 2550  
ccattgacgt caataatgac gtatgttccc atagtaacgc caataggac 2600  
25 tttccattga cgtcaatggg tggagtattt acggtaaact gccacttg 2650  
cagtacatca agtgtatcat atgccaagta cgcctctat tgacgtcaat 2700  
gacggtaaatt ggccgcctg gcattatgcc cagtacatga ccttatggga 2750  
cttctctact tggcagtaca tctacgtatt agtcacgct attaccatgg 2800  
tgatgcggtt ttggcagtac atcaatgggc gtggatagcg gtttgactca 2850  
30 cggggatttc caagtctcca cccattgac gtcaatggga gtttgtttg 2900



actagtagca agytcgccac gcacaagatc aatattaaca atcagtcacc 2950  
 tctcttttagc aataaaaagg tgaaaaatta catttttaaaa atgacaccat 3000  
 agacgatgta tgaaaataat ctacttggaa ataaatctag gcaaagaagt 3050  
 gcaagactgt taccagaaaa acttacaat tgtaaagag aggttagtga 3100  
 5 agatttaaat gaatgaagat ctataataac ttataaattg tgagagaaat 3150  
 taatgaatgt ctaagttaat gcagaaacgg agagacatac tatattcatg 3200  
 aactaaaaga cttaatattg tgaaggtata ctttcttttc acataaattt 3250  
 gtagtcaata tgttcacccc aaaaaagctg tttgttaact tgtcaacctc 3300  
 atttcaaaat gtatatagaa agcccaaaga caataacaaa aatattcttg 3350  
 10 tagaacaaaa tgggaaagaa tgttccacta aatatcaaga tttagagcaa 3400  
 agcatgagat gtgtggggat agacagtgag gctgataaaa tagagtagag 3450  
 ctcagaaaca gaccattga tatatgtaag tgacctatga aaaaaatatg 3500  
 gcattttaca atgggaaaat gatgatcttt ttctttttta gaaaaacagg 3550  
 gaaatatatt tatatgtaaa aaataaaaagg gaacccatat gtcataccat 3600  
 15 acacacaaaa aaattccagt gaattataag tctaatgga gaaggcaaaa 3650  
 ctttaaattc tttagaaaat aatatagaag catgccatca tgacttcagt 3700  
 gtagagaaaa atttcttatg actcaaagtc ctaaccacaa agaaaagatt 3750  
 gttaattaga ttgcatgaat attaagactt attttttaaaa ttaaaaaacc 3800  
 attaagaaaa gtcaggccat agaatgacag aaaatatttg caacacccca 3850  
 20 gtaaagagaa ttgtaatatg cagattataa aaagaagtct tacaatcag 3900  
 taaaaaataa aactagacaa aaatttgaac agatgaaaga gaaactctaa 3950  
 ataatcatta cacatgagaa actcaatctc agaaatcaga gaactatcat 4000  
 tgcatataca ctaaattaga gaaatattaa aaggctaagt aacatctgtg 4050  
 gcaatattga tggatatataa ccttgatatg atgtgatgag aacagtactt 4100  
 25 taccatcatg gcttctctcc caaacctta cccagttata aatcatgaca 4150  
 aatatacttt aaaaaccatt accctatata taaccagtac tcctcaaaac 4200  
 tgtcaaggtc atcaaaaata agaaaagtct gaggaactgt caaaactaag 4250  
 aggaacccaa ggagacatga gaattatatg taatgtggca ttctgaatga 4300  
 gatccagaa cagaaaaaga acagtagcta aaaaactaat gaaatataaa 4350  
 30 taaagtttga acttttagttt ttttttaaaa agagtagcat taacacggca 4400

aagtcattttt cacattttttc ttgaacatta agtacaagtc tataattaaa 4450  
 aatttttttaa atgtagtctg gaacattgcc agaaacagaa gtacagcagc 4500  
 tatctgtgct gtcgcctaac tatccatagc tgattggctct aaaatgagat 4550  
 acatcaacgc tcttccatgt tttttgtttt ctttttaaat gaaaaacttt 4600  
 5 atttttttaag aggagtttca ggttcatagc aaaattgaga ggaagggtaca 4650  
 ttcaagctga ggaagttttc ctctattcct agtttactga gagattgcat 4700  
 catgaatggg tgttaaattt tgtcaaatgc tttttctgtg tctatcaata 4750  
 tgaccatgtg attttcttct ttaacctgtt gatgggacaa attacgttaa 4800  
 ttgattttca aacgttgaac cacccttaca tatctggaat aaattctact 4850  
 10 tggttgtggt gtatattttt tgatacatte ttggattctt tttgctaata 4900  
 ttttgttgaa aatgtttgta tctttgttca tgagagatat tggctctgtg 4950  
 ttttcttttc ttgtaatgtc attttctagt tccggtatta aggtaatgct 5000  
 ggccatagtg aatgatttag gaagtattcc ctctgcttct gtcttctgag 5050  
 gtaccgcggc cgcccgctgt tttacaacgt cgtgactggg aaaaccctgg 5100  
 15 cgttacccaa cttaatcgcc ttgcagcaca tcccccttcc gccagctggc 5150  
 gtaatagcga agaggccgc accgatcgcc cttcccaaca gttgcgcagc 5200  
 ctgaatggcg aatggcgccct gatgcggtat tttctcctta cgcattctgtg 5250  
 cggatattca caccgcatac gtcaaagcaa ccatagtacg cgccctgtag 5300  
 cggcgcatta agcgcggcgg gtgtgggtgg taccgcgcagc gtgaccgcta 5350  
 20 cacttgccag cgccctagcg cccgctcctt tcgctttctt cccttccttt 5400  
 ctgcgccagt tcgccggctt tccccgtcaa gctctaaatc gggggctccc 5450  
 tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg 5500  
 atttgggtga tggttcacgt agtgggcat cgccctgata gacggttttt 5550  
 cgccctttga cgttggagtc cacgttcttt aatagtggac tcttgttcca 5600  
 25 aactggaaca aactcaacc ctatctcggg ctattctttt gatttataag 5650  
 ggattttgcc gatttcggcc tattgggttaa aaaatgagct gatttaacaa 5700  
 aaatttaacg cgaattttta caaaatatta acgtttacaa ttttatgggtg 5750  
 cactctcagt acaatctgct ctgatgcgc atagttaagc cagccccgac 5800  
 acccgccaac acccgctgac gcgcctgac gggcttgtct gctcccggca 5850  
 30 tccgcttaca gacaagctgt gaccgtctcc gggagctgca tgtgtcagag 5900

gttttcaccg tcaatcaccga aacgcgcgag acgaaagggc ctcgtgatac 5950  
gcctatTTTT ataggTTaat gTcatgataa taatggTTtc ttagacgtca 6000  
ggTggcactt ttcggggaaa tgtgcgcgga acccctattt gtttattttt 6050  
ctaaatacat tcaaatatgt atccgctcat gagacaataa ccctgataaa 6100  
5 tGcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt 6150  
gtcgccctta tTccctTTTT tgcggcattt tgccttccTg tttttgctca 6200  
cccagaaacg ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac 6250  
gagtgggtta catcgaactg gatctcaaca gcggtaaagat ccttgagagt 6300  
tttcgccccg aagaacgttt tccaatgatg agcactttta aagttctgct 6350  
10 atgtggcgcg gtattatccc gtattgacgc cgggcaagag caactcggtc 6400  
gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca 6450  
gaaaagcatc ttacggatgg catgacagta agagaattat gcagtgctgc 6500  
cataaccatg agtgataaca ctgcggccaa cttacttctg acaacgatcg 6550  
gaggaccgaa ggagctaacc gcttttttgc acaacatggg ggatcatgta 6600  
15 actcgcttg atcgTTggga accggagctg aatgaagcca taccaaacga 6650  
cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg ttgcgcaaac 6700  
tattaactgg cgaactactt actctagctt cccggcaaca attaatagac 6750  
tggtggagg cggataaagt tgcaggacca cttctgcgct cggcccttcc 6800  
ggctggctgg tttattgctg ataaatctgg agccggtgag cgtgggtctc 6850  
20 gcggtatcat tgcagcactg gggccagatg gtaagccctc ccgtatcgta 6900  
gttatctaca cgacggggag tcaggcaact atggatgaac gaaatagaca 6950  
gatcgctgag ataggTgcct cactgattaa gcattggtaa ctgtcagacc 7000  
aagtttactc atatatactt tagattgatt taaaacttca tttttaattt 7050  
aaaaggatct aggtgaagat cttttttgat aatctcatga ccaaaatccc 7100  
25 ttaacgtgag ttttcgTTcc actgagcgtc agaccccgta gaaaagatca 7150  
aaggatcttc ttgagatcct ttttttctgc gcgtaatctg ctgcttgcaa 7200  
acaaaaaaac caccgctacc agcggTgggt tgtttgccgg atcaagagct 7250  
accaactctt tttccgaagg taactggctt cagcagagcg cagataccaa 7300  
atactgtcct tctagtgtag ccgtagttag gccaccactt caagaactct 7350  
30 gtagcaccgc ctacatacct cgctctgcta atcctgttac cagtggctgc 7400

tgccagtggc galaagtcgt gtcttaccgg gttggactca agacgatagt 7450  
taccggataa ggcgacagcg tctgggtgaa cgggggggttc gtgcacacag 7500  
cccagcttgg agcgaacgac ctacaccgaa ctgagatacc tacagcgtga 7550  
gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg gacaggatc 7600  
5 cggtaagcgg cagggtcggg acaggagagc gcacgaggga gcttccaggg 7650  
ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc acctctgact 7700  
tgagcgtcga tttttgtgat gctcgtcagg ggggaggagc ctatggaaaa 7750  
acgccagcaa cgcggccttt ttacgggttc tggccttttg ctggcctttt 7800  
gctcacatgt tctttcctgc gttatcccct gattctgtgg ataaccgtat 7850  
10 taccgccttt gagtgagctg ataccgctcg ccgcagccga acgaccgagc 7900  
gcagcgagtc agtgagcgag gaagcggaag agcccgcggg caaggctgcc 7950  
acgcacaaga tcaatattaa caatcagtca tctctcttta gcaataaaaa 8000  
ggtgaaaaat tacattttta aaatgacacc atagacgatg tatgaaaata 8050  
atctacttgg aaataaatct aggcaaagaa gtgcaagact gttaccaga 8100  
15 aaacttacia attgtaaatg agaggtagt gaagatttaa atgaatgaag 8150  
atctaaataa acttataaat tgtgagagaa attaataat gtctaagtta 8200  
atgcagaaac ggagagacat actatattca tgaactaaaa gacttaatat 8250  
tgtgaaggta tactttcttt tcacataaat ttgtagtcaa tatgttcacc 8300  
ccaaaaaagc tgtttggtta cttgtcaacc tcatttcaaa atgtatatag 8350  
20 aaagcccaaa gacaataaca aaaatattct tgtagaacaa aatgggaaag 8400  
aatgttccac taaatatcaa gatttagagc aaagcatgag atgtgtgggg 8450  
atagacagtg aggctgataa aatagagtag agctcagaaa cagaccatt 8500  
gatatatgta agtgacctat gaaaaaaata tggcatttta caatgggaaa 8550  
atgatgatct ttttcttttt tagaaaaaca gggaaatata tttatatgta 8600  
25 aaaaataaaa gggaacccat atgtcatacc atacacacaa aaaaattcca 8650  
gtgaattata agtctaaatg gagaaggcaa aactttaaat cttttagaaa 8700  
ataatataga agcatgccat catgacttca gtgtagagaa aaatttctta 8750  
tgactcaaag tcttaaccac aaagaaaaga ttgttaatta gattgcatga 8800  
atattaagac ttatttttaa aattaaaaaa ccattaagaa aagtcaggcc 8850  
30 atagaatgac agaaaatatt tgcaacaccc cagtaaagag aattgtaata 8900

tgcagattat aaaaagaagt cttacaaatc agtaaaaaat aaaactagac 8950  
aaaaatttga acagatgaaa gagaaactct aaataatcat tacacatgag 9000  
aaactcaatc tcagaaatca gagaaactatc attgcatata cactaaatta 9050  
gagaaatatt aaaaggctaa gtaacatctg tggcaatatt gatggtatat 9100  
5 aaccttgata tgatgtgatg agaacagtac tttaccccat gggcttcctc 9150  
cccaaaccct taccacagta taaatcatga caaatatact ttaaaaacca 9200  
ttaccctata tctaaccagt actcctcaaa actgtcaagg tcatcaaaaa 9250  
taagaaaagt ctgaggaact gtcaaaacta agaggaaccc aaggagacat 9300  
gagaattata tgtaatgtgg cattctgaat gagatcccag aacagaaaaa 9350  
10 gaacagtagc taaaaaacta atgaaatata aataaagttt gaactttagt 9400  
tttttttaaa aaagagtagc attaacacgg caaagtcatt ttcataatttt 9450  
tcttgaacat taagtacaag tctataatta aaaatttttt aaatgtagtc 9500  
tggaacattg ccagaaacag aagtacagca gctatctgtg ctgtcgcta 9550  
actatccata gctgattggt ctaaaatgag atacatcaac gctcctccat 9600  
15 gttttttgtt ttctttttaa atgaaaaact ttatttttta agaggagt 9650  
caggttcata gcaaaattga gaggaaggta cattcaagct gaggaagttt 9700  
tcctctattc ctagtttact gagagattgc atcatgaatg ggtgttaa 9750  
tttgtcaaat gctttttctg tgtctatcaa tatgaccatg tgattttctt 9800  
ctttaacctg ttgatgggac aaattacgtt aattgatattt caaacgttga 9850  
20 accaccctta catatctgga ataaattcta cttgggtgtg gtgtatat 9900  
tttgatacat tcttggaattc tttttgctaa tattttgttg aaaatgtttg 9950  
tatctttgtt catgagagat attggtctgt tgttttcttt tcttgtaatg 10000  
tcattttcta gttccggtat taaggtaatg ctggcctagt tgaatgattt 10050  
aggaagtatt ccctctgctt ctgtcttctg aagcggaaga gcgccaata 10100  
25 cgcaaaccgc ctctccccgc gcgttggccg attcattaat gcagctggca 10150  
cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaatg 10200  
tgagttagct cactcattag gcaccccagg ctttacactt tatgcttccg 10250  
gctcgtatgt tgtgtggaat tgtgagcgga taacaatttc acacaggaaa 10300  
cagctatgac atgattacga attaa 10325

30 &lt;210&gt; 54

<211> 10379  
 <212> DNA  
 <213> Artificial

<220>

5 <221> Artificial  
 <222> 1-10379  
 <223> Sequence is synthesized

<400> 54

```

aagctttact cgtaaagcga gttgaaggat catatctagt tgcgtttatg 50
10 agataagatt gaaagcacgt gtaaaatggt tcccgcgcgt tggcacaact 100
atttacaatg cggccaagtt ataaaagatt ctaatctgat atgtttttaa 150
acacctttgc ggcccgagtt gtttgcgtag gtgactagcg aagaagatgt 200
gtggaccgca gaacagatag taaaacaaaa ccctagtatt ggagcaataa 250
tcgatttaac caacacgtct aaatattatg atggtgtgca ttttttgctg 300
15 gcgggcctgt tatacaaaaa aattcaagta cctggccaga ctttgccgcc 350
tgaaagcata gttcaagaat ttattgacac ggtaaaagaa ttacagaaa 400
agtgtcccg catgttggtg ggcgtgcact gcacacacgg tattaatcgc 450
accggttaca tgggtgtgcag atatttaatg cacaccctgg gtatgtgcgc 500
gcaggaagcc atagatagat tcgaaaaagc cagaggtcac aaaattgaaa 550
20 gacaaaatta cgttcaagat ttattaatct aattaatatt atttgcattc 600
tttaacaaat actttatcct attttcaa atgttgcgctt cttccagcga 650
acaaaacta tgcttcgctt gctccgttta gcttgtagcc gatcagtggc 700
gttgttccaa tcgacggtag gattaggccg gatattctcc accacaatgt 750
tggcaacggt gatgttacgt ttatgctttt ggttttccac gtacgtcttt 800
25 tggccggtaa tagccgtaaa cgtagtgccg tcgcgcgtca cgcacaacac 850
cggatgtttg cgcttgctcg cggggtattg aaccgcgcga tccgacaaat 900
ccaccacttt ggcaactaaa tcggtgacct gcgcgtcttt tttctgcatt 950
atttcgtctt tcttttgc atgtttcctgg aagccggtgt acatgcggtt 1000
tagatcagtc atgacgcgcg tgacctgcaa atctttggcc tcgatctgct 1050
30 tgtccttgat ggcaacgatg cgttcaataa actcttggtt tttaacaagt 1100
tcctcggttt tttgcgccac caccgcttgc agcgcgtttg tgtgctcgg 1150
gaatgtcgca atcagcttag tcaccaactg tttgctctcc tcctcccgtt 1200
gtttgatcgc gggatcgtag ttgccggtgc agagcacttg aggaattact 1250

```



tcttctaaaa gccattcttg taattctatg gcgtaaggca atttggactt 1300  
cataatcagc tgaatcacgc cggatttagt aatgagcact gtatgcggct 1350  
gcaaatacag cgggtcgccc cttttcacga cgctgttaga ggtagggccc 1400  
ccattttgga tggctctgctc aaataacgat ttgtatttat tgtctacatg 1450  
5 aacacgtata gctttatcac aaactgtata ttttaaactg ttagcgacgt 1500  
ccttggccac gaaccggacc tgttggtcgc gctctagcac gtaccgcagg 1550  
ttgaacgtat cttctccaaa tttaaattct ccaattttta cgcgagccat 1600  
tttgatacac gtgtgtcgat ttgcaacaa ctattgtttt ttaacgcaaa 1650  
ctaaacttat tgtggttaagc aataattaaa tatgggggaa catgcgccgc 1700  
10 tacaacactc gtcgttatga acgcagacgg cgccggtctc ggcgcaagcg 1750  
gctaaaacgt gttgcgcgtt caacgcggca aacatcgcaa aagccaatag 1800  
tacagttttg atttgcata taacggcgat tttttaaat atcttattta 1850  
ataaatagtt atgacgccta caactccccg cccgcgttga ctcgctgcac 1900  
ctcgagcagt tcgttgacgc cttcctccgt gtggccgaac acgtcgagcg 1950  
15 ggtggtcgat gaccagcggc gtgcccgcac cgacgcacaa gtatctgtac 2000  
accgaatgat cgtcggggcga aggcacgtcg gcctccaagt ggcaatattg 2050  
gcaaattcga aaatatatac agttggggtt tttgcgcata tctatcgttg 2100  
cgttgggcat gtacgtccga acgttgattt gcatgcaagc cgaaattaaa 2150  
tcattgcgat tagtgcgatt aaaacgttgt acatcctcgc ttttaatcat 2200  
20 gccgtcgatt aaatcgcgca atcgagtcaa gtgatcaaag tgtggaataa 2250  
tgttttcttt gtattcccga gtcaagcgca gcgcgtattt taacaaacta 2300  
gccatcttgt aagttagttt catttaatgc aactttatcc aataatatat 2350  
tatgtatcgc acgtcaagaa ttaacaatgc gcccggtgtc gcatctcaac 2400  
acgactatga tagagatcaa ataaagcgcg aattaaatag cttgcgacgc 2450  
25 aacgtgcacg atctgtgcac gcgttccggc acgagctttg attgtaataa 2500  
gtttttacga agcgatgaca tgacccccgt agtgacaacg atcacgcca 2550  
aaagaactgc cgactacaaa attaccgagt atgtcgggtga cgttaaaact 2600  
attaagccat ccaatcgacc gttagtcgaa tcaggaccgc tggtgcgaga 2650  
agccgcgaag tatggcgaat gcatcgtata acgtgtggag tccgctcatt 2700  
30 agagcgatcat gtttagacaa gaaagctaca tatttaattg atcccgatga 2750

ttttattgat aaattgaccc taactccata cacggtattc tacaatggcg 2800  
gggttttggg caaaatttcc ggactgcatggt tgtacatgct gttaacggct 2850  
ccgcccacta ttaatgaaat taaaaattcc aatttttaaaa aacgcagcaa 2900  
gagaaacatt tgtatgaaag aatgcgtaga aggaaagaaa aatgtcgtcg 2950  
5 acatgctgaa caacaagatt aatatgcctc cgtgtataaa aaaaatattg 3000  
aacgatttga aagaaaacaa tgtaccgcg cgcgggtatgt acaggaagag 3050  
gtttatacta aactgttaca ttgcaaacgt ggtttcgtgt gccaaagtgtg 3100  
aaaaccgatg tttaatcaag gctctgacgc atttctacaa ccacgactcc 3150  
aagtgtgtgg gtgaagtcac gcatctttta atcaaattccc aagatgtgta 3200  
10 taaaccacca aactgccaaa aaatgaaaac tgcgacaag ctctgtccgt 3250  
ttgctggcaa ctgcaagggt ctcaatccta tttgtaatta ttgaataata 3300  
aaacaattat aaatgctaaa tttgtttttt attaacgata caaaccaaac 3350  
gcaacaagaa catttgtagt attatctata attgaaaacg cgtagttata 3400  
atcgctgagg taatatttaa aatcattttc aaatgattca cagttaattt 3450  
15 gcgacaatat aattttattt tcacataaac tagacgcctt gtcgtcttct 3500  
tcttcgtatt ccttctcttt ttcatttttc tcctcataaa aattaacata 3550  
gttattatcg tatccatata tgtatctatc gtatagagta aattttttgt 3600  
tgtcataaat atatatgtct tttttaatgg ggtgtatagt accgctgcgc 3650  
atagtttttc tgtaatttac aacagtgcga ttttctggta gttcttcgga 3700  
20 gtgtgttgct ttaattatta aatttatata atcaatgaat ttgggatcgt 3750  
cggttttgta caatatgttg ccggcatagt acgcagcttc ttctagttca 3800  
attacacat ttttttagcag caccggatta acataacttt ccaaaatggt 3850  
gtacgaaccg ttaaacaata acagttcacc tcccttttct atactattgt 3900  
ctgcgagcag ttgtttgttg ttaaaaataa cagccattgt aatgagacgc 3950  
25 acaaactaat atcacaaact ggaaatgtct atcaatatat agttgctgat 4000  
atcatggaga taattaaaat gataaccatc tcgcaataa ataagtattt 4050  
tactgttttc gtaacagttt tgtaataaaa aaacctataa atattccgga 4100  
ttattcatac cgtcccacca tcgggcgcgg atccgcggcc gcgaattcta 4150  
aaccaccatg gctagcaggc ctgacaaaac tcacacatgc ccaccgtgcc 4200  
30 cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa 4250

cccaaggaca ccccatgat ctcccggacc cctgaggtca catgcgtggt 4300  
 ggtggacgtg agccacgaag accctgaggt caagttcaac tggtagctgg 4350  
 acggcgtgga ggtgcataat gccaaagacaa agccgcggga ggagcagtac 4400  
 aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg 4450  
 5 gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa gccctcccag 4500  
 ccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 4550  
 caggtgtaca cctgcccccc atcccgggaa gagatgacca agaaccaggt 4600  
 cagcctgacc tgcttgggtca aaggcttcta tcccagcgac atcgccgtgg 4650  
 agtgggagag caatgggcag ccggagaaca actacaagac cagcctccc 4700  
 10 gtgctggact ccgacggctc cttcttctc tacagcaagc tcaccgtgga 4750  
 caagagcagg tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg 4800  
 aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt 4850  
 aatgacata gggcatcatc atcatcatca tcatcattaa ttctagacta 4900  
 gtctgcagat ctgatccttt cctgggaccc ggcaagaacc aaaaactcac 4950  
 15 tctcttcaag gaaatccgta atgttaaacc cgacacgatg aagcttgctg 5000  
 ttggatggaa aggaaaagag ttctacaggg aaacttggac ccgcttcatg 5050  
 gaagacagct tccccattgt taacgaccaa gaagtgatgg atgttttcct 5100  
 tgttgtcaac atgcgtccca ctagacccaa ccgttggttac aaattcctgg 5150  
 cccaacacgc tctgcgttgc gaccccgact atgtacctca tgacgtgatt 5200  
 20 aggatcgctg agccttcatg ggtgggcagc aacaacgagt accgcatcag 5250  
 cctggctaag aagggcggcg gctgccaat aatgaacctt cactctgagt 5300  
 acaccaactc gttogaacag ttcacgatc gtgtcatctg ggagaacttc 5350  
 tacaagccca tcgtttacat cggtagcgac tctgctgaag aggaggaaat 5400  
 tctccttgaa gtttccctgg tgttcaaagt aaaggagttt gcaccagacg 5450  
 25 cacctctgtt cactggtccg gcgtattaaa acacgataca ttgttattag 5500  
 tacatttatt aagcgctaga ttctgtgcgt tgttgattta cagacaattg 5550  
 ttgtacgtat tttaataatt cattaaattt ataatcttta gggtaggtatg 5600  
 ttagagcgaa aatcaaatga ttttcagcgt ctttatatct gaatttaaat 5650  
 attaaatcct caatagattt gtaaaatagg tttcgattag tttcaaacaa 5700  
 30 gggttgtttt tccgaaccga tggctggact atctaattga ttttcgctca 5750

acgccacaaa acccgccaaa tcttgtagca gcaatctagc tttgtcgata 5800  
ttcgtttgtg ttttgttttg taataaaggt tgcacgtcgt tcaaaatatt 5850  
atgcgctttt gtatttcttt catcactgtc gttagtgtac aattgactcg 5900  
acgtaaacac gttaaataaa gcttggacat atttaacatc gggcgtgtta 5950  
5 gctttattag gccgattatc gtcgtcgtcc caaccctcgt cgtagaagt 6000  
tgcttccgaa gacgattttg ccatagccac acgacgccta ttaattgtgt 6050  
cggctaacac gtccgcgatc aaatttgtag ttgagctttt tggaattatt 6100  
tctgattgcg ggcgtttttg ggcgggtttc aatctaactg tgcccgatth 6150  
taattcagac aacacgttag aaagcgatgg tgcaggcggg ggtaacattt 6200  
10 cagacggcaa atctactaat ggcggcgggt gtggagctga tgataaatct 6250  
accatcgggtg gaggcgcagg cggggctggc ggcggaggcg gaggcggagg 6300  
tggtggcggg gatgcagacg gcggtttagg ctcaaagtgc tctttaggca 6350  
acacagtcgg cacctcaact attgtactgg ttccgggcgc cgtttttggg 6400  
ttgacgggtc tgagacgagt gcgatttttt tcgtttctaa tagcttccaa 6450  
15 caattgttgt ctgtcgtcta aaggtgcagc gggttgaggt tccgtcggca 6500  
ttggtggagc gggcggcaat tcagacatcg atggtgggtg tggtgggtgga 6550  
ggcgctggaa tgtaggcac gggagaaggt ggtggcggcg gtgccgccgg 6600  
tataatttgt tctggtttag tttgttcgcg cacgattgtg ggcaccggcg 6650  
caggcgccgc tggctgcaca acggaaggte gtctgcttcg aggcagcgct 6700  
20 tgggggtggtg gcaattcaat attataattg gaatacaaat cgtaaaaatc 6750  
tgctataagc attgtaattt cgctatcgtt taccgtgccg atatttaaca 6800  
accgctcaat gtaagcaatt gtattgtaaa gagattgtct caagctccgc 6850  
acgccgataa caagcctttt catttttact acagcattgt agtggcgaga 6900  
cacttcgctg tcgtcgacgt acatgtatgc tttgttgtca aaaacgtcgt 6950  
25 tggcaagctt taaaatattt aaaagaacat ctctgttcag caccactgtg 7000  
ttgtcgtaaa tggtgttttt gataatttgc gcttccgcag tatcgacacg 7050  
ttcaaaaaat tgatgcgcat caattttgtt gttcctatta ttgaataaat 7100  
aagattgtac agattcatat ctacgattcg tcatggccac cacaaatgct 7150  
acgctgcaaa cgctgggtaca attttacgaa aactgcaaaa acgtcaaaac 7200  
30 tcggtataaa ataatcaacg ggcgctttgg caaaatatct attttatcgc 7250

acaagcccac tagcaaattg tatattgcaga aaacaatttc ggcgacacat 7300  
tttaacgctg acgaaataaa agttcaccag ttaatgagcg accacccaaa 7350  
ttttataaaa atctatttta atcacgggtc catcaacaac caagtgatcg 7400  
tgatggacta cattgactgt cccgatttat ttgaaacact acaaattaaa 7450  
5 ggcgagcttt cgtaccaact tgtagcaat attattagac agctgtgtga 7500  
agcgctcaac gatttgcaca agcacaattt catacacaac gacataaaac 7550  
tcgaaaatgt cttatatattc gaagcacttg atcgcgtgta tgtttgcgat 7600  
tacggattgt gcaaacacga aaactcactt agcgtgcacg acggcacggt 7650  
ggagtatttt agtccggaaa aaattcgaca cacaactatg cacgtttcgt 7700  
10 ttgactggta cgcggcgtgt taacatacaa gttgctaacc ggcggttcgt 7750  
aatcatggtc atagctgttt cctgtgtgaa attgttatcc gctcacaatt 7800  
ccacacaaca tacgagccgg aagcataaag tgtaaagcct ggggtgccta 7850  
atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc 7900  
agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg 7950  
15 gggagaggcg gtttgcgat tgggcgctct tccgcttcct cgctcactga 8000  
ctcgctgcgc tcggtcgttc ggctgcggcg agcggatatca gctcactcaa 8050  
aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac 8100  
atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcggt 8150  
gctggcggtt ttccataggc tccgcccccc tgacgagcat cacaaaaatc 8200  
20 gacgctcaag tcagaggtgg cgaaaccgga caggactata aagataccag 8250  
gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 8300  
gcttaccgga tacctgtccg cttttctccc ttcgggaagc gtggcgcttt 8350  
ctcatagctc acgctgtagg tatctcagtt cgggtgtaggc cgttcgctcc 8400  
aagctgggct gtgtgcacga accccccgtt cagcccgacc gctgcgcctt 8450  
25 atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc 8500  
cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc 8550  
ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag 8600  
gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa 8650  
gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt 8700  
30 ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 8750

agatcctttg atccttttcta cggggtctga cgctcagtgg aacgaaaact 8800  
cacgttaagg gatttttggtc atgagattat caaaaaggat cttcacctag 8850  
atccttttaa attaaaaatg aagtttttaa tcaatctaaa gtatatatga 8900  
gtaaacttgg tctgacagtt accaatgctt aatcagtggag gcacctatct 8950  
5 cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgctcgtg 9000  
tagataacta cgatacggga gggcttacca tctggcccca gtgctgcaat 9050  
gataccgcga gaccacgct caccggctcc agatttatca gcaataaacc 9100  
agccagccgg aagggccgag cgcagaagtg gtcctgcaac tttatccgcc 9150  
tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc 9200  
10 agttaatagt ttgcgcaacg ttggtgcat tgctacaggc atcgtggtgt 9250  
cacgctcgtc gtttggtatg gcttcattca gctccggtc ccaacgatca 9300  
aggcgagtta catgatcccc catgttgtgc aaaaagcgg ttagctcctt 9350  
cggtcctccg atcgttgtca gaagtaagt ggccgcagtg ttatcactca 9400  
tggttatggc agcactgcat aattctctta ctgtcatgcc atccgtaaga 9450  
15 tgcttttctg tgacgggtga gtactcaacc aagtcattct gagaatagtg 9500  
tatgcggcga ccgagttgct cttgccggc gtcaatacgg gataataccg 9550  
cgccacatag cagaacttta aaagtgtca tcattggaaa acgttcttcg 9600  
gggcgaaaac tctcaaggat cttaccgctg ttgagatcca gttcgatgta 9650  
accactcgt gcaccaact gatcttcagc atcttttact ttcaccagcg 9700  
20 tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata 9750  
agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta 9800  
ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat 9850  
gtatttagaa aaataaacia ataggggttc cgcgcacatt tccccgaaaa 9900  
gtgccacctg acgtctaaga aaccattatt atcatgacat taacctataa 9950  
25 aaataggcgt atcacgaggc cctttcgtct cgcgcgtttc ggtgatgacg 10000  
gtgaaaacct ctgacacatg cagctcccgg agacggtcac agcttgtctg 10050  
taagcggatg ccgggagcag acaagcccgt cagggcgcgt cagcgggtgt 10100  
tggcgggtgt cggggctggc ttaactatgc ggcacagag cagattgtac 10150  
tgagagtgca ccatatatgc ggtgtgaaat accgcacaga tgcgtaagga 10200  
30 gaaaataccg catcaggcgc cattegccat tcaggctgcg caactgttgg 10250



gaagggcgat cggcgcgggc ctcttcgcta ttacgccagc tggcgaaagg 10300  
 gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt 10350  
 cacgacgttg taaaacgacg gccagtgcc 10379

5 <210> 55  
 <211> 9690  
 <212> DNA  
 <213> Artificial

10 <220>  
 <221> Artificial  
 <222> 1-9690  
 <223> Sequence is synthesized

<400> 55  
 aagctttact cgtaaagcga gttgaaggat catatttagt tgcgtttatg 50  
 agataagatt gaaagcacgt gtaaaatggt tcccgcgcgt tggcacaact 100  
 15 atttacaatg cggccaagtt ataaaagatt ctaatctgat atgttttaaa 150  
 acacctttgc ggcccagatt gtttgcgtac gtgactagcg aagaagatgt 200  
 gtggaccgca gaacagatag taaaacaaaa ccctagtatt ggagcaataa 250  
 tcgattttac caacacgtct aaatattatg atgggtgtgca ttttttgcgg 300  
 gcgggcctgt tatacaaaaa aattcaagta cctggccaga ctttgccgcc 350  
 20 tgaaagcata gttcaagaat ttattgacac ggtaaaagaa tttacagaaa 400  
 agtgtcccgg catgttgggtg ggcgtgcact gcacacacgg tattaatcgc 450  
 accggttaca tgggtgtgcag atattttaatg cacaccctgg gtattgcgcc 500  
 gcaggaagcc atagatagat tcgaaaaagc cagaggtcac aaaattgaaa 550  
 gacaaaatta cgttcaagat ttattaattt aattaatatt atttgcattc 600  
 25 tttaacaaat actttatcct attttcaa atgttgcgctt cttccagcga 650  
 accaaaacta tgettcgctt gctccgttta gcttgtagcc gatcagtggc 700  
 gttgttccaa tcgacggtag gattaggcgc gatattctcc accacaatgt 750  
 tggcaacggt gatgttacgt ttatgctttt ggttttccac gtacgtcttt 800  
 tggccggtaa tagccgtaaa cgtagtgcgc tcgcgcgtca cgcacaacac 850  
 30 cggatgtttg cgcttgtccg cgggggtattg aaccgcgcga tccgacaaat 900  
 ccaccacttt ggcaactaaa tcggtgacct gcgcgtcttt tttctgcatt 950  
 atttcgtctt tcttttgcac ggtttcctgg aagccggtgt acatgcgggt 1000  
 tagatcagtc atgacgcgcg tgacctgcaa atctttggcc tcgatctgct 1050

tgtccttgat ggcaacgatg cgttcaataa actccttgttt tttacaagt 1100  
tcctcgggtt tttgcgccac caccgcttgc agcgcgtttg tgtgctcggg 1150  
gaatgtcgca atcagcttag tcaccaactg tttgctctcc tcctcccgtt 1200  
gtttgatcgc gggatcgtag ttgccgggag agagcacttg aggaattact 1250  
5 tcttctaaaa gccattcttg taattctatg gcgtaaggca atttggactt 1300  
cataatcagc tgaatcacgc cggatttagt aatgagcact gtatgcggct 1350  
gcaaatacag cgggtcgccc cttttcacga cgctgtaga ggtagggccc 1400  
ccattttgga tggctcgtc aaataacgat ttgtatttat tgtctacatg 1450  
aacacgtata gctttatcac aaactgtata ttttaaactg ttagcgacgt 1500  
10 ccttgggcac gaaccggacc tgttggtcgc gctctagcac gtaccgcagg 1550  
ttgaacgtat cttctccaaa tttaaattct ccaattttta cgcgagccat 1600  
tttgatacac gtgtgtcgat tttgcaacaa ctattgtttt ttaacgcaaa 1650  
ctaaacttat tgtggtaagc aataattaaa tatgggggaa catgcgcgcg 1700  
tacaacactc gtcgttatga acgcagacgg cgccggtctc ggcgcaagcg 1750  
15 gctaaaacgt gttgcgcgtt caacgcggca aacatcgcaa aagccaatag 1800  
tacagttttg atttgcatat taacggcgat tttttaaat atcttattta 1850  
ataaatagtt atgacgccta caactccccg cccgcgttga ctgcgtgcac 1900  
ctcgagcagt tcgttgacgc cttcctccgt gtggccgaac acgtcgagcg 1950  
gggtggtcgat gaccagcggc gtgccgcacg cgacgcacaa gtatctgtac 2000  
20 accgaatgat cgtcgggcca aggcacgtcg gcctccaagt ggcaatattg 2050  
gcaaattcga aaatatatac agttgggttg tttgcgcata tctatcgtgg 2100  
cggtgggcat gtacgtccga acgttgattt gcatgcaagc cgaaattaaa 2150  
tcattgcgat tagtgcgatt aaaacgttgt acatcctcgc ttttaatcat 2200  
gccgtcgatt aaatcgcgca atcgagtcaa gtgatcaaag tgtggaataa 2250  
25 tgttttcttt gtattcccga gtcaagcgca gcgcgtattt taacaaacta 2300  
gccatcttgt aagttagttt catttaatgc aactttatcc aataatatat 2350  
tatgtatcgc acgtcaagaa ttaacaatgc gcccgttgtc gcatctcaac 2400  
acgactatga tagagatcaa ataaagcgcg aattaaatag cttgcgacgc 2450  
aacgtgcacg atctgtgcac gcgttccggc acgagctttg attgtaataa 2500  
30 gtttttacga agcgatgaca tgacccccgt agtgacaacg atcacgcca 2550

aaagaactgc cgactacaaa attaccgagt atgtcgggtga cgttaaaaact 2600  
 attaagccat ccaatcgacc gttagtcgaa tcaggaccgc tgggtgcgaga 2650  
 agccgcgaag tatggcgaat gcatcgtata acgtgtggag tccgctcatt 2700  
 agagcgtcat gtttagacaa gaaagctaca tatttaattg atcccgatga 2750  
 5 ttttattgat aaattgaccc taactccata cacgggtattc tacaatggcg 2800  
 gggtttttggc caaaatttcc ggactgcatgac tgtacatgct gttacacggct 2850  
 ccgcccacta ttaatgaaat taaaaattcc aatttttaaaa aacgcagcaa 2900  
 gagaaacatt tgtatgaaag aatgcgtaga aggaaagaaa aatgtcgtcg 2950  
 acatgctgaa caacaagatt aatatgcctc cgtgtataaa aaaaatattg 3000  
 10 aacgatttga aagaaaacaa tgtaccgcgc ggcgggtatgt acaggaagag 3050  
 gtttatacta aactgttaca ttgcaaacgt ggtttcgtgt gccaaagtgtg 3100  
 aaaaccgatg tttaatcaag gctctgacgc atttctacaa ccacgactcc 3150  
 aagtgtgtgg gtgaagtcac gcatctttta atcaaatacc aagatgtgta 3200  
 taaaccacca aactgccaaa aaatgaaaac tgtcgacaag ctctgtccgt 3250  
 15 ttgctggcaa ctgcaagggt ctcaatccta tttgtaatta ttgaataata 3300  
 aaacaattat aaatgctaaa tttgtttttt attaacgata caaaccaaac 3350  
 gcaacaagaa catttgtagt attatctata attgaaaacg cgtagttata 3400  
 atcgtcgagg taatatattaa aatcattttc aaatgattca cagttaattt 3450  
 gcgacaatat aattttattt tcacataaac tagacgcctt gtcgtcttct 3500  
 20 tcttcgtatt ccttctcttt ttcatttttc tcttcataaa aattaacata 3550  
 gttattatcg tatccatata tgtatctatc gtatagagta aattttttgt 3600  
 tgtcataaat atatatgtct tttttaatgg ggtgtatagt accgctgcgc 3650  
 atagtttttc tgtaatttac aacagtgcct tttcttggtg gttcttcgga 3700  
 gtgtgttgct ttaattatta aatttatata atcaatgaat ttgggatcgt 3750  
 25 cggtttttga caatatgttg ccggcatagt acgcagcttc ttctagttca 3800  
 attacaccat ttttttagcag caccggatta acataacttt ccaaaatggt 3850  
 gtacgaaccg ttaaacaata acagttcacc tcccttttct atactattgt 3900  
 ctgcgagcag ttgtttgttg ttaaaaataa cagccattgt aatgagacgc 3950  
 acaaactaat atcacaact ggaaatgtct atcaatatat agttgctgat 4000  
 30 atcatggaga taattaaaat gataaccatc tcgcaaataa ataagtattt 4050

tactgttttc gtaacagttt tgtaataaaa aaacctataa atattccgga 4100  
ttattcatac cgtcccacca tcgggcgcgg atccgcggcc gcgaattcta 4150  
aaccaccatg ggcagctgcc cgggcatcat catcatcatc atcatcatta 4200  
attctagact agtctgcaga tctgattcctt tcctgggacc cggcaagaac 4250  
5 caaaaactca ctctcttcaa ggaaatccgt aatgttaaac ccgacacgat 4300  
gaagcttgtc gttggatgga aaggaaaaga gttctacagg gaaacttgga 4350  
cccgcttcat ggaagacagc ttccccattg ttaacgacca agaagtgatg 4400  
gatgttttcc ttgttgtaaa catgcgtccc actagacca accgttgta 4450  
caaattcctg gcccaacacg ctctgcgttg cgaccccgac tatgtacctc 4500  
10 atgacgtgat taggatcgtc gagccttcat ggggtgggcag caacaacgag 4550  
taccgcatca gcctggctaa gaagggcggc ggctgcccac taatgaacct 4600  
tcactctgag tacaccaact cgttcgaaca gttcatcgat cgtgtcatcc 4650  
gggagaactt ctacaagccc atcgtttaca tcggtaccga ctctgctgaa 4700  
gaggaggaaa ttctccttga agtttccctg gtgttcaaag taaaggagtt 4750  
15 tgcaccagac gcacctctgt tcaactggcc ggcgtattaa aacacgatac 4800  
attgttatta gtacatttat taagcgttag attctgtgcg ttgttgattt 4850  
acagacaatt gttgtacgta ttttaataat tcattaaatt tataatcttt 4900  
agggtggtat gttagagcga aaatcaaattg attttcagcg tctttatatac 4950  
tgaatttaaa tattaaatcc tcaatagatt tgtaaaatag gtttcgatta 5000  
20 gtttcaaaca agggttgttt ttccgaaccg atggctggac tatctaattg 5050  
attttcgctc aacgccacaa aacttgccaa atcttgtagc agcaatctag 5100  
ctttgtcgat attcgtttgt gttttgtttt gtaataaagg ttcgacgtcg 5150  
ttcaaaatat tatgcgcttt tgtatttctt tcatcactgt cgttagtgta 5200  
caattgactc gacgtaaaca cgttaaataa agcttggaca tatttaacat 5250  
25 cgggcgtgtt agctttatta ggccgattat cgtcgtcgtc ccaaccctcg 5300  
tcgttagaag ttgcttccga agacgatttt gccatagcca cacgacgcct 5350  
attaattgtg tcggctaaca cgtccgcgat caaatttgta gttgagcttt 5400  
ttggaattat ttctgattgc gggcggtttt gggcgggttt caatctaact 5450  
gtgcccgatt ttaattcaga caacacgtta gaaagcgatg gtgcaggcgg 5500  
30 tggtaacatt tcagacggca aatctactaa tggcggcggt ggtggagctg 5550

atgataaatc taccatcggc ggaggcgcag gcggggctgg cggcggaggc 5600  
ggaggcggag gtggtggcgg tgatgcagac ggcggtttag gctcaaatgt 5650  
ctcttttaggc aacacagtcg gcacctcaac tattgtactg gtttcgggcg 5700  
ccgtttttgg tttgaccggc ctgagacgag tgcgattttt ttcgtttcta 5750  
5 atagcttcca acaattggtg tctgtcgtct aaagggtgcag cgggttgagg 5800  
ttccgtcggc attggtggag cgggcggcaa ttcagacatc gatggtggtg 5850  
gtggtggtgg aggcgctgga atgttaggca cgggagaagg tgggtggcggc 5900  
ggtgccgccg gtataatttg ttctggttta gtttgttcgc gcacgattgt 5950  
gggcaccggc gcaggcgccg ctggctgcac aacggaaggc cgtctgcttc 6000  
10 gaggcagcgc ttgggggtggg ggcaattcaa tattataatt ggaatacaaa 6050  
tcgtaaaaat ctgctataag cattgtaatt tcgctatcgt ttaccgtgcc 6100  
gatatttaac aaccgctcaa tgtaagcaat tgtattgtaa agagattgtc 6150  
tcaagctccg cagcccgata acaagccttt tcatttttac tacagcattg 6200  
tagtggcgag acacttcgct gtcgtcgacg tacatgtatg ctttgttgtc 6250  
15 aaaaacgtcg ttggcaagct ttaaaatatt taaaagaaca tctctgttca 6300  
gcaccactgt gttgtcgtaa atgttgtttt tgataatttg cgcttccgca 6350  
gtatcgacac gttcaaaaaa ttgatgcgca tcaattttgt tgttcctatt 6400  
attgaataaa taagattgta cagattcata tctacgattc gtcatggcca 6450  
ccacaaatgc tacgctgcaa acgctggtag aattttacga aaactgcaaa 6500  
20 aacgtcaaaa ctcggtataa aataatcaac gggcgctttg gcaaaatata 6550  
tattttatcg cacaagccca ctagcaaatt gtatttgcag aaaacaattt 6600  
cggcgcacaa ttttaacgct gacgaaataa aagttcacca gttaatgagc 6650  
gaccacccaa attttataaa aatctatttt aatcacgggt ccatcaacaa 6700  
ccaagtgatc gtgatggact acattgactg tcccgattta tttgaaacac 6750  
25 tacaaattaa aggcgagctt tcgtaccaac ttgtagcaa tattattaga 6800  
cagctgtgtg aagcgctcaa cgatttgcac aagcacaatt tcatacacia 6850  
cgacataaaa ctcgaaaatg tcttatattt cgaagcactt gatcgcgtgt 6900  
atgtttgcga ttacggattg tgcaaacacg aaaactcact tagcgtgcac 6950  
gacggcacgt tggagtattt tagtccggaa aaaattcgac acacaactat 7000  
30 gcacgtttcg tttgactggc acgcggcggtg ttaacataca agttgctaac 7050

cggcgggttcg taaccatggc catagctgtt tcctgtgtga aattgttatc 7100  
 cgctcacaat tccacacaac atacgagccg gaagcataaa gtgtaaagcc 7150  
 tgggggtgcct aatgagttag ctaactcaca ttaattgcgt tgcgtcact 7200  
 gcccgctttc cagtcgggaa acctgtcgtg ccagctgcat taatgaatcg 7250  
 5 gccaacgcgc ggggagagggc ggtttgcgta ttgggcgctc ttccgcttcc 7300  
 tcgctcactg actcgtcgcg ctccggtcgtt cggctgcggc gagcggatc 7350  
 agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg 7400  
 caggaaagaa catgtgagca aaaggccagc aaaaggccag gaaccgtaaa 7450  
 aaggccgcgt tgctggcgtt tttccatagg ctccgcccc ctgacgagca 7500  
 10 tcacaaaaat cgacgctcaa gtcagaggtg gcgaaaccgc acaggactat 7550  
 aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt 7600  
 ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc ctccgggaag 7650  
 cgtggcgctt tctcatagct cacgctgtag gtatctcagt tcggtgtagg 7700  
 tcgttcgctc caagctgggc tgtgtgcacg aacccccgt tcagcccgac 7750  
 15 cgctgcgcct tatccggtaa ctatcgtctt gagtcaacc cggtaagaca 7800  
 cgacttatcg ccaactggcag cagccactgg taacaggatt agcagagcga 7850  
 ggtatgtagg cggtgctaca gagttcttga agtgggtggc taactacggc 7900  
 tacactagaa ggacagtatt tggatatctg gctctgctga agccagttac 7950  
 ctccggaaaa agagttggta gctcttgatc cggcaaaca accaccgctg 8000  
 20 gtagcggtgg tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa 8050  
 ggatctcaag aagatccttt gatcttttct acgggggtctg acgctcagtg 8100  
 gaacgaaaac tcacgttaag ggattttggc catgagatta tcaaaaagga 8150  
 tcttcaccta gatcctttta aattaaaaat gaagttttta atcaatctaa 8200  
 agtatatatg agtaaaactg gtctgacagt taccaatgct taatcagtga 8250  
 25 ggcacctatc tcagcgatct gtctatttct ttcattcata gttgcctgac 8300  
 tccccgtcgt gtagataact acgatacggg agggcttacc atctggcccc 8350  
 agtgctgcaa tgataccgcg agaccacgc tcaccggctc cagatttatc 8400  
 agcaataaac cagccagccg gaagggccga gcgcagaagt ggtcctgcaa 8450  
 ctttatccgc ctccatccag tctattaatt gttgccggga agctagagta 8500  
 30 agtagttcgc cagttaatag tttgcgcaac gttgttgcca ttgctacagg 8550



catcgtggtg tcaugctcgt cgtttggtat ggcttcattc agctccggtt 8600  
 cccaacgata aaggcgagtt acatgatccc ccatgttgtg caaaaaagcg 8650  
 gttagctcct tcggctcctcc gatcgttgtc agaagtaagt tggccgcagt 8700  
 gttatcactc atggttatgg cagcactgca taattctctt actgtcatgc 8750  
 5 catccgtaag atgcttttct gtgactggtg agtactcaac caagtcattc 8800  
 tgagaatagt gtatgcggcg accgagttgc tcttgcccgg cgtcaatacg 8850  
 ggataatacc gcgccacata gcagaacttt aaaagtgtc atcattggaa 8900  
 aacgttcttc ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc 8950  
 agttcgatgt aaccactcg tgcacccaac tgatcttcag catcttttac 9000  
 10 tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa 9050  
 aaaagggaat aaggcgaca cggaatgtt gaatactcat actcttcctt 9100  
 tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcggata 9150  
 catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat 9200  
 tccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 9250  
 15 ttaacctata aaaataggcg tatcacgagg ccctttcgtc tcgcgcgttt 9300  
 cggatgatgac ggtgaaaacc tctgacacat gcagctcccg gagacgggtca 9350  
 cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg 9400  
 tcagcgggtg ttggcgggtg tcggggctgg cttaactatg cggcatcaga 9450  
 gcagattgta ctgagagtgc accatatatg cgggtgtgaaa taccgcacag 9500  
 20 atgcgtaagg agaaaatacc gcatcaggcg ccattcgcca ttcaggctgc 9550  
 gcaactgttg ggaaggcgca tcggtgcggg cctcttcgct attacgccag 9600  
 ctggcgaaag ggggatgtgc tgcaaggcga ttaagttggg taacgccagg 9650  
 gttttcccag tcacgacgtt gtaaaacgac ggccagtgcc 9690

25 <210> 56  
 <211> 249  
 <212> PRT  
 <213> Human

30 <400> 56  
 Arg Gly Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys  
 1 5 10 15  
 Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr  
 20 25 30  
 Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val

|    |   |     |   |     |  |     |
|----|---|-----|---|-----|--|-----|
|    |   | 35  |   | 40  |  | 45  |
|    | Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly | 50  |   | 55  |  | 60  |
| 5  | Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu | 65  |   | 70  |  | 75  |
|    | Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys | 80  |   | 85  |  | 90  |
|    | Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu | 95  |   | 100 |  | 105 |
| 10 | Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys | 110 |   | 115 |  | 120 |
|    | Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu | 125 |   | 130 |  | 135 |
| 15 | Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val | 140 |   | 145 |  | 150 |
|    | Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly | 155 |   | 160 |  | 165 |
|    | Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe | 170 |   | 175 |  | 180 |
| 20 | Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu | 185 |   | 190 |  | 195 |
|    | Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly | 200 |   | 205 |  | 210 |
| 25 | Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu | 215 |   | 220 |  | 225 |
|    | Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg | 230 |   | 235 |  | 240 |
|    | Gly Arg Ser Pro Gln Asn Ser Ala Phe                         | 245 |   | 249 |  |     |
| 30 | <210> 57  |     |   |     |  |     |
|    | <211> 248   |     |   |     |  |     |
|    | <212> PRT   |     |   |     |  |     |
|    | <213> Human   |     |   |     |  |     |
|    | <400> 57  |     |   |     |  |     |
| 35 | Gly Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu | 1   | 5 | 10  |  | 15  |
|    | Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys | 20  |   | 25  |  | 30  |
| 40 | Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu | 35  |   | 40  |  | 45  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu | 50  | 55  | 60  |
|    | Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val | 65  | 70  | 75  |
| 5  | Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu | 80  | 85  | 90  |
|    | Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr | 95  | 100 | 105 |
| 10 | Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg | 110 | 115 | 120 |
|    | Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp | 125 | 130 | 135 |
|    | Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu | 140 | 145 | 150 |
| 15 | Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly | 155 | 160 | 165 |
|    | Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser | 170 | 175 | 180 |
| 20 | Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp | 185 | 190 | 195 |
|    | Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met | 200 | 205 | 210 |
|    | Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr | 215 | 220 | 225 |
| 25 | Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly | 230 | 235 | 240 |
|    | Arg Ser Pro Gln Asn Ser Ala Phe                             | 245 | 248 |     |
| 30 | <210> 58  |     |     |     |
|    | <211> 247   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 58  |     |     |     |
| 35 | Thr Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu | 1   | 5   | 10  |
|    | Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro | 20  | 25  | 30  |
|    | Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp | 35  | 40  | 45  |
| 40 | Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro | 50  | 55  | 60  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys | 65  | 70  | 75  |
|    | Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu | 80  | 85  | 90  |
| 5  | Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg | 95  | 100 | 105 |
|    | Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys | 110 | 115 | 120 |
| 10 | Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val | 125 | 130 | 135 |
|    | Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val | 140 | 145 | 150 |
|    | Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly | 155 | 160 | 165 |
| 15 | Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly | 170 | 175 | 180 |
|    | Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser | 185 | 190 | 195 |
| 20 | Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala | 200 | 205 | 210 |
|    | Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln | 215 | 220 | 225 |
|    | Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg | 230 | 235 | 240 |
| 25 | Ser Pro Gln Asn Ser Ala Phe                                 | 245 | 247 |     |
|    | <210> 59  |     |     |     |
|    | <211> 246   |     |     |     |
|    | <212> PRT   |     |     |     |
| 30 | <213> Human   |     |     |     |
|    | <400> 59  |     |     |     |
|    | Pro Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser | 1   | 5   | 10  |
| 35 | Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp | 20  | 25  | 30  |
|    | Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly | 35  | 40  | 45  |
|    | Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys | 50  | 55  | 60  |
| 40 | Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln | 65  | 70  | 75  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala | 80  | 85  | 90  |
|    | Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu | 95  | 100 | 105 |
| 5  | Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu | 110 | 115 | 120 |
|    | Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg | 125 | 130 | 135 |
| 10 | Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu | 140 | 145 | 150 |
|    | Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu | 155 | 160 | 165 |
|    | Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu | 170 | 175 | 180 |
| 15 | Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr | 185 | 190 | 195 |
|    | Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr | 200 | 205 | 210 |
| 20 | Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg | 215 | 220 | 225 |
|    | Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser | 230 | 235 | 240 |
|    | Pro Gln Asn Ser Ala Phe                                     | 245 | 246 |     |
| 25 | <210> 60  |     |     |     |
|    | <211> 245   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 60  |     |     |     |
| 30 | Lys Thr His Leu Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys | 1   | 5   | 10  |
|    | Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro | 20  | 25  | 30  |
| 35 | Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys | 35  | 40  | 45  |
|    | Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp | 50  | 55  | 60  |
|    | Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro | 65  | 70  | 75  |
| 40 | Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu | 80  | 85  | 90  |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Asp   | Asp   | Ser | Ser | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | Arg | Glu | Gly |  |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Glu   | Thr   | Phe | Gln | Pro | His | Cys | Ser | Ile | Arg | Cys | Arg | Cys | Glu | Asp |  |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 5  | Gly   | Gly   | Phe | Thr | Cys | Val | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu |  |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Pro   | Ser   | Trp | Asp | Cys | Pro | His | Pro | Arg | Arg | Val | Glu | Val | Leu | Gly |  |
|    |       |       |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
| 10 | Lys   | Cys   | Cys | Pro | Glu | Trp | Val | Cys | Gly | Gln | Gly | Gly | Gly | Leu | Gly |  |
|    |       |       |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Thr   | Gln   | Pro | Leu | Pro | Ala | Gln | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val |  |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Ser   | Ser   | Leu | Pro | Pro | Gly | Val | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| 15 | Trp   | Gly   | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Val   | Ser   | Asn | Gln | Asn | Arg | Phe | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 20 | Leu   | Cys   | Leu | Ser | Arg | Pro | Cys | Pro | Pro | Ser | Arg | Gly | Arg | Ser | Pro |  |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Gln   | Asn   | Ser | Ala | Phe |     |     |     |     |     |     |     |     |     |     |  |
|    |       |       |     |     | 245 |     |     |     |     |     |     |     |     |     |     |  |
| 25 | <210> | 61    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> | 244   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <400> | 61    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Thr   | His   | Leu | Leu | Ala | Phe | Ser | Leu | Leu | Cys | Leu | Leu | Ser | Lys | Val |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
| 30 | Arg   | Thr   | Gln | Leu | Cys | Pro | Thr | Pro | Cys | Thr | Cys | Pro | Trp | Pro | Pro |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Pro   | Arg   | Cys | Pro | Leu | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 35 | Cys   | Cys   | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Pro | Cys | Asp | Gln |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Leu   | His   | Val | Cys | Asp | Ala | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly |  |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Ala   | Gly   | Pro | Gly | Gly | Arg | Gly | Ala | Leu | Cys | Leu | Leu | Ala | Glu | Asp |  |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
| 40 | Asp   | Ser   | Ser | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | Arg | Glu | Gly | Glu |  |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |



|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Thr         | Phe | Gln | Pro | His | Cys | Ser | Ile | Arg | Cys | Arg | Cys | Glu | Asp | Gly |  |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
|    | Gly         | Phe | Thr | Cys | Val | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro |  |
|    |             |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
| 5  | Ser         | Trp | Asp | Cys | Pro | His | Pro | Arg | Arg | Val | Glu | Val | Leu | Gly | Lys |  |
|    |             |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Cys         | Cys | Pro | Glu | Trp | Val | Cys | Gly | Gln | Gly | Gly | Gly | Leu | Gly | Thr |  |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| 10 | Gln         | Pro | Leu | Pro | Ala | Gln | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val | Ser |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Ser         | Leu | Pro | Pro | Gly | Val | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala | Trp |  |
|    |             |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Gly         | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg | Val |  |
|    |             |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| 15 | Ser         | Asn | Gln | Asn | Arg | Phe | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg | Leu |  |
|    |             |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
|    | Cys         | Leu | Ser | Arg | Pro | Cys | Pro | Pro | Ser | Arg | Gly | Arg | Ser | Pro | Gln |  |
|    |             |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
| 20 | Asn         | Ser | Ala | Phe |     |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     | 244 |     |     |     |     |     |     |     |     |     |     |  |
|    | <210> 62    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> 243   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 25 | <400> 62    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | His         | Leu | Leu | Ala | Phe | Ser | Leu | Leu | Cys | Leu | Leu | Ser | Lys | Val | Arg |  |
|    | 1           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Thr         | Gln | Leu | Cys | Pro | Thr | Pro | Cys | Thr | Cys | Pro | Trp | Pro | Pro | Pro |  |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
| 30 | Arg         | Cys | Pro | Leu | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys |  |
|    |             |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
|    | Cys         | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Pro | Cys | Asp | Gln | Leu |  |
|    |             |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
| 35 | His         | Val | Cys | Asp | Ala | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala |  |
|    |             |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Gly         | Pro | Gly | Gly | Arg | Gly | Ala | Leu | Cys | Leu | Leu | Ala | Glu | Asp | Asp |  |
|    |             |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Ser         | Ser | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | Arg | Glu | Gly | Glu | Thr |  |
|    |             |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
| 40 | Phe         | Gln | Pro | His | Cys | Ser | Ile | Arg | Cys | Arg | Cys | Glu | Asp | Gly | Gly |  |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |

|    |                     |   |     |     |       |
|----|---------------------|---|-----|-----|-------|
|    | Phe Thr Cys Val     | Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser | 125 | 130 | 135   |
|    | Trp Asp Cys Pro His | Pro Arg Arg Val Glu Val Leu Gly Lys Cys     | 140 | 145 | 150   |
| 5  | Cys Pro Glu Trp Val | Cys Gly Gln Gly Gly Gly Leu Gly Thr Gln     | 155 | 160 | 165   |
|    | Pro Leu Pro Ala Gln | Gly Pro Gln Phe Ser Gly Leu Val Ser Ser     | 170 | 175 | 180   |
| 10 | Leu Pro Pro Gly Val | Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly     | 185 | 190 | 195   |
|    | Pro Cys Ser Thr Thr | Cys Gly Leu Gly Met Ala Thr Arg Val Ser     | 200 | 205 | 210   |
|    | Asn Gln Asn Arg Phe | Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys     | 215 | 220 | 225   |
| 15 | Leu Ser Arg Pro Cys | Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn     | 230 | 235 | 240   |
|    | Ser Ala Phe         |   | 243 |     |       |
| 20 | <210> 63            |   |     |     |       |
|    | <211> 242           |   |     |     |       |
|    | <212> PRT           |   |     |     |       |
|    | <213> Human         |   |     |     |       |
|    | <400> 63            |   |     |     |       |
| 25 | Leu Leu Ala Phe Ser | Leu Leu Cys Leu Leu Ser Lys Val Arg Thr     | 1   | 5   | 10 15 |
|    | Gln Leu Cys Pro Thr | Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg     | 20  | 25  | 30    |
|    | Cys Pro Leu Gly Val | Pro Leu Val Leu Asp Gly Cys Gly Cys Cys     | 35  | 40  | 45    |
| 30 | Arg Val Cys Ala Arg | Arg Leu Gly Glu Pro Cys Asp Gln Leu His     | 50  | 55  | 60    |
|    | Val Cys Asp Ala Ser | Gln Gly Leu Val Cys Gln Pro Gly Ala Gly     | 65  | 70  | 75    |
| 35 | Pro Gly Gly Arg Gly | Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser     | 80  | 85  | 90    |
|    | Ser Cys Glu Val Asn | Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe     | 95  | 100 | 105   |
|    | Gln Pro His Cys Ser | Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe     | 110 | 115 | 120   |
| 40 | Thr Cys Val Pro Leu | Cys Ser Glu Asp Val Arg Leu Pro Ser Trp     | 125 | 130 | 135   |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys | 140 | 145 | 150 |
|    | Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu Gly Thr Gln Pro | 155 | 160 | 165 |
| 5  | Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu | 170 | 175 | 180 |
|    | Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro | 185 | 190 | 195 |
| 10 | Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn | 200 | 205 | 210 |
|    | Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu | 215 | 220 | 225 |
|    | Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser | 230 | 235 | 240 |
| 15 | Ala Phe   | 242 |     |     |
|    | <210> 64  |     |     |     |
|    | <211> 241   |     |     |     |
|    | <212> PRT   |     |     |     |
| 20 | <213> Human   |     |     |     |
|    | <400> 64  |     |     |     |
|    | Leu Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln | 1   | 5   | 10  |
|    |   |     |     | 15  |
| 25 | Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys | 20  | 25  | 30  |
|    | Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg | 35  | 40  | 45  |
|    | Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val | 50  | 55  | 60  |
| 30 | Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro | 65  | 70  | 75  |
|    | Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser | 80  | 85  | 90  |
| 35 | Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln | 95  | 100 | 105 |
|    | Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr | 110 | 115 | 120 |
|    | Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp | 125 | 130 | 135 |
| 40 | Cys Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro | 140 | 145 | 150 |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Glu Trp Val Cys Gly Gln Gly Gly Gly Leu Gly Thr Gln Pro Leu | 155 | 160 | 165 |
|    | Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro | 170 | 175 | 180 |
| 5  | Pro Gly Val Pro Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys | 185 | 190 | 195 |
|    | Ser Thr Thr Cys Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln | 200 | 205 | 210 |
| 10 | Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser | 215 | 220 | 225 |
|    | Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala | 230 | 235 | 240 |
|    | Phe   | 241 |     |     |
| 15 | <210> 65  |     |     |     |
|    | <211> 240   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 65  |     |     |     |
| 20 | Ala Phe Ser Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu | 1   | 5   | 10  |
|    | Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro | 20  | 25  | 30  |
| 25 | Leu Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val | 35  | 40  | 45  |
|    | Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys | 50  | 55  | 60  |
|    | Asp Ala Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly | 65  | 70  | 75  |
| 30 | Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys | 80  | 85  | 90  |
|    | Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro | 95  | 100 | 105 |
| 35 | His Cys Ser Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys | 110 | 115 | 120 |
|    | Val Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys | 125 | 130 | 135 |
|    | Pro His Pro Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu | 140 | 145 | 150 |
| 40 | Trp Val Cys Gly Gln Gly Gly Gly Leu Gly Thr Gln Pro Leu Pro | 155 | 160 | 165 |

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Ala         | Gln | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val | Ser | Ser | Leu | Pro | Pro |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Gly         | Val | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala | Trp | Gly | Pro | Cys | Ser |  |
|    |             |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| 5  | Thr         | Thr | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg | Val | Ser | Asn | Gln | Asn |  |
|    |             |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Arg         | Phe | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg | Leu | Cys | Leu | Ser | Arg |  |
|    |             |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 10 | Pro         | Cys | Pro | Pro | Ser | Arg | Gly | Arg | Ser | Pro | Gln | Asn | Ser | Ala | Phe |  |
|    |             |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | <210> 66    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> 239   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 15 | <400> 66    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Phe         | Ser | Leu | Leu | Cys | Leu | Leu | Ser | Lys | Val | Arg | Thr | Gln | Leu | Cys |  |
|    | 1           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Pro         | Thr | Pro | Cys | Thr | Cys | Pro | Trp | Pro | Pro | Pro | Arg | Cys | Pro | Leu |  |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
| 20 | Gly         | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys | Arg | Val | Cys |  |
|    |             |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
|    | Ala         | Arg | Arg | Leu | Gly | Glu | Pro | Cys | Asp | Gln | Leu | His | Val | Cys | Asp |  |
|    |             |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
| 25 | Ala         | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly | Pro | Gly | Gly |  |
|    |             |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Arg         | Gly | Ala | Leu | Cys | Leu | Leu | Ala | Glu | Asp | Asp | Ser | Ser | Cys | Glu |  |
|    |             |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Val         | Asn | Gly | Arg | Leu | Tyr | Arg | Glu | Gly | Glu | Thr | Phe | Gln | Pro | His |  |
|    |             |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
| 30 | Cys         | Ser | Ile | Arg | Cys | Arg | Cys | Glu | Asp | Gly | Gly | Phe | Thr | Cys | Val |  |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
|    | Pro         | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro |  |
|    |             |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
| 35 | His         | Pro | Arg | Arg | Val | Glu | Val | Leu | Gly | Lys | Cys | Cys | Pro | Glu | Trp |  |
|    |             |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Val         | Cys | Gly | Gln | Gly | Gly | Gly | Leu | Gly | Thr | Gln | Pro | Leu | Pro | Ala |  |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Gln         | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val | Ser | Ser | Leu | Pro | Pro | Gly |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
| 40 | Val         | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr |  |
|    |             |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Thr         | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg |  |
|    |             |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Phe         | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro |  |
|    |             |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 5  | Cys         | Pro | Pro | Ser | Arg | Gly | Arg | Ser | Pro | Gln | Asn | Ser | Ala | Phe |     |  |
|    |             |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 239 |  |
|    | <210> 67    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> 238   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 10 | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <400> 67    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Ser         | Leu | Leu | Cys | Leu | Leu | Ser | Lys | Val | Arg | Thr | Gln | Leu | Cys | Pro |  |
|    | 1           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
| 15 | Thr         | Pro | Cys | Thr | Cys | Pro | Trp | Pro | Pro | Pro | Arg | Cys | Pro | Leu | Gly |  |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Val         | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys | Arg | Val | Cys | Ala |  |
|    |             |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
|    | Arg         | Arg | Leu | Gly | Glu | Pro | Cys | Asp | Gln | Leu | His | Val | Cys | Asp | Ala |  |
|    |             |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
| 20 | Ser         | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly | Pro | Gly | Gly | Arg |  |
|    |             |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Gly         | Ala | Leu | Cys | Leu | Leu | Ala | Glu | Asp | Asp | Ser | Ser | Cys | Glu | Val |  |
|    |             |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
| 25 | Asn         | Gly | Arg | Leu | Tyr | Arg | Glu | Gly | Glu | Thr | Phe | Gln | Pro | His | Cys |  |
|    |             |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Ser         | Ile | Arg | Cys | Arg | Cys | Glu | Asp | Gly | Gly | Phe | Thr | Cys | Val | Pro |  |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
|    | Leu         | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro | His |  |
|    |             |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
| 30 | Pro         | Arg | Arg | Val | Glu | Val | Leu | Gly | Lys | Cys | Cys | Pro | Glu | Trp | Val |  |
|    |             |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Cys         | Gly | Gln | Gly | Gly | Gly | Leu | Gly | Thr | Gln | Pro | Leu | Pro | Ala | Gln |  |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| 35 | Gly         | Pro | Gln | Phe | Ser | Gly | Leu | Val | Ser | Ser | Leu | Pro | Pro | Gly | Val |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Pro         | Cys | Pro | Glu | Trp | Ser | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr | Thr |  |
|    |             |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Cys         | Gly | Leu | Gly | Met | Ala | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg | Phe |  |
|    |             |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| 40 | Cys         | Arg | Leu | Glu | Thr | Gln | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro | Cys |  |
|    |             |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |



Pro Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
230 235 238

<210> 68  
<211> 237  
5 <212> PRT  
<213> Human

<400> 68  
Leu Leu Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr  
1 5 10 15

10 Pro Cys Thr Cys Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val  
20 25 30

Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg  
35 40 45

15 Arg Leu Gly Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser  
50 55 60

Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly  
65 70 75

Ala Leu Cys Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn  
80 85 90

20 Gly Arg Leu Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser  
95 100 105

Ile Arg Cys Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu  
110 115 120

25 Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro  
125 130 135

Arg Arg Val Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys  
140 145 150

Gly Gln Gly Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly  
155 160 165

30 Pro Gln Phe Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro  
170 175 180

Cys Pro Glu Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys  
185 190 195

35 Gly Leu Gly Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys  
200 205 210

Arg Leu Glu Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro  
215 220 225

Pro Ser Arg Gly Arg Ser Pro Gln Asn Ser Ala Phe  
230 235 237

40 <210> 69  
<211> 236

<212> PRT  
<213> Human

<400> 69

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| 5  | Leu | Cys | Leu | Leu | Ser | Lys | Val | Arg | Thr | Gln | Leu | Cys | Pro | Thr | Pro | 1   | 5   | 10  | 15 |
|    | Cys | Thr | Cys | Pro | Trp | Pro | Pro | Pro | Arg | Cys | Pro | Leu | Gly | Val | Pro | 20  | 25  | 30  |    |
|    | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys | Arg | Val | Cys | Ala | Arg | Arg | 35  | 40  | 45  |    |
| 10 | Leu | Gly | Glu | Pro | Cys | Asp | Gln | Leu | His | Val | Cys | Asp | Ala | Ser | Gln | 50  | 55  | 60  |    |
|    | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly | Pro | Gly | Gly | Arg | Gly | Ala | 65  | 70  | 75  |    |
| 15 | Leu | Cys | Leu | Leu | Ala | Glu | Asp | Asp | Ser | Ser | Cys | Glu | Val | Asn | Gly | 80  | 85  | 90  |    |
|    | Arg | Leu | Tyr | Arg | Glu | Gly | Glu | Thr | Phe | Gln | Pro | His | Cys | Ser | Ile | 95  | 100 | 105 |    |
|    | Arg | Cys | Arg | Cys | Glu | Asp | Gly | Gly | Phe | Thr | Cys | Val | Pro | Leu | Cys | 110 | 115 | 120 |    |
| 20 | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro | His | Pro | Arg | 125 | 130 | 135 |    |
|    | Arg | Val | Glu | Val | Leu | Gly | Lys | Cys | Cys | Pro | Glu | Trp | Val | Cys | Gly | 140 | 145 | 150 |    |
| 25 | Gln | Gly | Gly | Gly | Leu | Gly | Thr | Gln | Pro | Leu | Pro | Ala | Gln | Gly | Pro | 155 | 160 | 165 |    |
|    | Gln | Phe | Ser | Gly | Leu | Val | Ser | Ser | Leu | Pro | Pro | Gly | Val | Pro | Cys | 170 | 175 | 180 |    |
|    | Pro | Glu | Trp | Ser | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr | Thr | Cys | Gly | 185 | 190 | 195 |    |
| 30 | Leu | Gly | Met | Ala | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg | Phe | Cys | Arg | 200 | 205 | 210 |    |
|    | Leu | Glu | Thr | Gln | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro | Cys | Pro | Pro | 215 | 220 | 225 |    |
| 35 | Ser | Arg | Gly | Arg | Ser | Pro | Gln | Asn | Ser | Ala | Phe |     |     |     |     | 230 | 235 | 236 |    |

<210> 70  
<211> 235  
<212> PRT  
<213> Human

40 <400> 70  
Cys Leu Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys

|    |       |       |     |     |     |     |     |
|----|-------|-------|-----|-----|-----|-----|-----|
|    | 1     |       | 5   |     | 10  |     | 15  |
|    | Thr   | Cys   | Pro | Trp | Pro | Pro | Pro |
|    |       |       |     | 20  |     |     | 25  |
|    |       |       |     |     |     |     | 30  |
| 5  | Val   | Leu   | Asp | Gly | Cys | Gly | Cys |
|    |       |       |     | 35  |     |     | 40  |
|    |       |       |     |     |     |     | 45  |
|    | Gly   | Glu   | Pro | Cys | Asp | Gln | Leu |
|    |       |       |     | 50  |     |     | 55  |
|    |       |       |     |     |     |     | 60  |
|    | Leu   | Val   | Cys | Gln | Pro | Gly | Ala |
|    |       |       |     | 65  |     |     | 70  |
|    |       |       |     |     |     |     | 75  |
| 10 | Cys   | Leu   | Leu | Ala | Glu | Asp | Asp |
|    |       |       |     | 80  |     |     | 85  |
|    |       |       |     |     |     |     | 90  |
|    | Leu   | Tyr   | Arg | Glu | Gly | Glu | Thr |
|    |       |       |     | 95  |     |     | 100 |
|    |       |       |     |     |     |     | 105 |
| 15 | Cys   | Arg   | Cys | Glu | Asp | Gly | Gly |
|    |       |       |     | 110 |     |     | 115 |
|    |       |       |     |     |     |     | 120 |
|    | Glu   | Asp   | Val | Arg | Leu | Pro | Ser |
|    |       |       |     | 125 |     |     | 130 |
|    |       |       |     |     |     |     | 135 |
|    | Val   | Glu   | Val | Leu | Gly | Lys | Cys |
|    |       |       |     | 140 |     |     | 145 |
|    |       |       |     |     |     |     | 150 |
| 20 | Gly   | Gly   | Gly | Leu | Gly | Thr | Gln |
|    |       |       |     | 155 |     |     | 160 |
|    |       |       |     |     |     |     | 165 |
|    | Phe   | Ser   | Gly | Leu | Val | Ser | Ser |
|    |       |       |     | 170 |     |     | 175 |
|    |       |       |     |     |     |     | 180 |
| 25 | Glu   | Trp   | Ser | Thr | Ala | Trp | Gly |
|    |       |       |     | 185 |     |     | 190 |
|    |       |       |     |     |     |     | 195 |
|    | Gly   | Met   | Ala | Thr | Arg | Val | Ser |
|    |       |       |     | 200 |     |     | 205 |
|    |       |       |     |     |     |     | 210 |
|    | Glu   | Thr   | Gln | Arg | Arg | Leu | Cys |
|    |       |       |     | 215 |     |     | 220 |
|    |       |       |     |     |     |     | 225 |
| 30 | Arg   | Gly   | Arg | Ser | Pro | Gln | Asn |
|    |       |       |     | 230 |     |     | 235 |
|    |       |       |     |     |     |     |     |
|    | <210> | 71    |     |     |     |     |     |
|    | <211> | 234   |     |     |     |     |     |
|    | <212> | PRT   |     |     |     |     |     |
| 35 | <213> | Human |     |     |     |     |     |
|    |       |       |     |     |     |     |     |
|    | <400> | 71    |     |     |     |     |     |
|    | Leu   | Leu   | Ser | Lys | Val | Arg | Thr |
|    | 1     |       |     | 5   |     |     | 10  |
|    |       |       |     |     |     |     | 15  |
| 40 | Cys   | Pro   | Trp | Pro | Pro | Pro | Arg |
|    |       |       |     | 20  |     |     | 25  |
|    |       |       |     |     |     |     | 30  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly | 35  | 40  | 45  |
|    | Glu Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu | 50  | 55  | 60  |
| 5  | Val Cys Gln Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys | 65  | 70  | 75  |
|    | Leu Leu Ala Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu | 80  | 85  | 90  |
| 10 | Tyr Arg Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys | 95  | 100 | 105 |
|    | Arg Cys Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu | 110 | 115 | 120 |
|    | Asp Val Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val | 125 | 130 | 135 |
| 15 | Glu Val Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly | 140 | 145 | 150 |
|    | Gly Gly Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe | 155 | 160 | 165 |
| 20 | Ser Gly Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu | 170 | 175 | 180 |
|    | Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly | 185 | 190 | 195 |
|    | Met Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu | 200 | 205 | 210 |
| 25 | Thr Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg | 215 | 220 | 225 |
|    | Gly Arg Ser Pro Gln Asn Ser Ala Phe                         | 230 | 234 |     |
| 30 | <210> 72  |     |     |     |
|    | <211> 233   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 72  |     |     |     |
| 35 | Leu Ser Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys | 1   | 5   | 10  |
|    | Pro Trp Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu | 20  | 25  | 30  |
|    | Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu | 35  | 40  | 45  |
| 40 | Pro Cys Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val | 50  | 55  | 60  |

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Cys         | Gln | Pro | Gly | Ala | Gly | Pro | Gly | Gly | Arg | Gly | Ala | Leu | Cys | Leu | 65  | 70  | 75  |
|    | Leu         | Ala | Glu | Asp | Asp | Ser | Ser | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | 80  | 85  | 90  |
| 5  | Arg         | Glu | Gly | Glu | Thr | Phe | Gln | Pro | His | Cys | Ser | Ile | Arg | Cys | Arg | 95  | 100 | 105 |
|    | Cys         | Glu | Asp | Gly | Gly | Phe | Thr | Cys | Val | Pro | Leu | Cys | Ser | Glu | Asp | 110 | 115 | 120 |
| 10 | Val         | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro | His | Pro | Arg | Arg | Val | Glu | 125 | 130 | 135 |
|    | Val         | Leu | Gly | Lys | Cys | Cys | Pro | Glu | Trp | Val | Cys | Gly | Gln | Gly | Gly | 140 | 145 | 150 |
|    | Gly         | Leu | Gly | Thr | Gln | Pro | Leu | Pro | Ala | Gln | Gly | Pro | Gln | Phe | Ser | 155 | 160 | 165 |
| 15 | Gly         | Leu | Val | Ser | Ser | Leu | Pro | Pro | Gly | Val | Pro | Cys | Pro | Glu | Trp | 170 | 175 | 180 |
|    | Ser         | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Met | 185 | 190 | 195 |
| 20 | Ala         | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg | Phe | Cys | Arg | Leu | Glu | Thr | 200 | 205 | 210 |
|    | Gln         | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro | Cys | Pro | Pro | Ser | Arg | Gly | 215 | 220 | 225 |
|    | Arg         | Ser | Pro | Gln | Asn | Ser | Ala | Phe |     |     |     |     |     |     |     | 230 | 233 |     |
| 25 | <210> 73    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <211> 232   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <400> 73    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 30 | Ser         | Lys | Val | Arg | Thr | Gln | Leu | Cys | Pro | Thr | Pro | Cys | Thr | Cys | Pro | 1   | 5   | 10  |
|    | Trp         | Pro | Pro | Pro | Arg | Cys | Pro | Leu | Gly | Val | Pro | Leu | Val | Leu | Asp | 20  | 25  | 30  |
| 35 | Gly         | Cys | Gly | Cys | Cys | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Pro | 35  | 40  | 45  |
|    | Cys         | Asp | Gln | Leu | His | Val | Cys | Asp | Ala | Ser | Gln | Gly | Leu | Val | Cys | 50  | 55  | 60  |
|    | Gln         | Pro | Gly | Ala | Gly | Pro | Gly | Gly | Arg | Gly | Ala | Leu | Cys | Leu | Leu | 65  | 70  | 75  |
| 40 | Ala         | Glu | Asp | Asp | Ser | Ser | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | Arg | 80  | 85  | 90  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Glu Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys | 95  | 100 | 105 |
|    | Glu Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val | 110 | 115 | 120 |
| 5  | Arg Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val | 125 | 130 | 135 |
|    | Leu Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly | 140 | 145 | 150 |
| 10 | Leu Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly | 155 | 160 | 165 |
|    | Leu Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser | 170 | 175 | 180 |
|    | Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala | 185 | 190 | 195 |
| 15 | Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln | 200 | 205 | 210 |
|    | Arg Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg | 215 | 220 | 225 |
| 20 | Ser Pro Gln Asn Ser Ala Phe                                 | 230 | 232 |     |
|    | <210> 74  |     |     |     |
|    | <211> 231   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
| 25 | <400> 74  |     |     |     |
|    | Lys Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp | 1   | 5   | 10  |
|    | Pro Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly | 20  | 25  | 30  |
| 30 | Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys | 35  | 40  | 45  |
|    | Asp Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln | 50  | 55  | 60  |
| 35 | Pro Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala | 65  | 70  | 75  |
|    | Glu Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu | 80  | 85  | 90  |
|    | Gly Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu | 95  | 100 | 105 |
| 40 | Asp Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg | 110 | 115 | 120 |



Leu Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu  
 125 130 135  
 Gly Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu  
 140 145 150  
 5 Gly Thr Gln Pro Leu Pro Ala Gln Gly Pro Gln Phe Ser Gly Leu  
 155 160 165  
 Val Ser Ser Leu Pro Pro Gly Val Pro Cys Pro Glu Trp Ser Thr  
 170 175 180  
 10 Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Met Ala Thr  
 185 190 195  
 Arg Val Ser Asn Gln Asn Arg Phe Cys Arg Leu Glu Thr Gln Arg  
 200 205 210  
 Arg Leu Cys Leu Ser Arg Pro Cys Pro Pro Ser Arg Gly Arg Ser  
 215 220 225  
 15 Pro Gln Asn Ser Ala Phe  
 230 231  
 <210> 75  
 <211> 230  
 <212> PRT  
 20 <213> Human  
 <400> 75  
 Val Arg Thr Gln Leu Cys Pro Thr Pro Cys Thr Cys Pro Trp Pro  
 1 5 10 15  
 25 Pro Pro Arg Cys Pro Leu Gly Val Pro Leu Val Leu Asp Gly Cys  
 20 25 30  
 Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Pro Cys Asp  
 35 40 45  
 Gln Leu His Val Cys Asp Ala Ser Gln Gly Leu Val Cys Gln Pro  
 50 55 60  
 30 Gly Ala Gly Pro Gly Gly Arg Gly Ala Leu Cys Leu Leu Ala Glu  
 65 70 75  
 Asp Asp Ser Ser Cys Glu Val Asn Gly Arg Leu Tyr Arg Glu Gly  
 80 85 90  
 35 Glu Thr Phe Gln Pro His Cys Ser Ile Arg Cys Arg Cys Glu Asp  
 95 100 105  
 Gly Gly Phe Thr Cys Val Pro Leu Cys Ser Glu Asp Val Arg Leu  
 110 115 120  
 Pro Ser Trp Asp Cys Pro His Pro Arg Arg Val Glu Val Leu Gly  
 125 130 135  
 40 Lys Cys Cys Pro Glu Trp Val Cys Gly Gln Gly Gly Gly Leu Gly  
 140 145 150

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Thr         | Gln | Pro | Leu | Pro | Ala | Gln | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val |  |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Ser         | Ser | Leu | Pro | Pro | Gly | Val | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
| 5  | Trp         | Gly | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg |  |
|    |             |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Val         | Ser | Asn | Gln | Asn | Arg | Phe | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg |  |
|    |             |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| 10 | Leu         | Cys | Leu | Ser | Arg | Pro | Cys | Pro | Pro | Ser | Arg | Gly | Arg | Ser | Pro |  |
|    |             |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
|    | Gln         | Asn | Ser | Ala | Phe |     |     |     |     |     |     |     |     |     |     |  |
|    |             |     |     |     | 230 |     |     |     |     |     |     |     |     |     |     |  |
|    | <210> 76    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> 229   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 15 | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <400> 76    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Arg         | Thr | Gln | Leu | Cys | Pro | Thr | Pro | Cys | Thr | Cys | Pro | Trp | Pro | Pro |  |
|    | 1           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
| 20 | Pro         | Arg | Cys | Pro | Leu | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly |  |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Cys         | Cys | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Pro | Cys | Asp | Gln |  |
|    |             |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 25 | Leu         | His | Val | Cys | Asp | Ala | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly |  |
|    |             |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Ala         | Gly | Pro | Gly | Gly | Arg | Gly | Ala | Leu | Cys | Leu | Leu | Ala | Glu | Asp |  |
|    |             |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Asp         | Ser | Ser | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | Arg | Glu | Gly | Glu |  |
|    |             |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
| 30 | Thr         | Phe | Gln | Pro | His | Cys | Ser | Ile | Arg | Cys | Arg | Cys | Glu | Asp | Gly |  |
|    |             |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Gly         | Phe | Thr | Cys | Val | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro |  |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 35 | Ser         | Trp | Asp | Cys | Pro | His | Pro | Arg | Arg | Val | Glu | Val | Leu | Gly | Lys |  |
|    |             |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Cys         | Cys | Pro | Glu | Trp | Val | Cys | Gly | Gln | Gly | Gly | Gly | Leu | Gly | Thr |  |
|    |             |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Gln         | Pro | Leu | Pro | Ala | Gln | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val | Ser |  |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| 40 | Ser         | Leu | Pro | Pro | Gly | Val | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala | Trp |  |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Gly   | Pro   | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg | Val |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Ser   | Asn   | Gln | Asn | Arg | Phe | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg | Leu |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| 5  | Cys   | Leu   | Ser | Arg | Pro | Cys | Pro | Pro | Ser | Arg | Gly | Arg | Ser | Pro | Gln |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
|    | Asn   | Ser   | Ala | Phe | 229 |     |     |     |     |     |     |     |     |     |     |  |
|    | <210> | 77    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 10 | <211> | 228   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <400> | 77    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 15 | Thr   | Gln   | Leu | Cys | Pro | Thr | Pro | Cys | Thr | Cys | Pro | Trp | Pro | Pro | Pro |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Arg   | Cys   | Pro | Leu | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Cys   | Arg   | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Pro | Cys | Asp | Gln | Leu |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 20 | His   | Val   | Cys | Asp | Ala | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Gly   | Pro   | Gly | Gly | Arg | Gly | Ala | Leu | Cys | Leu | Leu | Ala | Glu | Asp | Asp |  |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
| 25 | Ser   | Ser   | Cys | Glu | Val | Asn | Gly | Arg | Leu | Tyr | Arg | Glu | Gly | Glu | Thr |  |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Phe   | Gln   | Pro | His | Cys | Ser | Ile | Arg | Cys | Arg | Cys | Glu | Asp | Gly | Gly |  |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Phe   | Thr   | Cys | Val | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser |  |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 30 | Trp   | Asp   | Cys | Pro | His | Pro | Arg | Arg | Val | Glu | Val | Leu | Gly | Lys | Cys |  |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Cys   | Pro   | Glu | Trp | Val | Cys | Gly | Gln | Gly | Gly | Gly | Leu | Gly | Thr | Gln |  |
|    |       |       |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
| 35 | Pro   | Leu   | Pro | Ala | Gln | Gly | Pro | Gln | Phe | Ser | Gly | Leu | Val | Ser | Ser |  |
|    |       |       |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Leu   | Pro   | Pro | Gly | Val | Pro | Cys | Pro | Glu | Trp | Ser | Thr | Ala | Trp | Gly |  |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Pro   | Cys   | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Met | Ala | Thr | Arg | Val | Ser |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| 40 | Asn   | Gln   | Asn | Arg | Phe | Cys | Arg | Leu | Glu | Thr | Gln | Arg | Arg | Leu | Cys |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |

-87-

|    |   |     |
|----|---|-----|
|    | Arg Ser His Gly Ser Trp Asn Ser Ala Phe                     |     |
|    | 245   | 250 |
|    | <210> 79  |     |
|    | <211> 249   |     |
| 5  | <212> PRT   |     |
|    | <213> Human   |     |
|    | <400> 79  |     |
|    | Gly Asn Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile |     |
|    | 1   | 15  |
| 10 | Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys |     |
|    | 20  | 30  |
|    | Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu |     |
|    | 35  | 45  |
| 15 | Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu |     |
|    | 50  | 60  |
|    | Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val |     |
|    | 65  | 75  |
|    | Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu |     |
|    | 80  | 90  |
| 20 | Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr |     |
|    | 95  | 105 |
|    | Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg |     |
|    | 110   | 120 |
| 25 | Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp |     |
|    | 125   | 135 |
|    | Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln |     |
|    | 140   | 150 |
|    | Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val |     |
|    | 155   | 165 |
| 30 | Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu |     |
|    | 170   | 180 |
|    | Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn |     |
|    | 185   | 195 |
| 35 | Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly |     |
|    | 200   | 210 |
|    | Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu |     |
|    | 215   | 225 |
|    | Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg |     |
|    | 230   | 240 |
| 40 | Ser His Gly Ser Trp Asn Ser Ala Phe                         |     |
|    | 245   | 249 |

<210> 80  
 <211> 248  
 <212> PRT  
 <213> Human

5 <400> 80  
 Asn Pro Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu  
 1 5 10 15  
 Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro  
 20 25 30  
 10 Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp  
 35 40 45  
 Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser  
 50 55 60  
 15 Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys  
 65 70 75  
 Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe  
 80 85 90  
 Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu  
 95 100 105  
 20 Asp Glu Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys  
 110 115 120  
 Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val  
 125 130 135  
 25 Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val  
 140 145 150  
 Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met  
 155 160 165  
 Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser  
 170 175 180  
 30 Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp  
 185 190 195  
 Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile  
 200 205 210  
 35 Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile  
 215 220 225  
 Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser  
 230 235 240  
 His Gly Ser Trp Asn Ser Ala Phe  
 245 248  
 40 <210> 81  
 <211> 247



&lt;212&gt; PRT

&lt;213&gt; Human

&lt;400&gt; 81

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |   |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|---|-----|-----|-----|
| 5  | Pro | Leu | Ile | His | Leu | Leu | Ala | Ile | Ser | Phe | Leu | Cys | Ile | Leu | Ser | 1 | 5   | 10  | 15  |
|    | Met | Val | Tyr | Ser | Gln | Leu | Cys | Pro | Ala | Pro | Cys | Ala | Cys | Pro | Trp |   | 20  | 25  | 30  |
|    | Thr | Pro | Pro | Gln | Cys | Pro | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly |   | 35  | 40  | 45  |
| 10 | Cys | Gly | Cys | Cys | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Ser | Cys |   | 50  | 55  | 60  |
|    | Asp | His | Leu | His | Val | Cys | Asp | Pro | Ser | Gln | Gly | Leu | Val | Cys | Gln |   | 65  | 70  | 75  |
| 15 | Pro | Gly | Ala | Gly | Pro | Ser | Gly | Arg | Gly | Ala | Val | Cys | Leu | Phe | Glu |   | 80  | 85  | 90  |
|    | Glu | Asp | Asp | Gly | Ser | Cys | Glu | Val | Asn | Gly | Arg | Arg | Tyr | Leu | Asp |   | 95  | 100 | 105 |
|    | Gly | Glu | Thr | Phe | Lys | Pro | Asn | Cys | Arg | Val | Leu | Cys | Arg | Cys | Asp |   | 110 | 115 | 120 |
| 20 | Asp | Gly | Gly | Phe | Thr | Cys | Leu | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg |   | 125 | 130 | 135 |
|    | Leu | Pro | Ser | Trp | Asp | Cys | Pro | Arg | Pro | Arg | Arg | Ile | Gln | Val | Pro |   | 140 | 145 | 150 |
| 25 | Gly | Arg | Cys | Cys | Pro | Glu | Trp | Val | Cys | Asp | Gln | Ala | Val | Met | Gln |   | 155 | 160 | 165 |
|    | Pro | Ala | Ile | Gln | Pro | Ser | Ser | Ala | Gln | Gly | His | Gln | Leu | Ser | Ala |   | 170 | 175 | 180 |
|    | Leu | Val | Thr | Pro | Ala | Ser | Ala | Asp | Gly | Pro | Cys | Pro | Asn | Trp | Ser |   | 185 | 190 | 195 |
| 30 | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Ile | Ala |   | 200 | 205 | 210 |
|    | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg | Phe | Cys | Gln | Leu | Glu | Ile | Gln |   | 215 | 220 | 225 |
| 35 | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro | Cys | Leu | Ala | Ser | Arg | Ser | His |   | 230 | 235 | 240 |
|    | Gly | Ser | Trp | Asn | Ser | Ala | Phe |     |     |     |     |     |     |     |     |   | 245 | 247 |     |

&lt;210&gt; 82

&lt;211&gt; 246

&lt;212&gt; PRT

&lt;213&gt; Human

<400> 82  
 Leu Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met  
 1 5 10 15  
 Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr  
 5 20 25 30  
 Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys  
 35 40 45  
 Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp  
 50 55 60  
 10 His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro  
 65 70 75  
 Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu  
 80 85 90  
 Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly  
 15 95 100 105  
 Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp  
 110 115 120  
 Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu  
 125 130 135  
 20 Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly  
 140 145 150  
 Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro  
 155 160 165  
 25 Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu  
 170 175 180  
 Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr  
 185 190 195  
 Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr  
 200 205 210  
 30 Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg  
 215 220 225  
 Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly  
 230 235 240  
 35 Ser Trp Asn Ser Ala Phe  
 245 246  
 <210> 83  
 <211> 245  
 <212> PRT  
 <213> Human  
 40 <400> 83  
 Ile His Leu Leu Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | 1     |       | 5   |     | 10  |     | 15  |     |     |     |     |     |     |     |     |
|    | Tyr   | Ser   | Gln | Leu | Cys | Pro | Ala | Pro | Cys | Ala | Cys | Pro | Trp | Thr | Pro |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |
| 5  | Pro   | Gln   | Cys | Pro | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |
|    | Cys   | Cys   | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Ser | Cys | Asp | His |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |
|    | Leu   | His   | Val | Cys | Asp | Pro | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |
| 10 | Ala   | Gly   | Pro | Ser | Gly | Arg | Gly | Ala | Val | Cys | Leu | Phe | Glu | Glu | Asp |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |
|    | Asp   | Gly   | Ser | Cys | Glu | Val | Asn | Gly | Arg | Arg | Tyr | Leu | Asp | Gly | Glu |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |
| 15 | Thr   | Phe   | Lys | Pro | Asn | Cys | Arg | Val | Leu | Cys | Arg | Cys | Asp | Asp | Gly |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |
|    | Gly   | Phe   | Thr | Cys | Leu | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |
|    | Ser   | Trp   | Asp | Cys | Pro | Arg | Pro | Arg | Arg | Ile | Gln | Val | Pro | Gly | Arg |
|    |       |       |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |
| 20 | Cys   | Cys   | Pro | Glu | Trp | Val | Cys | Asp | Gln | Ala | Val | Met | Gln | Pro | Ala |
|    |       |       |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |
|    | Ile   | Gln   | Pro | Ser | Ser | Ala | Gln | Gly | His | Gln | Leu | Ser | Ala | Leu | Val |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |
| 25 | Thr   | Pro   | Ala | Ser | Ala | Asp | Gly | Pro | Cys | Pro | Asn | Trp | Ser | Thr | Ala |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |
|    | Trp   | Gly   | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Ile | Ala | Thr | Arg |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |
|    | Val   | Ser   | Asn | Gln | Asn | Arg | Phe | Cys | Gln | Leu | Glu | Ile | Gln | Arg | Arg |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |
| 30 | Leu   | Cys   | Leu | Ser | Arg | Pro | Cys | Leu | Ala | Ser | Arg | Ser | His | Gly | Ser |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
|    | Trp   | Asn   | Ser | Ala | Phe |     |     |     |     |     |     |     |     |     |     |
|    |       |       |     |     | 245 |     |     |     |     |     |     |     |     |     |     |
| 35 | <210> | 84    |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <211> | 244   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 40 | <400> | 84    |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | His   | Leu   | Leu | Ala | Ile | Ser | Phe | Leu | Cys | Ile | Leu | Ser | Met | Val | Tyr |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Ser   | Gln   | Leu | Cys | Pro | Ala | Pro | Cys | Ala | Cys | Pro | Trp | Thr | Pro | Pro |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Gln   | Cys   | Pro | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 5  | Cys   | Arg   | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Ser | Cys | Asp | His | Leu |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | His   | Val   | Cys | Asp | Pro | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala |  |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
| 10 | Gly   | Pro   | Ser | Gly | Arg | Gly | Ala | Val | Cys | Leu | Phe | Glu | Glu | Asp | Asp |  |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Gly   | Ser   | Cys | Glu | Val | Asn | Gly | Arg | Arg | Tyr | Leu | Asp | Gly | Glu | Thr |  |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Phe   | Lys   | Pro | Asn | Cys | Arg | Val | Leu | Cys | Arg | Cys | Asp | Asp | Gly | Gly |  |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 15 | Phe   | Thr   | Cys | Leu | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser |  |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Trp   | Asp   | Cys | Pro | Arg | Pro | Arg | Arg | Ile | Gln | Val | Pro | Gly | Arg | Cys |  |
|    |       |       |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
| 20 | Cys   | Pro   | Glu | Trp | Val | Cys | Asp | Gln | Ala | Val | Met | Gln | Pro | Ala | Ile |  |
|    |       |       |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Gln   | Pro   | Ser | Ser | Ala | Gln | Gly | His | Gln | Leu | Ser | Ala | Leu | Val | Thr |  |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Pro   | Ala   | Ser | Ala | Asp | Gly | Pro | Cys | Pro | Asn | Trp | Ser | Thr | Ala | Trp |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| 25 | Gly   | Pro   | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Ile | Ala | Thr | Arg | Val |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Ser   | Asn   | Gln | Asn | Arg | Phe | Cys | Gln | Leu | Glu | Ile | Gln | Arg | Arg | Leu |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 30 | Cys   | Leu   | Ser | Arg | Pro | Cys | Leu | Ala | Ser | Arg | Ser | His | Gly | Ser | Trp |  |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Asn   | Ser   | Ala | Phe |     |     |     |     |     |     |     |     |     |     |     |  |
|    |       |       |     |     | 244 |     |     |     |     |     |     |     |     |     |     |  |
|    | <210> | 85    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> | 243   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 35 | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <400> | 85    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Leu   | Leu   | Ala | Ile | Ser | Phe | Leu | Cys | Ile | Leu | Ser | Met | Val | Tyr | Ser |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
| 40 | Gln   | Leu   | Cys | Pro | Ala | Pro | Cys | Ala | Cys | Pro | Trp | Thr | Pro | Pro | Gln |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Cys   | Pro   | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
|    | Arg   | Val   | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Ser | Cys | Asp | His | Leu | His |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
| 5  | Val   | Cys   | Asp | Pro | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly |  |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
|    | Pro   | Ser   | Gly | Arg | Gly | Ala | Val | Cys | Leu | Phe | Glu | Glu | Asp | Asp | Gly |  |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
| 10 | Ser   | Cys   | Glu | Val | Asn | Gly | Arg | Arg | Tyr | Leu | Asp | Gly | Glu | Thr | Phe |  |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Lys   | Pro   | Asn | Cys | Arg | Val | Leu | Cys | Arg | Cys | Asp | Asp | Gly | Gly | Phe |  |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
|    | Thr   | Cys   | Leu | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp |  |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
| 15 | Asp   | Cys   | Pro | Arg | Pro | Arg | Arg | Ile | Gln | Val | Pro | Gly | Arg | Cys | Cys |  |
|    |       |       |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Pro   | Glu   | Trp | Val | Cys | Asp | Gln | Ala | Val | Met | Gln | Pro | Ala | Ile | Gln |  |
|    |       |       |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| 20 | Pro   | Ser   | Ser | Ala | Gln | Gly | His | Gln | Leu | Ser | Ala | Leu | Val | Thr | Pro |  |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Ala   | Ser   | Ala | Asp | Gly | Pro | Cys | Pro | Asn | Trp | Ser | Thr | Ala | Trp | Gly |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Pro   | Cys   | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Ile | Ala | Thr | Arg | Val | Ser |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| 25 | Asn   | Gln   | Asn | Arg | Phe | Cys | Gln | Leu | Glu | Ile | Gln | Arg | Arg | Leu | Cys |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
|    | Leu   | Ser   | Arg | Pro | Cys | Leu | Ala | Ser | Arg | Ser | His | Gly | Ser | Trp | Asn |  |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
| 30 | Ser   | Ala   | Phe |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    |       |       |     |     | 243 |     |     |     |     |     |     |     |     |     |     |  |
|    | <210> | 86    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> | 242   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 35 | <400> | 86    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Leu   | Ala   | Ile | Ser | Phe | Leu | Cys | Ile | Leu | Ser | Met | Val | Tyr | Ser | Gln |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Leu   | Cys   | Pro | Ala | Pro | Cys | Ala | Cys | Pro | Trp | Thr | Pro | Pro | Gln | Cys |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
| 40 | Pro   | Pro   | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys | Arg |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |

|    |   |         |
|----|---|---------|
|    | Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His Val |         |
|    | 50  | 55 60   |
|    | Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro |         |
|    | 65  | 70 75   |
| 5  | Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly Ser |         |
|    | 80  | 85 90   |
|    | Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys |         |
|    | 95  | 100 105 |
| 10 | Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr |         |
|    | 110   | 115 120 |
|    | Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp |         |
|    | 125   | 130 135 |
|    | Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro |         |
|    | 140   | 145 150 |
| 15 | Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro |         |
|    | 155   | 160 165 |
|    | Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala |         |
|    | 170   | 175 180 |
| 20 | Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro |         |
|    | 185   | 190 195 |
|    | Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn |         |
|    | 200   | 205 210 |
|    | Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu |         |
|    | 215   | 220 225 |
| 25 | Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser |         |
|    | 230   | 235 240 |
|    | Ala Phe   |         |
|    | 242   |         |
| 30 | <210> 87  |         |
|    | <211> 241   |         |
|    | <212> PRT   |         |
|    | <213> Human   |         |
|    | <400> 87  |         |
| 35 | Ala Ile Ser Phe Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu |         |
|    | 1 5 10 15   |         |
|    | Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro |         |
|    | 20 25 30  |         |
|    | Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val |         |
|    | 35 40 45  |         |
| 40 | Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu His Val Cys |         |
|    | 50 55 60  |         |



|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | Asp   | Pro   | Ser | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly | Pro | Ser | 65  | 70  | 75  |
|    | Gly   | Arg   | Gly | Ala | Val | Cys | Leu | Phe | Glu | Glu | Asp | Asp | Gly | Ser | Cys | 80  | 85  | 90  |
| 5  | Glu   | Val   | Asn | Gly | Arg | Arg | Tyr | Leu | Asp | Gly | Glu | Thr | Phe | Lys | Pro | 95  | 100 | 105 |
|    | Asn   | Cys   | Arg | Val | Leu | Cys | Arg | Cys | Asp | Asp | Gly | Gly | Phe | Thr | Cys | 110 | 115 | 120 |
| 10 | Leu   | Pro   | Leu | Cys | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp | Asp | Cys | 125 | 130 | 135 |
|    | Pro   | Arg   | Pro | Arg | Arg | Ile | Gln | Val | Pro | Gly | Arg | Cys | Cys | Pro | Glu | 140 | 145 | 150 |
|    | Trp   | Val   | Cys | Asp | Gln | Ala | Val | Met | Gln | Pro | Ala | Ile | Gln | Pro | Ser | 155 | 160 | 165 |
| 15 | Ser   | Ala   | Gln | Gly | His | Gln | Leu | Ser | Ala | Leu | Val | Thr | Pro | Ala | Ser | 170 | 175 | 180 |
|    | Ala   | Asp   | Gly | Pro | Cys | Pro | Asn | Trp | Ser | Thr | Ala | Trp | Gly | Pro | Cys | 185 | 190 | 195 |
| 20 | Ser   | Thr   | Thr | Cys | Gly | Leu | Gly | Ile | Ala | Thr | Arg | Val | Ser | Asn | Gln | 200 | 205 | 210 |
|    | Asn   | Arg   | Phe | Cys | Gln | Leu | Glu | Ile | Gln | Arg | Arg | Leu | Cys | Leu | Ser | 215 | 220 | 225 |
|    | Arg   | Pro   | Cys | Leu | Ala | Ser | Arg | Ser | His | Gly | Ser | Trp | Asn | Ser | Ala | 230 | 235 | 240 |
| 25 | Phe   |       |     |     |     |     |     |     |     |     |     |     |     |     |     | 241 |     |     |
|    | <210> | 88    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <211> | 240   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 30 | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <400> | 88    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | Ile   | Ser   | Phe | Leu | Cys | Ile | Leu | Ser | Met | Val | Tyr | Ser | Gln | Leu | Cys | 1   | 5   | 10  |
| 35 | Pro   | Ala   | Pro | Cys | Ala | Cys | Pro | Trp | Thr | Pro | Pro | Gln | Cys | Pro | Pro | 20  | 25  | 30  |
|    | Gly   | Val   | Pro | Leu | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys | Arg | Val | Cys | 35  | 40  | 45  |
|    | Ala   | Arg   | Arg | Leu | Gly | Glu | Ser | Cys | Asp | His | Leu | His | Val | Cys | Asp | 50  | 55  | 60  |
| 40 | Pro   | Ser   | Gln | Gly | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly | Pro | Ser | Gly | 65  | 70  | 75  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu | 80  | 85  | 90  |
|    | Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn | 95  | 100 | 105 |
| 5  | Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu | 110 | 115 | 120 |
|    | Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro | 125 | 130 | 135 |
| 10 | Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp | 140 | 145 | 150 |
|    | Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser | 155 | 160 | 165 |
|    | Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala | 170 | 175 | 180 |
| 15 | Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser | 185 | 190 | 195 |
|    | Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn | 200 | 205 | 210 |
| 20 | Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg | 215 | 220 | 225 |
|    | Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe | 230 | 235 | 240 |
|    | <210> 89  |     |     |     |
|    | <211> 239   |     |     |     |
| 25 | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 89  |     |     |     |
|    | Ser Phe Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro | 1   | 5   | 10  |
| 30 | Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly | 20  | 25  | 30  |
|    | Val Pro Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala | 35  | 40  | 45  |
| 35 | Arg Arg Leu Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro | 50  | 55  | 60  |
|    | Ser Gln Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg | 65  | 70  | 75  |
|    | Gly Ala Val Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val | 80  | 85  | 90  |
| 40 | Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys | 95  | 100 | 105 |

|    |       |       |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Arg   | Val   | Leu | Cys | Arg | Cys | Asp | Asp | Gly | Gly | Phe | Thr | Cys | Leu | Pro |  |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
|    | Leu   | Cys   | Ser | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro | Arg |  |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
| 5  | Pro   | Arg   | Arg | Ile | Gln | Val | Pro | Gly | Arg | Cys | Cys | Pro | Glu | Trp | Val |  |
|    |       |       |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
|    | Cys   | Asp   | Gln | Ala | Val | Met | Gln | Pro | Ala | Ile | Gln | Pro | Ser | Ser | Ala |  |
|    |       |       |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| 10 | Gln   | Gly   | His | Gln | Leu | Ser | Ala | Leu | Val | Thr | Pro | Ala | Ser | Ala | Asp |  |
|    |       |       |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Gly   | Pro   | Cys | Pro | Asn | Trp | Ser | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr |  |
|    |       |       |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
|    | Thr   | Cys   | Gly | Leu | Gly | Ile | Ala | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg |  |
|    |       |       |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| 15 | Phe   | Cys   | Gln | Leu | Glu | Ile | Gln | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro |  |
|    |       |       |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
|    | Cys   | Leu   | Ala | Ser | Arg | Ser | His | Gly | Ser | Trp | Asn | Ser | Ala | Phe |     |  |
|    |       |       |     |     | 230 |     |     |     |     | 235 |     |     |     | 239 |     |  |
| 20 | <210> | 90    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <211> | 238   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <212> | PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | <213> | Human |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| 25 | <400> | 90    |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|    | Phe   | Leu   | Cys | Ile | Leu | Ser | Met | Val | Tyr | Ser | Gln | Leu | Cys | Pro | Ala |  |
|    | 1     |       |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Pro   | Cys   | Ala | Cys | Pro | Trp | Thr | Pro | Pro | Gln | Cys | Pro | Pro | Gly | Val |  |
|    |       |       |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Pro   | Leu   | Val | Leu | Asp | Gly | Cys | Gly | Cys | Cys | Arg | Val | Cys | Ala | Arg |  |
|    |       |       |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| 30 | Arg   | Leu   | Gly | Glu | Ser | Cys | Asp | His | Leu | His | Val | Cys | Asp | Pro | Ser |  |
|    |       |       |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Gln   | Gly   | Leu | Val | Cys | Gln | Pro | Gly | Ala | Gly | Pro | Ser | Gly | Arg | Gly |  |
|    |       |       |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
| 35 | Ala   | Val   | Cys | Leu | Phe | Glu | Glu | Asp | Asp | Gly | Ser | Cys | Glu | Val | Asn |  |
|    |       |       |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Gly   | Arg   | Arg | Tyr | Leu | Asp | Gly | Glu | Thr | Phe | Lys | Pro | Asn | Cys | Arg |  |
|    |       |       |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Val   | Leu   | Cys | Arg | Cys | Asp | Asp | Gly | Gly | Phe | Thr | Cys | Leu | Pro | Leu |  |
|    |       |       |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 40 | Cys   | Ser   | Glu | Asp | Val | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro | Arg | Pro |  |
|    |       |       |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Arg Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp val Cys | 140 | 145 | 150 |
|    | Asp Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln | 155 | 160 | 165 |
| 5  | Gly His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly | 170 | 175 | 180 |
|    | Pro Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr | 185 | 190 | 195 |
| 10 | Cys Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe | 200 | 205 | 210 |
|    | Cys Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys | 215 | 220 | 225 |
|    | Leu Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe         | 230 | 235 | 238 |
| 15 | <210> 91  |     |     |     |
|    | <211> 237   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 91  |     |     |     |
| 20 | Leu Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro | 1   | 5   | 10  |
|    | Cys Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro | 20  | 25  | 30  |
| 25 | Leu Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg | 35  | 40  | 45  |
|    | Leu Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln | 50  | 55  | 60  |
|    | Gly Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala | 65  | 70  | 75  |
| 30 | Val Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly | 80  | 85  | 90  |
|    | Arg Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val | 95  | 100 | 105 |
| 35 | Leu Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys | 110 | 115 | 120 |
|    | Ser Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg | 125 | 130 | 135 |
|    | Arg Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp | 140 | 145 | 150 |
| 40 | Gln Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly | 155 | 160 | 165 |

His Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro  
 170 175 180  
 Cys Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys  
 185 190 195  
 5 Gly Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys  
 200 205 210  
 Gln Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu  
 215 220 225  
 10 Ala Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe  
 230 235 237  
 <210> 92  
 <211> 236  
 <212> PRT  
 <213> Human  
 15 <400> 92  
 Cys Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys  
 1 5 10 15  
 Ala Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu  
 20 25 30  
 20 Val Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu  
 35 40 45  
 Gly Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly  
 50 55 60  
 25 Leu Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val  
 65 70 75  
 Cys Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg  
 80 85 90  
 Arg Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu  
 95 100 105  
 30 Cys Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser  
 110 115 120  
 Glu Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg  
 125 130 135  
 35 Ile Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln  
 140 145 150  
 Ala Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His  
 155 160 165  
 Gln Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys  
 170 175 180  
 40 Pro Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly  
 185 190 195

Leu Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln  
 200 205 210  
 Leu Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala  
 215 220 225  
 5 Ser Arg Ser His Gly Ser Trp Asn Ser Ala Phe  
 230 235 236  
 <210> 93  
 <211> 235  
 <212> PRT  
 10 <213> Human  
 <400> 93  
 Ile Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala  
 1 5 10 15  
 15 Cys Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val  
 20 25 30  
 Leu Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly  
 35 40 45  
 Glu Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu  
 50 55 60  
 20 Val Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys  
 65 70 75  
 Leu Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg  
 80 85 90  
 25 Tyr Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys  
 95 100 105  
 Arg Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu  
 110 115 120  
 Asp Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile  
 125 130 135  
 30 Gln Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala  
 140 145 150  
 Val Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln  
 155 160 165  
 35 Leu Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro  
 170 175 180  
 Asn Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu  
 185 190 195  
 Gly Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu  
 200 205 210  
 40 Glu Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser  
 215 220 225



Arg Ser His G., Ser Trp Asn Ser Ala Phe  
230 235

<210> 94  
<211> 234  
5 <212> PRT  
<213> Human

<400> 94  
Leu Ser Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys  
1 5 10 15

10 Pro Trp Thr Pro Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu  
20 25 30

Asp Gly Cys Gly Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu  
35 40 45

15 Ser Cys Asp His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val  
50 55 60

Cys Gln Pro Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu  
65 70 75

Phe Glu Glu Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr  
80 85 90

20 Leu Asp Gly Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg  
95 100 105

Cys Asp Asp Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp  
110 115 120

25 Val Arg Leu Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln  
125 130 135

Val Pro Gly Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val  
140 145 150

Met Gln Pro Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu  
155 160 165

30 Ser Ala Leu Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn  
170 175 180

Trp Ser Thr Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly  
185 190 195

35 Ile Ala Thr Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu  
200 205 210

Ile Gln Arg Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg  
215 220 225

Ser His Gly Ser Trp Asn Ser Ala Phe  
230 234

40 <210> 95  
<211> 233

<212> PRT  
<213> Human

<400> 95

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 5  | Ser | Met | Val | Tyr | Ser | Gln | Leu | Cys | Pro | Ala | Pro | Cys | Ala | Cys | Pro | 15  |
|    | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     |     |     |
|    | Trp | Thr | Pro | Pro | Gln | Cys | Pro | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | 30  |
|    |     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     |     |     |
|    | Gly | Cys | Gly | Cys | Cys | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Ser | 45  |
|    |     |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     |     |     |
| 10 | Cys | Asp | His | Leu | His | Val | Cys | Asp | Pro | Ser | Gln | Gly | Leu | Val | Cys | 60  |
|    |     |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     |     |     |
|    | Gln | Pro | Gly | Ala | Gly | Pro | Ser | Gly | Arg | Gly | Ala | Val | Cys | Leu | Phe | 75  |
|    |     |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     |     |     |
|    | Glu | Glu | Asp | Asp | Gly | Ser | Cys | Glu | Val | Asn | Gly | Arg | Arg | Tyr | Leu | 90  |
| 15 |     |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     |     |     |
|    | Asp | Gly | Glu | Thr | Phe | Lys | Pro | Asn | Cys | Arg | Val | Leu | Cys | Arg | Cys | 105 |
|    |     |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     |     |     |
|    | Asp | Asp | Gly | Gly | Phe | Thr | Cys | Leu | Pro | Leu | Cys | Ser | Glu | Asp | Val | 120 |
|    |     |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     |     |     |
| 20 | Arg | Leu | Pro | Ser | Trp | Asp | Cys | Pro | Arg | Pro | Arg | Arg | Ile | Gln | Val | 135 |
|    |     |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     |     |     |
|    | Pro | Gly | Arg | Cys | Cys | Pro | Glu | Trp | Val | Cys | Asp | Gln | Ala | Val | Met | 150 |
|    |     |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     |     |     |
|    | Gln | Pro | Ala | Ile | Gln | Pro | Ser | Ser | Ala | Gln | Gly | His | Gln | Leu | Ser | 165 |
| 25 |     |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     |     |     |
|    | Ala | Leu | Val | Thr | Pro | Ala | Ser | Ala | Asp | Gly | Pro | Cys | Pro | Asn | Trp | 180 |
|    |     |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     |     |     |
|    | Ser | Thr | Ala | Trp | Gly | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Ile | 195 |
|    |     |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     |     |     |
| 30 | Ala | Thr | Arg | Val | Ser | Asn | Gln | Asn | Arg | Phe | Cys | Gln | Leu | Glu | Ile | 210 |
|    |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     |     |     |
|    | Gln | Arg | Arg | Leu | Cys | Leu | Ser | Arg | Pro | Cys | Leu | Ala | Ser | Arg | Ser | 225 |
|    |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |     |     |
|    | His | Gly | Ser | Trp | Asn | Ser | Ala | Phe |     |     |     |     |     |     |     |     |
| 35 |     |     |     |     | 230 |     |     |     |     | 233 |     |     |     |     |     |     |

<210> 96  
<211> 232  
<212> PRT  
<213> Human

40 <400> 96  
Met Val Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp

|    |             |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|    | 1           |     | 5   |     | 10  |     | 15  |     |     |     |     |     |     |     |     |
|    | Thr         | Pro | Pro | Gln | Cys | Pro | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |
| 5  | Cys         | Gly | Cys | Cys | Arg | Val | Cys | Ala | Arg | Arg | Leu | Gly | Glu | Ser | Cys |
|    |             |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |
|    | Asp         | His | Leu | His | Val | Cys | Asp | Pro | Ser | Gln | Gly | Leu | Val | Cys | Gln |
|    |             |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |
|    | Pro         | Gly | Ala | Gly | Pro | Ser | Gly | Arg | Gly | Ala | Val | Cys | Leu | Phe | Glu |
|    |             |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |
| 10 | Glu         | Asp | Asp | Gly | Ser | Cys | Glu | Val | Asn | Gly | Arg | Arg | Tyr | Leu | Asp |
|    |             |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |
|    | Gly         | Glu | Thr | Phe | Lys | Pro | Asn | Cys | Arg | Val | Leu | Cys | Arg | Cys | Asp |
|    |             |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |
| 15 | Asp         | Gly | Gly | Phe | Thr | Cys | Leu | Pro | Leu | Cys | Ser | Glu | Asp | Val | Arg |
|    |             |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |
|    | Leu         | Pro | Ser | Trp | Asp | Cys | Pro | Arg | Pro | Arg | Arg | Ile | Gln | Val | Pro |
|    |             |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |
|    | Gly         | Arg | Cys | Cys | Pro | Glu | Trp | Val | Cys | Asp | Gln | Ala | Val | Met | Gln |
|    |             |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |
| 20 | Pro         | Ala | Ile | Gln | Pro | Ser | Ser | Ala | Gln | Gly | His | Gln | Leu | Ser | Ala |
|    |             |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |
|    | Leu         | Val | Thr | Pro | Ala | Ser | Ala | Asp | Gly | Pro | Cys | Pro | Asn | Trp | Ser |
|    |             |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |
| 25 | Thr         | Ala | Trp | Gly | Pro | Cys | Ser | Thr | Thr | Cys | Gly | Leu | Gly | Ile | Ala |
|    |             |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |
|    | Thr         | Arg | Val | Ser | Asn | Gln | Asn | Arg | Phe | Cys | Gln | Leu | Glu | Ile | Gln |
|    |             |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |
|    | Arg         | Arg | Leu | Cys | Leu | Ser | Arg | Pro | Cys | Leu | Ala | Ser | Arg | Ser | His |
|    |             |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |
| 30 | Gly         | Ser | Trp | Asn | Ser | Ala | Phe |     |     |     |     |     |     |     |     |
|    |             |     |     |     | 230 |     | 232 |     |     |     |     |     |     |     |     |
|    | <210> 97    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <211> 231   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <212> PRT   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 35 | <213> Human |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | <400> 97    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|    | Val         | Tyr | Ser | Gln | Leu | Cys | Pro | Ala | Pro | Cys | Ala | Cys | Pro | Trp | Thr |
|    | 1           |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |
| 40 | Pro         | Pro | Gln | Cys | Pro | Pro | Gly | Val | Pro | Leu | Val | Leu | Asp | Gly | Cys |
|    |             |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Gly Cys Cys Ala Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp | 35  | 40  | 45  |
|    | His Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro | 50  | 55  | 60  |
| 5  | Gly Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu | 65  | 70  | 75  |
|    | Asp Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly | 80  | 85  | 90  |
| 10 | Glu Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp | 95  | 100 | 105 |
|    | Gly Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu | 110 | 115 | 120 |
|    | Pro Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly | 125 | 130 | 135 |
| 15 | Arg Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro | 140 | 145 | 150 |
|    | Ala Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu | 155 | 160 | 165 |
| 20 | Val Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr | 170 | 175 | 180 |
|    | Ala Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr | 185 | 190 | 195 |
|    | Arg Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg | 200 | 205 | 210 |
| 25 | Arg Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly | 215 | 220 | 225 |
|    | Ser Trp Asn Ser Ala Phe                                     | 230 | 231 |     |
| 30 | <210> 98  |     |     |     |
|    | <211> 230   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
|    | <400> 98  |     |     |     |
| 35 | Tyr Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro | 1   | 5   | 10  |
|    | Pro Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly | 20  | 25  | 30  |
|    | Cys Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His | 35  | 40  | 45  |
| 40 | Leu His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly | 50  | 55  | 60  |

|    |   |     |     |     |
|----|---|-----|-----|-----|
|    | Ala Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp | 65  | 70  | 75  |
|    | Asp Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu | 80  | 85  | 90  |
| 5  | Thr Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly | 95  | 100 | 105 |
|    | Gly Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro | 110 | 115 | 120 |
| 10 | Ser Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg | 125 | 130 | 135 |
|    | Cys Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala | 140 | 145 | 150 |
|    | Ile Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val | 155 | 160 | 165 |
| 15 | Thr Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala | 170 | 175 | 180 |
|    | Trp Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg | 185 | 190 | 195 |
| 20 | Val Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg | 200 | 205 | 210 |
|    | Leu Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser | 215 | 220 | 225 |
|    | Trp Asn Ser Ala Phe   | 230 |     |     |
| 25 | <210> 99  |     |     |     |
|    | <211> 229   |     |     |     |
|    | <212> PRT   |     |     |     |
|    | <213> Human   |     |     |     |
| 30 | <400> 99  |     |     |     |
|    | Ser Gln Leu Cys Pro Ala Pro Cys Ala Cys Pro Trp Thr Pro Pro | 1   | 5   | 10  |
|    | Gln Cys Pro Pro Gly Val Pro Leu Val Leu Asp Gly Cys Gly Cys | 20  | 25  | 30  |
| 35 | Cys Arg Val Cys Ala Arg Arg Leu Gly Glu Ser Cys Asp His Leu | 35  | 40  | 45  |
|    | His Val Cys Asp Pro Ser Gln Gly Leu Val Cys Gln Pro Gly Ala | 50  | 55  | 60  |
|    | Gly Pro Ser Gly Arg Gly Ala Val Cys Leu Phe Glu Glu Asp Asp | 65  | 70  | 75  |
| 40 | Gly Ser Cys Glu Val Asn Gly Arg Arg Tyr Leu Asp Gly Glu Thr | 80  | 85  | 90  |

Phe Lys Pro Asn Cys Arg Val Leu Cys Arg Cys Asp Asp Gly Gly  
 95 100 105  
 Phe Thr Cys Leu Pro Leu Cys Ser Glu Asp Val Arg Leu Pro Ser  
 110 115 120  
 5 Trp Asp Cys Pro Arg Pro Arg Arg Ile Gln Val Pro Gly Arg Cys  
 125 130 135  
 Cys Pro Glu Trp Val Cys Asp Gln Ala Val Met Gln Pro Ala Ile  
 140 145 150  
 10 Gln Pro Ser Ser Ala Gln Gly His Gln Leu Ser Ala Leu Val Thr  
 155 160 165  
 Pro Ala Ser Ala Asp Gly Pro Cys Pro Asn Trp Ser Thr Ala Trp  
 170 175 180  
 Gly Pro Cys Ser Thr Thr Cys Gly Leu Gly Ile Ala Thr Arg Val  
 185 190 195  
 15 Ser Asn Gln Asn Arg Phe Cys Gln Leu Glu Ile Gln Arg Arg Leu  
 200 205 210  
 Cys Leu Ser Arg Pro Cys Leu Ala Ser Arg Ser His Gly Ser Trp  
 215 220 225  
 20 Asn Ser Ala Phe  
 229  
 <210> 100  
 <211> 22  
 <212> DNA  
 <213> Artificial  
 25 <220>  
 <221> Artificial  
 <222> 1-22  
 <223> Sequence is synthesized  
 30 <400> 100  
 ccagccagag gaggccacga ac 22  
 <210> 101  
 <211> 24  
 <212> DNA  
 <213> Artificial  
 35 <220>  
 <221> Artificial  
 <222> 1-24  
 <223> Sequence is synthesized  
 40 <400> 101  
 gtacttgggt cggtagggtgc gtgt 24  
 <210> 102  
 <211> 23  
 <212> DNA



<213> Artificial

<220>  
<221> Artificial  
<222> 1-23  
5 <223> Sequence is synthesized

<400> 102  
gtggcccatg ctctggcaga ggg 23

<210> 103  
<211> 24  
10 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
15 <223> Sequence is synthesized

<400> 103  
gactggagca aggtcgtcct cgcc 24

<210> 104  
<211> 24  
20 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
25 <223> Sequence is synthesized

<400> 104  
gcaccaccca caaggaagcc atcc 24

<210> 105  
<211> 24  
30 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
35 <223> Sequence is synthesized

<400> 105  
gacgaaaggg aagccggcat cacc 24

<210> 106  
<211> 24  
40 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
45 <223> Sequence is synthesized

<400> 106  
 gagaagggtcg tggttcgagca aacc 24

<210> 107  
 <211> 24  
 5 <212> DNA  
 <213> Artificial

<220>  
 <221> Artificial  
 <222> 1-24  
 10 <223> Sequence is synthesized

<400> 107  
 cttctcgtgt acttcctgtg cctg 24

<210> 108  
 <211> 24  
 15 <212> DNA  
 <213> Artificial

<220>  
 <221> Artificial  
 <222> 1-24  
 20 <223> Sequence is synthesized

<400> 108  
 cacgtcagct ggccgtgcca gctc 24

<210> 109  
 <211> 23  
 25 <212> PRT  
 <213> Artificial

<220>  
 <221> Artificial  
 <222> 1-23  
 30 <223> Sequence is synthesized

<400> 109  
 Gln Pro Glu Glu Ala Thr Asn Phe Thr Leu Ala Gly Cys Val Ser  
 1 5 10 15

Thr Arg Thr Tyr Arg Pro Lys Tyr  
 35 20 23

<210> 110  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <221> Artificial  
 <222> 1-24  
 40 <223> Sequence is synthesized

<400> 110  
 45 ggccctggcc tgccagaagt gtgg 24

<210> 111  
<211> 24  
<212> DNA  
<213> Artificial

5 <220>  
<221> Artificial  
<222> 1-24  
<223> Sequence is synthesized

10 <400> 111  
gtgtgccttt cctgatctga gaac 24

<210> 112  
<211> 50  
<212> DNA  
<213> Artificial

15 <220>  
<221> Artificial  
<222> 1-50  
<223> Sequence is synthesized

20 <400> 112  
gtgattccat ctcttcatgt tcccagaaaa ttcttcccag ccgggcaggg 50

<210> 113  
<211> 70  
<212> DNA  
<213> Artificial

25 <220>  
<221> Artificial  
<222> 1-70  
<223> Sequence is synthesized

30 <400> 113  
ccagccagag gaggccacga acttcactct cgcaggctgt gtcagcacac 50  
gcacctaccg acccaagtac 70

35 <210> 114  
<211> 50  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-50  
<223> Sequence is synthesized

40 <400> 114  
gccctggag cccttgctcc accagctgcg gcctgggggt ctccactcgg 50

<210> 115  
<211> 23  
<212> DNA  
45 <213> Artificial

<220>  
<221> Artificial  
<222> 1-23  
<223> Sequence is synthesized

5 <400> 115  
aaaggtgcgt acccagctgt gcc 23

<210> 116  
<211> 24  
<212> DNA  
10 <213> Artificial

<220>  
<221> Artificial  
<222> 1-24  
<223> Sequence is synthesized

15 <400> 116  
ggtcttggcg aagacggctg acct 24

<210> 117  
<211> 51  
<212> DNA  
20 <213> Artificial

<220>  
<221> Artificial  
<222> 1-51  
<223> Sequence is synthesized

25 <400> 117  
cctggtgctg gatggctgtg gctgctgccg ggtatgtgca cggcggctgg 50  
g 51

<210> 118  
<211> 28  
30 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-28  
35 <223> Sequence is synthesized

<400> 118  
gtcttgtgca agcaacaaaa tggactcc 28

<210> 119  
<211> 27  
40 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-27  
45 <223> Sequence is synthesized

<400> 119  
gctgtcgcaa ggctgaatgt aacacag 27

<210> 120  
<211> 50  
5 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-50  
10 <223> Sequence is synthesized

<400> 120  
gctccagaac atgtgggatg ggaatatcta acaggggtgac caatgaaaac 50

<210> 121  
<211> 23  
15 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-23  
20 <223> Sequence is synthesized

<400> 121  
cctggagtga gcctggtgag aga 23

<210> 122  
<211> 27  
25 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-27  
30 <223> Sequence is synthesized

<400> 122  
acaatacagc cctttgtgtg ggtcaca 27

<210> 123  
<211> 44  
35 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-44  
40 <223> Sequence is synthesized

<400> 123  
tggttgcttg gcacagattt tacagcatcc acagccatct ctca 44

<210> 124  
<211> 27  
45 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-27  
<223> Sequence is synthesized

5 <400> 124  
tgacttccag gcatgaggtg gctcctg 27

<210> 125  
<211> 34  
<212> DNA  
10 <213> Artificial

<220>  
<221> Artificial  
<222> 1-34  
<223> Sequence is synthesized

15 <400> 125  
attggcaatc tcttcgaagt cagggttaaga ttcc 34

<210> 126  
<211> 40  
<212> DNA  
20 <213> Artificial

<220>  
<221> Artificial  
<222> 1-40  
<223> Sequence is synthesized

25 <400> 126  
ggtacgtcta gactaattgg caatctcttc gaagtcaggg 40

<210> 127  
<211> 42  
<212> DNA  
30 <213> Artificial

<220>  
<221> Artificial  
<222> 1-42  
<223> Sequence is synthesized

35 <400> 127  
tttccctttg gatcctaaac caacatgagg tggctcctgc cc 42

<210> 128  
<211> 20  
<212> DNA  
40 <213> Artificial

<220>  
<221> Artificial  
<222> 1-20  
<223> Sequence is synthesized

45 <400> 128  
cagattggtg ctggatatgc 20



<210> 129  
<211> 20  
<212> DNA  
<213> Artificial

5 <220>  
<221> Artificial  
<222> 1-20  
<223> Sequence is synthesized.

<400> 129  
10 actgccttga ttactcctac 20

<210> 130  
<211> 18  
<212> DNA  
<213> Artificial

15 <220>  
<221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 130  
20 agttgcagat gtggctct 18

<210> 131  
<211> 18  
<212> DNA  
<213> Artificial

25 <220>  
<221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 131  
30 agtccaagag tctcagca 18

<210> 132  
<211> 18  
<212> DNA  
<213> Artificial

35 <220>  
<221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 132  
40 acaactggaa gcactgga 18

<210> 133  
<211> 18  
<212> DNA  
<213> Artificial

45 <220>  
<221> Artificial

<222> 1-18  
<223> Sequence is synthesized

<400> 133  
tcttattcca gaggaacc 18

5 <210> 134  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
10 <221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

<400> 134  
tccctgtacg cttctggtcg ta 22

15 <210> 135  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
20 <221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

<400> 135  
tctcaaagtc caaagccaca ta 22

25 <210> 136  
<211> 18  
<212> DNA  
<213> Artificial

<220>  
30 <221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 136  
cacagttcca gcaaatac 18

35 <210> 137  
<211> 18  
<212> DNA  
<213> Artificial

<220>  
40 <221> Artificial  
<222> 1-18  
<223> Sequence is synthesized

<400> 137  
ggaatcaggc ggtacagt 18

45 <210> 138

<211> 31  
<212> DNA  
<213> Artificial

<220>  
5 <221> Artificial  
<222> 1-31  
<223> Sequence is synthesized

<400> 138  
agcctttcca agtcactaga agtcctgctg g 31

10 <210> 139  
<211> 21  
<212> DNA  
<213> Artificial

<220>  
15 <221> Artificial  
<222> 1-21  
<223> Sequence is synthesized

<400> 139  
ctggactaca cccaagcctg a 21

20 <210> 140  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
25 <221> Artificial  
<222> 1-23  
<223> Sequence is synthesized

<400> 140  
catttcttgg gatttaggca aga 23

30 <210> 141  
<211> 19  
<212> DNA  
<213> Artificial

<220>  
35 <221> Artificial  
<222> 1-19  
<223> Sequence is synthesized

<400> 141  
tctagccac tccctgct 19

40 <210> 142  
<211> 21  
<212> DNA  
<213> Artificial

<220>  
45 <221> Artificial  
<222> 1-21

<223> Sequence is synthesized

<400> 142  
gaagtcggag agaaagctcg c 21

<210> 143  
5 <211> 30  
<212> DNA  
<213> Artificial

<220>  
10 <221> Artificial  
<222> 1-30  
<223> Sequence is synthesized

<400> 143  
cacacacagc ctatatcaaa catgcacacg 30

<210> 144  
15 <211> 38  
<212> DNA  
<213> Artificial

<220>  
20 <221> Artificial  
<222> 1-38  
<223> Sequence is synthesized

<400> 144  
cttgagactg aaagatttag ccataatgta aactgcct 38

<210> 145  
25 <211> 22  
<212> DNA  
<213> Artificial

<220>  
30 <221> Artificial  
<222> 1-22  
<223> Sequence is synthesized

<400> 145  
caaatgcaac ctcacaacct tg 22

<210> 146  
35 <211> 24  
<212> DNA  
<213> Artificial

<220>  
40 <221> Artificial  
<222> 1-24  
<223> Sequence is synthesized

<400> 146  
ttcttttatg cccaaagtcc aatt 24

<210> 147  
45 <211> 48

<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
5 <222> 1-48  
<223> Sequence is synthesized

<400> 147  
ggattctaatac gactcact atagggcgtc cctggccagt gctgtgag 48

<210> 148  
10 <211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
15 <222> 1-48  
<223> Sequence is synthesized

<400> 148  
ctatgaaatt aaccctcact aaaggaggagg ccaggctttg cttccatt 48

<210> 149  
20 <211> 47  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
25 <222> 1-47  
<223> Sequence is synthesized

<400> 149  
ggattctaatac gactcact atagggctgg aggcattggca caggaac 47

<210> 150  
30 <211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
35 <222> 1-48  
<223> Sequence is synthesized

<400> 150  
ctatgaaatt aaccctcact aaagggatcc ggatcaggct tgggtgta 48

<210> 151  
40 <211> 48  
<212> DNA  
<213> Artificial

<220>  
<221> Artificial  
45 <222> 1-48  
<223> Sequence is synthesized

<400> 151  
ggattctaatac gactcact atagggcagc ttgggatgga ggtctttc 48

<210> 152  
<211> 44  
5 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-44  
10 <223> Sequence is synthesized

<400> 152  
ctatgaaatt aaccctcact aaagggaggg cactgggggtg gtgt 44

<210> 153  
<211> 45  
15 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-45  
20 <223> Sequence is synthesized

<400> 153  
ggattctaatac gactcact atagggcgcg aggacggcgg cttca 45

<210> 154  
<211> 48  
25 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-48  
30 <223> Sequence is synthesized

<400> 154  
ctatgaaatt aaccctcact aaaggaaga gtcgcggcgg cccttttt 48

<210> 155  
<211> 48  
35 <212> DNA  
<213> Artificial

<220>  
<221> Artificial  
<222> 1-48  
40 <223> Sequence is synthesized

<400> 155  
ggattctaatac gactcact atagggcggg gctcctcttc tccactct 48

<210> 156  
<211> 48  
45 <212> DNA  
<213> Artificial



&lt;220&gt;

&lt;221&gt; Artificial

&lt;222&gt; 1-48

&lt;223&gt; Sequence is synthesized

5

&lt;400&gt; 156

ctatgaaatt aaccctcact aaaggagct gtcgcaaggc tgaatgta 48

# INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/US 98/22991

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C12N15/62 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
|----------|--|-----------------------|

|   |   |  |
|---|---|--|
| Y | <p>DATABASE EMBL - EMBEST1<br/>           Entry Aa592984, Acc.no. AA592984,<br/>           24 September 1997<br/>           STRAUSBERG, R.: "nn03e01.s1 NCI_CGAP_Pr4.1<br/>           Homo sapiens cDNA clone IMAGE:1076664<br/>           similar to TR:G984956 G984956 CONNECTIVE<br/>           TISSUE GROWTH FACTOR"<br/>           XP002094092<br/>           see the whole document</p> | <p>47,<br/>           49-54,<br/>           57-60,<br/>           62-68,<br/>           71,72,<br/>           79,81,<br/>           83,85,86</p> |
|---|---|--|

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### ° Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 February 1999

Date of mailing of the international search report

05/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/22991

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |
|----------|--|--|
| Y        | <p>DATABASE EMBL - EMHUM1<br/>Entry Hs14217, Acc.no. Z99289,<br/>17 September 1997<br/>TUBBY B.: "Homo sapiens DNA sequence from<br/>PAC 142L7 on chromosome 6q21. Contains<br/>a...Connective tissue growth factor (NOV,<br/>GIG) LIKE gene,..."<br/>XP002094093<br/>nt. 12398-12855</p> <p>---</p>   | <p>47,<br/>49-54,<br/>57-60,<br/>62-68,<br/>71,72,<br/>79,81,<br/>83,85,86</p> |
| Y        | <p>OEMAR, B.S. ET AL.: "Connective tissue<br/>growth factor - friend or foe?"<br/>ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR<br/>BIOLOGY,<br/>vol. 17, no. 8, August 1997, pages 1483-9,<br/>XP002094090<br/>cited in the application<br/>see the whole document</p> <p>---</p>  | <p>47,<br/>49-54,<br/>57-60,<br/>62-68,<br/>71,72,<br/>79,81,<br/>83,85,86</p> |
| A        | <p>DATABASE EMBL - EMEST10<br/>Entry HS01627, Acc.no T55016,<br/>28 February 1995<br/>HILLIER, L. ET AL.: "yb42e03.r1 Homo<br/>sapiens cDNA clone 73852 5'"<br/>XP002094094<br/>see abstract</p> <p>---</p>  | <p>1,13</p>  |
| A        | <p>DATABASE EMBL - EMEST18<br/>Entry Hszz82583, Acc.no. AA377456,<br/>18 April 1997<br/>ADAMS, M.D. ET AL.: "EST90040 Synovial<br/>membrane Homo sapiens cDNA 5' end."<br/>XP002094095<br/>see the whole document<br/>-&amp; ADAMS, M.D. ET AL.: "Initial<br/>assessment of human gene diversity and<br/>expression patterns based upon 83 million<br/>nucleotides of cDNA sequence"<br/>NATURE,<br/>vol. 377, 1995, pages 3-17, XP002042918<br/>see the whole document</p> <p>---</p> | <p>26,<br/>28-30,35</p>  |
| P,X      | <p>HASHIMOTO, Y. ET AL.: "Expression of the<br/>Elm1 gene, a novel gene of the CCN<br/>(Connective tissue growth factor,<br/>Cyr61/Cef10, and neuroblastoma<br/>overexpressed gene) family, suppresses in<br/>vivo tumor growth and metastasis of K-1735<br/>murine melanoma cells."<br/>JOURNAL OF EXPERIMENTAL MEDICINE,<br/>vol. 187, no. 3, 2 February 1998, pages<br/>289-96, XP002094091<br/>cited in the application<br/>see whole document, particularly fig. 1</p> <p>---</p> | <p>1,9,10,<br/>12-19,<br/>24,25</p>  |

-/--

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/22991

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication where appropriate, of the relevant passages   | Relevant to claim No.  |
|----------|---|--|
| P, X     | <p>WO 98 21236 A (HUMAN GENOME SCIENCES INC<br/>;CHOPRA ARVIND (US); EBNER REINHARD (US))<br/>22 May 1998</p> <p>see whole document, particularly seq. 1<br/>and 2, example 1, claim 18</p> <p style="text-align: center;">---</p>  | <p>26,<br/>28-30,<br/>35-46,<br/>77, 78,<br/>83, 85,<br/>86, 88,<br/>92, 111</p> |
| P, X     | <p>ZHANG, R. ET AL.: "Identification of<br/>rCop-1, a new member of the CCN protein<br/>family, as a negative regulator for cell<br/>transformation"<br/>MOLECULAR AND CELLULAR BIOLOGY,<br/>vol. 18, no. 10, October 1998, pages<br/>6131-41, XP002094139<br/>cited in the application<br/>see whole document, particularly fig.2 and<br/>p.6132, left-hand column, second full<br/>paragraph</p> <p style="text-align: center;">-----</p> | <p>26,<br/>30-32,<br/>34, 35,<br/>37-40,<br/>42-46, 92</p>                       |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/22991

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 2, 11, 27, 48, 61  
because they relate to subject matter not required to be searched by this Authority, namely:  
See Further Information sheet PCT/ISA/210
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
See Further Information sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 98 /22991

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 89-91 and 101, and claims 102-104 and 107 in as far as they relate to use in vivo, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----  
Claims Nos.: 2,11,27,48,61

Claims 2,11,27,48, and 61, referring to biological activities of the claimed WISP proteins, could not be searched due to lack of support of such activities in the discription (Article 6, PCT).

Claims 74,76,78,80,82,105,108,111,114, and 115 referring to antagonists of the claimed WISP polypeptides and/or inhibitors of expression of the claimed WISP genes, could not be searched to completion due to insufficient disclosure of the compounds in the discription (Article 6, PCT).



# INTERNATIONAL SEARCH REPORT

**Information on patent family members**

Internal Application No

PCT/US 98/22991

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9821236 A                              | 22-05-1998          | AU 7610396 A               | 03-06-1998          |